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Abstract 
 
This thesis is divided in five chapters, highlighting natural products as 
valuable sources for the treatment of mankind diseases. The first chapter 
gives a general introduction into the early research and development of 
natural products and their history as suitable drugs in the past time. For a 
long time, a common strategy was the use of small molecules. Often, natural 
products proved to be valuable sources or were the initial step or the 
fundament for the development of drugs.  
 
The second chapter is based on a long-known but poorly investigated 
natural product named fragin. The structurally fascinating and rare 
diazeniumdiolate moiety captured our attention. An enantioselective synthesis 
was elaborated to clarify the unknown stereogenic center. Furthermore, a 
racemic intermediate in the biosynthesis of fragin, named valdiazen, was 
isolated and confirmed via chemical synthesis. SAR-studies on fragin 
identified the activity-driven part of the molecule and the influence of the 
substituents on the antibacterial activity. 
 
 
Neurodegenerative diseases are affecting increasing numbers of people 
worldwide and will become a serious problem for our health system. The 
third chapter shows the current state of the art in neurodegenerative disease 
treatment and how chemists were providing small molecules with potent 
activity to this research field. The genus Illicium is known to deliver natural 
products with potent neurite outgrowth inducing activity. One of these 
molecules is (2R)-hydroxynorneomajucin, which comprises a rare nor-type 
structure. We aimed to provide a total synthesis and SAR-studies to this 
synthetically challenging scaffold. An advanced intermediate was successfully 
synthesized in 18 steps. 
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Malaria is one of the deadliest diseases since ages and the uprising 
problem of strain resistance makes the future outlook even less promising. 
The fourth chapter describes the serendipity of a reaction to access novel 
endoperoxides. The formation of the endoperoxidal structure was first 
achieved in the presence of pure oxygen and further improved by the addition 
of a catalyst to induce this formal [2 + 2 + 2] cycloaddition. SAR-studies on 
these potent antimalarials provided a first insight into the active parts of the 
compounds. 
  
The fifth chapter is dedicated to the field of antibiotics research. Natural 
products showed their value in the early development steps of antibiotics, but 
became then an almost forgotten research field. Nevertheless, emerging 
bacterial strain resistance becomes more of a problem worldwide, and the 
discovery of novel antibiotics is desperately needed. The chapter reports on 
our synthetic efforts towards the antibiotic striatal A. The goal of this project is 
to provide a synthetic entry into the striatal family. However, the first attempt 
was not fruitful and led to several problems such as low yields or by-product 
formation. A new strategy was evaluated, that targets the synthesis of a bis-
diazoketone precursor to form the tricyclic core structure. 
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Zusammenfassung 
 
Die hier zusammengestellte wissenschaftliche Arbeit ist in fünf Kapitel 
unterteilt und beschreibt Naturstoffe als wertvolle Ausgangssubstrate zur 
Behandlung von verschiedenen Krankheitsbildern. Kapitel eins beinhaltet 
eine generelle Einleitung und gibt erste Einblicke in die Geschichte der 
Entwicklung moderner Wirkstoffe und den daraus resultierenden Therapien 
für diverse Krankheiten. Eine Strategie war die Verwendungen von kleinen 
Molekülen, wie zum Beispiel Naturstoffen. Diese Stoffe waren oftmals der 
erste Schritt für die weitere Entwicklung einer Therapie. 
 
Kapitel zwei basiert auf einem lange bekannten, jedoch kaum beachteten 
Naturstoff namens Fragin. Speziell die funktionelle Gruppe, ein 
Diazeniumdiolat, macht diesen Naturstoff besonders interessant. Eine 
enantioselektive Synthese von beiden Fragin Enantiomeren wurde erarbeitet 
um das unbekannte Chiralitätszentrum zu bestimmen. Zusätzlich wurde 
Valdiazen, eine biosynthetische Zwischenstufe von Fragin isoliert und die 
Struktur mittels chemischer Synthese vollumfänglich bestätigt. SAR-Studien 
von Fragin identifizierten desweiteren den aktiven Teil des Moleküls, sowie 
den Einfluss der Substituenten auf die antibakterielle Aktivität. 
 
Neurodegenerative Krankheiten betreffen eine zunehmende Anzahl an 
Personen in unserer Gesellschaft und werden daher in den kommenden 
Jahren grosse Auswirkungen auf unser Gesundheitssystem haben. Kapitel 
drei zeigt den aktuellen Forschungsstand von Nervenkrankheiten und wie 
Chemiker ihren Beitrag mittels wirksamen kleinen Molekülen beisteuern. Die 
Gattung Illicium ist bekannt für ihre Vielfalt an Neuritenwachstum-fördernden 
Molekülen. Eines dieser Natustoffe ist (2R)-Hydroxynorneomajucin, welches 
eine seltene nor-Struktur besitzt. Ziel unserer Arbeit ist dessen Totalsynthese 
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X 
um SAR-Studien zu ermöglichen. Eine Zwischenstufe konnte in 18 Schritten 
erfolgreich synthetisiert werden. 
 
Malaria ist seit Jahren eine der tödlichsten Krankheiten weltweit und 
aufkommende Resistenzen gegen heutige Therapien werden zunehmend 
problematisch. Kapitel vier beschreibt die zufällige Entdeckung einer 
Reaktion zur Herstellung neuer Endoperoxide. Die Bildung der Endoperoxid-
Struktur wurde mittels Sauerstoff über eine formale [2 + 2 + 2] Cycloaddition 
gebildet und dann weiter optimiert durch Zugabe eines Katalysators. SAR-
Studien dieser Antimalaria-aktiven Moleküle gaben einen ersten Einblick in 
die aktiven Teile des Moleküls. 
 
Das fünfte Kapitel ist der Antibiotika Forschung gewidmet. Naturstoffe 
haben Ihren Wert und Einfluss zu Beginn der Antibiotika Ära gezeigt. Wegen 
der stark aufkommenden Resistenz von Bakterien gegenüber Antibiotika, 
wird ein Nachschub an neuen Antibiotika dringender denn je benötigt. Das 
Kapitel beinhaltet unsere synthetischen Arbeiten zur Totalsynthese des 
Antibiotikums Striatal A. Erste Versuche basierend auf der Totalsynthese 
eines kürzlich synthetisierten Naturstoffes in unserer Gruppe konnten leider 
nicht auf das neue Substrat übertragen werden. Daher wurde eine neue 
Strategie evaluiert, welche eine Bis-Diazoketon Zwischenstufe beinhaltet um 
die dreizyklische Grundstruktur zu erhalten.  
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1 General Introduction – Dawn of a New Age of 
Natural Products Drug Discovery?   
 
Modern technology and pharmaceutical drugs have changed the life of 
today’s society. This progress has been greatly influenced by chemistry-
based inventions and in the last decade, several eras are referred to as the 
“Golden Ages” or “Golden Eras” for chemistry. In many cases, the discovery 
of natural products initiated a “Golden Era” and natural products continue to 
influence science until today.1 
 
The golden era of antibiotics discovery (1940 – 1960) had a huge impact 
on the health system (Figure 1.1).2 Sir Alexander Fleming discovered one of 
the first antibiotics already a few years earlier, in 1929.3 It took a few years for 
Fleming’s penicillin (1.1) to become world’s most famous antibiotic. A 
research article on penicillin’s activity in 1940 begun with the words “In recent 
years interest in chemotherapeutic effects has been almost exclusively 
focused on the sulphonamides and their derivatives. There are, however, 
other possibilities, notably those connected with naturally occurring 
substances” and landmarked the era of natural products as antibiotics (Figure 
1.1).4 In this era, numerous antibiotic natural products such as tetracycline 
(1.2)  (Pfizer, 1952), erythromycin (1.3) (Eli Lilly, 1949) and vancomycin (1.4)5 
(Eli Lilly, 1952) were discovered and antibiotic nature-inspired drugs were 
synthesized. The golden era ended along with the upcome of increased 
resistance of pathogens towards several antibiotics. The work on novel and 
potent antibiotics was not fruitful anymore as resistance became a serious 
problem and novel antibiotics were, and still are, saved as last-line drugs. 
                                                                                                    
1	  	   D.	  D.	  Baker,	  M.	  Chu,	  U.	  Oza,	  V.	  Rajgarhia,	  Nat.	  Prod.	  Rep.	  2007,	  24,	  1225.	  
2	  	   P.	  M.	  Wright,	  I.	  B.	  Seiple,	  A.	  G.	  Myers,	  Angew.	  Chem.	  Int.	  Ed.	  2014,	  53,	  8840.	  
3	  	   A.	  Fleming,	  Br.	  J.	  Exp.	  Pathol.	  1929,	  10,	  226.	  
4	  	   E.	   Chain,	  W.	   Florey,	   A.	   D.	   Gardner,	   N.	   G.	   Heatley,	  M.	   A.	   Jennings,	   J.	   Orr-­‐Erwing,	   A.	   G.	   Sanders,	  
	   Lancet	  1940,	  2,	  226.	  
5	  	   D.	  H.	  Williams,	  B.	  Bardsley,	  Angew.	  Chem.	  Int.	  Ed.	  1999,	  38,	  1172.	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Thus, pharmaceutical companies gave up on their research in finding more 
powerful treatment methods. However, a strong research for novel antibiotics 
is highly desirable. 
 
 
Figure 1.1: Famous antibiotics in the “golden era of antibiotics discovery”. 
 
The years 1960 – 1970 can be regarded as the golden era of 
chemotherapy. 6  In the beginning, the field of anticancer treatment was 
dominated by removal of the cancer by surgery or radiology. However, due to 
onset of metastasis in some cancer types, surgery or complete radiology was 
not always suitable and thus, small molecule drugs came into the focus of 
researchers. The discovery of the first anticancer agents (nitrogen mustard 
(1.5)7 and antifolates (folic acid (1.6) and methotrexate (1.7)8) begun already 
in the 1940’s (Figure 1.2). The breakthrough for small molecules in anticancer 
treatment goes back to researcher from Eli Lilly, who found active anticancer 
agents in the plant of Vinca rosea.9 These molecules showed also strong 
                                                                                                    
6	  	   B.	  A.	  Chabner,	  T.	  G.	  Roberts,	  jr.,	  Nature	  Reviews	  Cancer	  2005,	  5,	  65.	  
7	  	   H.	  A.	  A.	  M.	  Dirven,	  B.	  van	  Ommen,	  P.	  J.	  van	  Bladeren,	  Chem.	  Res.	  Toxicol.	  1996,	  9,	  351.	  
8	  	   N.	  Gonen,	  Y.	  G.	  Assaraf,	  Drug	  Resistance	  Updates	  2012,	  15,	  183.	  
9	  	   I.	  S.	  Johnson,	  J.	  G.	  Armstrong,	  M.	  Gorman,	  J.	  P.	  Burnett,	  jr.	  Cancer	  Res.	  1963,	  23,	  1390.	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activity against onchocerciasis (river blindness) and lymphatic filariasis 
(elephantiasis). One of the active principles was vinblastine (1.8) along with 
other members of the Vinca alkaloid family.  
 
Much earlier, Furth and Kahn demonstrated the danger of cancer by 
showing that a single cancer cell was sufficient to kill a mouse.10 Further 
studies showed that monotherapy was mostly not effective enough. This 
observation was then associated to hypothesis that an anticancer agent only 
kills a fraction of all cancer cells and surviving cancer cells are still able to 
grow. Therefore, on one hand, multiple treatment dosages and combination 
of therapies are necessary, and on the other hand, a successful treatment is 
strongly dependent on the initial cancer cell number.11 By the end of 1970, 
several cancer types (childhood leukemia, Hodgkin’s disease) could be cured 
or at least showed promising results in terms of remission. The value of small 
molecules in chemotherapy as anticancer agents could be fully confirmed 
during this golden era of chemotherapy. 
 
   
Figure 1.2: Famous chemotherapeutic agents in the “golden age of chemotherapy”. 
 
  
                                                                                                    
10	  	   J.	  Furth,	  M.	  C.	  Kahn,	  Am.	  J.	  Cancer	  1937,	  31,	  276.	  
11	  	   V.	  T.	  DeVita,	  jr.,	  E.	  Chu,	  Cancer	  Res.	  2008,	  68,	  8643.	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In the years of 1980 to present, novel techniques such as high-throughput 
screening methods and combinatorial chemistry came up, which allowed the 
broad screening of a vast number of molecules as well as a fast analysis of 
structure-activity relationship.12 Classical natural product discovery became 
less interesting and as a consequence, the natural product section in most 
pharmaceutical companies was down-sized or completely erased. However, 
a recent survey of launched marketed drugs in the year 2000 showed that 8 
out of 29 molecules are derived from natural products and the authors came 
to the conclusion that high-throughput screening did not have a significant 
impact on the finally launched structure.13  
 
The early golden ages in chemistry were strongly dependent on industrial 
partners, that directly influenced and developed novel techniques and 
molecules for commercial use. Nevertheless, a new golden era might arise, 
which is more needed than before. As possible landmark might act the 2015’s 
Nobel Prize in Physiology or Medicine, which was dedicated to the field of 
natural products and their contribution to mankind’s health system 
improvement. The Nobel laureate Youyou Tu was searching for a new 
treatment against malaria and found the anti-malarial agent artemisinin (1.9) 
in the plant Artemisia annua (Figure 1.3).14 This natural product significantly 
contributed to the prevention of malaria by reducing the patient’s mortality 
numbers suffering from malaria. William C. Campbell and Satoshi Omura 
were awarded for the discovery of avermectins (represented by avermectin 
B1 (1.10) and an improved analogue of it named ivermectin (1.11), Figure 
1.3).14 These molecules showed strong activity against onchocerciasis (river 
blindness) and lymphatic filariasis (elephantiasis). 
                                                                                                    
12	  	   J.	  G.	  Lombardino,	  J.	  A.	  Lowe,	  III,	  Nature	  Reviews	  Drug	  Discovery	  2004,	  3,	  853.	  
13	  	   a)	  J.	  R.	  Proudfoot,	  Bioorganic	  &	  Medicinal	  Chemistry	  Letters	  2002,	  12,	  1647;	  b)	  M.	  S.	  Butler,	  J.	  Nat.	  
Prod.	  2004,	  67,	  2141.	  
14	  	   B.	  Shen,	  Cell	  2015,	  163,	  1297.	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Figure 1.3. Natural products for which Youyou Tu as well as William C. Campbell and 
Satoshi Omura were awarded the Nobel Prize in Physiology or Medicine 2015.  
 
Omura described natural products as “splendid gifts” from nature,15 and it 
is rather obvious that natural products are main actors in the development of 
pharmaceutical drugs and reliefs. All these examples show that the best 
chemist in the world is still nature itself. 
 
                                                                                                    
15	  	   S.	  Omura,	  Tetrahedron	  2011,	  67,	  6420.	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2 Enantioselective Total Syntheses and SAR-Studies 
on the antifungal metabolite (−)-Fragin and 
Valdiazen 
2.1 Introduction 
2.1.1  Nitrogen Discovery and Synthetic Utility in Industrial     
    Processes 
 
Nitrogen (N2, 2.1) was discovered in 1772 by the physician Daniel 
Rutherford by analyzing the composition of air, which consists of around 78% 
N2 2.1. He and other researcher recognized that N2 2.1 was inert and often 
referred as “burnt air” or azote (from the greek “lifeless”). In 1870, Jean-
Antoine Chaptal called it nitrogène from the greek words “nitron genes“ (nitrite 
forming), due to the fact that “N2” was found in potassium nitrate (“nitrum”).16 
An entrance to nitrogen containing chemicals derived from N2 2.1 gas was 
achieved by the Birkeland-Eyde process (Scheme 2.1a). Nitrogen was passed 
trough an electric arc (>3000 °C) with oxygen to form nitric oxide (NO•, 2.2), 
which is further oxidized to nitrogendioxide (NO2, 2.3) and afterwards treated 
with water to form nitric acid (HNO3, 2.4).17,18 The Frank-Caro process (also 
called cyanamide process) was the first commercial synthesis, which used 
nitrogen (2.1). It was reacted with calcium carbide (CaC2) to yield cyanamide 
(2.5) and charcoal (2.6) as the product (Scheme 2.1b).17 However high 
temperatures were required for the reaction and small quantities are obtained. 
An alternative and more successful method is the Haber-Bosch process 
(Scheme 2.1c), which uses nitrogen (2.1) and hydrogen gas in combination 
with a catalyst (original osmium-based, nowadays ironoxide based) to form 
ammonia (NH3, 2.7).17 The process was used as a nitrogen feedstock for the 
                                                                                                    
16	  	   M.	  E.	  Weeks,	  J.	  Chem.	  Educ.	  1934,	  11,	  101.	  
17	  	   A.	  S.	  Travis,	  The	  Synthetic	  Nitrogen	  Industry	  in	  World	  War	  I	  It’s	  Emergence	  and	  Expansion	  2015,	  1st	  
ed.,	  Springer,	  Heidelberg.	  
18	  	   E.	  A.	  Ainscough,	  A.	  M.	  Brodie,	  J.	  Chem.	  Educ.	  1995,	  72,	  686.	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agriculture and had therefore an extreme influence on society growth and 
health.19 
   
Scheme 2.1: Initial nitrogen (2.1) fixation approaches. a) O2; b) O2, H2O; c) CaC2; d) H2, cat. 
2.1.2 Nature’s Nitrogen Sources 
 
In nature, nitrogen can be found in a variety of organic molecules such as 
alkaloids, amino acids and proteins derived from amino acids. The simplest 
nitrogen-species may be nitric oxide (NO•, 2.2, uncharged radical species).20 
NO• 2.2 is a gas and quite stable in its pure form, but gets easily oxidized in 
the presence of air. 21 NO• 2.2 is an important neurotransmitter in living beings 
and for its discovery, the scientists Robert F. Furchgott, Louis J. Ignarro and 
Ferid Murad were awarded with the Nobel Prize in Physiology or Medicine in 
1998 entitled “for their discoveries concerning nitric oxide as a signaling 
molecule in the cardiovascular system”.22  The small size and uncharged 
character of the radical NO• 2.2 allows a diffusion into cells and therefore 
allows interactions over a wider range with synapses and neurons compared 
to other neurotransmitters (acetylcholine, GABA, glutamate, glycin). NO• 2.2 is 
produced via an endogenous pathway by the enzyme nitric oxide synthase 
(NOS). 23  The enzyme converts L-arginine (2.8) via the hydroxylated 
intermediate N-hydroxy-L-arginine (2.9) to L-citruline (2.10) and NO• 2.2 is 
released (Scheme 2.2). 24 
                                                                                                    
19	  	   V.	  Smil,	  World	  Agriculture	  2011,	  2,	  9.	  
20	  	   a)	   R.	   F.	   Furchgott,	   J.	   V.	   Zawadzki,	  Nature	   1980,	   288,	   373;	   b)	   R.	   M.	   J.	   Palmer,	   A.	   G.	   Ferrige,	   S.	  
	   Moncada,	  Nature	  1987,	  327,	  524.	  
21	  	   C.	  S.	  Howard,	  F.	  Daniels,	  J.	  Phys.	  Chem.	  1958,	  62,	  360.	  
22	  	   R.	  SoRelle,	  Circulation	  1998,	  98,	  2365.	  
23	  	   R.	  G.	  Knowles,	  S.	  Moncada,	  Biochem.	  J.	  1994,	  298,	  249.	  
24	  	   a)	  J.	  B.	  Hibbs,	  Jr.,	  R.	  T.	  Traintor,	  Z.	  Vavrin,	  Science	  1987,	  235,	  473;	  b)	  P.	  G.	  Jorens,	  P.	  A.	  Vermeire,	  
	   A.	  G.	  Herman,	  Eur.	  Respir.	  J.	  1993,	  6,	  258;	  c)	  D.	  J.	  Stuehr,	  Biochim.	  Biophys.	  Acta	  1999,	  1411,	  217.	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Scheme 2.2: Enzymatic NO-generation from L-arginine.25 a) NADPH, O2. 
 
The main biological action of NO• 2.2 is the activation of the guanylate 
cyclase, which synthesizes cyclic guanosine monophosphate (cGMP), known 
as a second messenger (signal transmitter in the cell). Other pathways 
involves the direct conversion of NO• 2.2 to form reactive nitrogen species 
(RNS sometimes refers as RNI, reactive nitrogen intermediates),26 and are 
related to their oxygen analogues ROS (reactive oxygen species).27 Known 
intermediates are NO+ 2.11, NO- 2.12, N2O3 2.13, NO2 2.3, NO2- 2.14, NO3- 
2.15, OONO- 2.16, and metal-nitrosyl adducts 2.17. Oxidation of NO• 2.2 
forms nitrosonium (NO+,2.11), which can react with nucleophiles such as  
R-OH 2.18, R-SH 2.19 and amines 2.20 to form their nitrosylated species 2.21 
– 2.24. An one electron reduction forms nitroxyl-anion (NO-, 2.12), which 
converts under physiological conditions to N2O 2.25 shown in Scheme 2.3. 
  
                                                                                                    
25	  	   T.	  B.	  Cai,	  P.	  G.	  Wang,	  	  A.	  A.	  Holder,	  NO	  and	  NO	  Donors,	  in	  Nitric	  Oxide	  Donors:	  For	  
	   Pharmaceutical	  and	  Biological	  Applications	  2005,	  Wiley-­‐VCH	  Verlag	  GmbH	  &	  Co.	  KGaA,	  	  Weinheim.	  
26	  	   a)	  C.	  Bogdan,	  M.	  Röllinghoff,	  A.	  Diefenbach,	  Curr.	  Opin.	  Immunol	  2000,	  12,	  54;	  b)	  C.	  	  Nathan,	  M.	   U.	  
	   Shiloh,	  Proc.	  Natl.	  Acad.	  Sci.	  2000,	  97,	  8841.	  
27	  	   a)	   T.	   Rahman,	   I.	   Hosen,	   M.	   M.	   Towhidul	   Islam,	   H.	   U.	   Shekhar,	   Advances	   in	   Bioscience	   and	  
	   Biotechnology	  2012,	  3,	   997;	   b)	  B.	  D’Autréaux,	  M.	  B.	   Toledano,	  Nat.	  Rev.	  Mol.	   Cell	   Biol.	  2007,	  8,	  
	   813.	  
NH
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Scheme 2.3: Biological synthesis of NO• 2.2 and related oxidation and reduction pathways  
(M = metal; ox. = O2).25 
 
Theses reactive species have very interesting and biological important 
effects on infections, inflammation28 or erectile disfunction.29 
 
Nitroxyl-anion (NO-, 2.12, Scheme 2.3) is under physiological conditions a 
highly electrophilic species, which can be attacked by nucleophiles such as 
thiols 2.19 (N-acetyl-L-cysteine, dithiothreitol). 30  Nitroxyl (NO-, 2.12) is 
regarded as potent vasorelaxant and potential treatment for heart failure.31 
Peroxynitrites (ONOO-, 2.16) are formed from NO• 2.2 and superoxide  
(O2-, 2.26). 32  A wide range of biological activities is associated to 
peroxynitrites 2.16 such as apoptosis inducer, calcium dysregulation, DNA 
mutation or mitochondrial dysfunction.33 
                                                                                                    
28	  	   C.	  Nathan,	  J.	  Clin.	  Invest.	  1997,	  100,	  2417.	  
29	  	   a)	  A.	  L.	  Burnett,	  Int.	  J.	  Impot.	  Res.	  2004,	  16,	  15;	  b)	  J.	  Clin.	  Hypertens.	  2006,	  8,	  53.	  
30	  	   W.	  Flores-­‐Santana,	  D.	  J.	  Salmon,	  S.	  Donzelli,	  C.	  H.	  Switzer,	  D.	  Basudhar,	  L.	  Ridnour,	  R.	  Cheng,	  S.	  A.	  
	   Glynn,	  N.	  Paolocci,	  J.	  M.	  Fukuto,	  K.	  M.	  Miranda,	  D.	  A.	  Wink,	  Antioxid.	  Redox	  Signal.	  2011,	  14,	  1659.	  
31	  	   N.	  Paolocci,	  M.	   I.	   Jackson,	  B.	   E.	   Lopez,	  K.	  Miranda,	  C.	  G.	  Tochetti,	  D.	  A.	  Wink,	  A.	   J.	  Hobbs,	   J.	  M.	  
	   Fukuto,	  Pharmacol.	  Ther.	  2007,	  113,	  442.	  
32	  	   a)	  P.	  Pacher,	  J.	  S.	  Beckman,	  L.	  Liaudet,	  Physiol.	  Rev.	  2007,	  87,	  315;	  b)	  L.	  M.	  Slosky,	  T.	  W.	  Vanderah,	  
	   Expert	  Opin.	  Ther.	  Patens	  2015,	  25,	  443.	  
33	  	   C.	  Szabó,	  H.	  Ischiropoulos,	  R.	  Radi,	  Nat.	  Rev.	  Drug	  Discov.	  2007,	  6,	  663.	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2.1.3  Nitrogen Containing Structure Motifs 
 
An important class of nitrogen containing functional group is the 
hydroxamic acid (2.27, Figure 2.1). They are structurally related to amides, 
but with an additional hydroxy function on the nitrogen moiety. This structural 
change features in the ability to complex several cations,34 but mostly known 
to chelate Fe(III)-ions and therefore being siderophores.35 The synthesis of 
hydroxamic acids is normally achieved by the condensation of a carbon acid 
or ester with hydroxylamine.36 
 
Prominent representators of this functional group are ferrichrome 2.2837 
and suberoylanilide hydroxamic acid (SAHA, 2.29), depicted in Figure 2.1. A 
short synthesis was reported for SAHA 2.29.38  
SAHA 2.29 is used in cancer treatment,39 where it is acting as a histone 
deacetylase inhibitor (HDAC inhibitor, IC50 = 0.86 nM). Two of three HDAC 
classes are zinc-dependent and studies showed that SAHA 2.29 binds to zinc 
metal in the HDAC catalytic site.40 This mode of action results in a higher 
concentration of acetylated proteins and histones, finally leading to cell cycle 
arrest and apoptosis.41 
                                                                                                    
34	  	   Y.	  K.	  Agrawal,	  Russian	  Chem.	  Rev.	  1979,	  48,	  948.	  
35	  	   a)	  R.	  Saha,	  N.	  Saha,	  R.	  S.	  Donofrio,	  L.	  L.	  Bestervelt,	  J.	  Basic	  Microbiol.	  2013,	  53,	  303;	  b)	  S.	  Sah,	  R.	  
	   Singh,	   Agriculture	   (Polnohospodárstvo)	   2015,	   61,	   97;	   c)	   S.	   S.	   Ali,	   N.	   N.	   Vidhale,	   Int.	   J.	   Curr.	  
	   Microbiol.	  App.	  Sci.	  2013,	  2,	  303.	  
36	  	   a)	  H.	  L.	  Yale,	  Chem.	  Rev.	  1943,	  33,	  209;	  b)	  L.	  Bauer,	  O.	  Exner,	  Angew.	  Chem.	  In.	  Ed.	  1974,	  13,	  376.	  
37	  	   a)	  G.	  Müller,	  B.	  F.	  Matzanke,	  K.	  N.	  Raymond,	  J.	  Bacteriol.	  1984,	  160,	  313;	  b)	  M.	  Hannauer,	  Y.	  Barda,	  
	   G.	  L.	  A.	  Mislin,	  A.	  Shanzer,	  I.	  J.	  Schalk,	  J.	  Bacteriol.	  2010,	  192,	  1212.	  
38	  	   L.	  K.	  Gediya,	  P.	  Chopra,	  P.	  Purushottamachar,	  N.	  Maheshwari,	  V.	  C.	  O.	  Njar,	  J.	  Med.	  Chem.	  2005,	  
	   48,	  5047.	  
39	  	   M.	  Duvic,	  Hematology	  Meeting	  Reports	  2008,	  2,	  39.	  
40	  	   P.	  A.	  Marks,	  R.	  A.	  Rifkind,	  V.	  M.	  Richon,	  R.	  Breslow,	  T.	  Miller,	  W.	  K.	  Kelly,	  Nature	  2001,	  1,	  194.	  
41	  	   V.	  M.	  Richon,	  Br.	  J.	  Cancer	  2006,	  95,	  2.	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Figure 2.1: Hydroxamic acid containing molecules. 
 
Similar chemical and biological properties were found for diazeniumdiolates 
2.30 (Figure 2.2, left). The diazeniumdiolate functional group was first 
described by Davy in 1802.42 This unique functional group consists of two 
nitrogen and two oxygen. The term diazeniumdiolate is derived from “diazen”, 
which represents the N=N functional group. The tautomeric form is referred as 
N-nitrosohydroxylamine 2.31. Crystal structure analysis revealed that the 
diazeniumdiolate 2.30 is present. The oxygen atoms are further distinguished 
based on their alkylating pattern in O1 2.32 and O2 2.33 (Figure 2.2, left), 
which have an effect on their stability, especially on their NO-releasing 
properties. The diazeniumdiolate species is further distinguished by the 
attached residue such as oxygen- 2.34, nitrogen- 2.35 and carbon-containing 
diazeniumdiolate 2.36 (Figure 2.2, right). The main aspects of 
diazeniumdiolates 2.30 are covered in the review of Hrabie and Keefer.25,43  
  
                                                                                                    
42	  	   H.	  Davy,	  Bibl.	  Br.	  Sci.	  Arts	  1802,	  20,	  350.	  
43	  	   J.	  A.	  Hrabie,	  L.	  K.	  Keefer,	  Chem.	  Rev.	  2002,	  102,	  1135.	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Figure 2.2: Diazeniumdiolate nomenclature, O-alkylation pattern and different 
diazeniumdiolate species. 
 
Diazeniumdiolates 2.30 are potential NO• 2.2 releaser and have found 
numerous application in cancer treatment and other fields of drug research. 
Their differentiation, structures and biological profiles are discussed in the 
following section. 
 
O-Diazeniumdiolates 2.34 are rarely described and the most known 
compound is Angeli’s salt (2.37, also known as OXINO) discovered by the 
Italian chemist Angelo Angeli.44 The synthesis is derived from hydroxylamine 
2.23 and butylnitrite 2.38 as shown in Scheme 2.4. 
      
Scheme 2.4: Synthesis of Angeli’s salt (2.37).45 a) NaOH, MeOH. 
Experimental 46  and quantum mechanical calculations 47  revealed that the 
decomposition of Angeli’s salt (2.37) is pH dependent. At a lower pH < 4, the 
N2-oxygen-moiety is preferentially protonated and releases H2O and N2O 2.25 
                                                                                                    
44	  	   A.	  Angeli,	  Gazz.	  Chim.	  Ital.	  1896,	  26,	  17.	  
45	  	   J.	  F.	  DuMond,	  S.	  B.	  King,	  Antioxid.	  Redox	  Signal.	  2011,	  14,	  1637.	  
46	  	   M.	  N.	  Hughes,	  P.	  E.	  Wimbledon,	  J.	  Chem.	  Soc.,	  Dalton	  Trans.,	  1976,	  703.	  
47	  	   a)	  K.	  M.	  Miranda,	  A.	  S.	  Dutton,	  L.	  A.	  Ridnour,	  C.	  A.	  Foreman,	  E.	  Ford,	  N.	  Paolocci,	  T.	  Katori,	  C.	  G.	  
	   Tocchetti,	  D.	  Mancardi,	  D.	  D.	  Thomas,	  M.	  G.	  Espey,	  K.	  N.	  Houk,	   J.	  M.	  Fukuto,	  D.	  A.	  Wink,	   J.	  Am.	  
	   Chem.	  Soc.	  2005,	  127,	  722;	  b)	  A.	  S.	  Dutton,	  J.	  M.	  Fukuto,	  K.	  N.	  Houk,	  J.	  Am.	  Chem.	  Soc.	  2004,	  126,	  
	   3795.	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and at higher pH > 4, the N1-oxygen surrounding is protonated and NO2- 2.14 
and nitroxyl 2.12 is released. Nevertheless, further decomposition reactions 
indicating a complex mixture of several nitrogen-oxygen containing 
compounds are formed. Angeli’s salt (2.37) is used as an NO- 2.12 donor 
under physiological conditions and is used to promote vasodilation. However, 
the literature is inconsistent if NO• 2.2 or NO- 2.12 is responsible for 
vasorelaxation, due to different metabolic pathways of the applied NO-
donors.48,49 
N-diazeniumdiolates 2.35 are often referred as NONOates and are 
reported as the best NO-releasing functional group. The functional group is in 
general stable in the solid state as sodium adduct 2.35a but hydrolyses in 
solution to NO• 2.2 and amines 2.20 as shown in Scheme 2.5. The amount of 
released NO• 2.2 can vary from one to two equivalents.25,43 
 
         
Scheme 2.5: Hydrolysis of N-diazeniumdiolates (2.35, NONOates). a) H2O. 
 
For this class of compounds not many synthetic methods are reported and 
the most used procedures are shown in Scheme 2.6a,50 where an amine 2.20 
is treated with gaseous NO• 2.2 under basic conditions to form the sodium  
N-diazeniumdiolate 2.35a. In the absence of an external base, the ammonium 
adduct 2.35b is obtained (Scheme 2.6b). It was found that the sodium salts 
2.35a are more stable as their ammonium salts 2.35b, which have the 
tendency to be hygroscopic. Zwitterionic diazeniumdiolate species 2.39 are 
formed by an additional intramolecular amine function 2.40 (Scheme 2.6c). 
                                                                                                    
48	  	   a)	  J.	  C.	  Wanstall,	  T.	  K.	  Jeffrey,	  A.	  Gambino,	  F.	  Lovren,	  C.	  R.	  Triggle,	  Br.	  J.	  Pharmacol.	  2001,	  134,	  463;	  
	   b)	  S.	  Nelli,	  Lorraine	  McIntosh,	  W.	  Martin,	  Eur.	  J.	  Pharmacol.	  2001,	  412,	  281;	  c)	  Y.	  Shibata,	  H.	  Sato,	  
	   I.	  Sagami,	  T.	  Shimizu,	  Biochim.	  Biophys.	  Acta	  1997,	  1343,	  67;	  d)	  J.	  M.	  Fukuto,	  K.	  Chiang,	  R.	  Hszieh,	  
	   P.	  Wong,	  G.	  Chaudhuri,	  J.	  Pharmacol.	   Exp.	  Ther.	  1992,	  263,	  546.	  
49	  	   R.	  Zamora,	  A.	  Grzesiok,	  H.	  Weber,	  M.	  Feelisch,	  Biochem.	  J.	  1995,	  312,	  333.	  
50	   J.	  Konter,	  G.	  E.-­‐D.,	  A.	  A.	  Abou-­‐Rahma,	  A.	  El-­‐Emam,	  J.	  Lehmann,	  Eur.	  J.	  Org.	  Chem.	  2007,	  616.	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Scheme 2.6: Synthesis of NONOates.50 a) NaOMe; b) H+. 
 
Mainly the Z-conformation 2.41 is either observed for diazeniumdiolates. 
The interconversion barrier to the E-diazeniumdiolate 2.42 was calculated for 
the neutral species to be around 40 kcal/mol. The strong N=N bond is 
restricted for a conformation change. The anionic Z-diazeniumdiolate 2.43 
form showed a weaker bond energy of around 20 kcal/mol to the E-
diazeniumdiolate 2.44. The bond length of N3-N1 is 1.42 Å and of N1-N2 1.29 
Å (nitrogen-nomenclature 2.45, Scheme 2.7). The formation of the E-isomer 
was achieved by trapping the nucleophile with an installed electrophile on the 
O2-mioety to form an intramolecular ring.51  
  
                                                                                                    
51	  	   Y.-­‐N.	  Wang,	  D.	  S.	  Bohle,	  C.	  L.	  Bonifant,	  G.	  N.	  Chmurny,	  J.	  R.	  Collins,	  K.	  M.	  Davies,	  J.	  Deschamps,	  J.	  L.	  
	   Flippen-­‐Anderson,	  L.	  K.	  Keefer,	  J.	  R.	  Klose,	  J.	  E.	  Saavedra,	  D.	  J.	  Waterhouse,	  J.	  Ivanic,	  J.	  Am.	  Chem.	  
	   Soc.	  2005,	  127,	  5388.	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Scheme 2.7: Base promoted E/Z-isomerism of N-diazeniumdiolates 2.35. 
 
The formation of NONOates and their NO-releasing properties/stability 
strongly depends on the diazeniumdiolate structure. In general a slow 
NONOate formation corresponds to a slow NO-releaser. Steric and 
stereoelectronic effects influence the decomposition rate. More bulky 
substituents and incorporation of heteroatoms have an increasing effect on 
the NO-release properties. Cyclic substrates (2.48 and 2.49) accelerate the 
NO-release as shown in Figure 2.3.50  
 
 
Figure 2.3: Half life time of various NO-releasers (NONOates). 
 
So far, no N-diazeniumdiolate natural products have been found or 
reported, probably due to their instability towards physiological conditions. 
However, synthetic NONOate’s are used for cancer treatment, but they 
showed in early studies severe side effects such as tissue damaging.52 To 
increase the NONOate stability under physiological conditions, the O2-
substituent was modified to aryl-substituents. Furthermore, the stability under 
                                                                                                    
52	  	   P.	  J.	  Shami,	  J.	  E.	  Saavedra,	  L.	  Y.	  Wang,	  C.	  L.	  Bonifant,	  B.	  A.	  Diwan,	  S.	  V.	  Singh,	  Y.	  Gu,	  S.	  D.	  Fox,	  G.	  S.	  
Buzard,	  M.	  L.	  Citro,	  D.	  J.	  Waterhouse,	  K.	  M.	  Davies,	  X.	  Ji,	  L.	  K.	  Keefer,	  Mol.	  Cancer	  Ther.	  2003,	  2,	  
409.	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physiological conditions can be increased by attaching the NONOate part to 
an ester moiety, which releases the NONOate part upon ester degradation by 
esterases.53 
 
A promising anticancer candidate JS-K 2.50 possesses an IC50 value in the 
range of 0.2 – 0.5 µM in HL-60 (human myeloid leukemia) cell line.52 The 
mode of action is illustrated in Scheme 2.8. First, JS-K 2.50 reacts with 
gluthathione (2.51, GSH) to form a Meisenheimer-complex 2.52. The 
NONOate 2.53 is released, which further decomposes to the secondary 
amine 2.54 and NO• 2.2. The MAPK pathway (mitogen-activated protein 
kinase) is activated by NO• 2.2, which triggers cell apoptosis. Furthermore, 
DNP-SG 2.55 is formed, which has a supporting effect on cancer cell death or 
slower propagation. 
Scheme 2.8: Biological mechanism of JS-K 2.50.52  
  
                                                                                                    
53	  	   J.	  E.	  Saavedra,	  P.	  J.	  Shami,	  L.	  Y.	  Wang,	  K.	  M.	  Davies,	  M.	  N.	  Booth,	  M.	  L.	  Citro,	  L.	  K.	  Keefer,	  J.	  Med.	  
	   Chem.	  2000,	  43,	  261.	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5-Fluoroacyl (2.56, 5-FU) is used in the treatment of several cancer types. 
It represents an antimetabolite and possesses a similar structure as cytosin, 
thymin and uracil. It interacts with thymidylate-synthase and inhibits the cell 
division.54 However, 5-FU 2.56 is less selective in tumor selection and other 
tissues are affected. Wang reported on an improved NONOate 2.57 derivate 
of 5-FU 2.56 with improved drug profile.55 The NO-releasing mode is 
illustrated in Scheme 2.9. Porcine liver esterase cleaves the ester linker and 
the intermediates 2.58, which degrades to 5-FU 2.56, and 2.59 are formed. 
Latter decomposes to PYRRO/NO 2.49 and releases NO• 2.2. 5-FU/NONOate 
2.57 showed to be more active (65 mM in DU145 and 50 mM in HeLa cell) 
than 5-FU 2.56  (204 mM in DU145 and 278 mM in HeLa cell). It was claimed 
that a synergistic effect of NO• 2.2 and 5-FU 2.56 release increases the 
activity. However the safety profile was not evaluated. 
 
Scheme 2.9: Activation and NO-release mechanism of 5-FU/NONOate.55 
  
                                                                                                    
54	  	   a)	  D.	  B.	  Longley,	  D.	  P.	  Harkin,	  P.	  G.	   Johnston,	  Nat.	  Rev.	  Cancer	  2003,	  3,	  330;	  b)	  P.	  Noordhuis,	  U.	  
	   Holwerda,	  C.	  L.	  Van	  der	  Wilt,	  C.	  J.	  Van	  Groeningen,	  K.	  Smid,	  S.	  Meijer,	  H.	  M.	  Pinedo,	  G.	  J.	  Peters,	  
	   Ann.	  Oncol.	  2004,	  15,	  1025.	  
55	  	   T.	  B.	  Cai,	  X.	  Tang,	  J.	  Nagorski,	  P.	  G.	  Brauschweiger,	  P.	  G.	  Wang,	  Bioorg.	  Med.	  Chem.	  2003,	  11,	  4971.	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The most prominent C-diazeniumdiolate is cupferron (2.60), which is 
obtained via nitrosation of phenylhydroxylamine (2.61, Scheme 2.10a).56 Due 
to the acidic lability of the functional group, basic conditions are normally 
applied and the products are obtained as their ammonium salts. The free acid 
can be obtained under acidic conditions with a mixture of NaNO2 and HCl, as 
described by Behrend and König in their example of benzylhydroxylamine 
(2.62) to form the corresponding benzyl diazendiumdiolate 2.63 (Scheme 
2.10b).57 Addionally, an acidic work-up of the ammonium derivative will also 
yield in the free acid.  
      
Scheme 2.10: Synthesis of C-diazeniumdiolates under different conditions. a) isopentyl 
nitrite, NH3; b) NaNO2, HCl. 
 
Other methods include the use of enolates in a so called “Traube reaction” 
(Scheme 2.11).58 Acetone (2.64) was treated under basic conditions with NO• 
2.2 to form intermediate 2.65 and upon deacetylation, the bis-
diazeniumdiolate sodium salt 2.66 was obtained.  
 
  
Scheme 2.11: Traube reaction. a) NaOMe, nitric oxide (2.2); b) NaOMe. 
 
As well as in the N-diazeniumdiolates 2.35, also the Z-conformation 2.67 is 
predominantly present for C-diazeniumdiolates 2.36 (Figure 2.4a). This is 
                                                                                                    
56	  	   C.	  S.	  Marvel,	  O.	  Kamm,	  J.	  Am.	  Chem.	  Soc.	  1919,	  41,	  276.	  
57	  	   R.	  Behrend,	  E.	  Koenig,	  Justus	  Liebigs	  Ann.	  Chem.	  1891,	  263,	  175.	  
58	  	   W.	  Traube,	  Justus	  Liebigs	  Ann.	  Chem.	  1898,	  300,	  81.	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presumably by the fact of hydrogen bonding properties of O1-O2 as well as 
steric interactions, which might results from a E-conformation. 59  Low 
temperature NMR-measurements were applied and a E/Z-conformation (2.68 
and 2.69) change of around 15 kcal/mol was determined (Figure 2.4b).60 
However, for O2-derivaties (H or acyclic/alkyl) no E-isomers have been 
reported yet. 
 
    
Figure 2.4: E/Z-interconversion of C-diazeniumdiolates. 
 
Diazeniumdiolates are uncommon compounds and only a few of them have 
been isolated or reported. All of them are C-diazeniumdiolates. Figure 2.5 
shows the most studied natural products and cupferron, which found 
applications in trace metal analysis.61 Alanosine (2.70) is used as antitumor 
agent.62 It is produced by the strain Streptomyces alanosinicus63 and several 
syntheses64 have been reported for this molecule including an impressive 
stereoselective six step synthesis with an overall yield of 49%. 65 
Nitrosostromelin (2.71) was isolated from a Streptomyces culture and inhibits 
the protein stromelysin, which is proposed to be involved in tissue 
reconnection.66 The metalloprotein has a zinc in the active center and useful 
applications were investigated in the treatment of rheumatoid arthritis and 
                                                                                                    
59	  	   T.	  Axenrod,	  M.	  J.	  Wieder,	  G.	  W.	  A.	  Milne,	  Tetrahedron	  Lett.	  1969,	  10,	  401.	  
60	  	   I.	  I.	  Chervin,	  S.	  S.	  Nasibov,	  V.	  F.	  Rudchenko,	  V.	  G.	  Shtamburg,	  R.	  G.	  Kostyanovskii,	  Izv.	  Akad.	  Nauk.	  
	   SSSR,	  Ser.	  Khim.	  1981,	  30,	  544.	  
61	  	   N.	  H.	  Furman,	  W.	  B.	  Mason,	  J.	  S.	  Pecola,	  Anal.	  Chem.	  1949,	  21,	  1325.	  
62	  	   a)	  A.	  K.	  Tyagi,	  D.	  C.	  Thake,	  E.	  Mcgee,	  D.	  A.	  Cooney,	  Toxicology	  1981,	  21,	  56;	  b)	   J.	  Yu,	  Curr.	  Opin.	  
	   Investig.	  Drugs.	  2001,	  2,	  1623.	  
63	  	   Y.	  K.	  S.	  Murthy,	  J.	  E.	  Thiemann,	  C.	  Coronelli,	  P.	  Sensi,	  Nature	  1966,	  211,	  1198.	  
64	  	   a)	  G.	   C.	   Lancini,	   A.	  Diena,	   E.	   Lazzari,	  Tetrahedron	   Lett.	  1966,	  7,	   1769;	   b)	   Y.	   Isowa,	  H.	   Kurita,	  M.	  
	   Ohmori,	  M.	  Sato,	  K.	  Mori,	  Bull.	  Chem.	  Soc.	  Jpn.	  1973,	  46,	  1847.	  
65	  	   P.	  Strazzolini,	  M.	  G.	  Dall’Arche,	  M.	  Zossi,	  A.	  Pavsler,	  Eur.	  J.	  Org.	  Chem.	  2004,	  4710.	  
66	  	   T.	  Umino,	  H.	  Yoshizaki,	  H.	  Wakatabe,	  Chem.	  Abs.	  1996,	  125,	  245813.	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osteoarthritis.67 Dopastin (2.72) is another prominent antitumor candidate and 
inhibits β-dopamine-hydroxylase.68 A total synthesis was reported in eight 
steps.69 
Nitrosofungin (2.73, also sometimes referred as propanosine 70 ) is an 
antifungal isolated from the bacterium Alcaligenes. Higher isolation yields 
were obtained when the bacterium was grown in mixed cultures with 
Streptomyces plicatus.71 The authors proposed that a precursor is released 
from Streptomyces and incorporated into the synthesis of nitrosofungin (2.73) 
by Alcaligenes. A synthesis was reported by the same group starting from  
2-nitro-1-propanol.72 
Poecillanosine (2.74) has its origins from a marine sponge and therefore 
differs from other isolation sources.73 It showed inhibition of lipid peroxidation 
of a rat brain homogenate (IC50 = 0.04 µM) and cytotoxicity against P388 
murine leukemia cells (IC50 = 6.5 µM). Up to date only the O1-methylated 
poecillanosine was synthesized.74 
Cupferron (2.60) is not a natural product but found several applications in 
medicine (cupferron derivatives) and as metal-chelator, for the extraction of 
trace metal impurities in analytical chemistry. 
                                                                                                    
67	  	   S.	  Ye,	  P.	  Eriksson,	  A.	  Hamsten,	  M.	  Kurkinen,	  S.	  E.	  Humphries,	  A.	  M.	  Henney,	  J.	  Biol.	  Chem.	  1996,	  
	   271,	  13055.	  
68	  	   H.	  Iinuma,	  M.	  Matsuzaki,	  T.	  Nagatsu,	  T.	  Takeuchi,	  H.	  Umezawa,	  Agr.	  Biol.	  Chem.	  1974,	  38,	  2107.	  
69	  	   H.	   Iinuma,	   N.	   Yagisawa,	   S.	   Shibahara,	   Y.	   Suhara,	   S.	   Kondo,	   K.	  Maeda,	   T.	   Takeuchi,	  M.	   Ohno,	   H.	  
	   Umezawa,	  Agric.	  Biol.	  Chem.	  1974,	  38,	  2099.	  
70	  	   Y.	  Abe,	  J.-­‐I.	  Kadokura,	  A.	  Shimazu,	  H.	  Seto,	  N.	  Otake,	  Agric.	  Biol.	  Chem.	  1983,	  47,	  2703.	  
71	  	   L.	  A.	  Dolak,	  T.	  M.	  Castle,	  B.	  R.	  Hannon,	  A.	  D.	  Argoudelis,	  F.	  Reusser,	  J.	  Antibiot.	  1983,	  36,	  1425.	  
72	  	   L.	  A.	  Dolak,	  T.	  M.	  Castle,	  J.	  Antibiot.	  1983,	  36,	  916.	  
73	  	   T.	  Natori,	  Y.	  Kataoka,	  S.	  Kato,	  H.	  Kawai,	  N.	  Fusetani,	  Tetrahedron	  Lett.	  1997,	  38,	  8349.	  
74	  	   M.	  Xian,	  B.	  J.	  Shuhler,	  Tetrahedron	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  2007,	  48,	  1209.	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Figure 2.5: C-Diazeniumdiolate containing molecules. 
 
The biological formation of N=N bonds is still unclear and consists of a 
fundamental question in biological chemistry.75 The source of the 2nd nitrogen 
source is still under debate. Possible sources 76  could be delivered via 
nitrogen fixation,77 anammox pathway (anaerobic ammonium oxidation),78 via 
the nitrate-nitrite-NO pathway 79  or delivered from other amino acids via 
degradation to HNO2 2.14a.80 
Most C-diazeniumdiolates are not able to act as a NO-donor, because they 
decompose to nitroxyl 2.12, which reacts to N2O 2.25 and the C-nitroso 
analogue. Installation of electron withdrawing group on the carbon moiety 
increases the changes for an NO-release, as shown for cupferron (2.60), a  
C-diazeniumdiolate, which can release NO• 2.2 under thermal/photochemical 
conditions via an oxy-radical species 2.75 and further decomposition to 
nitrosobenzene 2.76 (Scheme 2.12).81 
 
                                                                                                    
75	  	   G.	  Le	  Goff,	  J.	  Ouazzani,	  Bioorg.	  Med.	  Chem.	  2014,	  22,	  6529.	  
76	  	   R.	  W.	  Ye,	  S.	  M.	  Thomas,	  Curr.	  Opin.	  Microbiol.	  2001,	  4,	  307.	  
77	  	   a)	   K.	   T.	   Shanmugam,	   F.	  O’Gara,	  K.	  Andersen,	  R.	  C.	  Valentine,	  Ann.	  Rev.	   Plant.	   Physiol.	  1978,	  29,	  
	   263;	  b)	  K.	  R.	  Schubert,	  Ann.	  Rev.	  Plant.	  Physiol.	  1986,	  37,	  539.	  
78	  	   J.	  Gijs	  Kuenen,	  Nat.	  Rev.	  Microbiol.	  2008,	  6,	  320.	  
79	  	   J.	  O.	  Lundberg,	  E.	  Weitzberg,	  M.	  T.	  Gladwin,	  Nat.	  Rev.	  Drug	  Discov.	  2008,	  7,	  156.	  
80	  	   Z.	  Huang,	  K.-­‐K.	  A.	  Wang,	  W.	  A.	  van	  der	  Donk,	  Chem.	  Sci.	  2015,	  6,	  1282.	  
81	  	   J.	  R.	  Hwu,	  C.	  S.	  Yau,	  S.-­‐C.	  Tsay,	  T.-­‐I.	  Ho,	  Tetrahedron	  Lett.	  1997,	  38,	  9001.	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Scheme 2.12: Generation of NO• 2.2 from cupferron (2.60) via 1e- reduction.  
 
Nevertheless, NO-releasing of C-diazeniumdiolates are known and follows 
an enzymatic induced degradation process as shown in Scheme 2.13 for the 
NO-release of alanosine (2.70).82 A transamination forms a α-ketoacid 2.77 
intermediate, which releases N2O2 2.78 and an enol 2.79. N2O2 2.78 is the 
dimeric form of NO• 2.2. 
 
Scheme 2.13: Enzymatic degradation of alanosine (2.70). 
In the laboratory, NO-gas can be synthesized by treating FeSO4 with 
NaNO2 under acidic conditions.83 
 
Metal-chelators are playing an important role in biological system, 84 
especially siderophores, 85  which are binding to Fe. As aforementioned,  
C-diazeniumdiolates 2.36 are less known for NO-release, but can act as 
metal-chelator especially to form copper-complexes.86 Chelating studies on 
the anticancer drug alanosine (2.70) showed a strong chelating effect on CuII 
with comparable binding affinities as EDTA.87 Furthermore, dopastin (2.72) is 
a potent inhibitor of the copper-dependent dopamine β-hydroxylase.69  
                                                                                                    
82	  	   T.	  A.	  Alston,	  D.	  J.	  T.	  Porter,	  H.	  J.	  Bright,	  J.	  Biol.	  Chem.	  1985,	  260,	  4069.	  
83	  	   M.	  G.	  Suryaraman,	  A.	  Viswanathan,	  J.	  Chem.	  Educ.	  1949,	  26,	  594.	  
84	  	   B.	  C.	  Pressman,	  Annu.	  Rev.	  Biochem.	  1976,	  45,	  501.	  
85	  	   a)	   K.	   D.	   Krewulak,	   H.	   J.	   Vogel,	   Biochim.	   Biophys.	   Acta	   2008,	   1778,	   1781;	   b)	   S.	   Sah,	   R.	   Singh,	  
	   Agriculture	  (Polnohospodárstvo)	  2015,	  61,	  97.	  
86	  	   a)	   D.	   Christodoulou,	   C.	   George,	   L.	   K.	   Keefer,	   J.	   Chem.	   Soc.,	   Chem.	   Commun.	   1993,	   937;	   b)	   R.	  
	   Longhi,	   R.	   S.	   Drago,	   Inorg.	   Chem.	  1963,	  2,	   85;	   c)	   J.	   L.	   Schneider,	   V.	  G.	   Young	   Jr.,	  W.	   B.	   Tolman,	  
	   Inorg.	  Chem.	  1996,	  35,	  5410;	  d)	  J.	  L.	  Schneider,	  J.	  A.	  Halfen,	  V.	  G.	  Young	  Jr.,	  W.	  B.	  Tolman,	  New.	  J.	  
	   Chem.	  1998,	  459.	  
87	  	   G.	  Powis,	  J.	  S.	  Kovach,	  Biochem.	  Pharmacol.	  1981,	  30,	  771.	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2.2 Goal of this Study and Synthetic and Biosynthetic    
   Investigations of Fragin 
 
In collaboration with the group of Prof. Dr. Leo Eberl and his student 
Christian Jenul, my colleague Dr. Simon Sieber from the Gademann group 
isolated the natural product fragin (2.80) from a Burkholderia cenocepacia 
sample (Figure 2.6).88 Interested by the potential biological activity of this 
compound and the mode of action, we elaborated a biological and synthetic 
program. Furthermore, the stereocenter of fragin (2.80) remained unknown 
and we started a synthetic program to synthesize fragin (2.80) in an 
enantioselective fashion. Additionally, further biological activity profile and 
biosynthetic pathway elucidation were studied in this chapter. 
      
Figure 2.6: Antifungal activity of fragin (2.80) against Burkholderia cenocepacia. Picture of 
the plate provided by Christian Jenul (University of Zurich). 
  
                                                                                                    
88	  	   S.	   Sieber,	   Ph.	   D.	   Thesis,	   „Addressing	   Fundamental	   Questions	   in	   Chemical	   Biology	   trough	  
	   Biochemical	  Investigations	  of	  Natural	  Products“,	  University	  of	  Basel	  2015.	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2.2.1 Tamura’s Total Synthesis of (±)-Fragin 
 
The natural product fragin (2.80) was first described by Tamura and co-
workers in 1967.89  It was isolated from Pseudomonas fragi and showed 
inhibiting activities against lettuce seedlings, Aspergillus niger and chlorella.90 
In the same year, a first racemic total synthesis of fragin (2.80) was published 
by the Tamura group (Scheme 2.14). 91  Starting from isobutyryl chloride 
(2.81), a Nierenstein reaction afforded chloromethyl ketone 2.82. A Gabriel 
synthesis furnished first the desired amide intermediate 2.83, which was 
cleaved under acidic conditions to the ammonium salt intermediate 2.84. 
Treating the salt 2.84 with octanoyl chloride afforded the fatty acid product 
2.85 in 73%. The same key intermediate 2.85 was synthesized in a second 
synthesis starting from isobutyryl aldehyde (2.86), which was treated under 
basic conditions in nitromethane (Henry-reaction) to afford the nitroalcohol 
2.87. The nitro group was hydrogenated to the corresponding free amine 
2.88, which was treated with octanoyl chloride to the fatty acid product 2.89. 
The alcohol 2.89 was then oxidized using Jones’ reagent to the common 
ketone intermediate 2.85 in 75% yield. The oxime 2.90 was synthesized in the 
presence of hydroxylamine hydrochloride and NaOAc in 85%. Reducing 
attempts to the hydroxylamine 2.91 with diborane were not successful due to 
the coordinating effect of the adjacent amide function. Finally, a catalytic 
hydrogenation over Pt/C furnished the hydroxylamine 2.91 in a good yield of 
70%. The final racemic natural product fragin (2.80) was achieved by treating 
the hydroxylamine 2.81 with NaNO2 under aqueous acidic conditions and  
(±)-fragin (2.80) was isolated as a white solid in 83% yield (eight steps, 23%). 
  
                                                                                                    
89	  	   S.	  Tamura,	  A.	  Murayama,	  K.	  Hata,	  Agr.	  Biol.	  Chem.	  1967,	  31,	  758.	  
90	  	   A.	  Murayama,	  K.	  Hata,	  S.	  Tamura,	  Agr.	  Biol.	  Chem.	  1969,	  33,	  1599.	  
91	  	   a)	   S.	   Tamura,	   A.	   Murayama,	   K.	   Kagei,	   Agr.	   Biol.	   Chem.	   1967,	   31,	   996;	   b)	   A.	   Murayama,	   S.	  
	   Tamura,	  Agr.	  Biol.	  Chem.	  1970,	  34,	  130.	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Scheme 2.14: Tamura’s total synthesis of (±)-fragin (2.80). a) diazomethane, HCl(g); b) 
potassium phthalimide, DMF; c) HCl, 63% (over three steps); d) octanoyl chloride, NaOH, 
73%; e) nitromethane, NaOH; f) Raney-Ni, H2, 62% (over two steps); g) octanoyl chloride, 
NaOH, 90%; h) Jones’ reagent, acetone, 75%; i) hydroxylamine hydrochloride, NaOAc, 85%; 
j) Pt/C, H2, MeOH, HCl, 70%; k) NaNO2, HCl, 83%. 
 
2.2.2 Retrosynthetic Analysis and Enantioselective Total Synthesis of 
   (−)-Fragin 
 
The stereocenter of the naturally isolated fragin (2.80) remained unknown 
and thereof, we decided to elaborate an enantioselective synthesis of fragin 
(2.80). A retrosynthetic analysis revealed that the molecule can be divided in 
an amine 2.92 and a fatty acid part (caprylic acid (2.93)) as shown in Scheme 
2.15. The installation of the diazeniumdiolate group will be done in the last 
step of the synthesis from a hydroxylamine intermediate 2.94, which is 
derived from the amino acid valine (2.95). 
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Scheme 2.15: Retrosynthetic analysis of fragin (2.80). 
 
The synthesis starts from enantiopure Fmoc-protected valine (2.96a and 
2.96b), which is commercially available in the respective enantiopure form 
(Scheme 2.16). The carboxylic acid 2.96a and 2.96b was reduced to the 
alcohol 2.97a and 2.97b in a one pot procedure according to Liskamp and co-
workers (Scheme 2.16).92 A modified Mitsunobu reaction furnished the azide 
2.98a and 2.98b. The reported reduction using Pd/C and H2 could only be 
reproduced in a moderate yield of around 50%. It is known that the Fmoc-
moiety could be sensitive under this condition and a milder reducing condition 
was found using Pd/C and triethylsilane as the H2-donor.93 The ammonium 
salt 2.99a and 2.99b could be filtrated and washed with pentane (to remove 
silane by-products) to yield the desired ammonium salt 2.99a in an excellent 
and reproducible yield of 87% and a moderate yield of 56% for ammonium 
salt 2.99b under the reported hydrogenation conditions. The fatty acid chain 
part was introduced with octanoyl chloride to yield the amide 2.100a and 
2.100b in moderate to excellent yields. The Fmoc-cleavage was found to be 
challenging. Under standard deprotection conditions with amine bases 
(piperidine, DBU) only small amounts of the free amine 2.101a and 2.101b 
could be isolated. Furthermore, the excess of base and the formed 
dibenzofulvene-adduct as a byproduct made the work-up as well as 
purification much more complicated. A base free Fmoc-deprotection condition 
using AlCl3 as Lewis-acid was conducted and a simple acidic and basic work-
up yielded the free amine 2.101a and 2.101b in a remarkable yield of 95% 
                                                                                                    
92	  	   A.	  Boeijen,	  J.	  van	  Ameijde,	  R.	  M.	  J.	  Liskamp,	  J.	  Org.	  Chem.	  2001,	  66,	  8454.	  	   
93	  	   P.	  K.	  Mandal,	  J.	  S.	  McMurray,	  J.	  Org.	  Chem.	  2007,	  72,	  6599.	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and 92%.94 The mechanism is unknown, but we are suggesting that the 
Lewis-acid binds to the carbonyl function and the released chloride is 
abstracting the hydrogen in a E1cb–fashion to form dibenzofulvene and CO2 
as the sole byproduct. Oxidation of amines to hydroxylamines95 or even nitro-
functionalities96 are rarely described in literature. Classical approaches for the 
conversion of amines to hydroxylamines involve a condensation of a 
benzaldehyde moiety followed by an oxaziridation of the formed imine, which 
is then cleaved under acidic conditions to the hydroxylamine.69 However, 
hydroxylamines are not very stable and can be oxidized to the undesired 
oxime. An alternative two step procedure was used in this case. The amine 
reacted with dibenzoylperoxide to the N-oxidized intermediate 2.102a and 
2.102b, however traces of the amide product was observed as a minor 
product.97 The cleavage of the benzoyl-group was achieved with hydrazine 
and the hydroxylamine 2.91a and 2.91b could be isolated with an acidic and 
basic work-up in a moderate (Scheme 2.16). We suggest the instability during 
the reaction and work-up process is responsible for this moderate yield. The 
final step was already reported by the Tamura group, using NaNO2 in acidic 
aqueous medium.91 To our surprise, several attempts failed, even with 
multiple additions of NaNO2 into the acidic solution. We were pleased that the 
missing NO-functionality could be introduced by isopentyl nitrite as the NO-
donor under basic conditions. A simple basic and acidic work-up furnished the 
desired natural product (−)-fragin (2.80a) and (+)-fragin (2.80b) as a white 
solid in a yield of 83%. The structure of (−)-fragin (2.80a) was secured by X-
ray crystal structure analysis. Overall, the enantioselective total synthesis (−)-
fragin (2.80a) was achieved in eight steps with an overall yield of 13%.  
                                                                                                    
94	  	   A.	  Leggio,	  A.	  Liguori,	  A.	  Napoli,	  C.	  Siciliano,	  G.	  Sindona,	  Eur.	  J.	  Org.	  Chem.	  2000,	  573.	  
95	  	   J.	  Hu,	  M.	  J.	  Miller,	  J.	  Am.	  Chem.	  Soc.	  1997,	  119,	  3462.	  
96	  	   a)	  J.	  K.	  Crandall,	  T.	  Reix,	  J.	  Org.	  Chem.	  1992,	  57,	  6759;	  b)	  K.	  E.	  Gilbert,	  W.	  T.	  Borden,	  J.	  Org.	  Chem.	  
	   1979,	  44,	  659.	  
97	  	   Z.-­‐Y.	  Chang,	  R.	  M.	  Coates,	  J.	  Org.	  Chem.	  1990,	  55,	  3475.	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Scheme 2.16: Enantioselective total synthesis and X-ray structure of (−)-fragin (2.80a) and 
(+)-fragin (2.80b), X-ray structure color code: blue = nitrogen; grey = carbon; red = oxygen; 
white = hydrogen. a) Isobutylchloroformiate, NaBH4, DME, r.t. 1.5 h; b) PPh3, DEAD, DPPA, 
THF, 0 °C − r.t., 10 h; c) Pd/C, Et3SiH, MeOH/CHCl3, 14 h, r.t.; d) octanoyl chloride, DIPEA, 
DMAP, 14 h, r.t.; e) AlCl3, toluene, 3.5 h, r.t.; f) dibenzoylperoxide, K2HPO4, THF, 21 h, r.t.; g) 
N2H4 x H2O, EtOH, 2.5 h, r.t.; h) isopentyl nitrite, NH3(g), EtOH, 0.5 h, r.t. 
 
The 1H- and 13C-NMR spectra were in good agreement with the isolated 
natural product as depicted in Figure 2.7. Both synthesized fragin 
enantiomers (2.80a and 2.80b) were compared with the optical rotation of the 
published molecule as well as the newly isolated fragin (2.80) in our group.88 
The stereocenter was finally assigned as (R)-configured (−)-fragin 2.80a. This 
was furthermore confirmed by X-ray crystal structure analysis of the isolated 
and synthesized sample.  
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Figure 2.7: 1H-NMR spectra of isolated fragin (2.80, top) and synthetic (−)-fragin (2.80a, 
bottom) (400 NMR, CDCl3). 
2.2.3  NO-Releasing Measurements of (−)-Fragin 
 
The degradation studies of Tamura and co-worker showed that an acetic 
acid treatment of fragin (2.80) formed the nitrosodimer.89 However, the two 
missing NO-parts were not further described. We assume that a release of 
NO• 2.2 might happen. To test this assumption, we followed a NO-detection 
procedure using 2,3-diaminonaphtalene (DAN, 2.103), which acts as a NO-
scavenger and forms the fluorescent 1-[H]-naphthotriazole (NAT, 2.104) as 
shown in Scheme 2.17.98 
        
Scheme 2.17: NO-detection by scavenging NO• 2.2 and measuring of the fluorescent NAT 
2.104. a) NO• 
                                                                                                    
98	  	   M.-­‐C.	  Carré,	  B.	  Mathieuxe,	  J.-­‐C.	  André,	  M.-­‐L.	  Viriot,	  Analusis	  1999,	  27,	  835.	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A mixture of (−)-fragin (2.80a) in CHCl3/AcOH and DAN (2.103) was 
measured. The expected peak at 405 nm was observed and a NO-release 
could be confirmed after 1 h and 5 h (representative spectra shown in Figure 
2.8). The emission spectra after 24 h showed a different spectra, probably 
due to degradation of DAN (2.103) or the resulting product. The quenched 
samples were analyzed by HPLC to quantify the NO-release. However, all the 
samples (time range from 1 h, 5 h and 24 h) showed no significant change in 
the (−)-fragin (2.80a) concentration as well no expected other products were 
detected. We could not reproduce the expected degradation of (−)-fragin 
(2.80a) as described by Tamura in our testing method.89 The DAN test is very 
sensitive and already minor amount of NO-release can be observed. 
 
      
Figure 2.8: UV-VIS spectra of quenched fragin-DAN-solution after 5 h. 
 
To conclude, the data suggest that (−)-fragin (2.80a) can act as a slow NO-
releaser, but other quantification methods should be tested for further 
evidence. Additionally, physiological conditions should be tested for possible 
in vivo NO-release properties. 
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2.3 Isolation and Enantioselective Synthesis of the  
   Signaling Molecule Valdiazen 
 
In the studies of the natural product (−)-fragin (2.80a), our collaborator 
Christian Jenul (University of Zurich) observed a signaling molecule 2.105, 
which regulates the ham-gene cluster and is suspected also to be an 
intermediate in the biosynthesis of (−)-fragin (2.80a). Encouraged by these 
findings, we focused on the isolation of this intermediate from the strain 
Burkholderia cenocepacia H111. The identification was achieved as 
described. First, gene sequence was identified. Secondly, the molecule 2.105 
was isolated by extraction, isolated by HPLC and analyzed by NMR, mass 
spectrometry and X-ray structure analysis. Based on this result a signaling 
molecule structure 2.105 was proposed. Thirdly, a synthesis confirmed the 
structural proposal. The general work-flow Scheme is highlighted in Figure 
2.9. 
 
Figure 2.9: Identification of the natural product valdiazen. 
 
A method to follow a biosynthetic pathway of a natural product is the 
identification of the gene-sequence and then the preparation of the knock-out 
strains. (The functions of the genes are discussed in detail in the biosynthetic 
investigation chapter 2.4.3). The knock-out strains of the ham-gene cluster 
were prepared by Christian Jenul from the group of Prof. Dr. Leo Eberl. Out of 
this gene, the knock-out strain hamF was found to produce the signaling 
molecule 2.105 in a suitable amount for further studies. The gene-analysis 
revealed that the signaling molecule should also consists of the 
diazeniumdiolate functional group and the extraction of the hamF supernatant 
was performed via a basic and acidic work-up (see experimental part for a 
detailed procedure). The extracts were purified by HPLC using a Synergi 
Hydro column (see experimental part for further details). The signaling 
molecule HPLC isolation trace is shown below (Figure 2.10) 
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Figure 2.10: HPLC-trace of the signaling molecule 2.105 (9.83 minutes) sample after 
extraction. 
 
The isolated fractions were tested on their biological activity for the 
signaling molecule 2.105 (9.83 min, Figure 2.10) activity by Christian Jenul. 
The active fractions were then further analyzed. A first NMR-analysis of a 
crude sample showed that the molecule consists of an isopropyl function and 
protons at 4.0 ppm (two protons) and 3.8 ppm (one proton). HSQC-analysis 
indicated the same carbon correlation of the one proton at 4.0 ppm and the 
signal at 3.8 ppm. The structure of 2.105 was further compared with the 1H-
NMR data of fragin (2.80).88 The fatty acid moiety is not present in the novel 
structure 2.105. The CH2-shifts (4.0 and 3.8 ppm) are too high for a free 
amine, therefore a free alcohol moiety was proposed. Based on the similar 
1H-NMR spectra of fragin (2.80) and the novel structure 2.105 as well as the 
basic and acidic extractive work up, a diazeniumdiolate group for the novel 
structure 2.105 was proposed. Furthermore, the shift for the second proton at 
4.0 ppm is in good agreement with the proton shift of fragin (2.80), containing 
a diazeniumdiolate function adjacent to this proton. Out of these structural 
findings, a first structural suggestion for the signaling molecule 2.105 was 
done and summarized in Figure 2.11. 
 
Figure 2.11: Structure elucidation pathways of the proposed signaling molecule structure 
2.105.  
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The enantioselective total synthesis for both enantiomers of the signaling 
molecule 2.105 are depicted in Scheme 2.18. Commercial available and 
enantiopure valinol (2.106a and 2.106b) was used and condensated with 
para-methoxybenzaldehyde. An oxaziridation of the formed imine and further 
opening of the oxaziridine intermediate with hydroxylaminehydrochloride 
furnished the desired hydroxylamines 2.107a and 2.107b which was used 
without further purification.99 The hydroxylamines 2.107a and 2.107b were 
treated with isopentyl nitrite under basic conditions and the desired signaling 
molecules (−)-2.105a and (+)-2.105b could be isolated by a simple basic and 
acidic work-up. The structure was additionally secured by X-ray crystal 
structure analysis (Scheme 2.18). Due to its similarity to fragin (2.80) and 
valinol (2.106), the compound was named valdiazen (2.105). 
 
 
Scheme 2.18: Total synthesis of both enantiomers of the signaling molecule 2.105 and X-ray 
structure of (R)-valdiazen 2.105a (X-ray structure color code: blue = nitrogen; grey = carbon; 
red = oxygen; white = hydrogen). a) PMP-CHO, CH2Cl2, r.t., 4 h, then m-CPBA, CH2Cl2, 0 °C 
to r.t., 2 h, then NH2OH x HCl, MeOH, r.t., 3 d; b) isopentyl nitrite, NH3 in MeOH, r.t., 45 min. 
 
The 1H-NMR (Figure 2.12) as well as the 13C-NMR (Figure 2.13) of isolated 
and synthetic valdiazen (2.105) are in good agreement with the synthetic 
onces. Small changes might arise from the acidic properties of the 
diazeniumdiolate function.  
  
                                                                                                    
99	  	   M.	  Breuning,	  T.	  Häuser,	  E-­‐.M.	  Tanzer,	  Org.	  Lett.	  2009,	  11,	  4032.	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Figure 2.12: 1H-NMR spectra of isolated 2.105 (top) and synthetic (−)-valdiazen (2.105a) 
(bottom) and peak overlays (600 NMR, MeOD).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13: 13C-spectra of synthetic (−)-2.105a (top) and isolated valdiazen (2.105)  
(500 NMR, MeOD). 
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The NMR data for valdiazen (2.105) are concluded in Table 2.1. 
            
atom Nr. 1Ha 13Ca COSY HMBC 
1 
1’ 
1.02 (d, J = 6.8 Hz) 
0.90 (d, J = 6.8 Hz) 
19.4; CH3 2 
1’, 2, 3 
1, 2, 3 
2 2.12 (m) 29.3; CH 1/1’, 3 1/1’, 3 
3 4.00 (m) 82.3; CH 2 4 
4 
4’ 
4.00 (m) 
3.83 (m) 
61.2; CH2 
- 
3, 4’ 
3, 4 
2, 3 
- 
OH - - - - 
N-OH - - - - 
Table 2.1: 1H- and 13C-NMR analysis of valdiazen (2.105) in MeOD. a (δ/ppm; signal) 
 
Due to the low amount from the isolation (0.5 – 1 mg), the stereocenter of 
isolated valdiazen (2.105) could not be unambiguously confirmed by optical 
rotation value and other methods were considered. Chiral GC was performed 
but the product could not be detected. However GC-analysis showed several 
fragments, which would correspond to a NO-released hydroxylamine fragment 
(mass = 88.0; EI-fragmentation). The same mass fragment spectrum was 
observed by injecting the pure hydroxylamine 2.107a. The isolation was 
performed by HPLC-separation and suitable conditions were found for chiral 
HPLC analysis. The racemate was prepared by mixing an equimolar amount 
of the synthetic enantiomers (−)-2.105a and (+)-2.105b. Additional both single 
enantiomers of synthetic valdiazen ((−)-2.105a and (+)-2.105b) were injected 
and finally the isolated valdiazen (2.105) as shown in Figure 2.14. The 
racemate could be separated and both enantiomers are stable under the used 
conditions and no racemization occurs. To our surprise, the isolated valdiazen 
(2.105) is racemic as shown in Figure 2.14. This observation is in detailed 
discussed in the biosynthesis section of this thesis (see chapter 2.4.3).  
Me1
2 3
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Figure 2.14: Chiral HPLC analysis of synthetic (R)-2.105a and (S)-valdiazen (2.105b), 
racemate (rac)-2.105) and isolated valdiazen (2.105).  
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The pKa of synthetic (−)-valdiazen (2.105a) was measured by Jrène 
Lehmann (Mass Spectrometry Service at the University of Zurich). It showed 
a pKa of 5.5 (see experimental part of this thesis), which is in good agreement 
with previously reported pKa-values for diazeniumolates.69,100 
To conclude, an intermediate in the biosynthesis of (−)-fragin (2.80a), 
named valdiazen (2.105) was isolated and confirmed by chemical synthesis 
and X-ray crystal structure analysis. The isolated signaling molecule valdiazen 
(2.105) is racemic. 
2.4 Biosynthetic Investigations of Fragin and Valdiazen 
 
We followed a bio- and synthetic guided approach to identify possible 
intermediates in the biosynthesis of (−)-fragin (2.80a) and valdiazen (2.105). 
We first proposed biointermediates by retrosynthetic analysis of (−)-fragin 
(2.80a) and valdiazen (2.105). Synthetic samples were compared on their 
retention time and MS-pattern with the extract by HPLC-MS-analysis. 
Biological analysis and preparation of mutants were performed by Christian 
Jenul (Leo Eberl group, University of Zurich). Christophe Daeppen conducted 
synthetic aspects. Vidya Mannancherril is acknowledged for skillful technical 
support for the synthesis of biointermediates and a derivative of (−)-fragin 
(2.80a). Dr. Simon Sieber analyzed and compared the synthetic compounds 
by HPLC-MS measurements on their occurrence in the crude extracts of 
Burkholderia cenocepacia H111 knock-out strains. 
 
2.4.1  Synthesis of Biointermediates 
 
The synthesis followed a modified racemic approach as described earlier 
by Tamura and co-workers (Scheme 2.19a).91b Starting from isobutyraldehyde 
(2.86), a Henry reaction with nitromethane and a catalytic amount of 
triethylamine furnished the nitroalcohol 2.87 in 94%. The nitro function was 
reduced under catalytic hydrogenation conditions to furnish the free amine to 
                                                                                                    
100	  	  a)	   A.	  Murayama,	   S.	   Tamura,	  Agr.	   Biol.	   Chem.	   1970,	   34,	   122;	   b)	   L.	   A.	   Dolak,	   T.	  M.	   Castle,	   B.	   R.	  
	   Hannon,	  A.	  D.	  Argoudelis,	  F.	  Reusser,	  J.	  Antibiot.	  1983,	  36,	  1425.	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2.88. A peptide coupling reaction mediated by HATU and octanoic acid 
yielded the desired amide 2.89 in 79%. The alcohol was oxidized to the 
ketone 2.85 using DMP. As a side-product, the enolacetate was observed, 
which might result from a ketone protonation of the released acetic acid and 
subsequent nucleophilic attack on the acetyl moiety. IBX or neutral oxidizing 
conditions might be more suitable for this oxidation step. For our purpose, the 
obtained amount was enough to proceed further. In the last step the ketone 
2.85 was reacted with hydroxylamine hydrochloride to form the desired oxime 
2.90. Nitro groups are found along with amines and hydroxylamines and could 
be a possible intermediate.101 The nitro compound 2.108 was obtained by 
treating the oxime 2.90 with m-CPBA (Scheme 2.19b). Degradation studies by 
Tamura showed that (−)-fragin (2.80a) decomposes under acidic conditions to 
the nitroso-dimer 2.109,89 which was achieved by treating the hydroxylamine 
2.91a with m-CPBA to yield the nitroso-dimer 2.109 in a quantitative yield. 
 
Scheme 2.19: Synthesis of proposed biointermediates. a) nitromethane, Et3N, r.t., 14 h, 94%; 
b) Pd/C, H2, MeOH, r.t., 30 h, 81%; c) HATU, DIPEA, octanoic acid, CH2Cl2/DMF, 0 °C to r.t., 
24 h, 79%; d) DMP, CH2Cl2, r.t., 4 h, 46%; e) NH2OH x HCl, NaOAc, MeOH, 70 °C, 2 h, yield 
n.d.; f) Na2HPO4, crushed urea, ACN, 90 °C, 30 min, then m-CPBA, 90 °C, 2h, 54%; g)  
m-CPBA, CHCl3, 0 °C to r.t., 3 h, quant. 
 
                                                                                                    
101	  	  J.	  Franke,	  K.	  Ishida,	  M.	  Ishida-­‐Ito,	  C.	  Hertweck,	  Angew.	  Chem.	  Int.	  Ed.	  2013,	  52,	  8271.	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The synthesized intermediates were compared with the retention time and 
MS-pattern of the extracts of Burkholderia cenocepacia H111, by HPLC-MS 
analysis. The amine 2.101a, hydroxylamine 2.91a and oxime 2.90 could be 
confirmed to be present in the extract.88 However only in low quantities. 
Therefore we assume that these products might be unstable under natural 
conditions or these products arise from degradation of fragin,91b and are not 
directly involved in the biosynthesis of the natural product. 
2.4.2  Gene-Analysis  
 
The gene-analysis of Burkholderia cenocepacia was performed by 
Christian Jenul. The following genes (named as ham = human antifungal 
metabolite) were identified to be involved in the biosynthesis of fragin (2.80) 
and valdiazen (2.105) and their function are discussed in detail. 
2.4.2.1 HamA: β-Ketoacyl Synthase 
 
The enzyme is responsible for the chain growth of fatty acids. A malonate-
unit 2.110 is first decarboxylated and binds then to acetyl-moiety of the acyl-
carrier protein (ACP) 2.111 to form acetoacetyl ACP (2.112) (Scheme 
2.20).102  
       
Scheme 2.20: Biological fatty acid synthesis. 
  
                                                                                                    
102	  	  L.	  Du,	  C.	  Sánchez,	  B.	  Shen,	  Met.	  Eng.	  2001,	  3,	  78.	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2.4.2.2 HamB: Dioxygenase 
 
Dioxygenases are transferring one or two units of oxygen on a 
substrate.103 As an example is illustrated the cleavage of a diketone 2.113 to 
their corresponding carboxylic acid 2.114 and aldehyde 2.115 (Scheme 2.21) 
 
     
Scheme 2.21: Oxidoreduction reaction. 
2.4.2.3 HamC: N-Oxygenase 
 
The gene prediction for this enzyme is very similar to the enzyme AurF. 
This enzyme is able to oxidize aromatic amines to their oxyamines derivatives 
as shown in Scheme 2.22.104 The enzyme belongs to a di-manganese mono-
oxygenase species. The authors found also iron impurities (around 15%), 
which they could not exclude to be involved in the catalytic oxidation cycle.105 
AurF mediated the amine oxidation of PABA (2.116) to PHABA (2.117) and 
further to the intermediates dihydroxy amine 2.118 and nitrosobenzene 
intermediate 2.119. Latter gets oxidized by AurF to PNBA (2.120). 
Furthermore, a recombination product of PHABA (2.117) and nitrosobenzene 
intermediate 2.119 was identified as azoxybenzene-4,4'-dicarboxylic acid 
(2.121). 
 
                                                                                                    
103	  	  a)	  G.	  D.	  Straganz,	  A.	  Glieder,	  L.	  Brecker,	  D.	  W.	  Ribbons,	  W.	  Steiner,	  Biochem.	  J.	  2003,	  369,	  573;	  b) 
	   G.	  D.	  Straganz,	  H.	  Hofer,	  W.	  Steiner,	  B.	  Nidetzky,	  J.	  Am.	  Chem.	  Soc.	  2004,	  126,	  12202.	  
104	  	  a)	  R.	  Winkler,	  C.	  Hertweck,	  ChemBioChem	  2007,	  8,	  973;	  b)	  Angew.	  Chem.	  Int.	  Ed.	  2005,	  44,	  4083.	  
105	  	  G.	  Zocher,	  R.	  Winkler,	  C.	  Hertweck,	  G.	  E.	  Schulz,	  J.	  Mol.	  Biol.	  2007,	  373,	  65.	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Scheme 2.22: AurF catalyzed enzymatic N-oxidation.104a PABA = p-aminobenzoate (2.116); 
PHABA = p-hydroxylaminobenzoate (2.117); PNBA = p-nitrobenzoate (2.120). 
2.4.2.4 HamD: NRPS 
 
The non-ribosomal peptide synthase NRPS (Figure 2.15) represents a 
complex with diverse functionalities. Our cluster consists of: 
 
• A: adenylation-domain (protein biosynthesis initiaton) 
• PP domain: PCP domain (thiolation)  
• R: Reductase (reduction to terminal aldehyde or alcohol) 
 
          
Figure 2.15: NRPS domain. 
2.4.2.5 HamE: Unknown 
 
The enzyme could not be assigned and the functionality in the biosynthesis 
remains unknown. 
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2.4.2.6 HamF: NRPS Condensation Domain 
 
The NRPS condensation domain is responsible for the formation of an 
amide bond 2.122, by the condensation of an amine 2.123 and thioester 
2.124 (Scheme 2.23).106  
      
Scheme 2.23: Condensation of two NRPS-bonded units. 
2.4.2.7 HamG: Aminotransferase 
 
Aminotransferases (transaminases) catalyzes the transfer of 
α-aminogroup (2.125a and 2.125b) to an acceptor such as α-keto acids 
(2.126a and 2.126b) as shown in Scheme 2.24.107 
        
Scheme 2.24: Amine transfer on a carbonyl function and vice versa. 
2.4.3 Proposed Biosynthesis of (−)-Fragin and Valdiazen 
 
Feeding experiments with labeled 13C-labeled (R)- and (S)-valine (2.95a 
and 2.95b) showed incorporation of both amino acids. This means that the 
NRPS is not selective for (R)- or (S)-valine (2.95a and 2.95b). HamF 
represents the condensation domain and might be involved in the fatty acid 
transfer. Knock-out experiments indicated that the gene hamB is not 
necessary for the production of (−)-fragin (2.80a). An explanation would be 
                                                                                                    
106	  	  E.	  S.	  Sattely,	  M.	  A.	  Fischbach,	  C.	  T.	  Walsh,	  Nat.	  Prod.	  Rep.	  2008,	  25,	  757.	  
107	  	  F.	  Kudo,	  A.	  Miyanaga,	  T.	  Eguchi,	  Nat.	  Prod.	  Rep.	  2014,	  31,	  1056.	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that hamA and hamB are involved in the preparation of valine (2.95) and are 
therefore not mandatory for the (−)-fragin (2.80a) and valdiazen (2.105) 
biosynthesis. Based on this result, a biosynthetic pathway is proposed in 
Scheme 2.25. 
 
First, valine (2.95) is attached by hamD to the NRPS to form thioester 
2.127. The free amine 2.127 is oxidized by hamC to the hydroxylamine 2.128, 
which gets condensed with an unknown nitrogen source to the 
diazeniumdiolate functional group 2.129. Out of this intermediate, two 
pathways might be possible for the synthesis of (−)-fragin (2.80a) and 
valdiazen (2.105). The reductive domain of hamD would release the molecule 
from the NRPS via an aldehyde intermediate, followed by a reduction directly 
valdiazen (2.105) would be formed.108 If hamG is acting, the free amine 2.92 
gets directly obtained via a reductive transaminase pathway. 108  The 
condensation domain hamF would finally attach the fatty acid chain on the 
amine 2.92 and the natural product (−)-fragin (2.80a) is formed. The found 
biosynthetic intermediates amine 2.101 and hydroxylamine 2.91 are probably 
formed by an early interaction of hamG and hamF by cleaving their 
corresponding amine 2.127 and hydroxylamine 2.128 on the NRPS via the 
intermediates 2.130 and 2.94. The free hydroxylamine 2.91 is then oxidized to 
the oxime 2.90. However, the gene hamE is not involved in our proposed 
biosynthetic pathway. The origin of the second nitrogen is still unclear and the 
racemic behavior of valdiazen can not be fully explained with our biosynthetic 
proposal. (−)-Fragin (2.80a) was isolated as an enantiopure material and the 
reaction of the fatty acid could be controlled by the NRPS surrounding and the 
chiral center, where only one epimer is preferred for the further synthesis of 
(−)-fragin (2.80a). The racemization itself can spontaneously take place on 
amine 2.127 or an oxidation could lead to an imine 2.131 intermediate and 
subsequently reduced back to the amine 2.127 in a non selective fashion as 
shown in Scheme 2.25. 
 
                                                                                                    
108	  	  Y.	  Li,	  K.	  J.	  Weissman,	  R.	  Müller,	  J.	  Am.	  Chem.	  Soc.	  2008,	  130,	  7554.	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Scheme 2.25: Proposed biosynthesis of (−)-fragin (2.80a), valdiazen (2.105), amine 2.101, 
hydroxylamine 2.91 and oxime 2.90. 
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2.5 SAR-Studies of Fragin and Valdiazen 
 
Several derivatives were synthesized and tested on their biological 
behavior. Christian Jenul performed the biological aspects (gene-sequencing 
and biological activity tests). Christophe Daeppen synthesized the fragin 
analogues. Vidya Mannancherril is acknowledged for the synthesis of a fragin 
derivative. 
2.5.1  Derivative Synthesis 
 
With the natural product in our hand, we were interested in the fragment, 
which is responsible for the antifungal activity. We started a SAR-study 
program by modifying the amino acid and fatty acid chain moiety. We further 
extended and investigated on the activity scope. The synthesis involved the 
same strategy as for the total synthesis of (−)-fragin (2.80a) and only 
modifications or problems will be discussed in detail. 
 
We started with the modification of the apolar amino acid residue by 
replacing the isopropyl function with other proteogenic amino acid (Scheme 
2.26). Starting from the corresponding Fmoc-protected amino acids the 
ammoniumchloride salts 2.132a-d were synthesized according to the 
procedure of Liskamp92 using the modified conditions as described for the 
total synthesis of (−)-fragin (2.80a). The attachment of the fatty acid 2.133a-d 
as well as the free amine intermediates 2.134a-d were achieved in good 
yields and purity. The synthetic sequence proved to be robust also for other 
derivatives so far. However, huge variation in the reproducibility and yields 
were observed for the N-oxidation step. Unfortunately, the nucleophilic attack 
of the free amine 2.134d occurred on the carbonyl and not on the peroxide 
moiety. The missing steric hindrance of the lacking alkyl functionality might 
support an attack on the peroxide moiety. Nevertheless, the molecules 
2.135a-c could be isolated in moderate yields. Due to the known instability of 
hydroxylamines, their isolation was omitted and the crude product was directly 
treated with isopentyl nitrite under basic conditions and the desired derivatives 
2.136a and 2.136b were obtained in good yields. To our surprise, the 
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phenylalanine-analogue 2.136c proofed to be unstable and was omitted for 
further studies. 
 
Scheme 2.26: Synthesis of amino-fragin-derivatives. a) octanoyl chloride, DIPEA, DMAP, r.t., 
14 h; b) AlCl3, toluene, r.t., 3.5 h; c) dibenzoylperoxide, K2HPO4, THF, r.t., 21 h; d) N2H4 x 
H2O, EtOH, r.t., 2.5 h, then isopentyl nitrite, NH3(g), EtOH, r.t., 0.5 h. 
 
The fatty acids chain modifications (Scheme 2.27) were attached on the 
ammonium salt intermediate 2.99a and the amides 2.137a-c were obtained in 
good yields. The deprotection only worked for the substrates 2.137a and 
2.137b to the corresponding free amine 2.138a and 2.138b. The other Fmoc-
deprotection attempts using the elaborated AlCl3 initiated Fmoc-deprotection 
for the substrates 2.137c were not successful. No product could be isolated 
as well as NMR-analysis of the crude showed only starting material or 
decomposition. The substrate was not soluble in toluene, not even under high 
temperature or when additional AlCl3 was added. The same insolubility was 
observed when standard conditions (piperidine or DBU) were used. We did 
not investigate further attempts for the deprotection of 2.137c. The  
N-oxidation yielded the desired products 2.139a and 2.139b and upon 
benzoyl cleavage the hydroxylamine was used as crude without further 
purification. The crude was directly treated with isopentyl nitrite to the desired 
fatty acid chain modified molecules 2.140a and 2.140b. 
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Scheme 2.27: Synthesis of fatty acid-fragin-derivatives. a) octanoyl chloride, DIPEA, DMAP, 
r.t., 14 h, b) AlCl3, toluene, r.t., 3.5 h; c) dibenzoylperoxide, K2HPO4, THF, r.t., 21 h; d) N2H4 x 
H2O, EtOH, r.t., 2.5 h, then isopentyl nitrite, NH3(g), EtOH, r.t., 0.5 h. 
 
Scheme 2.28 shows synthetic analogues of (−)-fragin (2.80a). Methylation 
using Me2SO4 and Na2CO3 as the base afforded the methylated-fragin 2.141 
in a good yield. (Scheme 2.28a) The amide functionality 2.100a was tried to 
be modified by an N-alkylation to form the methylated amide 2.142, however it 
was not successful under the used conditions109 and only the starting material 
could be recovered. Also under higher temperature, the molecule remained 
untouched (Scheme 2.28b). Steric hindrance from the Fmoc- and isopropyl 
part could inhibit the further transformation. It was also tried to replace the 
amide by an ester moiety (Scheme 2.28c). For this purpose, (−)-valdiazen 
(2.105a) was treated with octanoyl chloride and DIPEA to afford ester-fragin 
2.143, but only decomposition of the starting material was observed. The use 
of a coupling reagent might be more suitable for the sensitive 
diazeniumdiolate function.  
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  Q.	  Xia,	  X.	  Liu,	  Y.	  Zhang,	  C.	  Chen,	  W.	  Chen,	  Org.	  Lett.	  2013,	  15,	  3326.	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Scheme 2.28: Miscellaneous modifications. a) Me2SO4, Na2CO3, MeOH, 0 °C – r.t., 2.5 h, 
71%; b) di-tert-butyl peroxide, Cu(I)Cl, chlorobenzene, 130 °C, 12 h; c) octanoyl chloride, 
DIPEA, DMAP, 14 h, r.t. 
 
Initial results indicated an interaction of (−)-fragin (2.80a) with copper in a 
biological system.110 We were highly interested in the complexing behavior of 
the natural products (−)-fragin (2.80a) and the ammonium derivative of 
valdiazen (2.105c)111 to copper-metals and treated the corresponding natural 
products with Cu(OAc)2 to obtain Cu-fragin (2.144)90 and Cu-valdiazen 
(2.145) as blue solids (Scheme 2.29). Both tetradendate Cu-complex 
structures 2.144 and 2.145 were secured by X-ray crystal analysis (Scheme 
2.29). A closer look on both crystal structures showed again the expected cis-
conformation for the diazeniumdiolate group. The point group is C2 for both 
structures. The arrangement of the ligands needs a few comments. Ligand 
exchanges in square planar complexes follow associate (SN2-type) or 
dissociative (SN1-type) mechanisms. After incorporation of the first ligand, the 
attack of the 2nd ligand can be influenced by the first ligand via the trans- or 
cis-effect. Such effects can be derived from crystal structure analysis by 
                                                                                                    
110	  	  In	  collaboration	  with	  Dr.	  Dominic	  Hoepfner	  (Novartis	  Pharma	  AG),	  unpublished	  results.	  
111	  	  The	  ammonium	  salt	  is	  directly	  obtained	  as	  crude	  without	  further	  basic	  and	  acidic	  treatment.	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estimation of the bond lengths in the crystal. The measured bonds are 
indicating shorter bonds for one diazeniumdiolate unit and longer bonds for 
the second diazeniumdiolate ligand. A clear indication cannot be derived from 
the bond lengths. If the focus is laid on the metal center and less on the ligand 
surrounding, a covalent bonded oxygen (1st ligand) is trans to a coordinating 
oxygen of the 2nd ligand. Electronic effects probably influence the 
arrangement of the ligands, which would indicate a trans-effect. 112  The  
UV-VIS spectra showed a maxima at 238 nm for Cu-fragin (2.144) and 237 
nm for Cu-valdiazen (2.145).  
  
                                                                                                    
112	  	  a)	  F.	  R.	  Hartley,	  Chem.	  Soc.	  Rev.	  1973,	  2,	  163;	  b)	  J.	  V.	  Quagliano,	  L.	  Schubert,	  Chem.	  Rev.	  1952,	   50,	  
	   201.	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Scheme 2.29: Synthesis of Cu-complexes 2.144 and 2.145 with (−)-fragin (2.80a) and 
valdiazen (2.105c) as ligands. a) Cu(OAc)2, MeOH, r.t., 18 h, 91%; b) Cu(OAc)2, MeOH, r.t., 
15 h, 98%.  
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2.6 Biological Activity of Fragin- and Valdiazen-Derivatives 
 
The biological activity tests were performed by Christian Jenul (Leo Eberl 
group, University of Zurich). All synthesized and tested derivatives are 
summarized in Figure 2.16. The effect of the stereocenter of fragin (2.80a and 
2.80b) and the diazeniumdiolate in its free methylated form 2.141 was tested 
(Figure 2.16a). The length of the fatty acid chain was shortened 2.140a and 
enlarged 2.140b (Figure 2.16b) as well as the amino acid residue was 
modified to a methyl-2.136a and an isobutyl group 2.136b (Figure 2.16c). 
Valdiazen derivatives 2.105a and 2.105b were focused on the influence of the 
stereogenic center (Figure 2.16e). Cu-fragin complex (2.144, Figure 2.16d) 
and Cu-valdiazen complex (2.145, Figure 2.16f) were tested, if the 
diazeniumdiolate ligands will keep their activity bound in a complex. 
 
Figure 2.16: Overview of tested compounds in the bioassay. 
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A plate diffusion test was performed to evaluate the biological activity on 
Gram-positive (Bacillus cereus, Staphylococcus aureus) and Gram-negative 
bacteria (Pseudomonas putida, Escheria coli, Klebsiella oxytoca). These 
strains are either pathogenic or often found in the environment. The biological 
activities of the fragin (2.80a and 2.80b) and valdiazen (2.105) analogues are 
summarized in table 2.3 (triplicates were conducted and the mean value was 
taken). 
 
 Gram-pos. bacteria Gram-neg. bacteria 
Derivative  B. cereus S. aureus P. putida E. coli K. Oxytoca 
2.80a       
2.80b       
2.140a       
2.140b       
2.136a       
2.136b       
2.141       
2.144       
2.105a       
2.105b       
2.145       
Table 2.3: Activity test of fragin and valdiazen analogues (color code: green = 16 µg/ml, blue 
= 32 µg/ml, yellow = 64 µg/ml, orange = 128 µg/ml, red = no activity). 
 
The tested diazeniumdiolates analogues and natural products (2.80a, 
2.80b, 2.105a, 2.105b, 2.136a, 2.136b, 2.140a, 2.140b, 2.141, 2.144, 2.145) 
are not active against Gram-negative or only moderate against E. coli. 
Inhibition was observed for Gram-positive bacteria. Most interesting the chiral 
center has no influence on the activity (R)- and (S)-fragin (2.80a and 2.80b), 
which was also the case for other chiral biological active  
C-diazeniumdiolates.68 A closer look on the variable amino acid residue 
revealed comparable activity values for leucin-analogue 2.136b and a 
decreased activity for alanine-analogue 2.136a. A reason could be steric or 
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hydrophobic effects of the compounds. Based on an off-enzyme activity 
proposal, the amino acid residue is probably important for solubility or 
permeability reasons. This is also underlined for the shortened fatty acid 
analogue 2.140a, which shows much less activity compared to the natural 
product 2.80a. The elongated fatty acid product 2.140 has comparable activity 
to both fragin analogues (2.80a and 2.80b). Fatty acid chains have important 
biological activities as they are involved in biofilm formation, 113  quorum 
sensing 114  or bioactive lipid mediators such as prostaglandins, 115  which 
influences invasive cancer progression, eicanosoids116 with anti-inflammatory 
properties or sphingolipids 117  known for signaling and regulations in cell 
growth and death.  
 
The methylated fragin 2.141 was totally inactive, which showed to be a 
strong indication that the diazeniumdiolate function must be the activity giving 
part of the molecule. The mode of action is unknown but cellular stress, due to 
complexation event might be a reason. In contrast, the Cu-fragin complex 
2.144 is as well active. The results are in good agreement on earlier studies 
on the natural product dopastin (2.72).68 The authors could demonstrate that 
dopastin (2.72) binds to a copper-enzyme and inhibits further reactions of the 
enzyme. Competing effects by adding CuII-salts showed no decrease in 
dopastin (2.72) activity, which suggest a preferred copper-enzyme affinity 
than to free CuII-salts, which could arise from a hydrophobic surface 
interaction of the enzyme. Surprisingly, the biointermediates (R)- and (S)-
valdiazen (2.105a and 2.105b) as well as the Cu-valdiazen complex 2.145 are 
                                                                                                    
113	  	  C.	  N.	  H.	  Marques,	  D.	  G.	  Davies,	  K.	  Sauer,	  Pharmaceuticals	  2015,	  8,	  816.	  
114	  	  a)	  W.	  T.	  Watson,	  T.	  D.	  Minogue,	  D.	  L.	  Val,	  S.	  Beck	  von	  Bodman,	  M.	  E.	  A.	  Churchill,	  Mol.	  Cell	  	  2002,	  
	   9,	  685;	  b)	  C.	  M.	  Waters,	  B.	  L.	  Bassler,	  Annu.	  Rev.	  Cell	  Div.	  Biol.	  2005,	  21,	  319.	  
115	  	  a)	  D.	  G.	  menter,	  R.	  N.	  DuBois,	   Int.	  J.	  Cell	  Biol.	  2012,	  doi:10.1155/2012/723419;	  b)	  K.	  K.	  Mubarak,	  
	   Respiratory	  Medicine	  2010,	  104,	  9.	  
116	  	  a)	   E.	   A.	   Dennis,	   P.	   C.	   Norris,	  Nature	   Reviews	  2015,	  15,	   511;	   b)	   D.	   Stanley,	  Annu.	   Rev.	   Entomol.	  
	   2006,	  51,	  25.	  
117	  	  a)	   Y.	   A.	   Hannun,	   L.	  M.	   Obeid,	  Nature	   Reviews	   2008,	   9,	   139;	   b)	   R.	   P.	   Rao,	   N.	   Vaidyanathan,	  M.	  
	   Rengasamy,	   A.	   M.	   Oommen,	   N.	   Somaiya,	   M.	   R.	   Jagannath,	   Journal	   of	   Lipids	   2013,	  
	   http://dx.doi.org/10.1155/2013/178910.	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inactive for Gram-positive and Gram-negative bacteria. The more hydrophilic 
character was probably not able to enter the cell, which is underlined by the 
fact that the other tested fatty acid containing diazeniumdiolates are active for 
Gram-positive bacteria. Thus, the fatty acid chain might play an important roll 
in cellular uptake and penetration.  
2.7 Conclusion and Outlook 
 
In this chapter, the first enantioselective total synthesis of the natural 
product (−)-fragin (2.80a), a rare C-diazeniumdiolate containing molecule, was 
achieved in eight steps and an overall yield of 13%. The stereocenter could 
be assigned by chiral HPLC measuring to be (R)-configured. SAR-studies on 
(−)-fragin (2.80a) showed activity against Gram-positive and no activity 
against Gram-negative bacteria. The methylated diazeniumdiolate analogue 
2.141 yielded in a complete inactivity, which shows that the diazeniumdiolate 
functional group is a main actor for antibiotic activity on Gram-positive 
bacteria. The cellular uptake is influenced by the hydrophobic surrounding, 
where an activity for all tested linear fatty acid chains 2.140a-b and 
hydrophobic amino acid residues 2.136a-b could be observed, but not for 
more polar sidechains (2.105a-b). A significant NO-release could not be 
observed by fluorescence spectroscopy. 
 
Investigations on the biosynthesis of (−)-fragin (2.80a) brought a novel  
C-diazeniumdiolate compound, named valdiazen (2.105). The structure was 
elucidated by NMR-analysis and proofed by an enantioselective two step 
synthesis. The chiral center was determined by chiral-HPLC and compared 
with enantiopure synthetic (R)- and (S)-valdiazen (2.105a and 2.105b), 
indicating that natural occurring valdiazen (2.105) is racemic. The compound 
showed no activity against Gram-positive and Gram-negative bacteria, 
probably due to the polar hydroxy group, which makes a cellular uptake not 
feasible. 
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A biosynthesis of (−)-fragin (2.80a) and valdiazen (2.105) was proposed 
based on labeled feeding experiment, isolation and characterization of  
(−)-fragin (2.80a) and the biosynthetic intermediate valdiazen (2.105). Feeding 
experiments with 13C-labeled (R)- and (S)-valine (2.105a and 2.105b) showed 
incorporation of both starting materials in the biosynthesis. However,  
(−)-fragin (2.80a) was isolated as enantiopure material and indicates that the 
attachment of the fatty acid part is preferred for one of the enantiomers. The 
synthesis of the diazeniumdiolate group is proposed to occur on the NRPS-
cluster and then reductively cleaved to obtain valdiazen (2.105) or further 
condensated a fatty acid to form (−)-fragin (2.80a). 
 
Cu-complexes of (−)-fragin (2.80a) and (−)-valdiazen (2.105a) were 
synthesized and secured by X-ray crystal structure analysis showing a 1:2 
(host:guest) fashion. Applications of C-diazeniumdiolates should therefore be 
further investigated and considered as useful agents in metal-dependent 
diseases. The synthesis of bis-diazeniumdiolate molecules would probably 
increase the binding affinity and their applications for diseases and infection 
treatment should be tested.
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3 Synthetic Studies Towards Nor-Sesquiterpenoid 
(2R)-Hydroxynorneomajucin 
 
3.1 Neurodegenerative Diseases 
 
The use of modern technology and pharmaceutical drugs have changed 
the way today’s society lives. These circumstances have been greatly 
influenced by chemistry-based inventions like vaccines, insulin, caffeine, 
antibiotics or vitamins. An increased life expectancy has progressed from 48 
years in the mid-20th century, to around 70 years today and an anticipated 
age of 76 years by the mid-21st century. 118  As a consequence, 
neurodegenerative diseases have become a serious health problem. The 
common feature of all neurodegenerative diseases is the degradation of 
neurons and therefore a slowly progressive loss of memory and cognitive 
functions. Today, over 46 million people are affected by dementia and that 
number is expected to increase to around 130 million by the year 2050.119 
This has an huge effect on health cost, which is estimated to be around 818 
billion US-dollars and will further increase to a trillion by the year 2018. Mostly 
older people are affected by dementia. In the year 2010, around 4.7 million 
elderly people in the US were affected by dementia (> 65 years). This number 
will increase in the next years by a factor of three. Figure 3.1 shows the 
dementia distribution over the ages and demonstrates that dementia is 
associated or more evolved for the elderly.  
  
                                                                                                    
118	  	  G.	   W.	   Leeson,	   International	   Journal	   of	   Population	   Research	   2014,	   Article	   ID	   521523,	  
	   doi:10.1155/2014/521523.	  
119  Alzheimer’s	  Disease	  International:	  World	  Alzheimer	  Report	  2015. 
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Figure 3.1: Age dependency for Alzheimer’s disease evolution. 
 
A successful treatment or therapy for neurodegenerative diseases has not 
been discovered even until today. Medications were developed to suppress 
symptoms and to increase life expectancy. The reason for the development of 
neurodegenerative diseases is still not fully understood. The most known 
diseases are Alzheimer’s, Parkinson’s, Huntington’s diseases and 
amyotrophic lateral sclerosis (ALS). 
3.1.1  Alzheimer’s Disease 
 
Alzheimer’s disease is the most common neurodegenerative disease.119 It 
was named and discovered after the german physician Dr. Alois Alzheimer, 
who discovered the disease in 1906. He observed a slow memory and that 
the cognitive function control worsened over time. He could prove his 
hypothesis by a postmortem brain analysis of a patient. He observed on the  
outside of neurons a collection of dense deposits or plaques and bands of 
fibres or tangles within the brain cells. An observation, which is still accepted 
as the definition for developing Alzheimer’s. Today, the “plaques” have been 
identified as an accumulation of the protein fragment, β-amyloid (40-42 amino 
acids long), outside neurons in the brain and “tangles” as twisted strands of 
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the protein tau inside neurons.120 A consequence of such aggregations is the 
damage or death of neurons.121  
3.1.2  Parkinson’s Disease 
 
Parkinson’s disease was first described by the english doctor James 
Parkinson in 1817 in his essay on shaking palsy, and later refined by Jean-
Martin Charcot.122 The disease is defined by an evolving movement disorder 
caused by a dopamine deficiency (death of dopaminergic neurons).123  A 
common way to treat Parkinson’s is to stimulate dopamine receptors.124 It is 
considered that environmental and genetic factors are the main factors for 
Parkinson’s disease, which makes an early diagnosis difficult. 125  Several 
genes 126  involved in oxidative stress, mitochondrial and proteosomal 
dysfunction were identified. 127  Disease characteristics include protein 
aggregrates128 (α-synuclein with unknown function) inside nerve cells and the 
so-called Lewy bodies, discovered by the German-American neurologist 
Frederic Lewy in 1912. 
  
                                                                                                    
120	  a)	  G.	  B.	  Irvine,	  O.	  M.	  El-­‐Agnaf,	  G.	  M.	  Shankar,	  D.	  M.	  Walsh,	  Mol.	  Med.	  2008,	  14,	  451;	  b) A.	  Kumar,	  
	   A.	   Singh,	   Ekavali,	   Pharmacol	   Rep	   2015,	   67,	   195;	   c)	   H.	   W.	   Querfurth,	   F.	   M.	   LaFerla,	  N.	   Engl.	   J.	  
	   Med.	  2010,	  362,	  329.	  
121	   Alzheimer’s	   Association.	   2015	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   Facts	   and	   Figures.	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   &	   Dementia	  
	   2015,	  11,	  332.	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  C.	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  2011;	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  a008862.	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  2016,	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  Gasser,	  C.	  G.	  Goetz,	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  Piccini.	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   Schapira,	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  2011,	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  Kalia,	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  Lang,	  Lancet	  2015,	  386,	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   Klein,	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   Schlossmacher,	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   Clin.	   Pract.	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   2006,	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   136;	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   Klein,	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   Westenberger,	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   Spring	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  Dauer,	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  889.	  
128	  	  G.	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3.1.3  Huntington’s Disease 
 
Huntington’s disease was first described by George Huntington in 1872.129 
Mutations in the gene huntingtin yield an abnormally formed huntingtin 
protein. Characteristics include is a higher number (>36) of the N-terminal 
glutamine residue in the protein (encoded by the gene sequence cytosine-
adenine-guanine (CAG)).130 It acts directly as Huntington’s disease indicator 
and predictor for Huntington’s disease evolution (polyglutamic chain 
determines if a person will develop Huntington’s disease).131 The disease is 
hereditary and normally cognitive, motor, and psychiatric changes are 
observed. So far, only symptomatic drug treatments could be developed.132 
3.1.4  Amyotrophic Lateral Sclerosis 
 
Amyotrophic lateral sclerosis (also known as Lou Gehrig’s diseases, ALS 
or Charcot’s disease, named after it’s discoverer Jean-Martin Charcot) is a 
motor neuron disease that affects the nervous and muscles systems and 
yields in atrophy and weakness, spasticity and fasciculation. The origin of the 
disease is unknown, but might be influenced by failure in proteostasis, which 
results in protein misfolding133 and cellular stress.134 Identifications of several 
related genes and proteins support this fact, such as mutations in SOD1 
(copper/zinc ion-binding superoxide dismutase).135  
  
                                                                                                    
129	  	  Huntington,	  G.	  On	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  320.	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  83.	  
133	  	  S.	  Saxena,	  P.	  Caroni,	  Neuron	  2011,	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  2011,	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3.1.5  Neurotrophins 
 
The discovery of neurotrophins enabled the development of novel methods 
and strategies in neurobiology. The most prominent molecule is the nerve 
growth factor (NGF), first described by Elmer Bueker 136  and further 
investigated by Rita Levi-Montalcini and Stanley Cohen.137 NGF is a protein 
complex (130 kDa) of three subunits: α-NGF, β-NGF and γ-NGF, where only 
the β-subunit (dimeric polypeptdide chain, 2 x 13 kDa) is responsible for 
neuroninduction. 138  This protein is responsible for the survival and 
proliferation of neuronal cells. In 1986, both scientists were awarded with the 
Nobel Prize in Physiology and Medicine for their discovery of growth factors. 
The term “neurotrophin” was introduced by Levi-Montalcini and her mentor 
Viktor Hamburger as a molecule, which induces cell survival or proliferation. 
NGF was then considered as a potential treatment source for Alzheimer’s and 
related neurodegenerative diseases,139  where a common lack of NGF is 
observed.140 
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  E.	  D.	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  V.	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  Proc.	  Nat.	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  Sci.	  1954,	  40,	  1014;	  b)	  S.	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  Proc.	  Nat.	  Acad.	  Sci.	  1956,	  42,	  571;	  c)	  S.	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  Biochemistry	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  46,	  302;	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  R.	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  U.	  Angeletti,	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  1968,	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  534;	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   1987,	  237,	  1154.	  
138	  	  a)	  E.	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  Shooter,	  Ann.	  Rev.	  Neurosci.	  2001,	  24,	  601;	  b)	  M.	  V.	  Sofroniew,	  C.	  L.	  Howe,	  W.	  C.	  Mobley,	  
	   Ann.	  Rev.	  Neurosci.	  2001,	  24,	  1217.	  
139	  	  F.	  Hefti,	  W.	  J.	  Werner,	  Ann	  Neurol.	  1986,	  20,	  275.	  
140	  	  F.	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  Ann.	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  1983,	  13,	  109.	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3.1.6  Receptors and Signaling Pathways 
 
The involved enzymes, genes, pathways or other factors in 
neurodegeneration are by far more complex and still not fully understood. 138b, 
141 A simplified signaling pathway is shown in Figure 3.2. Neurothrophins such 
as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), 
neurotrophin 3 (NT3), neurotrophin 4 (NT4) or small molecules bind or interact 
with Trk (tropomyosin receptor kinase) or p75NTR (p75 neurotrophin receptor). 
Each TRK receptor binds selectively to a neurotrophin. NGF binds to TRKA, 
BDNF and NT4 bind to TRKB and NT3 binds to TRKC.142 This interaction 
activates several cascades,143 such as the phosphoinositide 3-kinase (PI3K)–
AKT pathway 144 , nuclear factor-κB (NF-κB), 145  mitogen-activated protein 
kinase (MAPK)146 and the JUN N-terminal kinase (JNK).147 TRK signaling is a 
tyrosine kinase-mediated pathway and promotes neurite outgrowth or cell 
survival.148 The p75NTR pathways are more complex and involve cell survival, 
as well as cell death (apoptosis). The signaling pathway is influenced by the 
receptor expression and intracellular mediators and factors. GSK3 is a cell 
proliferation inhibitor and is often referred to as a potential target for future 
drug development in neurodegenerative149 and other diseases.150  
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Figure 3.2: Neurotrophic cell signalling pathways; MAPK (mitogen-activatd protein kinase); 
Grb2 (Growth factor receptor-bound protein 2); Gab1 (GRB2-associated-binding protein 1); 
mTOR (mechanistic target of rapamycin); PI3K (phosphoinositide 3-kinase); Akt (Protein 
kinase-B (PKB)); IKKβ (inhibitor of nuclear factor kappa-B kinase subunit beta); NF-κB 
(nuclear factor-κB); JNK (JUN N-terminal kinase); TRK (tropomyosin receptor kinase); p75NTR 
(p75 neurotrophin receptor); GSK-3β, glycogen synthase kinase-3β; IRAK, interleukin-1 
receptor-associated kinase; NADE, p75NTR-associated cell death executor (NGFR); NRAGE, 
neurotrophin receptor-interacting MAGE homologue; NRIF, neurotrophin receptor-interacting 
factor; SHC, SRC homology domain-containing protein; TRAF6, TNF receptor-associated 
factor 6.  
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3.1.7  Natural Products as Potential Neuropharmaceuticals 
 
Neuroinduction can be achieved by the stimulation of neurotrophin 
production or direct stimulation of a neurotrophin receptor (Trk or p75NTR). 
However, a common problem in neurodegenerative treatment with potential 
agents is their stability towards physiological conditions, as well as their ability 
to cross the blood-brain-barrier (BBB)151 where neuroinduction should ideally 
take place. The BBB is a highly selective permeable barrier (filter)152 which 
prevents toxines, pathogens153 and other compounds to enter the brain.154 
Furthermore, it separates the blood circulation from the central nervous 
system. Molecules, which contain a certain mass (>400 Da) and consist of 
eight or more hydrogen bonds are not able to pass this barrier155 or have to 
be delivered via an active transport pathway.156 100% of large-molecules and 
<98% of small molecule drugs are not able to cross the blood-brain-barrier. 
Therefore there is a great interest to overcome this issue by using small 
organic molecules. Natural products are interesting lead structures as potent 
candidates.157 Figure 3.3 shows an overview where natural products are used 
in neurodegenerative disease treatment. 158  It has to be mentioned that 
Alzheimer’s is the most common neurodegenerative disease and therefore, of 
particular interest for the pharmaceutical industry and society. 
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Figure 3.3: Natural Products and their applications in neurodegenerative disease 
treatment.158 
Figure 3.4 illustrates the isolation source of natural products, which is 
dominated by plants.158 The huge variability and number of plants makes 
them still one of the most interesting natural product sources. Nevertheless, 
fungi and bacteria bear enormous potential for drug discovery and are 
surprisingly less explored or considered. 
    
Figure 3.4: Origin of natural products.158 
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However, small quantities are obtained from isolation and makes further 
exploration of their potential as future anti-neurodegenerative drugs 
challenging. Chemists all over the world took into account this problem and 
work to provide various strategies towards these rather complex structures. 
The duty of total synthesis allows further an entry into the discovery of natural 
products analogues through SAR-studies. Figure 3.5 summarizes several 
very important isolated structures from nature, accessed through total 
synthesis. 
 
Figure 3.5: Neurotropic active natural products. 
 
Polyprenylated acylphloroglucinols are charachteristic for their 
bicyclo[3.3.1]nonatrione motif and several groups have put their attention on 
it’s complex structure such as garsubellin A (3.1).159 Merrilactone A (3.2) is 
one of the most prominent molecules in neurodegenerative field and was 
isolated from the dried pericarps of Illicium merrillianum by Fukuyama and co-
workers in 2000.160 Merrilactone A (3.2) promotes neurite outgrowth in fetal 
rat cortical neurons at a concentration range of 0.1-10 µM. It’s high potency 
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  Tetrahedron	  Lett.	  2000,	  41,	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and unique structural oxetane feature clearly put this molecule in the focus of 
several natural product scientists.161 Huperzine A (3.3) was isolated162 in 1986 
from the club moss Huperzia serrate and showed to act as a potent AChE 
inhibitor (82 nM). 163  This rather simple molecule consists of a complex 
molecular scaffold, which could be achieved by racemic and enantioselective 
syntheses.164 
 
The Gademann group has contributed several neurotrophic natural 
products by total synthesis and investigated the neurite inducing properties of 
them. An extensively studied compound is militarinone D (3.4),165 isolated 
from the mycelial extract of the entomopathogenic fungi Paecilomyces 
militaris by Hamburger and co-workers.166 Comparable NGF activity (20 µM) 
and no cytotoxicity in PC12 cells using a lactate dehydrogenase assay was 
observed. The initial screening indicates that the activity is not linked to the 
length or the absolute configuration of the side chain. This study was then 
extended and truncated analogues were prepared for SAR-studies. 167 
Interestingly, the study showed that indeed the fatty acid part is not 
responsible for the activity and the 4’-hydroxy function of the aromatic moiety 
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is essential for the activity. These so called truncated analogues were shown 
to be equal or more potent as the natural lead structure 3.4.168  
 
Withanolide A (3.5) was isolated from Withania somnifera (“Ashwagandha” 
in Ayurveda or Indian ginseng), a plant used in traditional Indian medicine. A 
total synthesis169 and SAR-studies170 were performed and the activity was 
tested on human SH-SY5Y cells. These studies could identify slightly more 
potent withanolide analogues and concluded that the size rather than the 
functionality attached on the A-ring is important. 
 
Gelsemiol (3.6) posseses an iridoid171  structure and was isolated from 
Gelsemium sempervirens (Gentianales) 172  and analogues from Verbena 
littoralis (Lamiales).173 The enantioselective total synthesis was achieved in an 
impressive nine step synthesis with an overall yield of 14%.174 Gelsemiol 
induced neurite outhgrowth moderately. In contrast, it showed a higher 
potency in combination with NGF as the sole NGF control. 
Furthermore, several molecules are already approved by the FDA for 
neurodegenerative disease treatments and available on the market, as shown 
in Figure 3.6. Rivastigmine (3.7) is a reversible cholinesterase inhibitor used 
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for mild to moderate Alzheimer diseases.175 Memantine (3.8) acts as a NMDA 
receptor inhibitor (glutamate-agonist) and used in the treatment of moderate-
to-severe Alzheimer diseases. 176  Donepezil (3.9) is a reversible 
cholinesterase inhibitor and used for mild to moderate Alzheimer diseases.177 
 
Figure 3.6: FDA-approved anti-Alzheimer’s disease medication. 
3.1.8  A source of Natural Neuroinducers - The genus Illicium    
    (Illiciaceae) 
 
The genus Illicium contains 42 species and belongs to the family of 
Illiciaceae. Over 70% of Illicium species are found in southwestern and 
eastern Asia. The star-anise fruit (Illicium verum) is used for seasoning in 
Chinese and Southeast Asian food. 178  Most seco-prezizaane type 
sesquiterpenes were isolated from the genus Illicium. The most active 
majucin-type sesquiterpenes were isolated from Illicium jiadifengpi. The 
structure of (−)-jiadifenolide (3.10),179  jiadifenin (3.11),180  (2S)-hydroxy-3,4-
dehydro-neomajucin (3.12)180, jiadifenoxolane A (3.13),179 (2R)-hydroxynor-
neomajucin (3.14)181 and ODNM (3.15) 180 are presented in Figure 3.7. The 
neurite enhancement ability was tested in primary cultures of fetal rat cortical 
neuron cells with NGF as the positive control. 
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Figure 3.7: Neutrophic majucin-type sesquiterpenes. 
3.1.9  Biosynthesis of Seco-Prezizaane Sesquiterpenes 
 
Seco-prezizaanes have shown to be highly active as neurotropic 
mediators. Six classes are known and are distinguished by their skeletal 
scaffold 3.16 as shown in Figure 3.8. These bicyclic AB-scaffolds consist of a 
highly oxidized 15-carbon unit. The subunits are called anisatin- (3.17), 
majucin- (3.18), pseudomajucin- (3.19), pseudoanisatin- (3.20), minwanensin- 
(3.21) and cycloparvifloralone-type (3.22) sesquiterpenes. 
 
 
Figure 3.8: Seco-prezizaane classes and skeletal numbering. 
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The synthesis of terpenes (and sesquiterpenes) is derived from DMAPP 
(3.23) and IPP (3.24) and, upon condensation, farnesol pyrophosphate (FPP, 
3.25) is formed (Scheme 3.1). Releasing of the pyrophosphate moiety forms 
an allyl-cationic-species, which is attacked intramolecularly by the olefin to 
form bisabolane (3.26). The formed tertiary cation undergoes a 1,2-hydride 
shift to a cyclic tertiary cationic species (not shown). The acorane 
intermediate 3.27 is formed by a second intramolecular attack of the geminal 
methyl-containing olefin. A third rearrangement takes place, which forms the 
key intermediate allo-cedrane (3.28). Out of this structure, a variety of natural 
products are synthesized via this intermediate. Upon cleavage of the  
C-6/C-11 bond, the prezizaane (3.29) or seco-prezizaane (3.30) core 
structure is formed, from which neurotrophic active molecules are formed 
such as anisatin (3.17) or majucin (3.18).182 
 
Scheme 3.1: Biosynthesis of seco-prezizaane type structures. 
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3.2 Previous Total Syntheses of Majucin-Type       
   Sesquiterpenes  
3.2.1  Danishefsky’s Total Synthesis of (±)-Jiadifenin 
 
Danishefsky and co-workers published the first total synthesis of a majucin-
type natural product in 2004. They could achieve the total synthesis of (±)-
jiadifenin (3.11) in 18 linear steps with an overall yield of 1.9%  
(Scheme 3.2). 183  The synthesis started with the commercially available 
cyclohexanone 3.31, which represents the B-ring of the natural product. A 
desymmetrization of 3.31, was achieved by methylation with MeI, followed by 
hydroxymethylation with formaldehyde to install the β-hydroxy group, which 
was directly TBS-protected to afford 3.32 in 64% yield over three steps. A 
sequential allylation and carboethoxymethylation yielded the ester 3.33 in a 
diastereomeric ratio of 3:1. Conversion of the ester moiety to a  
β-ketophosphonate followed by an intramolecular HWE-reaction and global 
deprotection furnished the desired cyclopentenone 3.34. The C-ring lactone 
was achieved by an intramolecular Claisen-condensation. Oxidation with  
m-CPBA afforded the α-hydroxylated β-ketolactone and subsequent ketone 
reduction with NaBH4 furnished the alcohol in a completely diastereoselective 
manner. Methylation at C-1 followed by ozonolysis of the terminal alkene and 
subsequent Jones oxidation led to the ABCD bislactone ring system 3.35. A 
Luche reduction of the enone, followed by a α-hydroxylation of the D-ring 
using Davis’s oxaziridine afforded the α-hydroxy-lactone and finally a Jones 
oxidation afforded the natural product (±)-jiadifenin (3.11).  
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Scheme 3.2: Total synthesis of (±)-jiadifenin (3.11) by Danishefsky and co-workers. a) 
LiHMDS, THF, –78 °C, MeI, –78 °C to r.t.; b) 10% KOH, MeOH, aq. HCHO, 0 °C; c) TBSOTf, 
2,6-lutidine, CH2Cl2, 0 °C, 64% (over three steps); d) LiHMDS, THF, –78 °C; allyl bromide,  
–78 °C to r.t., 73%; e) LDA, THF, –78 °C to –20 °C, BrCH2CO2Et, HMPA, –78 °C, 97%, d.r. = 
3:1; f) LiCH2P(O)(OMe)2, THF, –78 °C, 81%; g) NaH, THF, reflux, 91%; h) 2 M HCl, THF, 
94%, i) ClCO2Et, py, DMAP, CH2Cl2, 0 °C to r.t., 93%; j) NaH, THF, reflux, 94%; k) m-CPBA, 
CH2Cl2, 90%; l) NaBH4, THF/MeOH (1:1), –78 °C, 93%; m) LDA, THF, –40 °C to –15 °C, MeI, 
HMPA, –35 °C, 64% (over two steps); n) O3, Sudan 7B Red, CH2Cl2/EtOH (1:1), –78 °C; o) 
Jones reagent, acetone, 90%; p) NaBH4, CeCl3 x 7 H2O, THF/MeOH (3:1), –65 °C, 88%; q) 
NaHMDS, THF, –78 °C, Davis’ oxaziridine, THF, –78 °C, 42% (over two steps); r) Jones 
reagent, acetone; MeOH, 40%. 
3.2.2  Zhai’s Enantioselective Total Synthesis of (–)-Jiadifenin 
 
Zhai and co-workers reported on an enantioselective route to (–)-jiadifenin 
(3.11, Scheme 3.3).184 The allylic bromide 3.36 was first treated with lithiated 
propyne to form the enyne 3.37, followed by a Sharpless asymmetric 
dihydroxylation to the diol in 93% ee, which was protected by an acetal group 
to the dioxolane. The PMP-protecting group was cleaved and the free alcohol 
was oxidized under Jones conditions to the carboxylic acid. An esterification 
with the alcohol 3.38 furnished precursor 3.39, ready for the Ireland-Claisen 
rearrangement (d.r. = 7:1). An acid-promoted lactonization, followed by 
dioxolane deprotection and TBS protection of the secondary alcohol furnished 
the enyne 3.40. An intramolecular Pauson-Khand reaction formed the 
cyclopentenone, which was irradiated in the presence of allene to form the  
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[2 + 2] photoadduct 3.41. An ozonolysis with NaOMe cleaved the terminal 
olefin to the methyl ester and the enone 3.42 was formed via a Saegusa-Ito 
reaction. Silyl deprotection using TBAF yielded directly in the lactone, which 
was α-hydroxylated in the presence of NaHMDS and Davis’ oxaziridine to 
form lactone 3.43. Finally, Jones oxidation furnished (−)-jiadifenin (3.11) in 18 
steps and 0.7% overall yield from allylic bromide 3.36. 
 
Scheme 3.3: Zhai’s synthesis of (−)-jiadifenin. a) 1-Bromo-1-propene, n-BuLi, CuI, THF, –78 
°C to r.t., 74%; b) AD-mix-β, MeSO2NH2, t-BuOH/H2O (1:1), 0 °C, 95%, >93% ee; c) KOH, 
CH2I2, [18]-crown-6, CH2Cl2, reflux, 80%; d) CAN, ACN/H2O (2.5:1), 90%; e) Jones reagent, 
acetone, −78 °C to r.t.; f) DCC, DMAP, 3.38, THF, r.t., 70% (over two steps); g) LDA, TMSCl, 
THF, –78 °C to r.t. to reflux; h) TsOH x H2O, MeOH, reflux, 54% (over two steps), d.r. = 7:1; i) 
Ph3CBF4, CH2Cl2, reflux, 60%; j) TBSOTf, Et3N, CH2Cl2, r.t., 85%; k) [Co2(CO)8], Bu3PS, 
toluene, r.t. to 75 °C, 67%; l) hν, allene, THF, –78 °C, 87%, d.r. = 4.8:1; m) O3, MeOH, 
CH2Cl2; Me2S, –78 °C to r.t.; NaOMe, MeOH, 89%; n) LDA, TMSCl, Et3N, THF, –78 °C to –20 
°C; o) Pd(OAc)2, O2, DMSO, 75 °C, 92% (over two steps); p) TBAF, THF, r.t., 96%; q) 
NaHMDS, (–)-trans-2-(phenylsulfonyl)-3-phenyloxaziridine, THF, −78 °C, 55%; r) Jones 
reagent, acetone, 0 °C; MeOH, r.t., 46%.  
  
Br OPMP Me
OPMPa-d
Me
e,f
O
O
Me
OTBSHO
Me
OTBS
k-l
O
O
OH
R
OTBS
Me
m-o
O
O
O
Me OTBS
HMe
OH
O
O
O
OTBS
Me
OH
Me CO2Me
p-q
O
O
O
Me
OH
Me O
O
HO
r
O
O
O
Me
OH
Me O
CO2MeHO
(−)-jiadifenin (3.11)
OO
g-j
3.38
3.36 3.37 3.39
3.40 3.41 3.42
3.43
CHAPTER 3 
	  
74 
3.2.3  Fukuyama’s Enantioselective Formal Synthesis of  
    (−)-Jiadifenin 
 
Fukuyama reported a formal synthesis of (−)-jiadifenin (3.11) in 2015 in 30 
steps and an overall yield of 0.09% (Scheme 3.4).185 The key step involved a 
tandem Tsuji-Trost and an intramolecular Mizoroki-Heck reaction. Diethyl-4-
oxopimelate (3.44) was subjected to a Wittig reaction to yield the trisubstituted 
olefin, followed by a global ester reduction and mono-alcohol protection to 
afford the desymmetrized product 3.45. The free alcohol was oxidized under 
Swern conditions to the aldehyde and a HWE-reaction afforded the 
unsaturated ester 3.46. The cyclization took place under a Pd-catalyzed, 
intramolecular Mizoroki-Heck reaction to afford the cyclized product 3.47. The 
olefin was first hydroborated and the obtained alcohol was protected with 
triethylsilane. The installation of the α−hydroxyketone function was achieved 
after conversion of the ester to the Weinreb amide and treatment with 
MeMgBr to afford the ketone. A Rubottom-oxidation furnished the desired  
α-hydroxyketone 3.48. The ketone was then treated with MeLi and the diol 
was transformed into the carbonate. An acidic cleavage of the TES-group and 
oxidation of the alcohol to the aldehyde was directly subjected to a Roskamp 
reaction with ethyl diazoacetate to furnish the β-ketoester 3.49. A tandem 
Tsuji-Trost reaction furnished the ABC-ring system 3.50 after and extensive 
condition and ligand screening. The olefin was installed after silyl deprotection 
and a Grieco dehydration. The hydroxy group was introduced with m-CPBA to 
yield the α-hydroxyester 3.51. The olefin was converted into the aldehyde 
under Johnson-Lemieux conditions and formed the lactol spontaneously, 
which was oxidized to Theodorakis lactone intermediate 3.52 using Fetizon’s 
reagent. The data were in good agreement with those reported by the 
Theodorakis group.186 
  
                                                                                                    
185	  	  K.	   Harada,	   A.	   Imai,	   K.	   Uto,	   R.	   G.	   Carter,	  M.	   Kubo,	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   Hioli,	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   Fukuyama,	  Tetrahedron	  2015,	  71,	  
	   2199.	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Scheme 3.4: Fukuyama’s formal synthesis of (−)-jiadifenin (3.11). a) EtPPh3Cl, n-BuOK, 
toluene, 81%; b) LiAlH4, THF, 81%; c) TPDPSCl, imid., CH2Cl2, 56%; (d) (COCl)2, DMSO, 
CH2Cl2, Et3N; e) (EtO)2P(O)CH2CO2Et, NaH, DME, Br2, KHMDS, 70% (over two steps); f) 
Pd(OAc)2, (o-tol)3P, Et3N, t-BuOH, 99%; g) TMSOK, Et2O, 98%; h) MeNHOMe, EDC, CH2Cl2, 
85%; i) 9-BBN, THF, NaOH, H2O, 78%; j) TESCl, Et3N, DMAP, CH2Cl2, 98%; k) MeMgBr, 
THF, 76%; l) TMSCl, LDA, THF; m) m-CPBA, CH2Cl2, K2CO3, 78% (over two steps); n) MeLi, 
THF (d.r. = 1:1); o) CDI, DMAP, CH2Cl2, 89% (over two steps); p) AcOH, H2O, THF, 88%; q) 
DMAP, CH2Cl2, 99%; r) SnCl2, N2CHCO2Et, CH2Cl2, 83%; s) Pd(OAc)2, LiOAc, (±)-BINAP, t-
BuOH, 65%; t) TBAF, THF, 94%; u) NCSeC6H4NO2, PPh3, py, 52%; v) H2O2, 97% (over three 
steps); w) m-CPBA, CH2Cl2, 86%; x) NaBH4, MeOH, 99%; y) OsO4, NaIO4, THF, H2O, 54%; 
z) Ag2CO3, CH2Cl2, 92%. 
3.2.4  Micalizio’s Enantioselective Total Synthesis of (−)-Jiadifenin 
 
The Micalizio group published a novel approach for the synthesis of (−)-
jiadifenin in 21 steps (Scheme 3.5). 187  The report highlights a hydroxy-
directed, metallacycle-mediated [2 + 2 + 2] annulation and an intramolecular 
radical cyclization cascade. Starting from the chiral epoxide 3.53, and addition 
of the organometallic derived vinylbromide 3.54 furnished the secondary 
alcohol 3.55. The enyne 3.56 was obtained from a desilylation, epoxide 
formation and opening with propynyl lithium. Cyclization in the presence of 
Ti(OiPr)4 and a stannyl-substituted TMS-acetylene 3.57 furnished the  
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[2 + 2 + 2] annulated product 3.58. The TMS-group was removed and the 
secondary alcohol TBDPS-protected. A tin-lithium exchange was performed 
and subsequent carboxylation followed by an esterification reaction gave the 
ester moiety. A dihydroxylation of the olefin furnished the precursor 3.59. The 
radical cyclization furnished the desired lactone 3.60, as well the unexpected 
ethyl ester 3.61, which might arise from a reaction of the tertiary radical with 
the acetal group, followed by acetal opening to the ethyl ester 3.61. 
Nevertheless, both compounds could be successfully converted in the lactone 
3.62 via a reduction and oxidation sequence. The A-ring was further modified 
by TBDPS-cleavage, oxidation of the secondary alcohol and a Saeguesa-Ito 
oxidation yielded in the enone 3.63. Out of this intermediate, the total 
synthesis of (2S)-3,4-dehydroneomajucin (3.12), (1R,10S)-2-oxo-3,4-
dehydroneomajucin (3.64) and (−)-jiadifenin (3.11) could be accomplished. 
 
Scheme 3.5: Micalizio’s total synthesis of (−)-jiadifenin (3.11). a) Mg, CuI, THF, 59% b) 
TBAF, THF, 81%; c) TsCl, Et3N, DMAP, CH2Cl2 (92%); d) NaH, THF, 76%; e) propynyl 
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lithium, BF3 x OEt2, 91%; f) Ti(OiPr)4, n-BuLi, PhMe, −78 °C  to 50 °C, then PhCHO, 73%; g) 
TBAF, DMSO, 65%; h) TBDPSCl, imid., CH2Cl2, 96%; i) MeLi, THF, then CO2; j) PhSeCH2Cl, 
iPr2Net, NaI, DME, 50% (over two steps); k) OsO4, pyridine, THF, 85%; l) Bu3SnH, AIBN, 
PhH, 80 °C, 80%; m) (COCl)2, DMSO, Et3N, 71%; n) HCl, THF, 85%; o) NaClO2, 2-methyl-2-
butene, NaH2PO4; p) NaBH4, then TsOH, toluene, 70% (over three steps); q) (COCl)2, DMSO, 
Et3N, 80%; r) NaBH4, MeOH, 97%; s) TsOH, PhMe, 86%; t) TBAF, THF, 87%; u) IBX, DMSO 
97%; v) LDA, TMSCl, then Pd(OAc)2, 83%; w) NaBH4, CeCl3 x 7 H2O, MeOH, 92%; x) 
NaHMDS, THF, 3-phenyl-2-(phenylsulfonyl)-1,2-oxaziridine, 50%; y) PPh3, DIAD, p-NO2-
benzoic acid; z) DMP; a’) NaBH4; b’) K2CO3, MeOH, 14% (over four steps); c’) TBAF, THF, 
70%; d’) NaHMDS, THF, 3-phenyl-2-(phenylsulfonyl)-1,2-oxaziridine, 54%; e’) Jones reagent, 
acetone, 0 °C; MeOH, r.t., 46%. 
3.2.5  Theodorakis’ Enantioselective Synthesis of (−)-Jiadifenolide 
 
The group of Theodorakis was the first to accomplish the enantioselective 
total synthesis of (−)-jiadifenolide (3.10) in 2011 (Scheme 3.6).188 Starting 
from diketone 3.65, a dialkylation was performed to the optically enriched 
diketone (>90% ee), which was prone to a D-prolinamide/PPTS-catalyzed 
asymmetric aldol condensation to furnish the AB-ring system 3.66. A 
carboxylation of the C-5 enolate and trapping of the carboxylic acid with 
Meerwein’s salt furnished the ethylester. Methyl insertion was achieved by 
formation of the silyl enol ether and subsequent silyl deprotection with 
TBAF/MeI furnished the α-methylated product as a single diastereomer. The 
installation of the C-ring was achieved by a global carbonyl reduction, silyl 
protection of the primary alcohol and oxidation of the secondary alcohol to the 
ketone. The ketone was transformed into the vinyltriflate, which was 
converted to the methylester via a Pd0-catalyzed carbomethoxylation and 
finally TBS-deprotection yielded directly in the lactone 3.67. The  
α,β-unsaturated lactone was epoxidized and the terminal olefin was subjected 
to Johnson-Lemieux conditions. The aldehyde was oxidized under Jones 
conditions to the carboxylic acid, which triggered a “6-exo-tet” epoxide 
opening to the lactone. A TBS-deprotection led to the free alcohol 3.68. 
Epoxidation of the trisubstitued olefin occurred from the β-face and epoxide 
opening was achieved in the presence of DMP to the translactonized product 
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3.69. The authors claimed that the released acid protonates the epoxide and 
opens it via an elimination reaction. Hydrogenation of the obtained double 
bond and TES-protection of the alcohol and then the ketone was readily 
converted into the vinyltriflate with Comins reagent, followed by a Pd0-
mediated cross-coupling using AlMe3 to furnish compound 3.70. The 
trisubstitued olefin was selectively hydrogenated from the β-face and the final 
assembly was achieved by applying Danishefsky’s conditions.183 Therefore, 
(−)-jiadifenolide (3.10) was enantioselective synthesized in 25 linear steps in 
0.5% overall yield from the commercially available diketone 3.65. 
 
Scheme 3.6: Theodorakis’ enantioselective synthesis of (−)-jiadifenolide (3.10). a) allyl 
acetate, [PdC3H5Cl2]2, BSA, cat. NaOAc, THF, reflux 24 h, 90%; b) methyl vinyl ketone, H2O, 
r.t., 54%; c) D-prolinamide (30 mol %), PPTS (30 mol %), MeCN, 40 °C, 14 d, 74% (>90% 
ee); d) NaBH4 (0.25 eq.), EtOH, 0 °C, 1 h; e) TBSCl, NH4NO3, DMF, r.t., 12 h, 92% (over two 
steps); f) MMC, DMF, 130 °C, 3 h; Et3OBF4, iPr2NEt, CH2Cl2, 0 °C, 5 min; g) TMSOTf, 2,6-
lutidine, CH2Cl2, 0 °C to r.t., 1 h; TBAF (1.0 eq.), MeI, THF, –78 °C to r.t., 3 h, 43% (over two 
steps); h) LiAlH4, THF, 0 °C to r.t., 1 h; i) TBSCl (1.0 eq.), imid., CH2Cl2, 0 °C, 30 min; j) IBX, 
DMSO, 80 °C, 1 h, 85% (over three steps); k) KHMDS, PhNTf2, THF, –78 °C, 1 h; l) CO (1 
atm), [Pd(PPh3)4] (1 mol%), MeOH, DMF, Et3N, 50 °C, 2 h; TFA, CH2Cl2, r.t., 5 h, 69% (over 
two steps); m) H2O2, 3 M NaOH, THF, 0 °C to r.t., 5 h, 99%; n) OsO4 (1 mol%), NaIO4, 1,4-
dioxane, H2O, r.t., 12 h; o) Jones reagent, acetone, 0 °C, 30 min, 70% (over two steps); p) 
TBAF, THF, r.t., 30 min, 95%; q) m-CPBA, THF, 50 °C, 3 h; r) DMP, acetone, r.t., 2h, 38%, 
(over two steps); s) H2, 10% Pd/C (5 mol%), MeOH, r.t., 24 h; t) TESOTf, 2,6-lutidine, THF, 0 
°C to r.t., 30 min, 90%, (over two steps); u) KHMDS, Comins reagent, THF, –78 °C, 1.5 h; v) 
AlMe3, [Pd(PPh3)4] (50 mol%), THF, r.t., 2 h, 57%, (over two steps); w) H2 (90 atm), PtO2 (20 
mol%), MeOH, r.t., 24 h; x) NaHMDS, (±)-trans-2-(phenylsulfonyl)-3-phenyloxaziridine, THF, 
–78 °C to r.t., 1.5 h; y) Jones reagent, acetone, 0 °C, 15 min, 33%, (over three steps).   
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3.2.6  Theodorakis’ Enantioselective Synthesis of (−)-Jiadifenin 
 
The first enantioselective synthesis of (−)-jiadifenin (3.11) was reported 
shortly after the accomplishment of (−)-jiadifenolide (3.10) by the same group 
(Scheme 3.7).186 Slight modifications of the endgame furnished (−)-jiadifenin 
(3.11) in 19 linear steps and an overall yield of 1.1% starting from the diketone 
3.65. The hydroxy-intermediate 3.68 was dehydrated using Martin’s sulfurane 
and the alkene selectively hydrogenated to the mono-alkene, which was 
oxidized in allylic position to the enone 3.71. α-Hydroxylation of the lactone 
moiety and α-methylation yielded the known precursor for Jones oxidation 
and finally the enantioselective synthesis of (−)-jiadifenin (3.11) was 
accomplished. 
 
Scheme 3.7: Theodorakis’ enantioselective synthesis of (−)-jiadifenin (3.11). a) Martin’s 
sulfurane, THF, r.t., 2 h; b) H2, Pd/C, MeOH, r.t., 1 h, 72%, (over two steps); c) Mn3O(OAc)9, 
t-BuOOH, EtOAc, 3Å molecular sieve, 40 °C, 16 h, 65%; d) NaHMDS, Davis’ oxaziridine, 
THF, –78 °C, 1 h, 61%; e) LDA, MeI, THF, HMPA, –78 °C to –10 °C, 4 h, 60% brsm; f) Jones 
reagent, acetone, r.t., 20 min; MeOH, r.t., 15 min, 45%. 
 
3.2.7  Paterson’s Total Synthesis of (±)-Jiadifenolide 
 
Paterson and co-workers reported a new synthetic approach for the 
synthesis of (±)-jiadifenolide (3.10) in 23 linear steps and an overall yield of 
2.3% (Scheme 3.8).189 Commercially available enone 3.72, representing the 
A-ring, was converted in four steps to the cyclopentanone 3.73. A HWE-
homologation with phosphonate ester 3.74 afforded the α,β-unsaturated ester 
3.75. After reduction and acetylation, an Ireland-Claisen-rearrangement 
afforded the quaternary C-9 with the desired stereochemistry. An ester 
reduction to the alcohol, followed by a TBS deprotection and oxidation 
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afforded the aldehyde 3.76. A boron-mediated aldol reaction with butenolide 
3.77 introduced the C-ring, which gave 3.78 after TES protection.  
 
Scheme 3.8: Paterson’s synthesis of (±)-jiadifenolide (3.10). a) NaBH4, CeCl3, MeOH,  
–78 °C to 0 °C; b) m-CPBA, CH2Cl2, 0 °C; c) TBSCl, imid., CH2Cl2 0 °C to r.t., 65 % (over 
three steps); d) BF3 x OEt2, CH2Cl2, –20 °C, 78%; e) NaH, r.t., 72 h, 73%; f) LiAlH4, Et2O, 0 
°C; g) Ac2O, py, DMAP, CH2Cl2, r.t., 77% (over two steps); h) LDA, TBSCl, THF, –78 °C to 
r.t.; toluene, reflux, 16 h; i) LiAlH4, Et2O, 0 °C, 63% (over two steps); j) 3 M HCl, MeOH, (1:3), 
r.t.; k) DMSO, (COCl)2, Et3N, CH2Cl2, –78 °C to r.t., 74% (over two steps); l) Bu2BOTf, 
iPr2NEt, THF, –78 °C to –20 °C, 98%, d.r. = 2:1; m) TESCl, imid., DMF, r.t., 65%; n) SmI2, 65 
°C, 2 h, 51%; o) p-TsOH, MeOH, CH2Cl2, r.t., 88%; p) PCC, NaOAc, SiO2, CH2Cl2, 81%; q) 
TMSOTf, Et3N, THF, –78 °C; r) OsO4, NMO, t-BuOH/H2O, r.t., 99% (over two steps); s) 
Me4NBH(OAc)3, AcOH, MeCN, –20 °C, 87%; t) TESCl, imid., DMF, r.t., 96%; u) OsO4, NMO, 
py, t-BuOH/H2O, r.t.; v) TPAP, NMO, 4Å molecular sieve, CH2Cl2, r.t., 84% (over two steps); 
w) HF · py, THF, r.t., 86%.  
 
The formation of the B-ring was achieved by a samarium-mediated 
cyclization as the key step. Figure 3.9 shows the proposed transition state 
3.79’ of the cyclization in which the coordination of the samarium led to a boat 
conformation and to the desired diastereomer 3.79. 
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Figure 3.9: Proposed radical cyclization transition state 3.79’ to ABC ring system 3.79.189 
 
After TES deprotection and oxidation of the secondary alcohol, the  
β-ketolactone was α-hydroxylated at C-6 to insert the last oxygen on the  
C-ring and to yield ketone 3.80. The terminal alkene was dihydroxylated, 
followed by a TPAP oxidation to form the ketoaldehyde (E-ring), which was 
subsequently converted to the ketolactone 3.81. The D-ring is then formed by 
an intramolecular nucleophilic attack of the C-7 alcohol to the α-ketolactone, 
completing the synthesis of (±)-jiadifenolide (3.10).  
3.2.8  Sorensen’s Enantiospecific Synthesis of (–)-Jiadifenolide  
 
The group of Sorensen reported on the enantioselective total synthesis of  
(–)-jiadifenolide (3.10) in 21 steps and an overall yield of 0.5%.190  They 
employed a similar “pattern recognition“ (Scheme 3.9) as described by 
Danishefsky for their synthesis. β-Ketoester 3.82, which was synthesized from 
enantiopure (R)-pulegone (3.83), was found to be an ideal starting material for 
the synthesis. It bears already seven carbons of the natural product  
(–)-jiadifenolide (3.10) with the correct configuration of the methyl group. 
   
  
Scheme 3.9: (R)-Pulegone (3.83), β-ketoester 3.82 and (−)-jiadifenolide (3.10) with “pattern 
recognition” (shown in red). 
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A Michael addition of methyl vinyl ketone on to β-ketoester (3.82), followed 
by a Robinson annulation furnished the AB-ring system (Scheme 3.10). After 
methylation on C-5 and acetal formation, the ester was reduced to the alcohol 
and then oxidized by Swern method to afford the aldehyde 3.84. A van 
Leusen homologation was used to afford the nitrile and upon hydrolysis, the 
ABE-lactone-ring system 3.85 was formed. Oxidation of the geminal methyl 
group was achieved by using Sanford’s oxime directed C-H activation to 
afford 3.86. Both methyl groups were hydroacetylated in a 1:1 ratio. After 
reductive cleavage of the oxime acetate, Comins’s reagent furnished the enol 
triflate, which could be converted into the methyl ester 3.87 in a palladium-
catalyzed carbomethoxylation. After deprotection of the acetate, the 
bislactone 3.88 was obtained. Epoxidation of the α-unsaturated-bislactone 
3.88 afforded the epoxide 3.89. Halogenation of the E-ring afforded the  
α-iodolactone 3.90. Oxidation with dimethyldioxirane yielded in the  
α-ketolactone, which was treated with LiOH to afford (–)-jiadifenolide (3.10).  
 
Scheme 3.10: Enantiospecific total synthesis of (–)-jiadifenolide (3.10) by the Sorensen 
group. a) methyl vinyl ketone, DBU, EtOH, r.t., 97%; b) p-TsOH, benzene, reflux, 85%; c) 
CH3I, KOt-Bu, t-BuOH, r.t., 91%; d) ethylene glycol, p-TsOH, benzene, reflux; e) DIBAL-H, 
CH2Cl2, –78 °C to 0 °C, 77% (over two steps); f) (COCl)2, DMSO, Et3N, CH2Cl2, –78 °C to r.t., 
90%; g) TosMIC, KOt-Bu, THF, –50 °C, CH3OH, 65 °C, 90%; h) H2SO4, MeOH, 100 °C, 73%; 
i) HONH2 · HCl, py, 80 °C, 91%; j) Pd(OAc)2, PhI(OAc)2, Ac2O/AcOH (1:1), 100 °C, 12 h, 
22%; k) Fe, AcOH, TMSCl, THF, r.t., 89%; l) KHMDS, Comins reagent, THF, –78 °C; 
m) Pd(OAc)2, PPh3, Et3N, CO (1 atm), MeOH, DMF, 40 °C, 49% (over two steps); n) K2CO3, 
O
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CH3OH, r.t.; o) 3 M NaOH, H2O2, MeOH, 0 °C to r.t., 61% (over two steps); p) TMSCl, 
LiHMDS, THF, –78 °C, NIS; q) DMDO, acetone, CH2Cl2, r.t.; r) LiOH, THF, r.t., 40% (over 
three steps).  
3.2.9  Shenvi’s Eight-Step Gram-Scale Synthesis of (–)-Jiadifenolide  
 
Shenvi and co-workers demonstrated a straightforward eight-step 
synthesis of (–)-jiadifenolide (3.10) in an overall yield of 9.2% (Scheme 
3.11).191 They used a convergent synthetic approach based on two main 
fragments 3.91 and 3.92, which are connected in a double Michael addition. 
The chiral butenolide fragment 3.91 was synthesized with a new synthetic 
strategy using (+)-citronellal (3.93) as a chiral starting material. Dehydration of 
the aldehyde afforded the alkyne and ozonolysis of the alkene furnished the 
corresponding aldehyde. A hetero-Pauson-Khand reaction using molybdenum 
hexacarbonyl and TBAB yielded in the butenolide 3.91, which already 
represents the AE-ring system of the natural product. Thermolysis of 
hydroxyacetone 3.94 and dioxinone 3.95 yielded into a linear β-ketoester, 
which cyclized to the acetyl butenolide 3.92, upon treatment with silica. The 
key step, a double Michael addition, led to the β-ketolactone 3.96. To prevent 
a [4 + 2] cycloaddition via intermediate 3.96’, Ti(OiPr)4 showed to be superior 
over other tested Lewis acids. The resulting β-ketolactone 3.96 was  
α-hydroxylated using m-CPBA and the ketone was reduced to yield the anti-
diol 3.97. A α-bromination on the E-ring lactone furnished α-bromolactone, 
which was treated with Davis’ oxaziridine to afford (–)-jiadifenolide (3.10).  
  
                                                                                                    
191	  	  H.-­‐H.	  Lu,	  M.	  D.	  Martinez,	  R.	  A.	  Shenvi,	  Nature	  Chemistry	  2015,	  7,	  604.	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Scheme 3.11: Shenvi’s gram-scale synthesis of (–)-jiadifenolide (3.10). a) BTPP, NfF, 22 °C; 
b) O3, CH2Cl2, –78°C; c) Mo(CO)6, Bu4NBr, CH2ClCH2Cl, 90 °C, 35% (over 
three steps); d) hydroxyacetone, PhMe, 120 °C; e) SiO2, 22 °C, EtOAc, C6H14, 45% (over two 
steps); f) LDA, 3.91, THF, –78 °C, 3.92, –100 °C, then Ti(OiPr)4, LDA, 0 °C, 70%; g) m-CPBA, 
CH2Cl2, r.t.; h) Me4NBH(OAc)3, AcOH, THF, 75% (over two steps); i) LDA, CBr4; j) NaHMDS, 
Davis’s oxaziridine, 50% (over two steps). 
3.2.10 Zhang’s Protecting-Group-Free Total Synthesis of  
    (−)-Jiadifenolide  
 
Recently, Zhang and co-workers reported on a protecting-group-free total 
synthesis of (−)-jiadifenolide (3.10). 192  The β-ketoester 3.98 was readily 
converted into the unsaturated butenolide 3.99 in four steps (Scheme 3.12). 
After ester reduction and olefin hydrogenation, the key cyclization using SmI2 
with alcohol 3.100 gave the ABC-structure 3.101. The authors proposed a 
chelating effect of SmI2 to the alcohol and ketone function (3.101’), resulting 
in a diastereomeric ratio of 7:1. C1-homologation was achieved via a formal  
[4 + 1] annulation reaction using with TMSCHN2 to form ether 3.102. Finally, 
several oxidation steps and a basic treatment furnished (−)-jiadifenolide (3.10) 
in 13 steps and an overall yield of 7.9% starting from the β-ketoester 3.98. 
  
                                                                                                    
192	  	  Y.	  Shen,	  L.	  Li,	  Z.	  Pan,	  Y.	  Wang,	  J.	  Li,	  K.	  Wang,	  X.	  Wang,	  Y.	  Zhang,	  T.	  Hu,	  Y.	  Zhang,	  Org.	  Lett.	  2015,	  17,	  
	   5480.	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Scheme 3.12: Zhang’s protecting-group-free total synthesis of (−)-jiadifenolide (3.10). a) 
allylbromide, Cs2CO3, acetone, 0 °C, 99%; b) O3, CH2Cl2, −78 °C then PPh3, 92%; c) 4-
methylfuran-2(5H)-one, Et3N, Bu2BOTf, CH2Cl2, −78 °C, 84%; d) Ac2O, Et3N, DMAP, CH2Cl2, 
85%; e) LDA, THF, DIBAL-H, −78 °C, 78%; f) PtO2, H2, EtOAc, 85%; h) SmI2, THF/H2O, 89%, 
d.r. = 7:1; i) DMSO, oxalyl chloride, Et3N, CH2Cl2, −78 °C, quant.; j) TMSCHN2, n-BuLi, LiCl, 
THF, −78 °C, 78%; k) KHMDS, PhSeBr, THF, −78 °C, then H2O2 or m-CPBA, 70-88%; l) 
DMDO, Na2SO4, 80%; m) RuCl3, NaIO4, CCl4, ACN, H2O, 84%; n) LiOH, THF, H2O, 71%. 
 
3.2.11 Synthetic Investigations and SAR-Studies on Nor-     
    Sesquiterpenoids 
 
Intensive SAR-studies contributed by Danishefsky193 and Theodorakis194 
on majucin type sesquiterpene structures gave an insight into the 
recommended structural features for neurotrophic properties as shown in 
Table 3.1. Modifications on the A-ring did not show an increased neurotrophic 
activity (3.103a-c). The α-substituents of the bridged E-ring lactone showed to 
be the important structural motif for neurotrophic activity (3.104a-d). This was 
further expanded to methyl (3.104d) and hydroxy substitution (3.104b-c) 
pattern, whereas only the α-configuration (3.104c) showed an increased 
activity. This is as well the case for a α-methyl substituent (3.104d), which 
indicates that the orientation at this position and less the substituent is 
inducing neurite outgrowth properties. 
                                                                                                    
193	  	  D.	  A.	  Carache,	  Y.	  S.	  Cho,	  Z.	  Hua,	  Y.	  Tian,	  Y.-­‐M.	  Li,	  S.	   J.	  Danishefsky,	  J.	  Am.	  Chem.	  Soc.	  2006,	  128,	  
	   1016.	  
194	  	  L.	  Trzoss,	  J.	  Xu,	  M.	  H.	  Lacoske,	  W.	  C.	  Mobley,	  E.	  A.	  Theodorakis,	  Chem.	  Eur.	  J.	  2013,	  19,	  6398.	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Table 3.1: Structural activity profile (inactive = less or similar neurotrophic activity; active = 
increased neurotrophic activity; − = structure not accessible) 
 
However, this in contrast to other neurotrophic nor-type sesquiterpens 
which are lacking the C-10 carbon. One of the most active nor-type molecules 
is (2R)-hydroxynorneomajucin (3.14), which consists of a carbonyl function at 
the C-10 carbon. A synthetic approach to the nor-type sesquiterpene scaffold 
should provide an access to a novel neurotrophic activity map. Furthermore, 
nor-type structure (3.105 - 3.107) of active natural products such as jiadifenin 
(3.11), majucin (3.18) and (2S)-hydroxy-3,4-dehydro-neomajucin (3.12) could 
be tested on their neurotrophic behavior as shown in Scheme 3.13. 
 
Scheme 3.13: Neurotropic activity development program on uninvestigated nor-type 
sesquiterpene natural products. 
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3.2.12 Structural Elucidation of Nor-Sesquiterpenoid  
    (2R)- Hydroxynorneomajucin 
Our main interest was in the highly active neurite promoter  
(2R)-hydroxynorneomajucin (3.14), which was isolated in 2012 by Fukuyama 
and co-workers from a methanol extract of the pericarps of Illicium 
jiadifengpi.181 It has remarkable activity in primary cultured rat cortical neurons 
with an activity range of 1 – 10 µM. The structure was elucidated via chemical 
modifications (Scheme 3.14) from (2S)-hydroxyneomajucin (3.108) via 
degradation to the norsesquiterpenoid 3.109. The secondary (S)-configured 
alcohol at C-2 was oxidized to the ketone and reduced to yield in a  
(R)-configured alcohol at C-2. The spectroscopic data were identical with the 
natural occurring (2R)-hydroxynorneomajucin (3.14)  
 
Scheme 3.14: Structural elucidation of (2R)-hydroxynorneomajucin (3.14) via chemical 
transformation. a) Ac2O, py, 99%; b) Jones reagent, acetone, 15%; c) K2CO3, MeOH, 99%; d) 
IBX, DMF, 66%; e) NaBH4, MeOH, 99%. 
Along with the structure elucidation of (2R)-hydroxynorneomajucin (3.14), a 
second inactive metabolite was isolated named jiadifenone (3.110). From this 
data, the authors proposed a biosynthesis for both compounds as depicted in 
Scheme 3.15. Neomajucin (3.111) is oxidized to the strained α-keto-δ-lactone 
3.112, which opens to the α-keto-carboxylic acid 3.113. An enzymatic 
oxidation leads to a decarboxylation and norneomajucin (3.114) is formed. 
Further oxidation at C-2 forms (2R)-hydroxynorneomajucin (3.14), whereas a 
hydrolysis opens the lactone moiety to yield the carboxylic acid 3.115, which 
decarboxylates and eliminates to the jiadifenone precursor 3.116. Oxidation at 
C-2 furnishes jiadifenone (3.110). 
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Scheme 3.15: Proposed biosynthesis of (2R)-hydroxynorneomajucin (3.14) and jiadifenone 
(3.110). 
3.3 Goal of this Study and Retrosynthetic Analysis of (2R)- 
   Hydroxynorneomajucin 
 
The goal of this project is to elucidate the neurite outgrowth inducing 
potential of nor-sesquiterpenoids. In a first step, a general synthetic pathway 
should be established, which targets a common advanced intermediate for 
further transformation and substitution to cover a broad spectra of nor-type 
related natural products. In a second step, the molecules should be tested on 
their neurite outgrowth potential. The synthetic aspects are shared with M.Sc. 
Joel Rösslein, who contributed ideas and synthetic effort on this project. 
 
The synthetic overview for the total synthesis of (2R)-
hydroxynorneomajucin (3.14) is summarized in Scheme 3.16. The 
hydroxylation events should take place at late stage via α-hydroxylation, 
allylic oxidation and epoxidation. This precursor 3.117 would allow further 
transformation to a broad spectra of nor-type sesquiterpenes. Formation of 
the B-ring will be accessed via a radical cyclization between a α,β-ketoester 
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radical and a tetrasubstitued olefin. A hydroxy directed relay C-H activation 
will stereospecifically introduce a hydroxy function on the geminal methyl 
functions, which is further used in the reductive cyclization to form the C-ring 
lactone. As a starting material the known methylester 3.118 from 
commercially available (R)-pulegone (3.83) and a β-ketoester 3.119 would be 
used.  
 
Scheme 3.16: Retrosynthetic analysis of (2R)-hydroxynorneomajucin (3.14). 
3.3.1  Synthetic Plan 
 
The two challenging steps in the synthesis are the assembly of the B- and  
C-ring via a planned radical cyclization and relay C-H oxidation (highlighted in 
Scheme 3.16). The methodology is discussed with literature known examples 
in this section. 
We could recently demonstrate195 that six-ring formation can be achieved 
via a manganese(III)-mediated cross coupling196 onto an internal olefin (the 
reaction is described in full detail in chapter four of this thesis). An oxygen free 
radical cyclization was used in the work of Alvarez and co-workers for their 
total synthesis of (+)-7-deoxynimbidiol (3.120, Scheme 3.17). A radical 
cyclization of the β-ketoester 3.121 formed the bis-chlorinated 6-ring 3.122. 
The chlorines were easily removed by a treatment with base.197  
  
                                                                                                    
195	  	  C.	  Daeppen,	  M.	  Kaiser,	  M.	  Neuburger,	  K.	  Gademann,	  Org.	  Lett.	  2015,	  17,	  5420.	  
196	  	  B.	  B.	  Snider,	  Chem.	  Rev.	  1996,	  96,	  339;	  Tetrahedron	  2009,	  65,	  10738.	  
197	  	  E.	   Alvarez-­‐Manzaneda,	   R.	   Chahboun,	   E.	   Cabrera,	   E.	   Alvarez,	   R.	   Alvarez-­‐Manzaneda,	   M.	  
	   Hmamouchi,	  H.	  Es-­‐Samti,	  Tetrahedron	  Lett.	  2007,	  48,	  8930.	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Scheme 3.17: Synthesis of (+)-7-deoxynimbidiol (3.120) with a Mn(III)-mediated cyclization 
as the key step. a) Mn(OAc)3 x 2 H2O (4.0 eq.), LiCl (3.0 eq.), Ac2O, r.t., 12 h. 
C-H activation is one of the biggest topics in modern chemistry and a lot of 
effort has been put into this field. 198  The goal is to achieve a certain 
functionalization of “inert” C-H groups (R3-CH, R2-CH2, R-CH3; R = alkyl). 
Often, a metal is needed or a directing group. One of the earliest reported C-H 
activations was the Hofmann-Löffler-Freytag reaction199 to convert a C(sp3)-H 
into a C(sp3)-N bond via a an alkyl halide. 
For our purposes, a hydroxy function should act as the directing group. 
This kind of C-H activation is well documented on steroid structures via a 
hydroxy-mediated C-H activation of the methyl function in δ-position200 3.123 
to the bridged ether 3.124 as shown in Scheme 3.18. This reaction was 
initially reported by Mihailovic and co-workers in 1959,201 who formed from the 
secondary alcohol the bridged ether. 
     
Scheme 3.18: Example of a C-H oxidation and subsequent cyclization. a) Pb(OAc)4 (10% 
HOAc), I2, CCl4, reflux, 4 h. 
  
                                                                                                    
198	  	  a)	  X.	  Chen,	  K.	  M.	  Eagle,	  D.-­‐H.	  Wang,	   J.-­‐Q.	  Yu,	  Angew.	  Chem.	   Int.	  Ed.	  2009,	  48,	  5094;	  b)	  H.	  M.	   L.	  
	   Davies,	  R.	  E.	  J.	  Beckwith,	  Chem.	  Rev.	  2003,	  103,	  2861.	  
199	  	  a)	  A.	  W.	  Hofmann,	  Ber.	  1885,	  18,	  109;	  b)	  K.	  Löffler,	  C.	  Freytag,	  Ber.	  1909,	  42,	  3427.	  
200	  	  J.	  Kalvoda,	  K.	  Heusler,	  Synthesis	  1971,	  501.	  
201	  	  a)	   G.	   Cainelli,	   M.	   Lj.	   Mihailovic,	   D.	   Arigoni,	   O.	   Jeger,	   Helv.	   Chim.	   Acta	   1959,	   42,	   1124;	   b)	   for	  
	   historical	  	  perspective	  on	  C-­‐H	  activation	  see:	  Y.	  Ishihara,	  P.	  S.	  Baran,	  Synlett	  2010,	  1733.	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In the meantime, the toxic Pb(OAc)4 could be replaced by hypervalent iodine 
species.202 A hydroxy directed geminal methyl functionalization is found in the 
total synthesis of nagilactone F (3.125) as shown in Scheme 3.19.203 The 
selectivity for the geminal methyl compound 3.126 to the ether bridge 3.127 
was quite moderate (1:1.4) but in a good yield of 71%. 
 
Scheme 3.19: Relay C-H activation of geminal methyl groups. a) PhI(OAc)2, I2, cyclohexane, 
hν, 50 °C. 
 
The reaction follows an in situ generation from a hydroxy-δ-methyl 3.128 
building block via a hypoiodite intermediate 3.129 which is cleaved to form an 
oxygen centered radical 3.130. The oxygen radical will abstract a hydrogen in 
δ-position to yield the carbon centered radical 3.131, which is then quenched 
by the iodo radical to form the iodoalkane 3.132. A nucleophilic attack on the 
alkyliodide bond furnishes the cyclized product 3.133 as summarized in 
Scheme 3.20.200 
 
Scheme 3.20: General mechanism for the iodine mediated hydroxy directed C-H activation. 
  
                                                                                                    
202	  	  a)	  H.	  Togo,	  M.	  Katohgi,	  Synlett	  2001,	  565;	  b)	  L.	  A.	  Paquette,	  L.-­‐Q.	  Sun,	  D.	  Friedrich,	  P.	  B.	  Savage,	  
	   Tetrahedron	  Lett.	  1997,	  38,	  195;	  c)	   J.	   I.	  Concepón,	  C.	  G.	  Francisco,	  R.	  Hernández,	   J.	  A.	  Salazar,	  E.	  
	   Suárez,	   Tetrahedron	   Lett.	   1984,	   25,	   1953;	   d)	   R.	   L.	   Dorta,	   C.	   G.	   Francisco,	   R.	   Freire,	   E.	   Suárez,	  
	   Tetrahedron	  Lett.	  1988,	  29,	  5429;	  e)	  R.	  Hernández,	  J.	  J.	  Marrero,	  E.	  Suárez,	  Tetrahedron	  Lett.	  1988,	  
	   29,	  5979.	  
203	  	  M.	   E.	   Kort,	   S.	  M.	   S.	   Strickland,	  H.	  M.	  Organ,	   L.	   A.	   Silks,	   S.	  D.	   Burke,	  Tetrahedron	   Lett.	  1994,	  35,	  
	   1503.	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3.3.2  Synthesis of the AB-Ring System 
 
(R)-Pulegone (3.83) was transformed via a Favorskii ring contraction 
reaction to the reported diastereomeric ester 3.118 (Scheme 3.21).204 To our 
surprise, direct α-alkylation reactions on this ester was not well established 
and several screening condition were conducted as well different alkylating 
reagents were tested to form the β-ketoester 3.134. First attempts by treating 
the ester with LDA and chloro ester 3.135 showed no conversion at all and 
the bromo ester 3.136 was tested in addition due to the higher expected 
reactivity, but only starting material 3.118 could be recovered. We suspect 
that the acidic α-protons might quench the nucleophilic enol ester. We 
switched to the brominated dioxin substrate 3.137 but already struggled with 
the preparation and only small quantities of the product could be obtained but 
also recovery of the starting material was observed due to the steric 
hindrance of the dioxin moiety. We simplified the alkylation reagent to TBS-
protected iodoethanol 3.138205  and the alkylated ester 3.139 was indeed 
formed using LDA. Commercially available LiHMDS (1 M solution in THF) 
showed only moderate yields. Optimization of the conditions showed that 
addition of HMPA or DMPU to LDA was crucial for full conversion, where in 
the absence of an additive only one of the diastereomers was alkylated. Both 
additives showed comparable yields and we proceeded the reaction with 
DMPU due to its safer handling. TBS-protecting group was removed using 
TBAF to the corresponding alcohol 3.140 and then oxidized with DMP to the 
corresponding aldehyde 3.141 in 89% yield. Finally, a Roskamp reaction206 
furnished the desired β-ketoester 3.134 in an excellent yield of 93%. Other 
methods like the Reformatsky reaction were not successful on this substrate. 
  
                                                                                                    
204	  	  R.	  M.	  Coates,	  P.	  R.	  Vettel,	  J.	  Org.	  Chem.	  1980,	  45,	  5430.	  
205	  	  C.	  Desroches,	  C.	  Lopes,	  V.	  Kessler,	  S.	  Parola,	  Dalton	  Trans.	  2003,	  2085.	  
206	  	  C.	  R.	  Holmquist,	  E.	  J.	  Roskamp,	  J.	  Org.	  Chem.	  1989,	  54,	  3258;	  Tetrahedron	  Lett.	  1992,	  33,	  1131.	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Scheme 3.21: Synthesis of the β-ketoester 3.134. a) Br2, NaHCO3, Et2O; b) NaOMe, MeOH, 
70 °C, 3 h, 80% (over two steps); c) LDA, THF, 3.135, –78 °C to r.t., 16 h; d) LDA, THF, 
3.136, –78 °C, to r.t., 16 h; e) LDA, DMPU, 3.138, THF, –78 °C to r.t., 77%; f) TBAF, AcOH, 
CH2Cl2, r.t., 16 h, 79%; g) DMP, CH2Cl2, 4 h, 89%; h) diazoacetoacetate, SnCl2 (cat.), CH2Cl2, 
r.t., 1 h, 93%. 
 
First reactions on the manganese(III)-mediated radical cyclization of the  
β-ketoster 3.134 to the desired cyclized product 3.142 showed a complex 
mixture of products or decomposition. Isolation of the reaction mixture by flash 
column chromatography yielded only in inseparable products, which made 
further analysis of the by-products unsuitable. Nevertheless, we suggest that 
the by-products arise from recombination of radical intermediates. We further 
tried to optimize the conditions (Table 3.2) by varying the temperature (entries 
2-3), solvent (entry 12), Mn(OAc)3 concentration (entries 4-6), salt source 
(entries 7-9) or order of addition (entries 10-11) in the reaction. To our 
disappointment, low yields or complex mixture were observed. We suggest 
that the substrate itself might not be suitable for this radical reaction. The best 
conditions were found with 50 °C in Ac2O yielding the cyclized product 3.142 
in a moderate yield of 39% (entry 1). Using this condition, the by-product 
formation could be suppressed, but the yield could not be further increased. 
We suggest that decomposition events of the starting material and radical 
intermediates may have taken place. 
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entry Mn(OAc)3 eq. salt, eq. conditions observation 
1 4.0 LiCl, 10 Ac2O, 50 °C 
39% 3.142 + 
polymer 
2 4.0 LiCl, 10 Ac2O, 80 °C 25% 3.142 
3 4.0 LiCl, 10 Ac2O, 120 °C complex mixture 
4 6.0 LiCl, 10 Ac2O, 50 °C 14% 3.142 
5 6.0 LiCl, 10 Ac2O, 80 °C 26% 3.142 
6 8.0 LiCl, 10 Ac2O, 50 °C 14% 3.142 
7 4.0 KCl, 10 Ac2O, 50 °C complex mixture 
8 4.0 NaCl,10 Ac2O, 50 °C complex mixture 
9 4.0 CuCl2, 4 Ac2O, 50 °C complex mixture 
10 4.0 LiCl, 10 
Ac2O, substrate 
add. over 1 h, 50 °C 
24% 3.142 
11 4.0 LiCl, 10 
Ac2O, Mn(OAc)3 
add. over 1 h, 50 °C 
decomposition 
12 4.0 LiCl, 10 AcOH, 50 °C 23% 3.142 + 
polymer 
Table 3.2: Screening conditions for the Mn(III)-mediated radical cyclization. 
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3.3.3  Formation of the C-Ring 
 
Assembly of the C-ring was initiated by the reduction of the ketone 3.142 to 
the alcohol 3.143 (Scheme 3.22). The reduction was completely 
diastereoselective and the absolute configuration was confirmed by X-ray 
crystal structure analysis. Similar substrates behaved the same for this 
reduction and a coordinating effect of the chlorine can be discounted, 
suggested a substrate controlled reduction.183 The alcohol 3.143 was then 
subjected to the regiospecific C-H activation in the presence of I2, a low-
pressure mercury lamp and CaCO3. The desired hydrofuran 3.144 was 
obtained in 81% yield along with the by-products 3.145 and 3.146. 
 
 
Scheme 3.22: Diastereoselective reduction and C-H activation. a) NaBH4, MeOH, 0 °C to r.t., 
4 h, 86%; b) Pb(OAc)4, I2, CaCO3, hν, r.t., 3 d, (81% 3.144, 15% 3.145, traces 3.146) 
 
The alcohol 3.143, hydrofuran 3.144 and the acetylated furan 3.145 
structures were secured by X-ray crystal structure analysis and represented in 
Figure 3.10. 
   
 
Figure 3.10: X-ray crystal structures of the alcohol 3.143, hydrofuran 3.144 and acetylated 
hydrofuran 3.145 (X-ray structure color code: green = chlorine; grey = carbon; red = oxygen; 
white = hydrogen). 
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The iodo-compound 3.146 was observed when the reaction time was 5 h, 
which indicates that the hydrofuran 3.144 formation is formed over time. Upon 
a reaction time extension and a higher loading of he reagents, the iodo-
compound 3.146 was only observed in traces but the acetylated by-product 
3.145 was additionally formed (confirmed by X-ray crystallography structure 
analysis). This is formed when the methyl group undergoes a second C-H 
activation, which is first attacked by the hydroxy group and then by an acetyl 
moiety. Both by-product formations are in agreement with the review of 
Kalvoda and Heusler.200 The isolated by-products could be successfully 
converted into the hydrofurane 3.144 in 88% yield by treating the iodo-
compound 3.146 with AgOAc and the acetylated hydrofurane 3.145 with BF3 x 
OEt2207 in 98% as shown in Scheme 3.23. 
  
Scheme 3.23: Conversion of the by-products 3.145 and 3.146 to the desired hydrofurane 
3.144. a) AgOAc, acetone, 60 °C, 10 h, 88%; b) BF3 x OEt2, Et3SiH, –78 °C to r.t., 15 h, 98%.  
 
β-Halo-ethers 3.144 can be eliminated to olefins through a Boord olefin 
synthesis.208 The elimination should directly form the α,β-unsaturated lactone 
3.147 as shown in Scheme 3.24. Classical elimination conditions using Zn209 
or ZnI2210 or alternative conditions using SmI2,211 CrCl2,212 Mn/TMSCl213 or  
BF3 x OEt2 yielded only in recovery of starting material. Also by heating the 
reactions, the starting material remained untouched.  
                                                                                                    
207	  	  S.	  Beszant,	  E.	  Giannini,	  G.	  Zanoni,	  G.	  Vidari,	  Tetrahedron:	  Asymmetry	  2002,	  13,	  1245.	  
208	  	  L.	  C.	  Swallen,	  C.	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  Boord,	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  Am.	  Chem.	  Soc.	  1930,	  52,	  651.	  
209	  	  M.	  Numazawa,	  K.	  Yamada,	  Steroids	  1999,	  64,	  320.	  
210	  	  A.	  K.	  Banerjee,	   J.	  A.	  Azócar,	  M.	  C.	  Sulbarán	  de	  Carrasco,	  M.	   L.	  Mimó,	  Synthetic	  Communications	  
	   2001,	  31,	  2471.	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  J.	  M.	  Concellón,	  H.	  Rodríguez-­‐Solla,	  M.	  Huerta,	  J.	  A.	  Pérer-­‐Andrés,	  Eur.	  J.	  Org.	  Chem.	  2002,	  1839.	  
212	  	  J.	  M.	  Concellón,	  H.	  Rodríguez-­‐Solla,	  C.	  Méjica,	  Tetrahedron	  Lett.	  2004,	  45,	  2977.	  
213	  	  J.	  M.	  Concellón,	  H.	  Rodríguez-­‐Solla,	  V.	  del	  Amo,	  P.	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  Synthesis	  2009,	  15,	  2634.	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Scheme 3.24: Boord elimination approach. a) Zn (activated), EtOH, 90 °C, 2 h or ZnI2, Ac2O, 
r.t., 15 h or SmI2, THF, r.t., 5 h or Mn, TMSCl, THF, 70 °C, 12 h or  CrCl2, THF, 70 °C, 12 h or 
BF3 x OEt2, AcOH, r.t. 5 h. 
 
We replaced the chlorine with a hydrogen using SnBu3H to yield the  
α-hydrogen furan 3.148, which gave the opportunity for further ring opening 
reactions (Scheme 3.25). We were pleased to see that the hydrofuran could 
smoothly be opened in the presence of BF3 x OEt2 yielding the bisacetyl 3.149 
and monoacetyl-compound 3.150. Interestingly, the same conditions were 
already applied on the α-chloro substrate 3.144, but only the starting material 
could be recovered. The fact that with substrate 3.148, the β,γ-unsaturated 
lactone 3.150 instead of the expected α,β-unsaturated lactone 3.151 is 
formed may be due to the more flexible structure, which is more suitable for 
elimination. Furthermore, basic treatment with LDA or LiHMDS to achieve 
elimination yielded only in recovery of the starting material, which might result 
from steric hindrance of the ether and ethylester moieties. 
 
 
Scheme 3.25: Hydrofuran opening. a) Bu3SnH, AIBN, 100 °C, 2 h, 95%; b) BF3 x OEt2, Ac2O, 
r.t., 15 h, 92% (3.149/3.150 = 3:1). 
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Material supply and an already installed oxygen function at C-7 made 
further synthetic progress more suitable with substrate 3.149. The bis-acetyl 
ester 3.149 was deprotected under standard conditions214 to the diol 3.152 in 
98% (Table 3.3). A bis-oxidation should readily install an aldehyde for the 
reductive cyclization and a β-ketoester moiety for the introduction of the 
alcohol in α-position. We first treated the diol 3.152 with DMP (Table 3.3, 
entry 1) and could isolate the desired oxidized product after flash column 
purification as the enol 3.153. However, the reduction was often not 
reproducible and alternative conditions were tested. Adding NaHCO3 (entry 2) 
to the reaction yielded only in a complex mixture. IBX showed a complex 
mixture in general, but further analysis showed the desired enol 3.153 along 
with another by-product, which was identified as the already α-hydroxylated 
product 3.154, but only in small quantities. Swern’s conditions showed only 
traces of the enol 3.155 but Ley-Griffith (entry 5) and Corey-Kim oxidation 
(entry 6) protocols showed good and reproducible yields of the enol 3.153. 
 
entry reagent conditions observation 
1 
 
DMP 
 
CH2Cl2, r.t., 3 h 
 
56% 3.153,  
not reproducible 
2 DMP, NaHCO3 CH2Cl2, r.t., 10 h complex mixture 
3 IBX CHCl3, r.t., 3 h 3.153 and 3.154 
4 DMSO, (COCl)2, 
NEt3 
CH2Cl2, –78 °C to r.t.,  
8 h 
3.153, traces 
5 
 
TPAP, NMO 
 
4Å molecular sieve, 
CH2Cl2, r.t., 16 h 
68% 3.153 
 
6 NCS, Me2S, NEt3 CH2Cl2, –78 °C, 3 h 72% 3.153 
Table 3.3: Deprotection and bis-oxdiation attempts. a) K2CO3, MeOH, r.t., 16 h, 98%. 
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The oxidation already indicated that a α-hydroxylation of the enol 3.153 is 
possible and we continued our efforts next on an effective hydroxylation 
insertion screening as summarized in Table 3.4. However the enol 3.153 
showed only limited reactivity for the described literature protocols (entries  
1-5). We increased further the amount of IBX and prolonged the reaction time, 
but only traces of the α-hydroxylated ketone 3.154 were found (entry 6). We 
were then pleased that the method of Christoffer’s, which produced desired 
compound 3.154 in traces for CoCl2 (entry 7) and in reasonable yields for 
CeCl3215 with O2 (entry 8) as the oxygen source.  
       
entry oxidation reagent conditions observation 
1 m-CPBA183 CH2Cl2, r.t., 16 h 3.153 
2 Mn(OAc)2 · 4 H2O, 
O2216 
CH2Cl2, r.t., 16 h 3.153 
3 Mn(OAc)3 · 2 H2O, O2 AcOH, r.t., 8 h 3.153 
4 OsO4, NMO189 t-BuOH, H2O, r.t., 16 h 3.153 
5 
 
Davis oxaziridine, 
LDA217 
THF, –25 °C to r.t., 16 h 
 
3.153 
 
6 IBX DMSO, r.t., 16 h traces of 3.154 
7 CoCl2, oxygen218 MeCN, iPrOH, 60 °C, 16 h traces of 3.154 
8 CeCl3 · 7 H2O, 
oxygen215 
iPrOH, r.t., 17 h 43% 3.154 
Table 3.4: α-Hydroxylation attempts. 
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  J.	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The proposed mechanism219 is depicted in Scheme 3.26. The oxygen acts 
as the oxidant and converts Ce(III) to Ce(IV), which forms with β-ketoester 
3.155 an enol-Ce(IV) intermediate 3.156 and a ligand-to-metal electron 
transfer (SET) occurs. The electrophilic α-radical 3.157 is then trapped by the 
nucleophilic water, which introduces the hydroxy function 3.158.220  
        
Scheme 3.26: Proposed Ce(III) radical α-hydroxylation mechanism.219 
3.3.4  Assembly of the ABCD-Ring System 
 
With the α-hydroxylated compound 3.154 in hand, we assumed that a 
reductive cyclization from the aldehyde to the ethylester should be highly 
favored (Scheme 3.27). However, a complex mixture of the triol 3.159 and 
cyclized product 3.160 was observed. This crude mixture was directly 
subjected to an acid catalyzed lactonization reaction to form the desired 
ABCD-ring 3.161 assembly in a low yield of 27% over two steps. A reason for 
the low yield could arise from solubility issues or instability of the triol 3.159. 
Due to material supply issues, we couldn’t further optimize these reaction 
conditions. 
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Scheme 3.27: Reduction and lactonization to obtain the ABCD-ring system 3.161. a) NaBH4, 
MeOH, 0 °C to r.t., 16 h; b) p-TsOH, PhMe, microwave, 70 °C, 2 h, 27% (over two steps). 
 
The olefin 3.161 was oxidized in allylic position to the enone 3.162 as 
shown in Scheme 3.28. A portion of the olefin 3.161 could be recovered and 
the yield was not determined due to the small reaction scale. The enone 
3.162 was further reduced using Luche conditions, yielding the allylic alcohol 
3.163 as a single diastereomer. However, NOESY-NMR and coupling 
constant analysis could not fully confirm the stereocenter orientation. In this 
sequence, we completed the synthesis of 3,4-dehydro-norneomajucin (3.161) 
and (1S)-2-oxo-3,4-dehydro-norneomajucin (3.162), which represents two 
nor-sesquiterpenes that will be evaluated for their neurotrophic properties. A 
third nor-sesquiterpenes was obtained, namely 2-hydroxy-3,4-dehydro-
norneomajucin (3.163), with unknown configuration at C-2 position. 
 
 
Scheme 3.28: Allylic oxidation of the bislactone 3.161 followed by Luche reduction. a) CrO3, 
3.5-DMP, CH2Cl2, r.t., 72 h, n.d.; b) CeCl3 x 7 H2O, NaBH4, MeOH/THF, –78 °C, 3 h, yield n.d. 
3.3.5  C1-Homologation Attempts Towards (−)-Jiadifenolide 
 
After a careful analysis of the hydrofuran 3.148 opening reaction, we saw 
that both products 3.149 and 3.150 can act as precursors for the synthesis of  
seco-prezizaanes as shown in Scheme 3.29. The diacetyl-compound 3.149 
can be further used to access the target structure (2R)-hydroxynorneomajucin 
(3.14), as most of the required oxygens are already placed. The eliminated 
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product 3.150 would be an ideal precursor for the sesquiterpene series such 
as (−)-jiadifenolide (3.10), because the C1-homologation of the methyl ester 
moiety would be much less problematic. 
 
Scheme 3.29: Strategic intermediates for the synthesis of nor-sesquiterpenes and 
sesquiterpenes. 
 
We first envisioned first to close the lactone moiety to the C-ring 3.164 and 
then a C1-homologation on the methyl ester-moiety to target intermediate 
3.165 in Sorensen total synthesis of (−)-jiadifenolide (3.10),190 as shown in 
Scheme 3.30. 
 
Scheme 3.30: C-ring formation and C1-homologation approach to target an advanced 
Sorensen’s intermediate 3.165 towards a formal synthesis of (−)-jiadifenolide (3.10). 
 
The acetyl deprotection of 3.150 using standard condition (K2CO3, MeOH) 
yielded in three C-ring products with 3.164 (confirmed by X-ray crystal 
structure analysis) as the major product (Scheme 3.31). Due to small 
quantities of compounds 3.166 and 3.167 we did not further investigate these 
products and continued our studies with substrate 3.164. 
 
Scheme 3.31: C-ring formation. a) K2CO3, MeOH, r.t., 16 h, 37% of 3.164, (3.166 and 3.167 
yield n.d; b) DBU, toluene, microwave, 110 °C, 12 h, yield n.d. 
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The methyl ester 3.164 can be manipulated in several ways for a  
C1-homologation. Kowalski and co-workers reported on a direct C1-
homologation of the reaction. However, this method is only rarely described in 
literature.221 The sequence attempted is shown in Scheme 3.32. However, 
monitoring the reaction by NMR or ESI-MS showed never the α-bromo ketone 
3.168 or the desired product 3.169. The dense shape of the molecule makes 
probably a nucleophilic attack of the reagents not feasible. 
    
Scheme 3.32: Kowalski’s ester homologation method. a) CH2Br2, LiTMP, THF, –78 °C; b) 
LiHMDS, n-BuLi, EtOH. 
 
We therefore switched to more common method for the C1-homologation 
such as reduction of the ester to an alcohol or aldehyde. The conditions and 
reaction is summarized in Table 3.5. Standard conditions using DIBAL-H 
(entries 1-6) yielded only in recovery of the starting material 3.164 or the 
complete reduced methyl functionality 3.170. Other reducing reagents (entries 
7-11) were not feasible to selectively obtain the desired aldehyde 3.171 or 
alcohol 3.172, and only the starting material 3.164 was recovered or a 
complex mixture was observed. Only super-hydride® (entry 12) showed traces 
of the aldehyde 3.171, unfortunately these result could not be reproduced. We 
concluded that the methyl ester is too sterically hindered already for a simple 
hydride and did not further investigate reductions or methyl ester 
manipulation. 
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entry reductant conditions observation 
1 DIBAL-H CH2Cl2, –78 °C to r.t., 16 h 3.170 
2 DIBAL-H CH2Cl2, –78 °C to r.t., 8 h 3.170 
3 DIBAL-H CH2Cl2, –78 °C to –40 °C, 4 h 3.170 
4 DIBAL-H CH2Cl2, –78 °C, 3 h 3.164 and 3.170 
5 DIBAL-H THF, –78 °C, 2 h 3.164 
6 DIBAL-H THF, –78 °C to 0°C, 12 h 3.170 
7 L-selectride CH2Cl2, –78 °C to –40 °C, 4 h 3.164 
8 Red-Al CH2Cl2, –78 °C to –40 °C, 4 h 3.164 
9 LiAlH4 THF, –78 °C to 0 °C, 2 h decomposition 
10 LAB THF, –20 °C, 3 h 3.164 
11 LAB THF, r.t., 3 h complex mixture 
12 Super-
hydride® 
CH2Cl2, –78 °C to –40 °C, 4 h traces of 3.171  
and by-products 
Table 3.5: Ester reduction conditions. 
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We targeted next the free carboxylic acid 3.173 as a suitable C1-
homologation precursor. The methylester 3.150 was saponificated with 
NaOH/iPrOH to yield the desired carboxylic acid 3.173 and we could observe 
that the C-ring was directly formed in an excellent yield of 88%. Further 
attempts to reduce the carboxylic acid 3.173 to the aldehyde 3.171 or alcohol 
3.172 were not successful (Table 3.6). DMS as a reducing reagent (entry 1) 
yielded only a complex mixture, as well as for super-hydride® (entry 2). Other 
conditions via the synthesis of the mixed anhydride and subsequent reduction 
to the alcohol is a known way to form alcohols from carboxylic acids. In our 
case, the mixed anhydride 3.174 was obtained (entry 3), but seemed to be 
quite unreactive under further reducing conditions. We next used a less 
sterically hindered anhydride but could never obtain the desired alcohol 3.172 
or mixed anhydride 3.175 and only the starting material 3.173 could be 
recovered (entries 4 and 5).  
 
entry reducing agent conditions observation 
1 DMS THF, 0 °C to r.t. complex mixture 
2 Super-hydride® CH2Cl2, –78 °C, 3 h complex mixture 
3 
 
NMM, ClC(O)Oi-Bu, 
Et3N, NaBH4 
THF, 0 °C to r.t. 
 
3.174 
 
4222 NMM, ClC(O)OMe, Et3N, 
NaBH4 
THF, 0 °C to r.t. 3.173 
5 NMM, ClC(O)OMe, Et3N, 
LiBH4 
THF, 0 °C to r.t. 3.173 
Table 3.6: C-ring formation and carboxylic acid 3.175 reduction attempts. a) NaOH, iPrOH, 
r.t., 16 h, 81%. 
  
                                                                                                    
222	  	  K.	  Prantz,	  J.	  Mulzer,	  Angew.	  Chem.	  Int.	  Ed.	  Engl.	  2009,	  48,	  5030. 
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The unreactivity towards several reducing conditions led finally to synthesis 
of the acyl chloride 3.176 by treating the carboxylic acid 3.173 with 
thionylchloride (Scheme 3.33). The crude acyl chloride 3.176 was then treated 
with Me3SiCN223, Me3SiCH2Li224 or MeLi but only the quenched carboxylic 
acid 3.173 was observed instead of the desired homologated products 3.177, 
3.178 or 3.179. 
 
    
Scheme 3.33: C1-homologation attempts on the acid chloride 3.176 moiety. a) SOCl2, 
CH2Cl2, 60 °C, 6 h; b) Me3SiCN (R = CN) or Me3SiCH2Li (R = CH2SiMe3) or MeLi (R = Me). 
 
To conclude, the C1-homologation was tested on several substrates 
(3.164, 3.173 and 3.176) but mostly the substrates were inert to any applied 
conditions (reduction, mixed anhydride, etc.). We propose that the ABC-ring 
system is shielding the carbonyl moiety towards nucleophiles. We therefore 
did not further investigate methyl ester 3.164 as a potential precursor for the 
synthesis of seco-prezizaane type sesquiterpenes. 
  
                                                                                                    
223	  	  K.	  Herrmann,	  G.	  Simchen,	  Synthesis	  1979,	  3,	  204.	  
224	  	  M.	  Obayashi,	  K.	  Utimoto,	  H.	  Nozaki,	  Bull.	  Chem.	  Soc.	  Jpn.	  1979,	  52,	  2646.	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3.4 Conclusion and Outlook 
 
In this project, the progress towards natural product-derived neurotrophins 
has been demonstrated. Several members of the genus Illicium are highly 
active neutrophic molecules and therefore, should be considered as potential 
treatment for neurodegenerative diseases, such as Alzheimer’s and 
Parkinson’s disease. (2R)-Hydroxynorneomajucin (3.14) represents a rare 
nor-sesquiterpenoid, which is a highly active neurotrophic modulator. The 
structure is of special interest, because nor-sesquiterpenoids are much less 
reported than their well-established sesquiterpene analogues. The presented 
synthesis herein was designed to target specifically nor-type structures and to 
create an activity map of nor-sesquiterpenoids. Our synthesis towards  
(2R)-hydroxynorneomajucin (3.14) is shown in Scheme 3.34. For the first 16 
steps, an overall yield of 0.5% was obtained. Starting from enantiopure (R)-
pulegone (3.83), the C2-unit 3.138 was introduced to the racemic ester 3.118 
and after deprotection of the TBS-protecting group, the free alcohol 3.140 was 
obtained. Synthesis of β-ketoester 3.134 involved a Roskamp reaction. A 
manganese(III)-mediated 6-endo-trig radical cyclization furnished the B-ring 
structure and alcohol 3.143 was obtained after a diastereoselective ketone 
reduction. A regiospecific, hydroxy-directed sp3 C-H activation gave the 
hydrofuran 3.144. Replacement of the chlorine by a hydrogen, opening of the 
hydrofurane ring and deprotection of the acetyl moieties furnished diol 3.152. 
The α-hydroxy group was inserted via a Ce-mediated hydroxylation to the  
α-hydroxyketone 3.154. A reductive cyclization furnished the ABCD-ring core 
3.161 of nor-sesquiterpenoid structures. This intermediate can be used as 
intermediate for further SAR-studies on nor-sesquiterpenoids. Furthermore 
three nor-sesquiterpenes, namely 3,4-dehydro-norneomajucin (3.161), (1S)-2-
oxo-3,4-dehydro-norneomajucin (3.162) and 2-hydroxy-3,4-dehydro-nor-
neomajucin (3.163) were synthesized and will be tested on their neurotrophic 
behavior. 
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Scheme 3.34: Synthetic progress towards (2R)-hydroxynorneomajucin (3.14). a) Br2, 
NaHCO3, Et2O, 0 °C, 1 h; b) NaOMe, MeOH, reflux; 3 h; 72% (over two steps); c) LDA, 
DMPU, 3.138, THF, –78 °C to r.t., 77% (single diastereomer); d) TBAF, THF, 0 °C to r.t., 18 
h, 79%; e) DMP, CH2Cl2, r.t., 2 h, 89%; f) ethyl diazoacetate, SnCl2 (cat), CH2Cl2, r.t., 12 h, 
93%; g) Mn(OAc)3, LiCl, Ac2O, 50 °C, 39%; h) NaBH4, MeOH, 0 °C to r.t., 4 h, 86%; i) 
Pb(OAc)4, I2, CaCO3, hν, 72 h, 95%; j) AIBN, Bu3SnH, PhH, 100 °C, 2 h, 95%; k) BF3 x OEt2, 
Ac2O, r.t., 15 h, 60%; l) K2CO3, MeOH, r.t., 16 h, 98%; m) NCS, Me2S, NEt3, –78 °C to r.t., 
72%; n) CeCl3 · 7 H2O, O2, iPrOH, r.t., 24 h, 43%; o) NaBH4, MeOH, 0 °C to r.t., 12 h; p)  
p-TsOH, toluene, 70 °C, microwave, 2 h, 27% (over two steps); q) CrO3, 3.5-DMP, CH2Cl2, 
r.t., 72 h, n.d.; r) CeCl3, NaBH4, MeOH/THF, –78 °C, 3 h, yield n.d.  
 
Due to time and material supply issues, the further steps towards (2R)-
hydroxynorneomajucin (3.14) could not be continued. Left to be completed is 
determination of the stereocenter in allylic alcohol 3.163. In case of a (R)-
configured alcohol 3.163a, the alcohol is protected 3.180 and the olefin 
(R)-(+)-Pulegone (3.83)
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epoxidized 3.181, followed by epoxide opening and deacetylation should 
furnish the target molecule (2R)-hydroxynorneomajucin (3.14, Scheme 3.35). 
 
Scheme 3.35: Proposed synthesis towards (2R)-hydroxynorneomajucin (3.14) from  
(R)-configured alcohol 3.163a. a) acetylation; b) epoxidation; c) epoxide opening; d) 
deacetylation. 
 
For a (S)-configured alcohol 3.163b, a hydroxy directed epoxidation to form 
epoxide 3.182 would be applied, followed by an epoxide opening to the known 
triol 3.109 (Scheme 3.36). Otherwise, the hydroxyepoxide 3.182 can be 
further oxidized to the ketone 3.183 and the epoxide opened to the β-
hydroxyketone 3.184. Substrates 3.109 and 3.184 are already known in 
literature as well as their further conversion to the final molecule  
(2R)-hydroxynorneomajucin (3.14).181 
 
 
Scheme 3.36: Proposed synthesis towards (2R)-hydroxynorneomajucin (3.14) from  
(S)-configured alcohol 3.163b. a) epoxidation; b) oxidation; c) epoxide opening; d) oxidation; 
e) reduction.
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4 Preparation of Antimalarial Endoperoxides by a 
Formal [2 + 2 + 2] Cycloaddition  
 
4.1 Introduction 
4.1.1  Malaria 
Malaria is a parasitic infectious disease225  and is still a public health 
problem of which almost half of earth’s population (3.2 billion people) is at risk 
of. Symptoms (fever, sweat, headache, vomiting, diarrhea, muscle pain and 
death) are developed after an incubation time of one to three weeks. Since 
malaria is still not curable, the WHO global anti-malaria program226 focused 
on suppression of its spreading and achieved promising results. The number 
of malaria cases dropped from 262 to 214 millionen cases (2000 – 2015), a 
decline of 18%. Even more satisfying is the decrease of reported deaths from 
839’000 to 438'000 (2000 – 2015), a decline of 48%. Around 80% of these 
deaths arose from 15 countries, mainly in Africa. 
 
The name malaria is derived from the Italian mal’ aria (bad air, introduced 
by Giovanni Maria Lancisi in 1717),227 which has its origin from foul-smelling 
swamps near Rome and it is speculated that malaria (known as “Roman 
fever”) had a tremendous impact of the fall of the Roman empire.228 The 
elucidation of the malaria infection pathway was identified by Sir Ronald Ross 
(1857 – 1932).229 He was awarded for his pioneering work with the Nobel 
Prize in Physiology or Medicine in 1902 “for his work on malaria, by which he 
has shown how it enters the organism and thereby has laid the foundation for 
                                                                                                    
225	  	  For	  a	  historical	  review	  of	  malaria	  see:	  E.	  Hempelmann,	  K.	  Krafts,	  Malaria	  Journal	  2013,	  12,	  232.	  
226	  	  World	  Malaria	  report	  WHO	  2015.	  
227	  	  E.	  Ferroni,	  T.	  Jefferson,	  G.	  Gachelin,	  J.	  R.	  Soc.	  Med.	  2012,	  105,	  35.	  
228	  	  R.	  Carter,	  K.	  N.	  Mendis,	  Clin.	  Microbiol.	  Rev.	  2002,	  15,	  564.	  
229	  	  E.	  Capanna,	  International	  Microbiology	  2006,	  9,	  69.	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successful research on this disease and methods of combating it”. 230 
However, Ross only described the infection of birds and not of humans. The 
complete life cycle of the parasite Plasmodium falciparum and its vector, the 
mosquito Anopheles claviger, was discovered by the italian physician and 
zoologist Giovanni Battista Grassi (1854 – 1925).231 The subtype Anopheles 
gambiae is the most effective vector and therefore the most dangerous one, 
because it needs human blood to feed their offspring. Malaria is caused by a 
protozoan (single-celled) parasite from the Plasmodium family. The most 
common are Plasmodium falciparum, which is also the deadliest, and 
Plasmodium vivax. Malaria can be detected232 by blood staining (Figure 4.1) 
         
Figure 4.1: Infected cells by P. falciparum. Purple spots = biomineralization “malaria-
pigment”.233  
 
The parasite itself cannot be seen by this method, but is indirectly detected 
by the dark violet spots, the so called “malaria-pigment”. In the mature step of 
                                                                                                    
230 	  "Ronald	   Ross	   -­‐	   Facts".	   Nobelprize.org.	   Nobel	   Media	   AB	   2014.	   Web.	   26	   Apr	   2016.	  
	   <http://www.nobelprize.org/nobel_prizes/medicine/laureates/1902/ross-­‐facts.html>	  
231	  	  F.	  E.	  G.	  Cox,	  Parasites	  &	  Vectors	  2010,	  3,	  5.	  
232	  	  a)	  N.	  Tangpukdee,	  C.	  Duangdee,	  P.	  Wilairatana,	  S.	  Krudsood,	  Korean,	  J.	  Parasitol.	  2009,	  47,	  93;	  b)	  
	   C.	  Wongsrichanalai,	  M.	  J.	  Barcus,	  S.	  Muth,	  A.	  Sutamihardja,	  W.	  H.	  Wernsdorfer,	  Am.	  J.	  Trop.	  Med.	  
	   Hyg.	  2007,	  77,	  119.	  
233	  	  Picture	  provided	  by	  Dr.	  Marcel	  Kaiser,	  Swiss	  Tropical	  and	  Health	  Institute	  Switzerland.	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the parasite, hemoglobin is degraded by proteases to amino acids and 
peptides needed for the further parasite development. A formed product in 
this process is heme(Fe(II)) and upon dimerization forms hematin(Fe(III)), 
which is toxic to the parasite. The parasite evolved a mechanism to 
circumvent the toxicity by a biomineralization process to form non-toxic 
hemozoin (malaria-pigment), which can be stained to indirectly identify the 
malaria infection.234 
4.1.2  Life Cycle of the Parasite 
The parasite life cycles235 involves various stages and forms as depicted in 
Figure 4.2.  
    
Figure 4.2: Schematic life cycle of the malaria parasite. 
Malaria parasites are first transmitted via the bite (saliva) of an infected 
female Anopheles mosquito (1). The released sporozoites infect the 
hepatocytes (liver cells) and mature into forms called schizont (2). Each 
                                                                                                    
234	  	  P.	  M.	  O’Neill,	  V.	  E.	  Barton,	  S.	  A.	  Ward,	  Molecules	  2010,	  15,	  1705.	  
235	  	  T.	  F.	  de	  Koning-­‐Ward,	  P.	  R.	  Gilson,	  B.	  S.	  Crabb,	  Nat.	  Rev.	  Microbiol.	  2015,	  13,	  373.	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schizont multiplies into thousands of their next form named merozoites (3). At 
this stage, the merozoites destroy hepatocyte cell and get released in the 
bloodstream, where they infect the erythrocytes (blood cells) (4). The 
parasites grow further, multiply and finally rapture the blood cell (5). So far 
only asexual replication occurred, where at this stage the parasite can 
replicate into male or female gametocytes (sexual pathway) (6). The 
anopheles mosquito then again takes up these sexual divided parasites from 
the bloodstream (7), where finally a combination of the gametocytes into a 
zygote occurs (8) and further processes finally releases again sporozoites into 
the saliva of the Anopheles mosquito (9). All these life cycle stages are 
potential treatments opportunities to combat the parasite in human and 
mosquito. However, due to the complex life cycle, each stage (liver cells, 
erythrocytes, blood stream etc.) had to be targeted specifically by the 
antimalarial drug. Otherwise not treated parasite forms will be still able to 
infect further tissues and the life cycle of the parasite starts again. An ideal 
drug should therefore combat at all mature stages with full effectivity.236 
4.1.3  Malaria Prevention Strategies 
 
The inhibition of malaria and its parasite can be addressed indirectly by 
treating their vector, the Anopheles mosquito. The so-called vector 
management control involves different strategies.237 An early method was the 
use of dichlorodiphenyltrichloroethane 238  (DDT, 4.1, Scheme 4.1), 
synthesized from chlorobenzene (4.2) and chloral (4.3). DDT 4.1 acts as a 
contact poison and was sprayed on house walls, where it gets in contact with 
the Anopheles mosquito. However, DDT 4.1 seems to be involved in cancer 
development and birds die, and therefore not often used anymore for malaria 
treatment.239  
                                                                                                    
236	  	  M.	  A.	  Biamonte,	  J.	  Wanner,	  K.	  G	  Le	  Roch,	  Bioorg.	  Med.	  Chem.	  Lett.	  2013,	  23,	  2829.	  
237	  	  F.	  Castelli,	  S.	  Odolini,	  B.	  Autino,	  E.	  Foca,	  R.	  Russo,	  Pharmaceuticals	  2010,	  3,	  3212.	  
238	  	  O.	  Zeidler,	  Berichte	  der	  deutschen	  chemischen	  Gesellschaft	  1874,	  7,	  1180.	  
239	  	  a)	  H.	  Bouwman,	  R.	  Bornan,	  H.	  van	  den	  Berg,	  H.	  Kylin,	  Environmental	  Health	  Perspectives	  2011,	  
	   119,	  744;	  b)	  C.	  S.	  Berry-­‐Cabán,	  Journal	  of	  Military	  and	  Veteran’s	  Health	  2011,	  19,	  19.	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Scheme 4.1: Synthesis of DDT (4.1) by Othmar Zeidler in 1874. a) H2SO4 (cat.). 
 
Another approach is the use of a net during sleep. This method prevents to 
get bitten by the mosquito during night, which is the active time of the 
mosquito. A biological approach for the combat of malaria is the use of 
larvivorous fishes, which are eating the larvae and pupae of the anopheles 
mosquito in water. However, the release of fishes into a new environment can 
tremendously influence the biological balance of the habitat.226 
4.1.4  Small Molecules as Potential Malaria Treatment Candidates 
 
Early malaria prevention was already reported in the 17th century. The 
extracts of the quina-quina bark had a positive effect on the malaria 
symptoms and quinine (4.4) was isolated as the active antimalarial agent 
(Figure 4.3).240 Methylene-blue (4.5) was the first fully synthetic compound241 
used against malaria. Paul Guttmann and Paul Ehrlich used in 1891 
methylene-blue (4.5) as the first malaria parasite stain and concluded that 
methylene-blue (4.5) also might be harmful to the parasite. However, it was 
not as effective as quinine (4.4).242 
 
A major contribution and a beginning of a new antimalarial treating era was 
the discovery of chloroquine (4.6) (or Resochin, from it’s salt resorcinate of a 
4-aminochinolin). Johann “Hans” Andersag (1902 – 1955) synthesized 
chloroquine (4.6) at the pharmaceutical company Bayer in 1934 and it is still 
one of the most used antimalarial agents up to today. Chloroquine (4.6) 
                                                                                                    
240	  	  J.	  Achan,	  A.	  O.	  Talisuna,	  A.	  Erhart,	  A.	  Yeka,	  J.	  K.	  Tibenderana,	  F.	  N.	  Baliraine,	  P.	  J.	  	  Rosenthal,	  U.	  
	   D’Alessandro,	  Malaria	  Journal	  2011,	  10,	  144.	  
241	  	  R.	   H.	   Schirmer,	   H.	   Adler,	   M.	   Pickhardt,	   E.	   Mandelkow,	   Neurobiol.	   Aging	   2011,	   32,	   2325.e7–
	   2325.e16.	  
242	  	  K.	  Krafts,	  E.	  Hempelmann,	  A.	  Skórska-­‐Stania,	  Parasitol.	  Res.	  2012,	  111,	  1.	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interrupts the biocrystallization of the non-toxic hemozoin (malaria-pigment) 
by binding to heme, which then still can act as antimalarial agent. 243 
Nevertheless, chloroquine (4.6) resistant parasite strains are reported and 
chloroquine (4.6) is nowadays used in combination with other antimalarial 
compounds such as artemisinin (1.9).226 
 
Figure 4.3: First malaria preventing agents. 
Artemisinin (1.9) (Scheme 4.2) was isolated from Artemisia annua 
(qinghaosu) 244  and is a sesquiterpene lactone with a characteristic 
endoperoxidal motif.245 The structure consists of five oxygen atoms, which are 
parts of cyclic ether, peroxy ether, a lactone as well as a cyclic acetal and 
ketal moiety. Initial structure studies showed that the peroxy bridge is crucial 
for the antimalarial activity and its reduced ether analogue completely lost its 
antimalarial activity.246 
The discovery and further beneficial applications for human health was then 
awarded with the Nobel Prize in Physiology or Medicine 2015 for Youyou Tu 
“for her discoveries concerning a novel therapy against Malaria”. 247 
Artemisinin (1.9) is one of the most common drugs for malaria treatment.  
  
                                                                                                    
243	  	  D.	  J.	  Sullivan	  Jr.,	  I.	  Y.	  Gluzman,	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  Goldberg,	  Proc.	  Natl.	  Acad.	  Sci.	  1996,	  93,	  11865.	  
244	  	   C-­‐ORGo,	  Chin.	  Med.	  J.	  (Engl.)	  1979,	  92,	  811.	  
245	  	  a)	  J.	  M.	  Liu,	  M.-­‐Y.	  Ni,	  Y.-­‐Y.	  Tou,	  Z.-­‐H.	  Wa,	  Y.-­‐L	  Wu,	  W.	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  Chou,	  Acta	  Chim.	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  1979,	  37,	  129;	  	  b)	  
	   D.	  L.	  Klayman;	  A.	  J.	  Lin,	  N.	  Acton,	  J.	  P.	  Scovill,	  J.	  M.	  Hoch,	  W.	  K.	  Milhous,	  A.	  D.	  Theoharides,	  A.	  S.	  
	   Dobek,	  J.	  Nat.	  Prod.	  1984,	  47,	  715;	  c)	  Y.	  Tu,	  Nat.	  Med.	  2011,	  17,	  1217.	  
246	  	  Z.	  Guo,	  Acta	  Pharmaceutica	  Sinica	  B	  2016,	  6,	  115.	  
247	  	  "Youyou	   Tu	   -­‐	   Facts".	   Nobelprize.org.	   Nobel	   Media	   AB	   2014.	   Web.	   26	   Apr	   2016.	  
	   <http://www.nobelprize.org/nobel_prizes/medicine/laureates/2015/tu-­‐facts.html>	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The possible artemisinin (1.9) interaction and degradation is shown in 
Scheme 4.2. It is proposed that the endoperoxide bridge is cleaved to 
elaborate a O1- or O2-centered-radical species (4.7 and 4.8). Upon 
rearrangement, C-centered radicals are formed (4.9 and 4.10) and these 
species are postulated to recombine with multiple molecules (degradation 
products 4.11, 4.12, 4.13 and 4.14) within the cell and initiates the parasites 
death.248 The selectivity of artemisinin (1.9) towards infected erythrocytes 
arises from the presence of heme(Fe(II)), due to parasitic hemoglobin 
degradation, whereat healthy tissues contain the intact oxyhemoglobin.249 
 
 
Scheme 4.2: Proposed radical-degradation pathway of artemisinin (1.9). 
  
                                                                                                    
248	  	  a)	  S.	  Krishna,	  A.-­‐C.	  Uhlemann,	  R.	  K.	  Haynes,	  Drug	  Resist.	  Updat.	  2004,	  7,	  233;	  b)	  P.	  M.	  O’Neill,	  V.	  E.	  
	   Barton,	  S.	  A.	  Ward,	  Molecules	  2010,	  15,	  1705.	  
249	  	  D.	  J.	  Creek,	  E.	  Ryan,	  W.	  N.	  Charman,	  F.	  C.	  K.	  Chiu,	  R.	  J.	  Prankerd,	  J.	  L.	  Vennerstrom,	  S.	  A.	  Charman,	  
	   Antimicrob.	  Agents	  Chemother.	  2009,	  53,	  3496.	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The biosyntheis250 (Scheme 4.3) of artemisinin (1.9) starts from acetyl-CoA 
(4.15) via mevalonate (4.16) to farnesyl diphosphate (FPP, 3.25). The enzyme 
amorphadiene synthase251 (ADS) cyclizes FPP to amorphadiene (4.17). The 
bicyclic intermediate is then oxidized to either artemisinic acid (4.18) or 
dihydroartemisinic acid (4.19) in an enzymatic pathway.252 The latter is then 
converted in a non-enzymatic fashion to artemisinin (1.9), via a sunlight driven 
photochemical253 reaction using chlorophyll as photosensitizer. 
 
 
Scheme 4.3: Biosynthesis of artemisinin (1.9). 
 
Enantioselective total syntheses of artemisinin (1.9) had been reported254 
as well as a flow chemistry process255 was developed. Scheme 4.4 shows the 
                                                                                                    
250	  	  C.	  J.	  Paddon,	  J.	  D.	  Keasling,	  Nat.	  Rev.	  Microbiol.	  2014,	  12,	  355.	  
251	  	  S.	  Picaud,	  P.	  Mercke,	  X.	  He,	  O.	  Sterner,	  M.	  Brodelius,	  D.	  E.	  Cane,	  P.	  E.	  Brodelius,	  Arch.	  Biochem.	  
	   Biophys.	  2006,	  448,	  150.	  
252	  	  M.	   E.	   Olsson,	   L.	   M.	   Olofsson,	   A.-­‐L.	   Lindahl,	   A.	   Lundgren,	   M.	   Brodelius,	   P.	   E.	   Brodelius,	  
	   Phytochemistry	  2009,	  70,	  1123.	  
253	  	  G.	  D.	  Brown,	  Molecules	  2010,	  15,	  7603.	  
254	  	  a)	  M.	   A.	   Avery,	  W.	   K.	  M.	   Chong,	   C.	   Jennings-­‐White,	   J.	   Am.	   Chem.	   Soc.	   1992,	   114,	   974;	   b)	   J.	   S.	  
	   Yadav,	  R.	  S.	  Babu,	  G.	  Sabitha,	  Tetrahedron	  Lett.	  2003,	  44,	  387;	  c)	  C.	  Zhu,	  S.	  P.	  Cook,	  J.	  Am.	  	   Chem.	  
Soc.	  2012,	  134,	  13577;	  d)	  J.	  S.	  Yadav,	  B.	  Thirupathaiah,	  P.	  Srihari,	  Tetrahedron	  2010,	  66,	  	   2005;	  e)	  G.	  
Schmid,	  W.	  Hofheinz,	  J.	  Am.	  Chem.	  Soc.	  1983,	  105,	  624.	  
255	  	  F.	  Lévesque,	  P.	  H.	  Seeberger,	  Angew.	  Chem.	  Int.	  Ed.	  2012,	  51,	  1706.	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general strategy for the synthesis of artemisinin (1.9). 256  The enol 4.20 
(Scheme 4.4a) undergoes first a photooxygenation to form the  
α-hydroperoxide 4.21, which undergoes an acid-mediated ring closure to form 
artemisinin (1.9). A semi-synthetic pathway was elaborated (Scheme 4.4b) 
starting from artemisinic acid (4.18), which can be isolated from Artemisia 
annua in high amounts. Key transformation is a Hock cleavage257 of the 
hydroperoxide 4.22 to enol 4.20 to form finally artemisinin (1.9). 
 
Scheme 4.4: General established synthetic strategies for the synthesis of artemisinin (1.9). 
4.1.5  Novel Endoperoxidal Antimalarial Scaffolds 
 
Endoperoxides have shown to be remarkable antimalarial agents since the 
discovery of artemisinin (1.9). Artemisinin (1.9) SAR-studies led to even more 
potent antiplasmodial agents258 and are recommended by the WHO for the 
treatment of malaria. 259  However, since it had been heavily used, the 
Plasmodium parasite developed widespread resistance against the drug.226 
Therefore, the research and development in the field of endoperoxide 
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  M.	  A.	  Corsello,	  N.	  K.	  Garg,	  Nat.	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  Rep.	  2015,	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  359.	  
257	  	  a)	  J.-­‐P.	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  Commun.	  2002,	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   Guidelines	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  treatment	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structures is urgently needed. Novel molecular endoperoxidal scaffolds260 
(molecules 4.23 – 4.28) are regarded as promising 2nd generation antimalarial 
agents and summarized in Figure 4.4.  
 
     
Figure 4.4: Endoperoxide scaffolds. 
 
These newly investigated endoperoxidal scaffolds236 have shown to be 
highly active in the sub-nanomolar range and showed good cytotoxic 
compatibility. OZ277 4.29 and OZ439 4.30 are promising candidates in 
clinical phases (Figure 4.5). 261  SAR-studies on OZ277 4.29 led to the 
identification of OZ439 4.30. An improved pharmacokinetic effect was 
achieved by varying the side chain from an alkyl to an aryl group,262 which led 
to a higher stability of the O-O bond towards Fe(II), probably due to steric 
reasons. In vivo test showed that a single dose of OZ439 4.30 was sufficient 
for a total cure of malaria, whereas a single dose treatment using artemisinin 
was insufficient. RKA 182 4.31 represents a tetraoxanescaffold.263,264 This 
scaffold is superior to dioxolane in terms of stability and often activity.265 
CDRI-97/78 4.32 consists of a trioxane moiety and clinical phase I tests are 
ongoing.266  
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  A.	  O.	  Terent’ev,	  D.	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  V.	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  2011,	  108,	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   7581;	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   4459;	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Figure 4.5: Scaffolds of novel antimalarial peroxides. 
4.1.6  Natural Products Containing a 1,2-Dioxan-3-ol Scaffold –  
    G-Factors 
 
The G-factor series 267 (plant growth regulators, molecules 4.33 – 4.35) 
were extensively studied by the group of Baltas and André-Barrès and their 
synthetic investigations as well as anitplasmodial activities are suggesting that 
1,2-dioxane-3-ol motifs are valuable antiplasmodial agents. 1,2-Dioxane-3-ol 
has an additional free hydroxy function in position 3 on the common 1,2-
dioxane scaffold. These antimalarial active natural products were isolated 
from Eucalyptus grandis268 and their general structure is illustrated in Figure 
4.6. 
        
Figure 4.6: G-factor (G1 4.33, G2 4.34, G3267a 4.35) series with the 1,2-dioxane-3-ol motif. 
 
SAR-studies showed that modifications of the free hydroxy (4.36 and 4.37) 
to a hemiketal function (4.38 and 4.39) have minor influences on the 
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  a)	  M.	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antimalarial activity (Scheme 4.5a).269  Further, it was found that the free 
hydroxy (G3, 4.35) or either acetylated hydroxy function 4.40 is crucial for 
antiplasmodial activity (Scheme 4.5b). 270  Substitution of the free hydroxy 
group with to a fluorine 4.41 led to decreased anitplasmodial activity. The 
studies indicated that the G-factor series with the general 1,2-dioxane-3-ol 
scaffold itself are promising for future malaria treatment agents.  
 
  
Scheme 4.5: Modified G-factors; values obtained from antiplasmodial tests269-270 against the 
Nigerian strain of Plasmodium falciparum. a) n-BuLi, THF, −78 °C, 1 h, then MeOTf, −78 °C, 3 
h, 83%; b) Ac2O, Et3N, CH2Cl2; c) DAST, 50%. 
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  a)	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4.1.7  Mn(III)-Catalyzed Approaches Towards 1,2-Dioxane-3-ol 
The endoperoxide scaffold acts as a synthon of furans and are therefore 
often used as an intermediate in total syntheses.271 In the protecting group 
free synthesis of (±)-yezo’otogirin C (4.42), Lee and co-workers applied an 
intramolecular manganese-mediated radical cyclization of a β-ketoester 4.43 
with an olefin to reach the 1,2-dioxane-3-ol intermediate 4.44. 272  After a 
tedious screening the bioinspired oxidative cyclization was achieved using 
Mn(II)/Mn(III) and oxygen (Kurosawa and Nishino’s conditions). 273  The 
peroxide bridge was then reduced to afford the desired furane moiety and 
further manipulations yielded the desired natural product (±)-yezo’otogirin C 
(4.42) as shown in Scheme 4.6. 
 
Scheme 4.6: Manganese mediated peroxide formation in Lee’s total synthesis of (±)-
yezo’otogirin C (4.42). a) Mn(OAc)2 x 4 H2O, Mn(OAc)3 x 2 H2O (cat.), O2, EtOH, r.t., 2 d, 
55%. 
 
An impressive manganese–mediated radical peroxide bridge formation was 
reported by Gao and co-workers in their synthesis of the anticancer agent  
(+)-fusarisetin A (4.45, Scheme 4.7).274 Their careful analysis of previously 
reported possible biosynthetic intermediates, 275  showed that equisetin 
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  2014,	  25,	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(4.46)276 could act as a suitable precursor. Treating equisetin (4.46) in the 
presence of a catalytic amount of Mn(III)acetate and oxygen formed 
peroxyfusarisetin (4.47) via a formal [2 + 2 + 2] cycloaddition reaction. The 
natural product was obtained after reduction of the peroxide bridge with zinc 
to form (+)-fusarisetin A (4.45). 
 
Scheme 4.7: Gao’s synthesis of (+)-fusarisetin A (4.45): a) Mn(OAc)3·2 H2O (cat.), O2, r.t., 
AcOH, 2 h; b) Zn, 50 °C, 2 h, 41% (over two steps).  
4.2 Goal of this Study 
 
In the course of our studies towards the natural product Striatal A (see 
chapter five of this thesis), we found an unexpected transformation in which a 
spontaneous reaction of an intermediate gave rise to a novel 1,2-dioxane-3-ol. 
Surprisingly, the reaction proceeded without the presence of any metal or 
solvent, solely air and sunlight was required for the transformation. In this 
study we aimed to elucidate the antimalarial activity of these novel 
endoperoxides and their derivatives. These possible new antimalarial agents 
would be readily available from inexpensive starting materials and provide a 
new lead compound for further antiplasmodial activity studies. 
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4.2.1  Synthesis of 1,2-Dioxane-3-ol via a Formal [2 + 2 + 2]     
    Cycloaddition 
 
The synthesis of the endoperoxides 4.48 and 4.49 commenced from 
commercially available enantiopure (S)-limonene (4.50) following a modified 
procedure from Wender and co-workers (Scheme 4.8).277 The terminal olefin 
was regioselectively reduced to the methyl function and the trisubstituted 
olefin cleaved via an ozonolysis to yield the desired ketoaldehyde 4.51. A 
Dieckmann condensation furnished the five-ring and the aldehyde was 
reduced to the allylic alcohol 4.52 using DIBAL-H. We were pleased to see 
that the Eschenmoser-Claisen rearrangement278 was superior to the reported 
Claisen-rearrangement.277 An improved diastereomeric ratio of 10:1 and 90% 
yield could be enhanced to a diastereomeric ratio of 24:1 and 95% yield for 
the formed amide 4.53 The inseparable diastereomeric amide mixture was 
then reduced 279  in the presence of 1,1,3,3-tetramethyldisiloxane in 
combination with Ti(OiPr)4 to the known aldehyde 4.54277 in 95% yield. Other 
reduction methods via an ate-complex, 280  DIBAL-piperidine complex281  or 
triethoxyaluminumhydride282 proved to be inefficient. Finally, the diketone 4.55 
was obtained from a L-proline catalyzed Knoevenagel condensation and the 
obtained olefin was reduced in situ in the presence of Hantzsch ester. NMR-
analysis showed the desired keto-enol products 4.55 along with a minor by-
product. NMR-measurements over several days gave a clean formation of the 
keto-enol product 4.55 to the by-product, which was identified after intensive 
NMR, mass spectrometry and crystal structure analysis as a novel 
endoperoxidal scaffold 4.48 and 4.49. Optimized conditions were found for 
                                                                                                    
277	  	  P.	  A.	  Wender,	  F.	  C.	  Bi,	  M.	  A.	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  F.	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  2001,	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  2105.	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  K.	  Steen,	  A.	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  Helv.	  Chim.	  Acta	  1964,	  47,	  2425;	  b)	  V.	  Bisai,	  R.	  
	   Sarpong,	  Org.	  Lett.	  2010,	  12,	  2551.	  
279	  	  a)	   S.	   Bower,	   K.	   A.	   Kreutzer,	   S.	   L.	   Buchwald,	  Angew.	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   Int.	   Ed.	   Engl.	   1996,	   35,	   1515;	   b)	   S.	  
	   Laval,	  W.	  Dayoub,	  A.	  Favre-­‐Reguillon,	  P.	  Demonchaux,	  G.	  Mignani,	  M.	  Lemaire,	  Tetrahedron	  Lett.	  
	   2010,	  51,	  2092.	  
280	  	  S.	  Kim,	  K.	  H.	  Ahn,	  J.	  Org.	  Chem.	  1984,	  49,	  1717.	  
281	  	  S.	  M.	  Woo,	  M.	  E.	  Kim,	  D.	  K.	  An,	  Bull.	  Korean	  Chem.	  Soc.	  2006,	  27,	  1913.	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  H.	  C.	  Brown,	  A.	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  J.	  Am.	  Chem.	  Soc.	  1964,	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  1089.	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this unexpected conversion by treating the instable diketone 4.55 with oxygen 
in EtOAc to yield the endoperoxides 4.48 and 4.49 in 65% and a 
diastereomeric ratio of 5:1. The yield was even further increased to 97% using 
a catalytic amount of Mn(OAc)3 in AcOH, which acts as a SET-transfer 
reagent.272,274 
 
Scheme 4.8: Synthesis of endoperoxides 4.48 and 4.49. a) H2, PtO2 (cat.), THF, r.t., 94%; b) 
O3, Zn/AcOH, CH2Cl2/MeOH (5:1), −78 °C, 94%; c) piperidine, AcOH, benzene, 110 °C, 75%; 
d) DIBAL-H, Et2O, 0 °C, 96%; e) 1,1-dimethoxyethyl(dimethyl)amine, p-xylene, 16 h, 150 °C, 
95% (d.r. = 24:1); f) 1,1,3,3-tetramethyldisiloxane, Ti(OiPr)4, THF, r.t., 18 h, 95%; g) L-proline, 
Hanztsch ester, CH2Cl2, r.t., 19 h, 91%; h) hν, O2, EtOAc, r.t., 16 h, 65%; i) AcOH, O2, 
Mn(OAc)3 (cat.), r.t., 19 h, 97%. 
4.2.2  Mechanistic considerations  
 
This unusual reaction can be regarded as a formal [2 + 2 + 2] cycloaddition 
and the use of this transformation was demonstrated by a variety of other 
groups.283 We propose a formal [2 + 2 + 2] cycloaddition mechanism, which is 
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  a)	  T.	  Yamada,	  Y.	  Iwahara,	  H.	  Nishino,	  K.	  J.	  Kurosawa,	  Chem.	  Soc.,	  Perkin	  Trans.	  1	  1993,	  609;	  b)	  S.-­‐I	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  T.	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  T.	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  Nishino,	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  D.	  Korp,	  K.	  Kurosawa,	  Tetrahedron	  Lett.	  1990,	  31,	  6371;	  c)	  
	   R.	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  H.	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  Nguyen,	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  Lett.	  2001,	  42,	  69;	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   Lett.	  2004,	  45,	   703;	   e)	   K.	  Asahi,	  H.	  Nishino,	  Tetrahedron	  
	   2005,	  61,	   11107;	   f)	   K.	   Asahi,	   H.	  Nishino,	  Eur.	   J.	   Org.	   Chem.	  2008,	  2008,	   2404;	   g)	  M.	   Persico,	   A.	  
	   Quintavalla,	   F.	   Rondinelli,	   C.	   Trombini,	  M.	   Lombardo,	   C.	   Fattorusso,	   V.	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   Parapini,	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   Chianese,	   E.	   Fattorusso,	  O.	   Taglialatela-­‐Scafati,	   J.	  Med.	   Chem.	  2011,	  54,	  
	   8526;	  h)	  G.	  Majetich,	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  2013,	  15,	  4924.	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initiated by an autooxidation284 to give the α-keto-radical 4.56 of the diketone 
4.55 as depicted in Scheme 4.9. A 6-endo-trig cyclization with the terminal 
double bond gives the tricyclic framework with a C-centered tertiary radical 
species 4.57 or 4.58. The diastereoselectivity can be explained by the 
hybridization of the tertiary radicals 4.57 and 4.58, where latter is less favored 
due to a 1,3-steric interaction of the methyl and isopropyl residue. 
Furthermore, a trans-[4.3.0]nonane framework is less preferred than the cis-
analogue. In addition, the intermediate 4.57 may have a better orbital overlap 
between the SOMO and the non-bonding orbital of the carbonyl function, than 
intermediate 4.58, which gives further a stabilizing effect. Addition of O2 to 
either 4.57 or 4.58 forms the peroxyradical intermediate 4.59 (only the major 
diastereomer pathway is shown). Upon ring flip, cyclization with the carbonyl 
function of 4.60 yields in the major endoperoxide diastereomer 4.48. 
 
 
Scheme 4.9: Proposed mechanism for the endoperoxide formation. 
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We further investigated on the proposed mechanism by adding the radical 
inhibitor BHT to the reaction mixture and indeed no endoperoxide product 
could be observed. Unfortunately, radical trapping experiments with TEMPO 
failed and only decomposition of the starting material could be observed. The 
intramolecular radical addition and steric effects of the condensed molecular 
scaffold might not allow a radical trapping with TEMPO. 
4.2.3  SAR-studies and Antiplasmodial Activity 
 
An initial antiplasmodial activity test of the endoperoxides 4.48 and 4.49 on 
the parasite Plasmodium falciparum showed promising IC50-values in the 
nanomolar range as well as low cytotoxicity values (rat myoblast L6 cells). We 
then further elucidated the activity dependency of the C-3 functionality and 
therefore synthesized derivatives of the parent compound (Scheme 4.10).285 
O-Methylation under standard methylation conditions (p-TsOH/MeOH) were 
not suitable due to low and incomplete conversion. Applying Irvine-Purdie 
conditions286 using Ag2O and MeI furnished the methylated endoperoxide 
acetals 4.61 and 4.62 in reasonable yields (88%, 54%). Both structures were 
secured by crystals structure analysis. Similar problems were observed for the 
acetoxy formation. Standard conditions (Ac2O/DMAP in Et3N or py)287 showed 
slow conversion towards the desired compounds 4.63 and 4.64. Satisfyingly 
the non-nucleophilic Barton’s base 4.65 288  furnished the desired acetoxy 
compound 4.63 in 76% yield. Surprisingly, the reacation did not proceed with 
diastereomer 4.64, probably due to steric hindrance of the densed molecule. 
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  a)	  G.	  Chianese,	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   Meunier,	   Org.	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   Chem.	   2003,	   1,	   2859;	   b)	   F.	   Najjar,	   L.	   Gorrichon,	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   H.	   Vial,	   T.	  
	   Tzedakis,	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   Andre-­‐ ́Barres,̀	   Bioorg.	   Med.	   Chem.	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   14,	   143;	   c)	   K.	   Asahi,	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   Nishino,	  
	   Tetrahedron	  2005,	  61,	  11107.	  
288	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  Barton,	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Scheme 4.10: Synthesis of endoperoxide derivatives for SAR-studies (X-ray structure color 
code: grey = carbon; red = oxygen; white = hydrogen). a) Ag2O, MeI, ACN, 40 °C, 16 h, 88%; 
b) Ag2O, MeI, ACN, 40 °C, 16 h, 54%; c) Barton’s base, Ac2O, DMAP, CH2Cl2, r.t., 20 h, 76%.  
 
The activity of the synthesized derivatives were tested in collaboration with 
Dr. Marcel Kaiser form the Swiss Tropical and Public Health Institute (see 
experimental part of this thesis for further information). The activity of the 
tested endoperoxides ranged from the submicromolar to nanomolar range 
(Table 4.1). Compound 4.48 (entry 2) was by far the most active 
endoperoxide with a good antiplasmodial activity of 180 nM, a cytotoxicity 
value of 169 and an excellent selectivity index of 939. The study showed 
clearly that the free hydroxyperoxide is crucial for the activity and further 
modifications of this group decreased its potency significantly (entries 3-5). 
This is in contrast to other published works, where substitution on the free 
hydroxyl group led to an increased activity by a factor of 10.285-286 The major 
diastereomeric analogue 4.48 (entry 1) is almost 40 times less active than the 
minor diastereomer 4.49 (entry 2). The same activity trend is also present in 
their methylated analogues 4.62 and 4.61 (entry 3 and 4) as well as for the 
acetylated compound 4.63 (entry 5). An unfavored steric interaction of the 
methyl and isopropyl moieties could shield the endoperoxide interaction to the 
Fe(II)-heme-cluster and yield in a decreased activity. 
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entry compound IC50 [µM]a LD50 [µM]b SIc 
1 4.48 7.1 165 23 
2 4.49 0.18 169 939 
3 4.62 24.3 59 2 
4 4.61 3 175 58 
5 4.63 32.2 168 5 
6 artemisinin (1.9)d 0.0035 349 98500 
7 chloroquine (4.6)d 0.0063 107 17145 
Table 4.1: Antiplasmodial activity and cytotoxicity screening. aPlasmodium falciparum NF54 
strain; brat myoblast L6 cells; cSelectivity index (SI) = LD50/IC50; dartemisinin (1.9) and 
chloroquine (4.6) were additionally tested for confirmation reasons.  
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4.3 Conclusion 
 
A serendipitous observation led to the discovery of a transformation leading 
to novel endoperoxide based antimalarial agents. In this reaction, a diketone 
moiety 4.55 underwent a spontaneous formal [2 + 2 + 2] cycloaddition onto a 
terminal olefin in the presence of oxygen to give a 1,2-dioxane-3-ol skeleton. 
This radical reaction could be further improved by the addition of a catalytic 
amount of manganese(III)acetate in the presence of oxygen. In vivo assays of 
the novel endoperoxides 4.48 and 4.49 and their hemiacetal derivatives  
4.61 – 4.63 on the malaria parasite Plasmodium falciparum showed 
submicromolar to nanomolar activity and good to excellent cytotoxicity values 
for the 1,2-dioxane-3-ol’s (IC50 = 180 nM activity, LD50 = 169 µM, SI = 939). 
The free hydroxy-endoperoxide function is crucial for antiplasmodial activity 
and steric interactions around the endoperoxide scaffold yielded in a 
decreased activity. 
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5 Synthetic Studies Towards the Natural Product 
Striatal A  
 
5.1 Fungal Natural Products – A Sustainable Source of   
   Novel Drug Leads 
 
Finding effective therapeutic options for combatting serious diseases such 
as cancer, AIDS or malaria is a continuous challenge for natural scientists. 
Nature’s inestimable biodiversity on earth is interdependently correlated to an 
immense treasure trove of natural products. Representatives of all six 
kingdoms of life289 (animals, plants, fungi, archaea, bacteria and protista) 
produce a vast diversity of structurally complex natural products that have 
very often served as a starting point for the development of novel 
pharmaceuticals and for the discovery of new modes of biological action. Up 
to date, most of these lead structures have been based on natural products 
isolated from bacteria and plants. Natural products derived from fungi have so 
far played a minor role for drug development, although fungi are known to 
produce a great variety of secondary metabolites and may thus provide novel 
scaffolds for medicinal chemistry.290  Fungal-derived pharmaceuticals have 
already shown their potential as effective drugs or precursors thereof (Figure 
5.1): Penicillium chrysogenum produces the antibacterial agent penicillin G 
(1.1) with its characteristic β-lactam structure. It was discovered by Sir 
Alexander Fleming in 1928 and inhibits the cell wall biosynthesis of 
bacteria.291 The immunosuppressive cyclosporin A (5.1), isolated from the 
fungus Tolypocladium inflatum, 292  prevents graft rejection following organ 
                                                                                                    
289	  	  An	  updated	  classification	  of	   living	  organisms	   see:	  T.	  Cavalier-­‐Smith,	  Biol.	  Rev.	  1998,	  73,	   203;	   for	  
	   an	  older	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  see:	  R.	  H.	  Whittaker,	  Science	  1969,	  163,	  150.	  
290	  	  S.	  P.	  Wasser,	  A.	  L.	  Weiss,	  International	  Journal	  of	  Medicinal	  Mushrooms	  1999,	  1,	  31.	  	  	  
291	  	  a)	  K.	  Lewis,	  Nat.	  Rev.	  Drug	  Discov.	  2013,	  12,	  371;	  b)	  A.	  Fleming,	  Br.	  J.	  Exp.	  Pathol.	  1929,	  10,	  226.	  
292	  	  H.	  Svarstad,	  H.	  C.	  Bugge,	  S.	  S.	  Dhillon,	  Biodiversity	  and	  Conservation	  2000,	  9,	  1521.	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transplantation by inhibiting indirectly the enzyme calcinerum.293 Overall, T-
cells activation is inhibited, which leads to a much higher survival rate of 
operated patients. Echinocandin B (5.2) was isolated from Aspergillus 
nidulans var. echinulatus in 1974.294 This large lipopeptide inhibits the enzyme 
1,3-β-d-glucan synthase (glucan synthesis), a component of the fungal cell.295 
Lovastatin (5.3) was isolated from a fermentation of Aspergillus terreus.296 As 
all other statins, lovastatin inhibits the enzyme HMG-CoA reductase, which is 
responsible for cholesterol synthesis. Therefore the cholesterol and 
cholesterol accumulation is reduced in the blood and yields to a reduced 
development of arteriosclerosis and cardiovascular diseases.297   
  
Figure 5.1: Fungal-derived pharmaceuticals. 
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A common strategy in the development of novel drugs is the chemical 
modification of natural product lead structures in order to improve their 
pharmacokinetic properties and simplify routes for the synthetic preparation of 
these agents. 298  The uncommon α-amino acid myriocin (5.4) has been 
isolated from the fungus Isaria sinclairii and shown to act as an antibiotic by 
inhibition of sphingosine biosynthesis.299 Fingolimod (5.5), a truncated version 
of myriocin (5.4) has been prepared, which has been shown to be an 
immunomodulating agent effective in the treatment of multiple sclerosis 
(Figure 5.2). Acting as an agonist on four of five sphingosine-1-phosphate 
receptors, 300 , 301  thus inhibits further infiltration of auto-aggressive 
lymphocytes, which causes inflammation by myelin sheath degeneration.302 
Furthermore, positive effects of fingolimod (5.5) on neuronal cell development 
have been reported.303 
 
Figure 5.2: From lead structure to approved drug. 
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5.2 Cyathane Diterpenoids Natural Products and Their   
   Biological Activities 
 
Around 105 members of the cyathane diterpenoid natural product family are 
described.304 The main characteristic of the cyathane family of diterpenoid 
natural products is the fused tricyclic 5-6-7 ring system with angular methyl 
groups at C-6 and C-9 (5.6, Figure 5.3).305 The relative configuration of these 
two methyl groups is anti in all cyathane natural products except for 
cyanthiwigin type structures, where these two methyl groups are found to be 
in a syn relationship. Within the cyathane family, several subtypes of natural 
products have been isolated and their biological activity will be discussed in 
full detail in this section. The most prominent natural products of this family 
have already been prepared by total syntheses, which will be discussed in full 
detail in chapter 5.4 of this thesis.306 
 
              
Figure 5.3: Cyathane skeleton numbering and ring labeling. 
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5.2.1  Cyathins and Cyafrins 
 
In 1971, Ayer and co-workers isolated a novel natural product scaffold from 
the bird’s nest fungus Cyathus helenae307 and successfully elucidated the 
structure of cyathin A3308 (5.7) and allocyathin B3309  (5.8, Figure 5.4a).310 The 
nomenclature of the C20 diterpenoids is based on the grade of unsaturation. 
Diterpenoid structures consist of 30 hydrogen atoms in their molecular 
formula are called cyathin A (5.7 and 5.9), those with only 28 hydrogen atoms 
are named cyathin B (5.8 and 5.10) and cyathin C (5.11 and 5.12) only 
contains 26 hydrogen atoms. The subscript numbers after the letter is referred 
to the amount of oxygens inside the molecule. The prefixes allo- or neoallo 
such as neoallocyathin A4 (5.13) are isomeric forms inside the cyathane 
family. The same nomenclature is applied on the closely related cyafrin family 
(5.14 – 5.17). The structural identification was rather complex due to the 
presence of a ketone-hemiketal equilibrium (5.18 and 5.19, Figure 5.4b).305 
These molecules are of particular interest due to their broad range of 
biological activity such as anti-inflammatory, antimicrobial and NGF-
stimulating properties. 
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Figure 5.4: Cyathin and cyafrin structures. 
5.2.2  Sarcodonins and Scabronines 
 
The first members of the sarcodonin family sarcodonin A (5.20) and 
sarcodonin G311 (5.21) were isolated from the fruiting body of the mushroom 
Sarcodon scabrosus by Shibata and co-workers in 1989.312 Various other 
derivatives were discovered soon after (Figure 5.5a and 5.5c). 313  The 
scabronines were isolated from the same mushroom source and the natural 
products scabronine B (5.22), scabronine E (5.23) and scabronine F (5.24) 
have been found to stimulate the NGF synthesis.314 The high potential of 
scabronines to treat neurological disorders has spurned extensive SAR-
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studies as shown in Figure 5.5b and 5.5d (represented by structures 5.25 
respectively 5.26).304 The unsaturation in the seven-membered ring is for the 
sarcodonin and scabronine family crucial for the activity. Furthermore, 
installation of a methylester group gave an increased activity. 
 
 
Figure 5.5: Representative sarcodonin and scabronine structures (left) and SAR-studies on 
their scaffold (right). 
5.2.3  Cyanthiwigins 
 
The biological source for the cyathane family of natural products are fungi, 
whereas the cyanthiwigins were isolated from marine sponges. Initially 
discovered by Kashman and co-workers in extracts from the marine sponge 
Epipolasis reiswigi and later by the group of Hammann from the Jamaican 
sponge Myrmekioderma styx, over 30 compounds of the cyanthiwigin family 
have been isolated.315 All congeners feature two angular methyl groups at C-6 
and C-9 in a syn-relationship to each other instead of an anti-configuration as 
common for cyathane structures. This hints at different terpene cyclases 
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being involved in the biosyntheses of these two classes of natural products. 
The biological activity of cyanthiwigins ranges from antimicrobial and cytotoxic 
activity to the stimulation of neurite outgrowth. Due to their biological 
significance, total syntheses of the cyanthiwigin compounds (5.27 – 5.29) 
shown in Figure 5.6 had been reported by several groups.316 
 
   
Figure 5.6: Cyanthiwigin members whose total synthesis has already been reported in 
literature. 
5.2.4  Glaucopines and Cyrneines 
 
The glaucopine and cyrneine families of natural products were discovered 
in the late 2000’s. They represent a new class of cyathane diterpenoids 
(Figure 5.7a). Glaucopine A (5.30), glaucopine B 317  (5.31) and later 
glaucopine C318  (5.32) were isolated from the fruiting body of Sarcodon 
glaucopus and were shown to have anti-inflammatory activity. The cyrneine 
family was isolated from the mushroom Sarcodon cyrneus and promotes 
neurite outgrowth (selected structures are shown in Figure 5.7a). Cyrneine 
B319 (5.33) induced the highest level of NGF gene expression (factor 7.3), 
whereas cyrneine C (5.34) and cyrneine D320 (5.35) were significantly less 
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active (factor 2.7 and 1.3, respectively) compared to no drug treatment in a 
PC12 cell assay. SAR-studies indicated that the α,β-unsaturated aldehyde is 
the most important structural feature for their biological activity (5.36, Figure 
5.7b). Incorporation of a tertiary alcohol at the point of five and six ring fusion 
showed an increased activity. Furthermore, a secondary alcohol is preferred 
over ketone functionality on the seven-ring. Modification on the five ring has 
only minor effects on the activity. 
 
Figure 5.7: Selected members of the glaucopine and cyrneine family of natural products (left) 
and results from SAR studies (right). 
5.2.5  Cyathane-Xylosides 
 
Some of the cyathane scaffolds are attached to one or various pentose 
units and are thus called cyathane-xylosides. These pentose substituents are 
connected to the core of the molecule via glycosidic bonds. Cyathane-
xyloside can either contain one or more pentose substituents and the sugars 
can have different oxidation patterns. 
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5.2.5.1 Striatoids and Laxitextines 
 
Striatoids 321  and laxitextines 322  are cyathane-xylosides that have only 
recently been discovered (Figure 5.8). The group of Gao isolated striatoid 
structures (represented by structures 5.37 – 5.39) from the fungus Cyathus 
striatus. Striatoid B (5.38) and some other congeners consist of a 
characteristic C-15 and C-4′ ether ring system. All newly isolated striatoid 
promote neurite outgrowth in combination with NGF in the PC12 cell assay. 
The laxitextines (represented by structures 5.40 – 5.41) are the latest class of 
cyathane-xylosides and were isolated from a tropical basidiomycete culture 
(Laxitextum incrustatum) by Süssmuth and co-workers.322 Laxitextines are 
closely related to the striatoids, but their A-ring is less oxidized compared to 
the striatoids’ A ring. The laxitextines exhibit anticancer activity in the 
submicromolar activity range. 
 
 
Figure 5.8: Cyathane-xylosides natural products from the laxitextine and striatoid family. 
  
                                                                                                    
321	  	  R.	  Bai,	  C.-­‐C.	  Zhang,	  X.	  Yin,	  J.	  Wie,	  J.-­‐M.	  Gao,	  J.	  Nat.	  Prod.	  2015,	  78,	  783.	  
322	  	  C.	   M.	   Mudalungu,	   C.	   Richter,	   K.	   Wittstein,	   M.	   A.	   Abdalla,	   J.	   C.	   Matasyoh,	   M.	   Stadler,	   R.	   D.	  
	   Süssmuth,	  J.	  Nat.	  Prod.	  2016,	  79,	  894. 
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5.2.5.2 Erinacine and Striatals  
 
Erinacine A (5.42), B (5.43) and C (5.44) were isolated from the fruiting 
body of Hericium erinaceum by Kawagishi and co-workers in 1994. 323 
Additional congeners of this family of natural products324 such as erinacine 
E325 (5.45) have been isolated from the same biological source (Figure 5.9).326 
Erinacines induce NGF production and might have great potential in the 
treatment of neurological disorders such as Alzheimer’s disease. 
 
 
Figure 5.9: Selected erinacine natural products. 
 
Another type of cyathane-xylosides are the striatals, first described by 
Steglich and co-workers (Figure 5.10).327 These antibiotics are produced by 
the basidiomycete species Cyathus striatus. 328  However, the striatals 
(structures 5.46 – 5.49) themselves have not been isolated, as methanolic 
extraction leads to hemiacetal formation to give the so-called striatins 
(structures 5.50 – 5.52). By treatment with acid, these hemiacetals can be 
cleaved to give the respective striatals. The striatals show antimicrobial 
activity against Gram-positive and few Gram-negative bacteria with activities 
                                                                                                    
323	  	  H.	  Kawagishi,	  A.	  Shimada,	  R.	  Shirai,	  K.	  Okamoto,	  F.	  Ojima,	  H.	  Sakamoto,	  Y.	  Ishiguro,	  S.	  Furukawa,	  
	   Tetrahedron	  Lett.	  1994,	  35,	  1569.	  
324	  	  H.	  Kawagishi,	  A.	  Masui,	  S.	  Tokuyama,	  T.	  Nakamura,	  Tetrahedron	  2006,	  62,	  8463.	  
325	  	  Total	  synthesis	  of	  erinacine	  E:	  H.	  Watanabe,	  M.	  Nakada,	  J.	  Am.	  Chem.	  Soc.	  2008,	  130,	  1150.	  
326	  	  H.	  Kawagishi,	  A.	  Shimada,	  S.	  Hosokawa,	  H.	  Mori,	  H.	  Sakamoto,	  Y.	   Ishiguro,	  S.	  Sakemi,	  J.	  Bordner,	  
	   N.	  Kojima,	  S.	  Furukawa,	  Tetrahedron	  Lett.	  1996,	  37,	  7399.	  
327	  	  a)	  T.	  Anke,	  F.	  Oberwinkler,	  W.	  Steglich,	  G.	  Höfle,	  J.	  Antibiot.	  1977,	  30,	  221;	  b)	  H.	  J.	  Hecht,	  G.	  Höfle,	  
	   W.	  Steglich,	  T.	  Anke,	  F.	  Oberwinkler,	  J.	  Chem.	  Soc.	  Chem.	  Comm.	  1978,	  665.	  
328	  	  for	   a	   review	  of	   antiobiotics	   from	  higher	   fungi	   see:	   a)	  W.	   Steglich,	  Pure	  &	  Appl.	   Chem.	  1981	  53,	  
	   1233;	  b)	  W.	  A.	  Ayer,	  L.	  M.	  Browne,	  Tetrahedron	  1981,	  37,	  2199.	  
Me
H
Me
Me Me
R
O
O O
OH
OH
erinacine B (R = CHO, 5.43)
erinacine C (R = CH2OH, 5.44)
erinacine A  (5.42)
Me
Me
Me Me
CHO
HO
O O
OH
OH
Me
H
Me
Me Me
erinacine E (5.45)
O
OH
OH
OH
HO
O
H
H
CHAPTER 5 
	  
142 
in the submicromolar range for Escherichia coli, Pseudomonas fluorescens, 
Staphylococcus aureus, Streptomyces viridochromogenes and 
Saccharomyces cerevisiae.327a 
 
   
Figure 5.10: Striatins are only formed by reaction with methanol during the isolation 
procedures; upon a treatment with acid the original natural products striatal are recuperated. 
 
5.3 Cyathane Biosynthesis (Striatal A) 
 
The biosynthesis of the striatals was extensively investigated by feeding 
the bird’s nest fungus Cyathus striatus with isotope-labeled glucose ([1-13C] or 
[2-13C]).329 These studies showed that the labeled glucose (5.53) acts as a 
precursor in two ways (Scheme 5.1). First, it is incorporated into the terpene 
structure via the mevalonate pathway330 and secondly, the glucose (5.53) is 
converted into the xylose moiety. D-Glucose (5.53) is first oxidized to  
D-glucoronic acid (5.54) and afterwards D-xylose (5.55) is formed by 
decarboxylation. The terpene building block is also obtained from D-glucose 
(5.53), which is converted to geranyl pyrophosphate (5.56) in the mevalonate 
pathway. Geranylgeranyl pyrophosphate (5.56) then serves as a building 
block for the 5-7-membered ring system (5.57). The trisubstituted olefin 
attacks the carbon center adjacent to the tertiary carbocation and induces a 
1,2-alkyl migration (Wagner-Meerwein shift) so that the 5-6-7-ring system 
(5.58) is formed. Subsequent hydride shift and deprotonation lead to the core 
structure 5.6 of the cyathanes. At this stage, combination with the pentose 
5.55 unit gives access to herical (5.59), which had also been identified from 
                                                                                                    
329	  	  T.	  Anke,	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  M.	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  Z.	  Naturforsch.	  2002,	  57,	  263.	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  J.	  L.	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  M.	  S.	  Brown,	  Nature	  1990,	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the fungal culture. Further oxidation leads to an enol 5.60 on the pentose 
moiety, which attacks the cyathane scaffold in a SN2’ fashion to form striatal D 
(5.49). Acetylation of the free hydroxy group in the pentose unit yields striatal 
A (5.46). 
 
 
Scheme 5.1: Biosynthesis of striatal A (5.46). 
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5.4 Syntheses of Cyathan Natural Products  
5.4.1  Wender’s Rhodium-Catalyzed [5 + 2] Cycloaddition Approach 
 
Wender’s strategy features a rhodium-catalyzed cycloaddition as key step 
to set up the cyathane core structure (Scheme 5.2).277 Starting from 
commercially available (S)-limonene (4.50), the first quaternary carbon center 
was introduced via a Claisen-rearrangement with a diastereomeric ratio of 
10:1 in favor of the desired aldehyde 4.51. A Lemieux-Johnson oxidation of 
the terminal olefin and a Ce(III)-mediated 1,2-addition of lithium 
cyclopropylacetylide on the keton followed reduction of the alkyne with 
LiAlH4/NaOMe furnished olefin 5.61. 331  Oxidation of the alcohol to the 
aldehyde and 1,2-addition of 1-propynylmagnesium bromide followed by 
oxidation of the secondary alcohol to the ketone furnished enyne-
vinylcyclopropane precursor 5.62. The rhodium complex is supposed to 
induce ring closure by oxidative addition to the alkyne and the alkene to give 
intermediate 5.63. Strain-induced cyclopropane cleavage furnishes a 
metallacyclooctadiene intermediate 5.64, which yields the tricyclic core 
structure 5.65 upon reductive elimination. The regioselectivity of this 
sequence has been studied by the Wender group in prior work on 1,1-
disubstituted cyclopropanes. 332  However, the enantioselectivity of this 
transformation might be better due to pre-coordination of the tertiary alcohol to 
the metal center, which then directs the attack of the Rh-complex on the 
substrate. 
                                                                                                    
331	  	  E.	  J.	  Corey,	  J.	  A.	  Katzenellenbogen,	  G.	  A.	  Posner,	  J.	  Am.	  Chem.	  Soc.	  1967,	  89,	  4245.	  
332	  	  P.	   A.	  Wender,	   A.	   J.	   Dyckman,	   C.	  O.	  Husfeld,	   D.	   Kadereit,	   J.	   A.	   Love,	  H.	   Rieck,	   J.	   Am.	   Chem.	   Soc.	  
	   1999,	  121,	  10442.	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Scheme 5.2: Wender’s approach towards the tricyclic core structure 5.65 using a rhodium 
catalyzed [5 + 2] cycloaddition. a) H2, PtO2, 94%; b) OsO4, NaIO4, THF/H2O, 97%; c) 
piperidine, AcOH, benzene, reflux, 75%; d) DIBAL-H, Et2O, 0 °C, 96%; e) EtOCH=CH2, 
Hg(OAc)2, reflux, then toluene, reflux, 90%; f) NaBH4, MeOH/H2O, 95%; g) TBSCl, imidazole, 
DMF, 90%; h) O3, CH2Cl2, −78 °C, Me2S, 65%; i) 1-ethynylcyclopropane, n-BuLi, CeCl3, 0 °C, 
91%; j) LiAlH4, NaOMe, THF, reflux, 69%; k) DMP, NaHCO3, CH2Cl2; l) MeCCMgBr, THF, 
75% (over two steps); m) DMP, NaHCO3, CH2Cl2, 93%; n) [Rh(CO)2Cl]2, 1,2-dichloroethane, 
80 °C, 3.5 h, 90%; L = ligand, n = number of ligands. 
 
5.4.2  Nakada’s Synthesis of (−)-Scabronine G 
 
The group of Nakada reported a 19 step synthesis (21% yield) of  
(−)-scabronine G (5.66, Scheme 5.3).333 Its synthesis features an impressive 
oxidative dearomatization and an intramolecular Diels-Alder reaction with 
inverse-electron-demand (IEDDA). Starting from the aromatic aldehyde334 
5.67, a propargylation followed by deoxygenation of the secondary alcohol 
and subsequent lithiation of the terminal alkyne give a nucleophile that cleanly 
adds to the Weinreb amide 5.68 335 to yield the desired ketone 5.69. The 
allene 5.70 was obtained by reduction of the ketone and phosphorylation of 
the resulting secondary alcohol followed by addition of isopropylmagnesium 
chloride in the presence of copper(I) cyanide. The TIPS group was removed 
                                                                                                    
333	  	  Y.	  Kobayakawa,	  M.	  Nakada,	  Angew.	  Chem.	  Int.	  Ed.	  2013,	  52,	  7569.	  
334	  	  T.	  S.	  Kaufman,	  J.	  Chem.	  Soc.	  Perkin	  Trans.	  1	  1996,	  2497.	  
335	  	  K.	  C.	  Nicolaou,	  K.	  P.	  Cole,	  M.	  O.	  Frederick,	  R.	  J.	  Aversa,	  R.	  M.	  Denton,	  Angew.	  Chem.	  Int.	  Ed.	  2007,	  
	   46,	  8875.	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and the resulting free alcohol was oxidized in the presence of PIDA to form 
the o-benzoquinone mono-dimethylacetal intermediate, which spontaneously 
undergoes an IEDDA reaction to the desired cyclic product 5.71 in 97% yield 
and with an excellent enantiomeric ratio of 95%. The authors claim that steric 
repulsion between the dimethyl acetal and the 2-benzyloxyethyl group in the 
Diels-Alder reaction’s transition state favors formation of the desired product 
5.71. Removal of the benzylic protecting group, Swern oxidation of the 
primary alcohol and a Wittig reaction furnish the terminal alkene. The ketone 
was reduced to the secondary alcohol and the acetal was hydrolyzed to yield 
the α-hydroxy ketone intermediate, which was subsequently treated with an 
allylzinc reagent 5.72336 to furnish the cis-1,2-diol 5.73. Oxidative cleavage of 
the diol in the presence of PIDA 337  yielded a ketoaldehyde, which was 
subjected to a metathesis reaction with Grubbs II catalyst to yield the  
seven-membered ring 5.74. Finally, the silyl-protecting group was removed 
and a Pinnick oxidation followed by Dess-Martin oxidation furnished the 
natural product (−)-scabronine G (5.66). Biological testing revealed that the 
methyl ester derivative of scabronine is a more potent stimulator of neurite 
outgrowth than the natural product itself.311b,338  
 
                                                                                                    
336	  	  R.	  W.	  Heidebrecht,	  Jr.,	  B.	  Gulledge,	  S.	  F.	  Martin,	  Org.	  Lett.	  2010,	  12,	  2492.	  
337	  	  K.	  C.	  Nicolaou,	  V.	  A.	  Adsool,	  C.	  R.	  H.	  Hale,	  Org.	  Lett.	  2010,	  12,	  1552.	  
338	  	  Y.	  Obara,	  H.	  Kobayashi,	  T.	  Ohta,	  Y.	  Ohizumi,	  N.	  Nakahata,	  Mol.	  Pharmacol.	  2001,	  59,	  1287.	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Scheme 5.3: Nakada’s synthesis of (−)-scabronine G (5.66). a) TIPSCl, imidazole, DMF, 40 
°C, 83%; b) propargyl bromide, Zn, TiCl4, THF, 0 °C; c) Et3SiH, BF3 x OEt2, CH2Cl2, 0 °C, 84% 
(over two steps); d) n-BuLi, 5.68, THF, −78 °C to r.t., 89 %; e) Ru[(R,R)-Tsdpen](p-cymene), 
iPrOH, r.t., 92% (95% ee); f) (EtO)2P(O)Cl, DMAP, Et3N, CH2Cl2, r.t., 97%; g) iPrMgCl, CuCN 
x 2 LiCl, THF, −78 °C, quant.; h) TBAF, THF, 0 °C, 97 % (95 % ee); i) PIDA, MeOH, r.t., 7 d, 
97%; j) H2, Pd/C, EtOAc, r.t., 92%, (95% ee, >99% ee (after recryst.)); k) (COCl)2, DMSO, 
Et3N, CH2Cl2, −78 °C to 0 °C, 98%; l) Ph3PCH3Br, t-BuOK, THF, 0 °C, 99%; m) NaBH4, 
MeOH, 0 °C; then, 3 N HCl (aq.), 95%; n) 5.72, Zn, THF, r.t., 91 %; o) PIDA, CH2Cl2, r.t., 
90%; p) Grubbs II cat., CH2Cl2, reflux, 98%; q) TBAF, AcOH, THF, r.t., 70%; r) NaClO2, 
NaH2PO4, 2-methyl-2-butene, THF, t-BuOH, H2O, r.t., 97 %; s) DMP, CH2Cl2, 0 °C, 89%. 
5.4.3  Snider’s Synthesis of (±)-Allocyathin B2 and (+)-Erinacine A 
 
Snider and co-workers reported the preparation of two natural products by 
the same synthetic route.339 (±)-Allocyathin B2340 (5.75) was obtained in 19 
steps (>5% yield) and erinacine A (5.42) by two additional steps from 5.75 
(Scheme 5.4). The seven-membered ring was constructed by an 
intramolecular ene-reaction. Starting from the advanced enone intermediate 
                                                                                                    
339	  	  B.	  B.	  Snider,	  N.	  H.	  Vo,	  S.	  V.	  O’Neil,	  J.	  Org.	  Chem.	  1998,	  63,	  4732.	  
340	  	  Another	   total	  synthesis	  was	  achieved	  by	  Tori	  and	  co-­‐workers:	  a)	  M.	  Tori,	  N.	  Toyoda,	  M.	  Sono,	   J.	  
	   Org.	  Chem.	  1998,	  63,	  306;	  for	  an	  enantioselective	  approach	  see:	  b)	  B.	  M.	  Trost,	  L.	  Dong	  and	  G.	  M.	  
	   Schroeder,	  J.	  Am.	  Chem.	  Soc.	  2005,	  127,	  2844;	  c)	  B.	  M.	  Trost,	  L.	  Dong,	  G.	  M.	  Schroeder,	  	  J.	  Am.	  
	   Chem.	  Soc.	  2005,	  127,	  10259.	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5.76,341 a deprotonation in δ-position and reaction with Tf2O furnished the 
corresponding vinyltriflate. A Pd(II) mediated carbonylation yielded the methyl 
ester, which was directly reduced to the alcohol and subsequently oxidized to 
the aldehyde by MnO2. Thereafter, reaction with the cuprate gave the axial 
addition product. α-Methylation afforded a mixture of methylated 
diastereomers 5.77 in a ratio of 15:1 (major isomer shown in Scheme 5.4). An 
AlMe2Cl-mediated ene-reaction gave access to the seven-membered ring 
system 5.78 as a single diastereomer. Protection of the alcohol, oxidative 
cleavage of the terminal olefin, enone formation with PhSeCl and H2O2, 
followed by silyl deprotection, oxidation of the alcohol and triflation of the enol 
furnished the desired vinyltriflate 5.79. The methyl ester was installed by a Pd-
mediated carbonylation, followed by double bond isomerization under alkaline 
conditions. A global reduction of both the ketone and the ester furnished the 
diol, whose primary alcohol group was chemoselectively oxidized to the 
aldehyde in the natural product (±)-allocyathin B2 (5.75). Finally, glycosylation 
with triacetyl-α-D-xyloyrhamnosyl bromide (5.80) gave an inseparable mixture 
of the two anomers in a 1:1 ratio. Deprotection of the acetyl residues yielded 
the natural product erinacine A (5.42), known as a NGF stimulator.342 
 
 
Scheme 5.4: Total Synthesis of (±)-allocyathin B2 (5.75) and (+)-erinacine A (5.42) by Snider 
and co-workers. a) proton sponge, Tf2O, 88%; b) Pd(OAc)2, Ph3P, CO, iPr2NEt, MeOH, 85%; 
c) DIBAL-H, 97%; d) MnO2, 95%; e) H2C=C(CH3)CH2CH2MgBr, CuBr x DMS, TMSCl, HMPA, 
91%; f) t-BuOK, MeI, 70%; g) Me2AlCl, 87%; h) iPrMe2SiCl, imid., 95%; i) OsO4, KIO4, 77%; j) 
                                                                                                    
341	  	  B.	  B.	  Snider,	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LiHMDS, PhSeCl, H2O2, 72%; k) HOAc, H2O, THF; l) DMP, 72% (over two steps); m) 
KHMDS, PhNTf2, 75%; n) Pd(OAc)2, Ph3P, CO, iPr2NEt, MeOH, 75%; o) Et3N, MeOH, 94%; 
p) LAH, 89%; q) MnO2, 94%; r) 5.80, Hg(CN)2, HgCl2, 34%; s) K2CO3, >90%. 
5.4.4  Nakada’s Enantioselective Total Synthesis of (−)-Erinacine B 
 
The group of Nakada reported on an enantioselective total synthesis of (−)-
erinacine B (5.43) featuring a C1-ring expansion (Scheme 5.5). 343  The 
synthesis starts from the tricyclic intermediate 5.81, which has already been 
described in the synthesis of (+)-allocyathin B2 (5.75).344 Elimination of water 
upon reaction of the alcohol with thionyl chloride, removal of the MPM 
protecting group and 1,4-reduction of the enone mediated by SmI2 yielded 
ketone 5.82. The isopropyl group was introduced by reaction with an 
isopropenyl cerium reagent and subsequent hydrogenation of the terminal 
olefin. The secondary alcohol was oxidized with DMP and the tertiary alcohol 
was subjected to an E1 elimination and the obtained trisubstituted olefin was 
isomerized under acidic conditions to form the thermodynamically more stable 
tetrasubstituted olefin 5.83. Applying Hagesawa’s conditions, 345  ring 
expansion was achieved by preparing the β-keto ester by reaction of the 
ketone with Mander’s reagent,346 iodomethylation with diiodomethane and 
SmI2-mediated rearrangement to give the seven-membered γ-keto ester 5.84. 
The corresponding TMS-enol ether was treated with PhSeCl and H2O2 to 
furnish the alkene in a selenoxide elimination. Base-induced isomerization 
and reduction of both ketone and ester furnished the desired 1,4-diol 5.85. A 
vanadyl acetylacetonate-mediated oxidation installed the desired epoxide as a 
single diastereomer. The primary alcohol was selectively protected, and the 
secondary alcohol oxidized to the ketone 5.86 by DMP. The epoxide was 
regioselectively opened and the resulting secondary alcohol protected to 
furnish enone 5.87. A CBS-reduction afforded the desired alcohol 5.88. The 
glycosylation proved to be challenging, as no conversion was observed with 
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  H.	  Watanabe,	  M.	  Takano,	  A.	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  9,	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  M.	  Takano,	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  E.	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  5425.	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various standard glycosylation protocols. Finally, MeOTf-mediated coupling 
with an MPM-protected derivative 5.89 of xylose phenyl thiol ether as glycosyl 
donor furnished the desired glycoside linkage with an anomeric ratio of 1:3.5 
(α:β). The silyl protecting group was removed and the allylic alcohol oxidized 
by DMP. Cleavage of the MPM protecting groups gave sugar 5.90, which up 
treatment with base brought about the ring closing SN2’ reaction with loss of 
benzoate to yield (−)-erinacine B (5.43) as a single diastereomer.  
(−)-Erinacine B (5.43) is a highly potent stimulator of NGF, even stronger as 
the control epinephrine.323 
 
Scheme 5.5: Nakada’s enantioselective synthesis of (−)-erinacine B (5.43). a) SOCl2, py, 
CH2Cl2, 0 °C to r.t., 91%; b) DBU, benzene, reflux, 92%; c) DDQ, CH2Cl2, t-BuOH, H2O, 0 °C 
to r.t., quant.; d) SmI2, HMPA, THF, −15 °C to r.t., 94%; e) 2-bromopropene, t-BuLi, CeCl3, 
Et2O, THF, −78 °C, 84%; f) H2, Pd/C, MeOH, r.t., 95%; g) DMP, CH2Cl2, r.t., 91%; h) SOCl2, 
py, CH2Cl2, 0 °C to r.t., quant.; i) TsOH, benzene, reflux, quant.; j) LiHMDS, NCCO2Me, THF, 
−78 °C, 79%; k) CH2I2, TBAF, THF, 0 °C to r.t., 66%; l) SmI2, HMPA, THF, −78 °C, 81%; m) 
TMSOTf, Et3N, CH2Cl2, 0 °C; n) PhSeCl, THF, −78 °C, then H2O2, py, 0 °C to r.t., 91% (over 
two steps); o) DBU, benzene, reflux, 98%; p) DIBAL-H, CH2Cl2, −78 °C, 96% (d.r. = 10:1); q) 
TBHP, VO(acac)2, CH2Cl2, −40 °C; r) TBDPSCl, imid., DMF, r.t.; s) DMP, CH2Cl2, r.t., 80% 
(over three steps); t) DBU, C6H6, 50 °C; u) Bz2O, py, DMAP, (CH2Cl)2, 50 °C, 78% (over two 
steps); v) (R)-CBS, BH3-SMe2, CH2Cl2, −40 °C, 95%; w) 5.89, MeOTf, Et2O, r.t.; x) HF x py, 
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THF, 0 °C to r.t., 77% (over two steps, (α/β = 1:3.5); y) DMP, CH2Cl2, r.t., 96%; z) TFA, 
CH2Cl2, −20 °C, quant.; a’) Et3N, LiBr, THF, r.t., 74% (over three steps). 
5.4.5  Gademann’s Synthesis of Cyrneine A 
 
In 2012, Gademann and co-workers reported on the first successful total 
synthesis of a natural product from the cyrneine family (Scheme 5.6). Their 
route to cyrneine A319 (5.91) contains 24 linear steps347 and features a Heck-
cyclization to form the B-ring and a Yamamoto ring expansion.348 Starting 
from enantiopure (R)-carvone (5.92), the ketone was reduced, the resulting 
alcohol protected by TBS and the exocyclic double bond hydrogenated. 
Ozonolysis with reductive workup led to the 1,6-ketoaldehyde 5.93. An 
intramoelcular aldol condensation mediated by piperidinium acetate gave the 
desired cyclopentene ring and the aldehyde was reduced to the alcohol and 
submitted to a Hg(II)-mediated transetherification to obtain allylether 5.94. The 
quaternary carbon center was installed by Claisen rearrangement to furnish 
the aldehyde 5.95. An organocatalytic Knoevenagel condensation with 
cyclohexa-1,3-dione and subsequent double bond reduction with Hantzsch 
ester yielded the unstable diketone, which was directly methylated to furnish 
1,3-diketone 5.96. Ozonolysis of the exocyclic olefin and position- and 
diastereoselective Luche reduction yielded an alcohol intermediate, which 
was subjected to mesylation and elimination to furnish the desired cyclohex-3-
en-1-one derivative 5.97. The latter was reduced by sodium borohydride and 
the resulting alcohol protected with TBS. Formation of the enol triflate and 
subsequent allylic oxidation with CrO3 gave the enone 5.98, which set the 
stage of the intramolecular Heck-cyclization that furnished tricycle 5.99.  
α-Addition of lithium dibromomethanide and subsequent treatment with n-BuLi 
yielded the cyclohept-3-en-1-one derivative 5.100 in a Yamamoto ring 
expansion reaction. Formation of the vinyl triflate was followed by Pd-
catalyzed reductive carbonylation349 to give the desired aldehyde. After global 
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  E.	  Elamparuthi,	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  1986,	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  452.	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deprotection, cyrneine A (5.91) was obtained and its structure confirmed by 
single crystal X-ray structure analysis. Cyrneine A (5.91) promotes neurite 
outgrowth in the absence of NGF with an activity comparable to NGF.319 
 
Scheme 5.6: Gademann’s enantioselective total synthesis of cyrneine A (5.91). a) LiAlH4, 
Et2O, −78 °C, 15 min; b) TBSCl, imidazole, CH2Cl2, r.t., 1.5 h; c) PtO2/H2, THF, r.t., 4 h, 96% 
(over three steps); d) O3, Zn/AcOH, CH2Cl2/MeOH (5:1), −78 °C, r.t., 1 h, 89%; e) piperidine, 
AcOH, Et2O, 70 °C, 20 h, 92%; f) NaBH4, MeOH, 0 °C, 15 min, 88%; g) Hg(OAc)2, ethyl vinyl 
ether, 60 °C, 24 h, 94%; h) toluene, 175 °C, 16 h, 81%, d.r. = 10:1; i) L-proline, cyclohexa-1,3-
diene, Hantzsch ester, CH2Cl2, 3 h, r.t.; j) MeI, DBU, LiI, THF, 14 h, 75 °C, 73% (over two 
steps); k) O3, CH2Cl2, SMe2, −78 °C, 1 h, 83%; l) CeCl3 x 7 H2O, NaBH4, THF/MeOH (1:5), 
−78 °C, 20 min, 68%; m) (MeSO2)2O, pyridine, DMAP, 5 h, r.t., 88%; n) LiBr, Li2CO3, DMF, 
140 °C, 1 h, 79%; o) NaBH4, MeOH, 0 °C, 20 min, 86%; p) TBSOTf, 2,6-lutidine, CH2Cl2, 2 h, 
r.t., 85%; q) KHMDS, PhNTf2, THF, −78 °C, 3 h, 83%; r) CrO3, DMP, CH2Cl2, 18 h, r.t., 71%; 
s) Pd(OAc)2, TBABr, PPh3, K2CO3, toluene, 120 °C, 1 h, 63%; t) CH2Br2, LiTMP, THF,  
−78 °C, 20 min, 76%; u) n-BuLi, THF, −90 °C, 30 min, 68%; v) KHMDS, PhNTf2, THF, −78 °C, 
20 min, 81%; w) Pd(PPh3)4, LiCl, CO, n-Bu3SnH, THF, 80 °C, 3 h, 77%; x) TBAF, THF, r.t.,  
14 h, 84%. 
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5.5 Goal of this Study, Retrosynthetic Analysis and     
   Synthetic Approaches towards the Tricyclic ABC Core  
   Structure of Striatal 
 
The tricyclic core structure of striatal A (5.46) is similar to the neurotrophic 
active natural product cyrneine A (5.91),347 which was recently synthesized in 
our group. The structural differences are the missing hydroxy function at C-1 
and double bond between C-5 and C-10 as shown in Figure 5.11. By adapting 
the synthetic precursor (R)-carvone (5.92) to (S)-limonene (4.50), the 
cyathane core structure should be in general accessible following the 
established synthetic route. Furthermore the planned route can be shorten by 
a few steps (lacking of initial ketone and hydroxy manipulation) towards the 
cyathane core structure of striatal A (5.46). To our best knowledge, the 
striatals had not yet been synthesized and a general route towards this highly 
complex and interesting natural products should be established. 
 
 
Figure 5.11: Structural similarity (shown in red) of cyrneine A (5.91) and striatal A (5.46). 
 
The retrosynthethic parts of the cyathane and the pentose unit are 
illustrated in Scheme 5.7a, respectively 5.7b. According to the biomimetic 
approach of Nakada,325 our approach is facing the opposite way via a 
nucleophilic attack of the cyathane to the pentose unit. Therefore, the C-13-C-
2’-bond can be connected via an aldol reaction out of intermediate 5.101. 
Nakada was already successful in the installation of the pentose unit via a 
glycosylation,325 thus using a modified pentose unit 5.102 with the cyathane 
structure 5.103 should be feasible. The hydroxy group should support a 
homoallylic hydrogenation of the trisubstituted olefin 5.104. Furthermore, a 
shielding effect of the adjacent methyl group at C-16 might favor a concave 
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hydrogenation. The ring expansion out of the 5-6-6-membered ring system 
5.105 follows our established route, as well as the Heck cyclization from 
vinyltriflate 5.106.347 The lacking oxygen function at position C-1 yields in an 
adopted starting material, thus our synthesis would start from commercially 
available (S)-limonene (4.50). 
The pentose unit itself is derived from D-arabinose (5.107). First the syn-
diol is protected350 5.108 and the anomeric hydroxy function is replaced by a 
thiophenol moiety351 to furnish thiophenol 5.109. Last the unprotected hydroxy 
function is oxidized to the ketone yielding the pentose building block 5.102.352 
Scheme 5.7: Retrosynthetic analysis of striatal A (5.46) and the pentose unit 5.102. 
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5.5.1  Synthetic Studies on Striatal A 
5.5.1.1 Cyrneine A Approach 
 
The synthesis was conducted with enantiopure (S)-limonene (4.50) as the 
starting material (Scheme 5.8). We first followed the footsteps of Wender,277 
but optimized conditions were finally applied. The first steps from (S)-
limonene (4.50) to diketone 4.55 are in detailed discussed in the 
endoperoxide chapter of this thesis (see chapter four).195 The instable key 
building block 4.55 was directly methylated to the methyldiketone 5.110 in a 
low yield of 34%. The low yield arises from a competing O-alkylation event. 
Furthermore, the instable precursor forms spontaneous endoperoxides in the 
presence of oxygen.195  
   
Scheme 5.8: Synthesis of the methylated intermediate 5.110. a) H2, PtO2 (cat.), THF, r.t., 
94%; b) O3, Zn/AcOH, CH2Cl2/MeOH (5:1), −78 °C, 94%; c) piperidine, AcOH, benzene, 110 
°C, 75%; d) DIBAL-H, Et2O, 0 °C, 96%; e) 1,1-dimethoxyethyl(dimethyl)amine, p-xylene, 16 h,  
150 °C, 95% (d.r. = 24:1); f) 1,1,3,3-tetramethyldisiloxane, Ti(OiPr)4, THF, r.t., 18 h, 95%; g)  
L-proline, Hanztsch ester, CH2Cl2, r.t., 19 h, 91%; h) MeI, DBU, LiI, THF, 80 °C, 15 h, 34%. 
 
The installation of the ketone function 5.111 was surprisingly quite 
challenging and summarized in Table 5.1. Applying our reported ozonolysis 
condition347 on the olefin 5.110 yielded a complex mixture (Table 5.1, entry 1). 
Therefore we searched for more appropriate neutral reducing agents. The 
crude mixture using DMS (entry 2 – 4) as reducing agents showed the 
formation of several products, which are a ketone 5.111, allylic alcohol 5.112 
and epoxide 5.113. The isolation yielded the ketone 5.111 and the allylic 
alcohol 5.112 in minor amounts. The epoxide 5.113 was observed by 1H-NMR 
analysis, but could not be isolated and might have opened to the allylic 
alcohol upon SiO2-flash column chromatography purification. Furthermore, 
sterical hindered olefins are known to form epoxides under ozonolysis 
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conditions.353 The solvent was swapped to MeOH and an improved yield of 
40% for the ketone 5.111 was obtained (entry 5). Nevertheless, the allylic 
alcohol 5.112 as a competing side reaction was observed too. Quenching the 
reaction with PPh3 gave 26% yield of the ketone 5.111 in (entry 6). 
Additionally a novel method was tested, which uses instead of a reducing 
agent only pyridine in a catalytic amount. However, only the alcohol 5.112 
product and an unidentified by-product was observed (entry 7). Compared to 
the reported method,347 only the OTBS-function at position C-1 is missing, but 
this seems to have a tremendous impact on the accessibility of the terminal 
olefin. The 5-membered ring junction probably leads to a sterically demanding 
olefin.353 Furthermore, the methyldiketone moiety might have a shielding 
effect, which makes an attack for the reagents not suitable.  
 
entry reducing agent solvent observation 
1347 
Zn (4 eq) 
AcOH (4 eq) 
CH2Cl2/MeOH 
(5:1) 
complex mixture 
2 DMS (2 eq) CH2Cl2 
16% 5.111,  
n.d. 5.112  
3354 DMS (2 eq) CH2Cl2 
25% 5.111,  
n.d. 5.112  
4 DMS (2 eq) CH2Cl2 
35% 5.111, 
25% 5.112  
5 DMS (2 eq) MeOH 40% 5.111, n.d. 5.112  
6 PPh3 (2 eq) CH2Cl2 26% 5.111  
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7355 py (cat.) CH2Cl2 5.112 formed 
Table 5.1: Optimization for the oxidative cleavage of the terminal olefin. 
 
The synthesis was continued by applying Luche’s condition on the ketone 
5.111 yielding the desired alcohol 5.114 in 67% and a low diastereomeric ratio 
of 1.7:1 (Scheme 5.9). After separation of the diastereomers, the hydroxy 
group was mesylated and after a short work-up directly eliminated to the olefin 
5.115. Both steps yielded in several unknown side-products. Based on the low 
yields and general sluggish outcome of the reactions, we thought about using 
more convenient diketone modifications. Initial studies on diketone 
modifications were already conducted by Simon Glauser (University of Basel) 
on similar molecules.356 
 
   
Scheme 5.9: Applying the reported diketone modification sequence. a) CeCl3 x 7 H2O, 
NaBH4, MeOH, THF, −78 °C, 1 h, 67%, d.r. = 1:1.7; b) (MeSO2)O, DMAP, r.t., 22 h, n.d.; c) 
LiBr, Li2CO3, DMF, 140 °C, 1 h, n.d. 
 
The diketone 5.110 was first treated with various reducing agents (Scheme 
5.10). NaBH4 showed a complex mixture (50% of diol 5.116) and LiBEt3H357 
only decomposition of the starting material 5.110. Finally, lithium tri-tert-
butoxyaluminium hydride (LTBA) was superior and yielded the desired diol 
5.116 in good yields and as a single diastereomer.358  The chiral center 
identification was not further investigated, due to a planned elimination step 
later in this sequence. The diol 5.116 was mesylated to obtain the bis-
mesylate 5.117. We applied again the ozonolysis conditions and the desired 
ketone 5.118 was formed in 30% along with the allylic alcohol 5.119. 
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Scheme 5.10: Improved diketone modification route. a) LTBA, THF, 0 °C to r.t., 4 h, 64%; b) 
MsCl, py, DMAP, 0 °C to r.t., 15 h, 74%; c) O3, CH2Cl2, −78 °C, then DMS, −78 °C for 30 min, 
2 h to r.t., 30% 5.118 and 34% 5.119. 
 
We swapped the conditions by applying Lemieux-Johnson conditions as a 
two step procedure gave the desired ketone 5.118 in a similar yield as shown 
in Scheme 5.11. The elimination of both mesyl functions yielded the bis-olefin 
5.120 in an impure manner. In summary, the novel route was successfully 
applied and the targeted compound could be synthesized. However, this route 
led as well to a disappointing overall yield. 
   
Scheme 5.11: Alternative route via oxidative cleavage. a) OsO4, NMO, t-BuOH/H2O (4:1),  
0 °C to r.t., 2.3 d, 95%; b) NaIO4, THF/H2O (2:1), r.t., 2.5 h, 52%; c) LiBr, Li2CO3, DMF,  
140 °C, 4 h, 74%. 
 
An advanced cyclohexadiene would shorten the route by far, since 
elimination events could be omitted. We envisioned the reported ipso-
methylated cyclohexadiene carboxylic acid 5.121 might be a suitable testing 
candidate (Scheme 5.12). 359  The carboxylic acid derivative 5.121 was 
condensed under Steglich esterification conditions360 to the allylic alcohol 
4.52, yielding the ester 5.122 in 75%. EDC x HCl was superior to other tested 
coupling reagents (DCC,361 TBTU), due to SiO2-column purification issues. 
The planned Claisen-rearrangement should then proceed via the enolether 
                                                                                                    
359	  	  K.	  Vorndran,	  T.	  Linker,	  Angew.	  Chem.	  Int.	  Ed.	  2003,	  42,	  2489.	  
360	  	  B.	  Neises,	  W.	  Steglich,	  Angew.	  Chem.	  Int.	  Ed.	  1978,	  17,	  522.	  
361	  	  A.	  K.	  Perepogu,	  D.	  Raman,	  U.	  S.	  N.	  Murty,	  V.	  J.	  Rao,	  Bioorganic	  Chemistry	  2009,	  37,	  46.	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5.123.362 The methods are somewhat limited for this transformation and are 
based mostly on low valent titanium species.363 Wittig and other olefination 
conditions are working well on aldehydes and ketone, but not on ester364 or 
amide moieties, due to their resonance stability. Furthermore, olefination 
conditions are of basic nature, whereas the oxophilic titanocene reagent365 
forms a Schrock carbene intermediate, which makes an carbonyl attack more 
feasible. Methylenation of the sterically demanding ester 5.122 led to no 
conversion for Tebbe’s, Takai-Utimoto’s or Lombardo’s conditions.363b-d 
Treating the ester 5.122 with the freshly prepared Petasis reagent366 formed 
in situ the instable enolether 5.123,367 which was purified over basic alumina. 
The enolether 5.123 was then directly used for the Claisen-rearrangement 
yielding the desired rearranged product 5.124 in a diastereomeric ratio of 9:1 
and a low yield of 10% (over two steps). The enolether 5.123 seems to be 
unstable as well as sterically not favored due to the adjacent methyl group. 
  
                                                                                                    
362	  	  J.	  S.	  Swenton,	  D.	  Bradin,	  B.	  D.	  Gates,	  J.	  Org.	  Chem.	  1991,	  56,	  6156.	  
363	  	  a)	  N.	  A.	  Petasis,	  E.	  I	  Bzowej,	  J.	  Am.	  Chem.	  Soc.	  1990,	  112,	  6392;	  b)	  F.	  N.	  Tebbe,	  G.	  W.	  Parshall,	  G.	  S.	  
	   Reddy,	   J.	  Am.	  Chem.	  Soc.	  1978,	  100,	  3611;	  c)	  T.	  Okazoe,	  K.	  Takai,	  K.	  Oshima,	  K.	  Utimoto,	   J.	  Org.	  
	   Chem.	   1987,	   52,	   4410;	   d)	   L.	   Lombardo,	   Tetrahedron	   Lett.	   1982,	   23,	   4293;	   e)	   Y.	   Horikawa,	   M.	  
	   Watanabe,	  T.	  Fujiwara,	  T.	  Takeda,	  J.	  Am.	  Chem.	  Soc.	  1997,	  119,	  1127;	  f)	  K.	  A.	  Brown-­‐Wensley,	  S.	  L.	  
	   Buchwald,	  L.	  Cannizzo,	  L.	  Clawson,	  S.	  Ho,	  D.	  Meinhardt,	   J.	  R.	  Stille,	  D.	  Straus,	  R.	  H.	  Grubbs,	  Pure	  
	   Appl.	  Chem.	  1983,	  55,	  1733.	  
364	  	  For	   applications	   in	   total	   synthesis	   see:	   a)	  H.	  C.	   Kolb,	   S.	  V.	   Ley,	  A.	  M.	   Z.	   Slawin,	  D.	   J.	  Williams,	   J.	  
	   Chem.	  Soc.,	  Perkin	  Trans.	  1,	  1992,	  2735;	  b)	  A.	  B.	  Smith,	  III,	  K.	  Basu,	  T.	  Bosanac,	  J.	  Am.	  Chem.	  Soc.	  
	   2007,	  129,	  14872;	  c)	  D.	  C.	  Harrowven,	  M.	  C.	  Lucas,	  P.	  D.	  Howes,	  Tetrahedron	  Lett.	  1999,	  40,	  4443.	  
365	  	  For	  a	  review	  see:	  a)	  R.	  C.	  Hartley,	  G.	  J.	  McKiernan,	  J.	  Chem.	  Soc.,	  Perkin	  Trans.	  1,	  2002,	  2763;	  b)	  R.	  
	   C.	  Hartley,	  J.	  Li,	  C.	  A.	  Main,	  G.	  J.	  Kiernan,	  Tetrahedron	  2007,	  63,	  4825.	  
366	  	  J.	  F.	  Payack,	  D.	  L.	  Hughes,	  D.	  Cai,	  I.	  F.	  Cottrell,	  T.	  R.	  Verhoeven,	  Org.	  Synth.	  2002,	  79,	  19.	  
367	  	  NMR-­‐measurements	   were	   not	   possible	   due	   to	   decomposition	   into	   the	   allylalcohol	   4.52	   and	  
	   acetophenon,	  nevertheless	  this	  indirectly	  proofed	  that	  enolether	  5.123	  was	  indeed	  formed.	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Scheme 5.12: Claisen rearrangement with an advanced cyclohexadiene moiety. a) 5.121, 
EDC x HCl, DMAP, CH2Cl2, 0 °C to r.t., 15 h, 82%; b) Petasis reagent, Cp2TiCl2 (cat.), THF, 
65 °C, 22 h, 30%; c) toluene, 110 °C, 19 h, 44%, d.r. = 9:1. 
 
This hypothesis was tested by using benzoic acid (5.125) as a less bulky 
substrate. The benzoic acid ester 5.126 was obtained in 87% yield from 
allylalcohol 4.52 and directly subjected to the used methylenation conditions 
(Scheme 5.13). The benzoic enolether 5.127 was obtained in a quantitative 
yield. The Claisen rearranged product 5.128 was received with 77% yield 
(over two steps from benzoic enolether 5.127). The diastereomeric ratio was 
13:1 for the desired diastereomer 5.128. 
    
Scheme 5.13: Test reaction with an aromatic moiety. a) benzoic acid (5.125), EDC x HCl, 
DMAP, CH2Cl2, 0 °C to r.t., 22 h, 87%; b) Petasis reagent, Cp2TiCl2 (cat.), THF, 65 °C, 13 h, 
quant.; c) toluene, 110 °C, 19 h, 79%, d.r. = 13:1. 
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To summarize, the initial attempt following an established procedure 
applied on our substrate showed remarkable differences in terms of reactivity 
and chemical behavior. Modifications following a more convergent synthetic 
approach did not show the expected improved reactivity. The future planned 
steps for this for this route is shown in Scheme 5.14. After the Claisen-
rearrangement, the ketone function of 5.124 should be removed to the alkane 
5.129.368 An allylic oxidation347 should furnish the enone system 5.130, which 
is then transformed to the vinyltriflate 369  5.131. The vinyltriflate 5.131 is 
subjected to Heck-cyclization conditions yielding the tricycle 5.132. Upon ring 
expansion 370  to the seven-membered ring 5.104 and a hydroxy directed 
homoallylic hydrogenation371 should take place and give rise to the access of 
cyathane core structure 5.103. The pentose will then be installed and finally 
lead to the natural product striatal A (5.46) 
 
Scheme 5.14: Planned route towards the cyathane structure and striatal A (5.46). 
                                                                                                    
368	  	  M.	  E.	  Furrow,	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  G.	  Myers,	  J.	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  Chem.	  Soc.	  2004,	  126,	  5436.	  
369	  	  M.	  C.	  Willis,	  C.	  K.	  Claverie,	  Tetrahedron	  Lett.	  2011,	  42,	  5105.	  
370	  	  E.	  J.	  Kantorowski,	  M.	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  Kurth,	  Tetrahedron	  2000,	  56,	  4317.	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  H.	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  Tetrahedron	  Lett.	  2008,	  49,	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5.5.1.2 Diazo Approach 
 
Facing the seven-membered ring as the challenging part in the synthesis, 
we envisioned a new strategy, which should directly form the seven-
membered ring via a ring expansion reaction as earlier planned. The group of 
List reported an interesting macrocyclization in their total synthesis of  
(+)-hirsutene (5.133, Scheme 5.15).372 Starting from bis-diazoketone 5.134 a  
Ru-mediated intramolecular carbene-carbene cyclization 373  furnished the 
eight-membered macrocyle 5.135. An intramolecular trans-annulation 
afforded the 5-5-5 tricycle 5.136 and further manipulation yielded the natural 
product (+)-hirsutene (5.133). 
 
Scheme 5.15. List’s intramolecular carbene-carbene cyclization in the synthesis of  
(+)-hirsutene (5.133). a) Ru(η5-C5H5)(PPh3)2 (cat.), CH2Cl2, 55 °C, 52%; b) H2, Pd/C, EtOAc, 
91%; c) trans-4-fluoro proline, DMSO, r.t., 15 h, 84%. 
 
This strategy can be applied on our system by targeting the diketone 5.137 
(Scheme 5.16). The six-membered ring 5.138 is obtained after an 
intramolecular aldol reaction on the enone 5.139. A chiral catalyst such as 
proline can be used if the aldol reaction is not fully substrate controlled. A 
diazotransfer on both ketone moieties would furnish the diazocompound 
5.140, which forms upon intramolecular carbene-carbene cyclization the 
desired 5-6-7-tricycle 5.141. Further manipulation on the seven membered 
ring furnishes the ketone 5.142, which is converted into the cyathane scaffold 
5.143. 
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  C.	  L.	  Chandler,	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Scheme 5.16: Proposed synthetic pathway via an intramolecular carbene-carbene coupling 
reaction towards the cyathane core structure 5.143. 
 
Starting from the same sequence, the aldehyde 4.54 was subjected to an 
HWE reaction to form the α,β-unsaturated ketone 5.144 (Scheme 5.17). 
Reductive attempts on the enone 5.144 to form the saturated ketone 5.145 
were not successful using Hantzsch ester 374  or Raney-Ni 375  conditions. 
Lipshutz’s modified Stryker reagent delivered the ketone 5.145 in a clean 
reaction and a good yield.376 Epoxidation of the olefin 5.145 gave the epoxide 
5.146, which upon SiO2-column purification directly gave the desired allylic 
alcohol 5.147 in 71% yield. Oxidation in the presence of DMP afforded the 
unsaturated aldehyde 5.148 in a good yield of 70%. The same conditions as 
aforementioned were applied for the HWE homologation to yield enone 5.149 
but the aldehyde 5.148 was completely inert to the used conditions. The 
phosphonate was swapped the to 2-oxopropyltriphenylphosphonium chloride 
and NaHMDS as the base, but also under this conditions only the starting 
material was recovered. Aldol condensation reaction with base (LDA, 377 
sodiumethoxide378 or piperidine/AcOH379) and acetone gave no reaction. 
                                                                                                    
374	  	  D.	  B.	  Ramachary,	  M.	  Kishor,	  J.	  Org.	  Chem.	  2007,	  72,	  5056.	  
375	  	  A.	   F.	   Barrero,	   E.	   J.	   Alvarez-­‐Manzaneda,	   R.	   Chaboun,	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   Rivas,	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   L.	   Palomino,	   Tetrahedron	  
	   2000,	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  6099.	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  B.	  A.	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  Z.	  V.	  Bošković,	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  H.	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  Org.	  Lett.	  2008,	  10,	  289.	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  P.	  Kraft,	  S.	  Jordi,	  N.	  Denizot,	  I.	  Felker,	  Eur.	  J.	  Org.	  Chem.	  2014,	  554.	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  C.	  Chapius,	  R.	  Brauchli,	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  Acta	  1993,	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  2070.	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  Tetrahedron:	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  2007,	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Scheme 5.17: Revised strategy approach for the synthesis of the diazo precursors 5.149. a) 
dimethyl 2-oxopropylphosphonate, DIPEA, LiCl, ACN, 5 h, 79%; b)  
1,2-bis(diphenylphosphino)benzene, Cu(OAc)2 x H2O, PMHS, t-BuOH, r.t., 3 h, 80%; c)  
m-CPBA, CH2Cl2, 0 °C to r.t., 4 h, 71%; d) DMP, CH2Cl2, r.t., 19 h, 70%; e) dimethyl 2-
oxopropylphosphonate, DIPEA, LiCl or 2-oxopropyltriphenylphosphonium chloride, NaHMDS 
or LDA, or acetone and NaOEt, or acetone and piperidine/AcOH. 
 
The group of Shishido faced this problem as well upon attempts via a Wittig 
reaction on a hindered aldehyde 5.150 as shown in Scheme 5.18.380 The 
sterically demanding aldehyde 5.150 was not reactive under standard 
homologation conditions such as Wittig or HWE reaction to yield the desired 
enone 5.151. The homologation was solved via a nitrile oxide–alkene [3 + 2] 
cycloaddition on a terminal olefin 5.152. The formed isoxazoline 5.153 was 
reduced to the β-hydroxyketone and upon elimination of water the 
unsaturated ketone 5.154 was obtained. 
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Scheme 5.18: Homologation attempts on a sterically hindered aldehyde 5.150 and their 
solution via a nitrile oxide–alkene [3 + 2] cycloaddition approach for the synthesis of the  
α,β-unsaturated ketone 5.154. a) N-hydroxyacetimidoyl chloride,381 Et3N, CH2Cl2, r.t.,10 h, 
75%; b) H2, Raney-Ni, (MeO)3B, MeOH/CH2Cl2/H2O (10:5:1), r.t., 4 h, 74%; c) Ac2O, py, 
DMAP, CH2Cl2, r.t., 5 h, then DBU, r.t., 11 h, 95%.  
 
The approach implements a lot of additional steps, which we thought to be 
less elegant. The synthesis of α,β-unsaturated ketone can also be envisioned 
by a Meyer-Schuster rearrangement382 of a tertiary alcohol 5.155 as shown in 
the synthesis of Hodgson and co-workers on their studies of (+)-anthecotulide 
(5.156, Scheme 5.19).383 
      
Scheme 5.19: Meyer-Schuster rearrangement applied by the Hodgson group in their 
synthesis of (+)-anthecotulide (5.156). a) MoO2(acac)2, AuCl(PPh)3, AgOTf, toluene r.t., 3h, 
87%. 
 
Starting from the allylic alcohol 5.147, the ketone was reduced to the 
alcohol 5.157 as shown in Scheme 5.20. The allylic alcohol was 
regioselectively oxidized in the presence of the secondary alcohol using 
                                                                                                    
381	  	  a)	   K.	   H.	  Meyer,	   K.	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  Chem.	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  Trans.	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Barium manganate(VI) to aldehyde 5.158 in 64% yield. MnO2384 proved to be 
not successful on this hindered allylic alcohol 5.157 and only starting material 
was recovered. The regioselective oxidation was not always reproducible, 
yielding in no conversion or oxidation of the secondary alcohol instead of the 
allylic alcohol. A HWE condition was applied on the aldehyde 5.158, but no 
conversion was observed. Treating the aldehyde 5.158 with a combination of 
LDA and 1,2-dibromopropane forming in situ the lithiated 1-propynyl species, 
which subsequently added to the aldehyde forming the 1-propynyl alcohol 
5.159. Several methods were tested for the Meyer-Schuster rearrangement, 
to our disappointment, not the Meyer-Schuster rearranged product 5.160 was 
obtained, but the known side reaction took place forming the Rupe rearranged 
product 5.161.385  
 
 
Scheme 5.20: Preparation attempts for the synthesis of the diazo precursor 5.140. a) LiAlH4, 
THF, 0 °C, 1 h, quant.; b) BaMnO4, CH2Cl2, r.t, 19 h, 64%; c) 1,2-dibromopropane, LDA,  
-78 °C to r.t., then –78 °C, 5.158,  –78 °C to r.t., 17 h, 85%; d) Cu(OTf)2, CH2Cl2/EtOH (4:1), 
r.t., 2.5 h. 
 
The side reaction could not be circumvented by applying several Lewis-
acids such as Sc(OTf)3,386 Cu(OTf)2 or InCl3387. We were quite surprised about 
these findings, because normally the Rupe side reactions takes place via 
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elimination of the adjacent β-hydrogen,388 which is in our case not present. 
However, δ-hydrogens are present and eliminated faster than the 1,3-allylic 
shift took place (5.162, Scheme 5.21 left). A common strategy is the 
installation of electron-donating-groups on the terminal alkine position, which 
favor the 1,3-allylic hydroxy shift. De Mesmaeker and co-workers used this 
method in their synthesis of 5-deoxystrigol, an intermediate in the 
biosynthesis of strigolactones (plant hormones, Scheme 5.21).389 Installation 
of an ethoxygroup on alkyne 5.163 furnished the desired unsaturated ester 
5.164. In our case, the resulting ester would need to be manipulated further 
and a double diazotransfer as it was planned might not be straightforward 
anymore. We therefore searched for alternative approaches. 
 
 
Scheme 5.21: Competing Rupe and Meyer-Schuster rearrangements (left, LA = Lewis acid) 
and installation of an electron-donating-group to force the Meyer-Schuster reaction (right). a) 
Sc(OTf)3 (5 mol%), CH2Cl2, EtOH, 82%, E:Z = 1:1; or AuCl3 (5 mol%), CH2Cl2, EtOH, 90%. 
 
The installation of an α,β-unsaturated ketone moiety can be achieved by 
installation of an allyl group and further oxidations on the terminal olefin. We 
started from the ketone 5.145 and reduced it to the alcohol 5.165 and 
protected the secondary alcohol 5.166 with a TBS-group to yield the protected 
secondary alcohol 5.166 (Scheme 5.22). The epoxidation of the terminal 
olefin 5.166 led to a stable epoxide 5.167 this time and did not open 
spontaneously to the desired allylic alcohol 5.168. Base promoted epoxide 
isomerization (LDA,390 LiTMP,391  DATMP392) showed only recovery of the 
epoxide 5.167. Treating the epoxide 5.167 with TMSOTf and DMAP gave the 
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allylic alcohol 5.168 in 19%. Improved epoxide opening yields could be 
obtained in the presence of the acidic Amberlyst IR-120 resin. The allylic 
alcohol 5.168 and TBS cleaved product 5.169 was obtained in yields ranging 
from 28% to 81%. We therefore subjected the epoxide to milder acidic 
conditions using SiO2 and were pleased to see that the allylic alcohol 5.168 
was slowly formed keeping the TBS protecting group intact. By simply heating 
the reaction to reflux, the epoxide 5.167 fully opened to the desired allylic 
alcohol 5.168 within a few hours in 67% yield. Oxidation of the allylic alcohol 
5.168 to the unsaturated aldehyde gave only moderate yields of 43% in the 
presence of DMP and no conversion using IBX. A reasonable amount was 
achieved using pyridinium chromate, and the crude material was directly used 
in the next step. The allylation gave the desired secondary alcohol 5.170 in a 
yield of 62% (over two steps).  
 
 
Scheme 5.22: Alternative approach towards the diazo precursor 5.170. a) LiAlH4, THF, 0 °C, 
1.2 h, 79%; b) TBSOTf, 2.6-lutidine, CH2Cl2, −20 °C to r.t., 14 h, 95%; c) m-CPBA, NaHCO3, 
CH2Cl2, 0 °C to r.t., 19 h, 80%; d) SiO2, EtOAc, 105 °C, 24 h, 67%; e) pyridinium dichromate, 
CH2Cl2, r.t., 3.5 h; f) allylmagnesiumbromide, THF, −78 °C to r.t., 1 h, 62% (over two steps). 
  
With the homoallyl alcohol 5.170 in hand a Wacker-type-oxidation was 
performed on the terminal olefin (Scheme 5.23).393 A catalytic method was 
described by Kaneda and co-workers using PdCl2, DMA and molecular 
oxygen as the oxidant to perform the Wacker-type-oxidation to furnish the 
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ketone 5.171. 394  To our disappointment, no reaction occurred on our 
substrate. Assuming that the free hydroxy group might coordinate to the Pd-
species and is shutting down any further reactions, we applied a described 
method suitable for challenging substrates.395 Furthermore, this method can 
overcome regioselectivity issues, which are observed when hydroxy groups or 
protecting groups are still able to coordinate to the Pd-species and the attack 
of water attacks both position of the olefin forming Markovnikov and anti-
Markovnikov products. TBHP is therefore used in combination with a 
bidendate ligand to prevent a free hydroxy function to coordinate to the Pd-
species. To our disappointing, no reaction occurred on the free hydroxy 
substrate 5.170. As described, an acetylation might be helpful and the acetyl 
group was installed with Ac2O and triethylamine afforded the protected 
alcohol 5.172 in a yield of 80%. The same conditions were again applied, but 
to our disappointment the desired ketone 5.173 was not obtained. The 
terminal olefin is probably too shielded from the surround making a general 
attack of multiple reagents not suitable. Another method is the 
hydroxymercuration, which should deliver the hydroxy function in a 
Markovnikov fashion.396  The acetylated substrate 5.172 was subjected to 
hydroxymercuration condition, but the persistent bright yellow reaction mixture 
already indicated that the Hg(OAc)2 was not consumed and therefore the 
secondary alcohol 5.174 not formed. The terminal olefin might be not 
accessible for the desired transformation and we did not further investigated 
on this synthetic approach towards intermediate 5.175. 
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Scheme 5.23: Synthetic attempts towards the α,β,γ,δ-unsaturated ketone 5.175. a) AgSbF6, 
Pd(quinox)Cl2, t-BuOOH, CH2Cl2, r.t., 16 h; b) Et3N, Ac2O, DMAP, CH2Cl2, 0 °C, 1 h, then r.t., 
30 min, 80%; c) AgSbF6, Pd(quinox)Cl2, t-BuOOH, CH2Cl2, r.t., 20 h; d) Hg(OAc)2, NaBH4, 
THF, H2O, r.t., 1.5 h. 
5.6 Conclusion 
 
In the course towards the total synthesis of the natural product striatal A 
(5.46), various synthetic aspects were evaluated. Striatal A (5.46) represents 
a highly complex diterpenoid with a cyathane core structure and an attached 
pentose unit. The 5-6-7-membered ring moiety is in close relation to our 
previous studies in the natural product cyrneine A (5.91). A modified strategy 
should furnish the core structure of the striatal family. Starting from  
(S)-limonene (4.50), the 5-ring motif was achieved following a reported 
procedure involving a Favorskii ring contraction reaction and a Dieckmann 
condensation. An Eschenmoser-Claisen rearrangement installed the first 
quaternary center, bearing a methyl group, in a diasteromeric ratio of 24:1. 
Surprisingly, the established methodology was not suitable anymore in the 
next steps. In general the desired products could be achieved in low yields for 
the first few initial steps of the project. Furthermore, the methods were 
dominated by side reactions, which made further steps not suitable towards a 
total synthesis. A reason might be the influence of the 5-ring junction as well 
as steric hindrance of other groups.  
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Therefore, a novel strategy was elaborated to build up the 5-6-7-membered 
ring motif via an intramolecular carbene-carbene cyclization, which would give 
access to an already highly functionalized 7-ring motif. However, a sterically 
demanding aldehyde made further reactions towards a C2-homolagtion under 
HWE conditions not feasible. More harsh conditions were applied by reaction 
of the aldehyde 5.158 with an organolithium species and the expected  
prop-1-yne product was indeed obtained. We envisioned applying a Meyer-
Schuster rearrangement, but the rearrangement gave exclusively the Rupe 
rearranged product 5.161, which made further progress impossible.  
 
Other attempts, on a homoallylic alcohol moiety 5.170 were not fruitful, due 
to the unreactivity of the terminal olefin towards the applied Wacker-oxidation 
conditions and oxymercuartion conditions. We therefore stopped our progress 
towards the total synthesis of striatal A (5.46), due to not promising 
preliminary results. 
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6 Conclusion 
 
This thesis entitled “Total Syntheses of (–)-Fragin and Valdiazen, and 
Synthetic Studies Towards Complex Neuritogenic Terpenoids” describes the 
synthesis of biologically active natural products for different mankind 
diseases, malaria, neurodegeneration, and bacterial infection. Each chapter 
gives an overview of the respective disease and describes the classes of 
natural products that have been developed as potential treatment so far.  
 
Chapter one highlights the “golden era” of natural products in drug 
discovery over the last decade. From early treatments as antibiotics over 
chemotherapeutic agents, the chapter includes as well an outlook for a new 
“golden era” of natural products. 
 
Chapter two updated synthetic and biological aspects of the natural 
product fragin. In a first step, we achieved an enantioselective synthesis of 
both fragin enantiomers in eight steps and 13% overall yield and determined 
the chiral center to be (R)-configured. In a second step, a racemic 
intermediate in the biosynthesis of fragin was isolated and named valdiazen. 
The biosynthetic intermediate was confirmed both using analytical techniques 
and chemical synthesis. SAR-studies on fragin indicated that the 
diazeniumdiolate motif is responsible for antibacterial activity and that the 
chiral center has no influence. Fragin is active against Gram-positive and only 
poorly active against Gram-negative bacteria, whereas the biosynthetic 
intermediate is inactive in both cases. 
 
Chapter three aimed at providing a synthetic route for the total synthesis 
of the natural product (2R)-hydroxynorneomajucin. The synthesis featured a 
manganese-induced 6-endo-trig cyclization and a regiospecific C-H activation 
of a sp3-center. The outlook provides further strategies for the insertion of the 
last missing hydroxy function on an advanced intermediate towards the total 
synthesis of (2R)-hydroxynorneomajucin. Furthermore, two nor-type 
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sesquiterpene structures, namely 3,4-dehydro-norneomajucin and  
(1S)-2-oxo-3,4-dehydronorneomajucin of known neurite outgrowth inducing 
sesquiterpenes could be successfully achieved in 16 respectively 17 steps 
and their activity profile will be evaluated. 
 
Chapter four evaluated the potency of a novel antimalarial agents. The 
spontaneous formation of endoperoxides had been discovered by serendipity 
on our synthetic efforts towards the total synthesis of striatal A (chapter five). 
The reaction was then used to access a wide array of antiplasmodial  
endoperoxides. The synthesis featured a manganese(III) mediated peroxide 
formation via a formal [2 + 2 + 2] cycloaddition. SAR-studies on the 
endoperoxidal skeleton revealed that conformational as well as the free 
hydroxy-endoperoxide structure play a crucial role for antiplasmodial activity. 
The synthetic strategy allows obtaining further endoperoxidal structures by 
changing the starting material or by using late stage-modifications. 
 
Chapter five showed synthetic studies on the natural product striatal A. 
Our initial synthetic strategy proved not be suitable, mainly due to steric 
hindrance of an intermediate. A newly elaborated strategy led to an advanced 
intermediate, however, its unreactivity or formation of by-products made 
further progress on this route impossible. A novel approach has to be 
considered towards the total synthesis of striatal A. 
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7 Experimental Part 
 
7.1 General Methods and Material 
 
General Reactions were carried out using oven-dried glassware under an 
atmosphere of dry Ar or N2 and magnetically stirred, unless noted otherwise. 
Air- and moisture-sensitive liquids and solutions were transferred via syringe 
or stainless steel canula.  
 
Reagents were purchased from commercial suppliers (Acros, Sigma-
Aldrich) and used without further purification, unless noted otherwise.  
 
Solvents (methylene chloride, diethylether, tetrahydrofuran, acetonitrile, 
toluene) for reactions were purified by filtration and dried by passage over 
activated anhydrous neutral A-2 alumina (Innovative Technology solvent 
drying system) under an atmosphere of dry nitrogen. Methanol (analytical 
grade) was used as received. Analytical grade solvents were used as 
received for extractions and chromatographic purifications. Deuterated-
solvents were purchased from Cambridge Isotope Laboratories, Inc. 
(Andover, MA, USA). Work-up was performed with dist. solvents. 
 
Thin Layer Chromatography was used for monitoring reactions and 
carried out using Merck silica gel 60 F254 plates, visualized with UV light or 
developed either with aqueous cerium ammonium molybdate (CAM) stain 
solution followed by heating.  
 
Flash Chromatography was performed using Silicycle SiliaFlash® P60 
(230-400 Mesh) at a pressure of ca. 0.3 bar. Eluents and Rf are indicated.  
 
1H NMR spectra were recorded on Varian Gemini Bruker DPX 400 MHz, 
Bruker Avance II 400 MHz NMR, Bruker Avance II 500 MHz NMR or Bruker 
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Avance I 600 MHz NMR spectrometer at 298K in the indicated deuterated 
solvent, unless otherwise stated. Data are reported as follow: chemical shift 
(δ, ppm), multiplicity (s, singulet; d, doublet; dd, doublet of doublets; dt, 
doublet of triplets; t, triplet, q, quartett, quin., quintet, m, multiplet or not 
resolved signal), coupling constant (J, Hz) and integration. All signals were 
referenced to the internal solvent signal as standard (CDCl3, δ = 7.26; MeOD, 
δ = 3.31).  
 
13C NMR spectra were recorded with 1H-decoupling on Varian Gemini 101 
MHz spectrometer at 298K in the indicated deuterated solvent, unless 
otherwise stated. All signals were referenced to the internal solvent signal as 
standard (CDCl3, δ = 77.16; MeOD, δ = 49.00).  
 
IR spectra were recorded on a Varian 800 FT-IR ATR spectrometer or ona 
Spectrum Two (UATR) FT-IR Spectrometer (Perkin Elmer). Data are reported 
in terms of frequency of absorption (ν, cm-1). 
 
Optical rotations 
€ 
α[ ] D
T  were measured at the sodium D line using a 1 mL 
cell with a 1 dm path length on a Jasco P-2000 digital polarimeter and the 
concentration c is given in g/100mL in the indicated solvent. 
 
Mass spectra: Were recorded on a QTOF-ESI spectrometer (bruker 
maXis 4G) or on a QExactive instrument (Thermo Fisher Scientific, Bremen, 
Germany) equipped with a heated electrospray (ESI) ionization source and 
connected to a Dionex Ultimate 3000 UHPLC system.  
 
Melting points (Mp) were determined using a Büchi B-545 apparatus in 
open capillaries and are uncorrected. 
 
X-ray analyses: University of Basel; data collections for all crystal 
structures were performed at low temperature (123 K) using MoKα or CuKα 
radiation on a Bruker Kappa APEX diffractometer. Integration of the frames 
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and data reduction was carried out using the APEX2 software. 397  The 
structures were solved by direct methods using SIR92.398 All non-hydrogen 
atoms were refined anisotropically by full-matrix least-squares on F using 
CRYSTALS.399 Univeristy of Zurich: All measurements were made on an 
Agilent Technologies SuperNova area-detector diffractometer400 using Cu Ka 
radiation (l = 1.54184 Å) from a micro-focus X-ray source and an Oxford 
Instruments Cryojet XL cooler. Data reduction was performed with 
CrysAlisPro. 400
 
The structure was solved by direct methods using SHELXS-
2013.401 
 
Fluorescence spectroscopy was measured on a Shimadzu 5301 PC 
spectrofluorophotometer. 
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7.2 Total Syntheses and SAR-Studies on (−)-Fragin and   
   Valdiazen 
 
Preparation and analytical data for intermediates (2.97b and 2.98b) and 
precursors for the ammonium salts 2.132a-d were reported by Liskamp and 
co-workers.92 
General procedure for the carboxylic acid to alcohol reduction:92 
Fmoc-protected amino acid (14.5 mmol, 1.0 eq) was dissolved in DME (28 
mL) and cooled to −15 °C. N-Methylmorpholine (14.5 mmol, 1.0 eq) and 
isobutyl chloroformiate (14.5 mmol, 1.0 eq) was added and the mixture stirred 
at −15 °C for 1.5 h. The suspension was filtered and the filter cake was 
washed with DME (10 mL). The filtrate was cooled to −15 °C and a solution of 
NaBH4 (21.8 mmol, 1.5 eq) in water (7.0 mL) was added in one portion and 
the mixture diluted with water (350 mL). The mixture was cooled to 0 °C and 
the white precipitate was filtered off and washed with water (3 x 10 mL) and 
pentane (2 x 15 mL). The white solid was dried at the rotavapor (70 °C, 35 
mbar) to yield the pure alcohol as a white solid.  
(9H-fluoren-9-yl)methyl-(R)-(1-hydroxy-3-methylbutan-2-yl)carbamate  
(2.97a):  
White solid (14.1 mmol, 98%, from 2.96a); Optical rotation: 𝛼 !!"  = +19.4 (c 1.02, CHCl3). The data were in good agreement 
with the reported.92 
 
General procedure for the Mitsunobu reaction: 
Alcohol (32.2 mmol, 1.0 eq) and PPh3 (64.4 mmol, 2.0 eq) were dissolved in 
dry THF (260 mL) and cooled to 0 °C. DEAD (40% in toluene, 64.4 mmol, 2.0 
eq) and then DPPA (64.4 mmol, 2.0 eq) were added and the mixture allowed 
to warm to r.t. over 3 h. The mixture was evaporated after 10 h in total. The 
crude was purified by flash column chromatography (pentane/EtOAc 8:1 to 
2:1) to yield the desired azide as a white solid. 
Me
Me
NH
OH
Fmoc
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(9H-fluoren-9-yl)methyl (R)-(1-azido-3-methylbutan-2-yl)carbamate-
(2.98a): 
White solid (26.9 mmol, 84%, from 2.97a); Optical rotation: 𝛼 !!"  = +22.8 (c 0.43, CHCl3); the data were in good agreement 
with the reported.92 
General procedure for the azide to ammonium salt reduction: 
Azide (0.26 mmol, 1.0 eq) was dissolved in dry MeOH/CHCl3 (1.1 mL + 0.2 
mL) and stirred for 20 minutes at r.t. The mixture was cooled to 0 °C and Pd/C 
(10%, 28 mg, 0.1 eq) was added under an argon atmosphere, then 
triethylsilane (312 mg, 0.43 mL, 2.63 mmol, 10 eq) was added dropwise into 
the open flask. After 4 h, additional CHCl3 (0.1 mL) and triethylsilane (1.32 
mmol, 5 eq) were added dropwise into the open flask and stirred over night at 
r.t. This procedure was repeated until no more starting material was detected 
by TLC. The mixture was filtered over Celite and washed with MeOH and the 
filtrate evaporated. The residue was suspended in pentane, filtered and 
washed several times with pentane. The residue was dried to dryness to yield 
the pure ammonium salt (2.99a-b and 2.132a-d), which was directly 
converted to fatty acids products. 
 
General procedure for fatty acid condensation: 
 
The ammonium salt (554 mmol, 1.0 eq) was suspended in CH2Cl2 (2.0 mL) 
and octanoyl chloride (0.61 mmol, 1.1 eq) was added. The mixture was 
cooled to 0 °C and DMAP (55.4 µmol, 0.1 eq) was added. A solution of DIPEA 
(1.11 mmol, 2.0 eq) in CH2Cl2 (0.8 mL) was then added. The solution was 
stirred for 30 minutes at 0 °C and then allowed to warm to r.t. and stirred for 
14 h. The mixture was diluted with EtOAc and washed with aq. HCl (1 M, 2.0 
mL), sat. aq. NaHCO3 (2 x 2.0 mL) and brine (2.0 mL). The organic layer was 
dried over Na2SO4, filtered and evaporated to obtain a brownish solid. The 
extract was recrystallized from cyclohexane (20 mg/3 mL) at reflux for 15 
minutes and then cooled to r.t. The white suspension was filtered and the 
residue washed with cold cyclohexane (3 x 2.0 mL) to afford the desired 
Me
Me
NH
N3
Fmoc
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amide. 
 
(9H-fluoren-9-yl)methyl (R)-(3-methyl-1-octanamidobutan-2-yl)carbamate 
(2.100a): 
White solid (870, 1.93 mmol, 77%, from 2.99a); 
M.p.: 128.3 – 129.0 °C; Rf = 0.52 (SiO2, 
pentane/EtOAc 1:1); Optical rotation: 𝛼 !!"   = 
+32.1 (c 0.53, CHCl3); FTIR (neat): ν = 3306, 2953, 2927, 2856, 1690, 1641, 
1540, 1450, 1376, 1288, 1252, 1122, 1036, 758, 734, 672 cm-1; 1H NMR (400 
MHz, CDCl3) δ = 7.76 (d, J = 7.4 Hz, 2H), 7.58 (dd, J = 7.2, 4.3 Hz, 2H), 7.40 
(d, J = 7.4 Hz, 2H), 7.31 (d, J = 7.5 Hz, 2H), 6.03 (bs, 1H), 5.02 (d, J = 8.9 Hz, 
1H), 4.44 – 4.40 (m, 1 H), 4.35 – 4.31 (m, 1H), 4.22 – 4.19 (m, 1H), 3.61 – 
3.54 (m, 1H), 3.48–3.41 (m, 1H), 3.29 – 3.23 (m, 1H), 2.13 (t, J = 7.5 Hz, 2H), 
1.81 (sext, J = 6.5 Hz, 1H), 1.59 – 1.52 (m, 2H), 1.25 – 1.19 (m, 8H), 0.96 (t, J 
= 7.2 Hz, 6H), 0.83 (t, J = 7.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 174.3, 
157.5, 144.0, 143.9, 141.4, 127.9, 127.9, 127.2, 125.2, 125.1, 120.1, 120,1. 
67.0, 57.1, 47.4, 42.4, 36.9, 31.8, 30.9, 29.4, 29.1, 25.9, 22.7, 19.4, 18.3, 
14.2; HRMS (ESI) m/z calcd for C28H39N2O3 [M+H]+: 451.2955, found: 
451.2957. 
 
(9H-fluoren-9-yl)methyl (S)-(3-methyl-1-octanamidobutan-2-yl)carbamate 
(2.100b):  
White solid (983 mg, 2.18 mmol, 94% from 
2.99b); Optical rotation:    𝛼 !!"  = –32.6 (c 0.20, 
CHCl3). 
 
(9H-fluoren-9-yl)methyl-(R)-(1-octanamidopropan-2-yl)carbamate 
(2.133a): 
White solid (46.4 mg, 0.11 mmol, 70%, from 
2.132a); M.p.: 145.2 – 145.6 °C (decomposition); 
Rf = 0.44 (SiO2, pentane/EtOAc 1:1); Optical 
rotation: 𝛼 !!"  = +17.0 (c 0.35, CHCl3); FTIR (neat): ν = 3306, 2928, 2863, 
1686, 1644, 1538, 1449, 1314, 1267, 1232, 1085, 1058, 736, 666 cm-1; 1H 
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NMR (400 MHz, CDCl3) δ = 7.76 (d, J = 7.4 Hz, 2H), 7.58 (dd, J = 2.8, 7.7 Hz, 
2H), 7.40 (t, J = 7.4 Hz, 2H), 7.31 (t, J = 7.5 Hz, 2H), 6.10 (bs, 1H), 5.24 (d, J 
= 7.5 Hz, 1H), 4.39 – 4.32 (m, 2H), 4.20 (t, J = 7.2 Hz, 1H), 3.83 (bs, 1H), 3.40 
– 3.33 (m, 1H), 3.28 – 3.23 (m, 1H), 2.15 (t, J = 7.6 Hz, 2H), 1.62 – 1.55 (m, 
2H), 1.28 – 1.17 (m, 11H), 0.84 (t, J = 6.9 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ = 174.3, 156.8, 144.0, 143.9, 141.4, 127.8, 127.2, 125.2, 125.2, 
120.1, 66.9, 48.0, 47.3, 45.6, 36.9, 31.8, 29.4, 29.1, 25.9, 22.7, 18.8, 14.2; 
HRMS (ESI) m/z calcd for C26H35N2O3 [M+H]+: 423.2642, found: 423.2647. 
 
(9H-fluoren-9-yl)methyl-(R)-(1-acetamido-3-methylbutan-2-yl)carbamate 
(2.137c): 
White solid (845 mg, 2.31 mmol, 49%, from 2.99a); M.p.: 
141.0 – 142.0 °C; Rf = 0.21 (SiO2, pentane/EtOAc 3:1); 
Optical rotation: 𝛼 !!"= +30.5 (c 0.93, CHCl3); FTIR (neat): ν = 3306, 2961, 1690, 1648, 1539, 1448, 1372, 1284, 1253, 1123, 1037, 735, 
676 cm-1; 1H NMR (400 MHz, CDCl3) δ = 7.77 (d, J = 7.7 Hz, 2H), 7.61 – 7.58 
(m, 2H), 7.41 (t, J = 7.4 Hz, 2H), 7.32 (t, J = 7.3 Hz, 2H), 5.92 (s, 1H), 4.91 (d, 
J = 9.0 Hz, 1H), 4.41 (d, J = 8.5 Hz, 2H), 4.22 (t, J = 6.9 Hz, 1H), 3.60 – 3.53 
(m, 1H), 3.45 – 3.37 (m, 1H), 3.28 (dt, J = 13.7, 4.1 Hz, 1H), 1.93 (s, 3H), 1.84 
– 1.76 (m, 1H), 0.97 (d, J = 7.3 Hz, 3H), 0.94 (d, J = 7.3 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ = 171.1, 157.5, 144.0, 143.9, 141.5, 127.9, 127.9, 127.2, 
125.2, 125.1, 120.1, 120.1, 66.9, 57.0, 47.4, 42.6, 30.9, 23.4, 19.4, 18.3; 
HRMS (ESI) m/z calcd for C22H27N2O3 [M+H]+: 367.2016, found: 367.2016. 
 
(9H-fluoren-9-yl)methyl (R)-(1-hexanamido-3-methylbutan-2-yl)-
carbamate (2.137a):  
White solid (250 mg, 592 µmol, 92%, from 2.99a); 
M.p.: 128.2 – 128.8 °C; Rf = 0.5 (SiO2, 
pentane/EtOAc 1:1); Optical rotation: 𝛼 !!"= +31.3 
(c = 0.35, CHCl3); FTIR (neat): ν = 3304, 3070, 2958, 2931, 2872, 2359, 
1690, 1542, 1449, 1374, 1251, 1124, 1039, 737, 675 cm-1; 1H NMR (400 
MHz, CDCl3) δ = 7.77 (d, J = 7.5 Hz, 2H), 7.59 (dd, J = 7.5, 3.1 Hz, 2H), 7.40 
(t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.4 Hz, 2H), 5.91 (s, 1H), 4.95 (d, J = 8.8 Hz, 
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1H), 4.45 – 4.41 (m, 1H), 4.36 – 4.31 (m, 1H), 4.21 (t, J = 7.0 Hz, 1H), 3.60 – 
3.54 (m, 1H), 3.48 – 3.40 (m, 1H), 3.27 (dt, J = 13.6, 3.8 Hz, 1H), 2.12 (t, J = 
7.7 Hz, 2H), 1.85 – 1.77 (m, 1H), 1.61 – 1.54 (m, 2H), 1.26 – 1.24 (m, 4H), 
0.96 (t, J = 7.2 Hz, 6H), 0.85 – 0.82 (m, 3H); 13C NMR (101 MHz, CDCl3) δ = 
174.4, 157.5, 144.0, 143.9, 141.5, 127.9, 127.9, 127.2, 125.2, 125.1, 120.1, 
120.1, 67.0, 57.1, 47.4, 42.5, 36.8, 31.5, 30.9, 25.5, 22.5, 19.4, 18.4, 14.0; 
HRMS (ESI) m/z calcd for C26H35N2O3 [M+H]+: 423.2642, found 423.2640. 
 
(9H-fluoren-9-yl)methyl (R)-(3-methyl 1-palmitamidobutan-2-yl)carbamate 
(2.137b):  
White solid (411.0 mg, 0.73 mmol, 
75%, from 2.99a); M.p.: 116.5 – 
117.3 °C; Rf = 0.29 (SiO2, 
pentane/EtOAc 2:1); Optical rotation: 𝛼 !!" = +23.2 (c 0.80, CHCl3); FTIR 
(neat): ν = 3392, 3307, 3195, 3069, 2919, 2851, 1691, 1643, 1543, 1468, 
1450, 1375, 1287, 1253, 1122, 1035, 736, 653 cm-1; 1H NMR (400 MHz, 
CDCl3) δ = 7.76 (d, J = 7.4 Hz, 2H), 7.58 (dd, J = 7.4, 4.0 Hz, 2H), 7.40 (t, J = 
7.5 Hz, 2H), 7.31 (t, J = 7.5 Hz, 2H), 5.91 (bs, 1H), 4.97 (d, J = 8.9 Hz, 1H), 
4.44 – 4.40 (m, 1H), 4.36 – 4.32 (m, 1H), 4.21 (t, J = 7.1 Hz, 1H), 3.60 – 3.53 
(m, 1H), 3.49 – 3.41 (m, 1H), 3.28 – 3.22 (m, 1H), 2.11 (t, J = 7.8 Hz, 2H), 
1.85 – 1.76 (m, 1H), 1.59 – 1.52 (m, 2H), 1.25 – 1.19 (m, 24H), 0.96 (t, J = 7.3 
Hz, 6H), 0.88 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 174.2, 
157.5, 144.0, 144.0, 141.5, 127.9, 127.9, 127.2, 125.2, 125.2, 120.1, 120.1, 
67.0, 57.1, 47.4, 42.4, 37.0, 36.0, 32.1, 30.9, 29.9, 29.8, 29.8, 29.8, 29.8, 
29.6, 29.5, 29.5, 29.5, 29.4, 25.9, 25.7, 22.8, 19.4, 18.3, 14.3; HRMS (ESI) 
m/z calcd for C36H55N2O3 [M+H]+: 563.4207, found: 563.4207. 
(9H-fluoren-9-yl)methyl (2-octanamidoethyl)carbamate (2.133d):  
White solid (1.86 g, 4.56 mmol, 68%, from 2.132d); 
M.p.: 154.3 – 154.6 °C (decomposition); Rf = 0.18 
(SiO2, pentane/EtOAc 1:1; FTIR (neat): ν  = 3331, 
2949, 2925, 2854, 1691, 1649, 1538, 1448, 1379, 1268, 1234, 1157, 995, 
736, 646 cm-1; 1H NMR (400 MHz, CDCl3) δ = 7.76 (d, J = 7.5 Hz, 2H), 7.58 
(d, J = 7.4 Hz, 2H), 7.40 (t, J = 7.4 Hz, 2H), 7.31 (t, J = 7.4 Hz, 2H), 6.10 (s, 
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1H), 5.36 (s, 1H), 4.39 (d, J = 7.0 Hz, 2H), 4.20 (t, J = 7.0 Hz, 1H), 3.39 – 3.32 
(m, 4H), 2.19 – 2.14 (m, 2H), 1.62 – 1.58 (m, 2H), 1.29 – 1.23 (m, 8H), 0.87 – 
0.84 (m, 3H); 13C NMR (101 MHz, CDCl3) δ = 174.3, 157.4, 144.0, 141.4, 
127.9, 127.2, 125.2, 120.1, 67.0, 47.3, 41.2, 40.3, 36.8, 31.8, 31.8, 29.4, 29.1, 
25.8, 22.7, 14.2; HRMS (ESI) m/z calcd for C25H33N2O3 [M+H]+: 409.2486, 
found: 409.2485. 
 
(9H-fluoren-9-yl)methyl (R)-(4-methyl-1-octanamidopentan-2-yl)-
carbamate (2.133b):  
White solid (2.33 g, 5.02 mmol, 46%, from 
2.132b); rotameric compound; M.p.: 136.8 – 
137.4 °C; Rf = 0.15 (SiO2, pentane/EtOAc 3:1); 
Optical rotation: 𝛼 !!" = +21.3 (c 1.11, CHCl3); FTIR (neat): ν = 3428, 3302, 
2955, 2926, 2854, 1682, 1647, 1538, 1450, 1316, 1272, 1234, 1121, 1084, 
1021, 951, 734 cm-1; 1H NMR (400 MHz, CDCl3) δ = 7.76 (d, J = 7.6 Hz, 2H), 
7.58 (dd, J = 7.5, 5.0 Hz, 2H), 7.40 (t, J = 7.5 Hz, 2H), 7.35 – 7.28 (m, 5H), 
7.26 – 7.23 (m, 2H), 7.20 – 7.15 (m, 1H), 6.29 (bs, 1H), 5.01 (d, J = 8.5 Hz, 
1H), 4.44 – 4.33 (m, 2H), 4.20 (t, J = 6.9 Hz, 1H), 3.79 (bs, 1H), 3.46 (bs, 1H), 
3.39 – 3.31 (m, 1H), 3.25 – 3.21 (m, 1H), 2.13 (t, J = 7.6 Hz, 2H), 1.69 – 1.62 
(m, 1H), 1.59 – 1.52 (m, 2H), 1.40 – 1.33 (m, 1H), 1.28 – 1.21 (m, 8H), 0.91 (t, 
J = 6.4 Hz, 6H), 0.83 (t, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 
174.4, 157.2, 150.9, 150.8, 143.9, 143.9, 141.4, 141.4, 129.9, 127.9, 127.2, 
127.2, 125.3, 125.3, 125.2, 125.1, 120.5, 120.4, 120.1, 120.1, 66.9, 50.0, 
47.4, 45.0, 42.1, 36.7, 31.8, 29.4, 29.1, 25.9, 24.9, 23.1, 22.7, 22.2, 14.2; 
HRMS (ESI) m/z calcd for C29H40N2O3Na [M+Na]+: 487.2931, found: 
487.2926. 
 
(9H-fluoren-9-yl)methyl (R)-(1-octanamido-3-phenylpropan-2-yl)-
carbamate (2.133c):  
Yellow solid (1.56 g, 3.12 mmol, 57%, from 
2.132c); M.p.: 160.1 – 160.7 °C; Rf = 0.49 
(SiO2, pentane/EtOAc 1:1); Optical rotation: 𝛼 !!"= +22.8 (c 0.42, CHCl3); FTIR (neat): ν = 3308, 3064, 2925, 2854, 1690, 
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1642, 1543, 1446, 1316, 1265, 1148, 1085, 1061, 1036, 736, 698 cm-1; 1H 
NMR (400 MHz, CDCl3) δ = 7.76 (d, J = 7.5 Hz, 2H), 7.54 (d, J = 7.4 Hz, 2H), 
7.40 (t, J = 7.5 Hz, 2H), 7.30 (t, J = 7.4 Hz, 4H), 7.23 – 7.19 (m, 3H), 5.87 (bs, 
1H), 5.27 (d, J = 7.9 Hz, 1H), 4.41 – 4.27 (m, 2H), 4.18 (t, J = 7.0 Hz, 1H), 
3.96 (bs, 1H), 3.49 – 3.28 (m, 2H), 2.93 – 2.76 (m, 2H), 2.17 – 2.12 (m, 2H), 
1.62 – 1.52 (m, 2H), 1.28 – 1.22 (m, 8H), 0.84 (t, J = 6.8, Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ = 174.5, 156.8, 144.0, 144.0, 141.4, 137.7, 129.3, 128.8, 
127.8, 127.2, 126.9, 125.3, 125.2, 120.1, 67.0, 53.5, 47.3, 43.4, 39.2, 36.8, 
31.8, 29.4, 29.1, 25.9, 22.7, 14.2; HRMS (ESI) m/z calcd for C32H39N2O3 
[M+H]+: 499.2955, found: 499.2955. 
 
General procedure for the Fmoc-deprotection: 
 
The Fmoc-protected amine (1.86 mmol, 1.0 eq) was dissolved in dry toluene 
(36 mL) and AlCl3 (5.59 mmol, 3.0 eq) was added at r.t. The yellow solution 
turned to dark violet over 4 h. Aq. HCl (1 M, 20 mL) was added (pH = 1) and 
the aq. layer extracted with Et2O (3 x 15 mL). Sat. NaHCO3 (45 mL) was 
added carefully added to the acidic layer. The basic aq. layer (pH = 8) was 
extracted with CH2Cl2 (5 x 15 mL). The combined organic layer was washed 
with brine (10 mL) and the organic layer was dried over Na2SO4, filtered and 
evaporated to obtain the desired free amine as a colorless oil. 
 
(R)-N-(2-amino-3-methylbutyl)octanamide (2.101a):  
Colorless oil (403 mg, 1.77 mmol, 95%, from 
2.100a); Rf = 0.13 (SiO2, CH2Cl2/MeOH 1:1); 
Optical rotation: 𝛼 !!"  = –34.4 (c 0.90, CHCl3); 
FTIR (neat): ν = 3291, 3074, 2956, 2926, 2868, 1642, 1548, 1464, 1369, 
1268, 1119, 1029, 671, 629 cm-1; 1H NMR (400 MHz, CDCl3) δ = 6.16 (bs, 
1H) 3.54 – 3.48 (m, 1H), 2.92 – 2.86 (m, 1H), 2.58 – 2.54 (m, 1H), 2.18 (t, J = 
7.5 Hz, 2H), 1.66 – 1.56 (m, 5H), 1.31 – 1.23 (m, 8H), 0.93 (d, J = 6.8 Hz, 
3H), 0.91 (d, J = 6.8 Hz, 3H), 0.86 (t, J = 6.9 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ = 173.5, 56.8, 43.1, 37.0, 32.6, 31.8, 29.4, 29.2, 26.0, 22.7, 19.3, 
17.9, 14.2; HRMS (ESI) m/z calcd for C13H28N2O [M+H]+: 229.2274, found: 
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229.2274. 
 
(S)-N-(2-amino-3-methylbutyl)octanamide (2.101b):  
Colorless oil  (330 mg, 1.45 mmol, 92% from 
2.100b); Optical rotation: 𝛼 !!"= +41.7 (c 0.32, 
CHCl3). 
 
(9H-fluoren-9-yl)methyl (R)-(1-octanamidopropan-2-yl)carbamate 
(2.134a):  
Colorless oil (545 mg, 2.72 mmol, 96%, from 
2.134a); Rf = 0.33 (SiO2, CH2Cl2/MeOH 1:1); 
Optical rotation: 𝛼 !!"   = –21.2 (c 0.57, CHCl3); 
FTIR (neat): ν = 3281, 3073, 2957, 2925, 2857, 1643, 1544, 1460, 1361, 
1269, 1240, 1116, 1033, 963, 831, 698 cm-1; 1H NMR (400 MHz, CDCl3) δ = 
6.16 (bs, 1H), 3.31 – 3.26 (m, 1H), 3.06 – 2.93 (m, 2H), 2.16 (t, J = 7.9 Hz, 
2H), 1.64 – 1.58 (m, 4H), 1.30 – 1.21 (m, 8H), 1.06 (d, J = 6.2 Hz, 3H), 0.84 (t, 
J = 7.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 173.6, 46.9, 46.7, 37.0, 31.8, 
29.4, 29.1, 26.0, 22.7, 21.9, 14.2; HRMS (ESI) m/z calcd for C11H25N2O 
[M+H]+: 201.1961, found: 201.1963. 
 
(R)-N-(2-amino-3-methylbutyl)hexanamide (2.138a):  
Colorless oil (57.0 mg, 285 µmol, 80%, from 2.137a); 
Rf = 0.12 (SiO2, CH2Cl2/MeOH 1:1); Optical 
rotation: 𝛼 !!" = –37.3 (c 0.16, CHCl3); FTIR (neat): ν = 3293, 3074, 2957, 2930, 2871, 2340, 1643, 1548, 1465, 1370, 1255, 
1188, 1115, 631 cm-1; 1H NMR (CDCl3, 400 MHz) δ = 6.31 (s, 1H), 3.43 (ddd, 
J = 13.4, 6.5, 3.8 Hz, 1H), 2.84 (ddd, J = 13.5, 9.2, 4.3 Hz, 1H), 2.50 (ddd, J = 
9.4, 5.6, 3.8 Hz, 1H), 2.15 – 2.11 (m, 2H), 1.61 – 1.50 (m, 3H), 1.39 (s, 2H), 
1.29 – 1.21 (m, 4H), 0.88 – 0.81 (m, 9H); 13C NMR (CDCl3, 101 MHz) δ = 
173.5, 56.6, 43.3, 36.8, 32.5, 31.5, 25.6, 22.4, 19.3, 17.7, 14.0; HRMS (ESI) 
m/z calcd for C11H25N2O [M+H]+: 201.1961, found 201.1964. 
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(R)-N-(2-amino-3-methylbutyl)palmitamide (2.138b):  
White solid (3.81 mg, 11.0 µmol, 
45%, from 2.137b); M.p.: 55.8 – 
57.5 °C; Rf = 0.41 (SiO2, CH2Cl2/MeOH 1:1); Optical rotation: 𝛼 !!" = –16.5 
(c 0.18, CHCl3); FTIR (neat): ν = 3309, 2957, 2916, 2850, 1635, 1548, 1469, 
1381, 1262, 1089, 1018, 800, 718 cm-1; 1H NMR (400 MHz, CDCl3) δ = 6.05 
(bs, 1H), 3.54 – 3.48 (m, 1H), 2.91 – 2.84 (m, 1H), 2.56 – 2.52 (m, 1H), 2.18 
(t, J = 7.8 Hz, 2H), 1.66 – 1.54 (m, 3H), 1.30 – 1.25 (m, 26H), 0.92 (t, J = 6.6 
Hz, 6H), 0.88 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 173.5, 56.7, 
43.3, 37.1, 32.8 32.1, 29.9, 29.8, 29.8, 29.7, 29.7, 29.5, 29.5, 29.5, 26.0, 22.9, 
19.4, 17.9, 14.3; HRMS (ESI) m/z calcd for C21H45N2O [M+H]+: 341.3526, 
found: 341.3528. 
N-(2-aminoethyl)octanamide (2.134d):  
White solid (380 mg, 2.04 mmol, 69%, from 2.133d); 
M.p.: 117.8 – 118.6 °C; Rf = 0.28 (SiO2, CH2Cl2/MeOH 
1:1); FTIR (neat): ν = 3287, 2955, 2921, 2853, 1637, 
1551, 1466, 1380, 1286, 1210, 1121, 1042, 927, 694 cm-1; 1H NMR (400 
MHz, CDCl3) δ = 6.10 (s, 1H), 3.29 (q, J = 5.8 Hz, 2H), 2.82 (t, J = 5.9 Hz, 
2H), 2.17 (t, J = 7.6 Hz, 2H), 1.73 (s, 2H), 1.61 (quin., J = 7.4 Hz, 2H), 1.30 – 
1.23 (m, 8H), 0.87 – 0.84 (m, 3H); 13C NMR (101 MHz, CDCl3) δ = 173.7, 
41.9, 41.5, 37.0, 31.8, 29.4, 29.1, 25.9, 22.7, 14.2; HRMS (ESI) m/z calcd for 
C10H23N2O [M+H]+: 187.1805, found: 187.1805. 
 
(R)-N-(2-amino-4-methylpentyl)octanamide (2.134b):  
White solid (200 mg, 0.825 mmol, 54%, from 
2.133b); M.p.: 83.9 – 84.6 °C; Rf = 0.46 (SiO2, 
CH2Cl2/MeOH 1:1); Optical rotation: 𝛼 !!"  =  
–11.9 (c 0.34, CHCl3); FTIR (neat): ν = 3303, 2955, 2920, 2852, 1645, 1557, 
1486, 1368, 1331, 1284, 1168, 1144, 1067, 816, 716, 636 cm-1; 1H NMR (400 
MHz, CDCl3) δ = 6.23 (bs, 1H), 3.44 – 3.41 (m, 1H), 3.01 – 2.95 (m, 2H), 2.30 
(bs, 2H), 2.19 (t, J = 7.8 Hz, 2H), 1.76 – 1.68 (m, 1H), 1.65 – 1.59 (m, 2H), 
1.32 – 1.22 (m, 10H), 0.92 (d, J = 6.5 Hz, 3H), 0.88 (t, J = 6.5 Hz, 3H), 0.87 (t, 
J = 7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 173.8, 49.3, 45.1, 44.7, 37.0, 
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31.8, 29.4, 29.2, 25.9, 24.7, 23.3, 22.8, 22.3, 14.2; HRMS (ESI) m/z calcd for 
C14H31N2O [M+H]+: 243.2431, found: 243.2434. 
 
(R)-N-(2-amino-3-phenylpropyl)octanamide (2.134c):  
Slightly yellow oil (8.0 mg, 0.029 mmol, 87%, 
from 2.133c); Rf = 0.50 (SiO2, CH2Cl2/MeOH 
1:1); Optical rotation: 𝛼 !!"  = –6.3 (c 0.27, 
CHCl3); FTIR (neat): ν = 3281, 3062, 2925, 2855, 1643, 1546, 1455, 1377, 
1265, 1086, 1030, 889, 799, 743, 702, 630 cm-1; 1H NMR (400 MHz, CDCl3)  
δ = 7.32 – 7.29 (m, 2H), 7.25 – 7.18 (m, 3H), 6.15 (t, J = 5.3 Hz, 1H), 3.52 – 
3.46 (m, 1H), 3.22 – 3.16 (m, 1H), 3.14 – 3.08 (m, 1H), 2.84 (dd, J = 13.4, 5.2 
Hz, 1H), 2.58 (dd, J = 13.4, 8.2 Hz, 1H), 2.28 (bs, 2H), 2.19 (t, J = 7.5, Hz, 
2H), 1.65 – 1.58 (m, 2H), 1.31 – 1.25 (m, 8H), 0.88 – 0.85 (m, 3H); 13C NMR 
(101 MHz, CDCl3) δ = 173.8, 138.1, 129.4, 128.8, 126.8, 52.8, 44.7, 42.0, 
37.0, 31.9, 29.5, 29.2, 25.9, 22.8, 14.2; HRMS (ESI) m/z calcd for C17H29N2O 
[M+H]+: 277.2274, found: 277.2278. 
 
General procedure for the N-oxidation: 
 
Dibenzoylperoxide (0.44 mmol, 1.3 eq) and K2HPO4 (0.55 mmol, 1.6 eq) were 
suspended in THF (2.1 mL). The free amine (0.34 mmol, 1.2 eq) was 
dissolved in THF (0.9 mL) and added to the mixture and stirred for 21.5 h at 
r.t. Eight drops of piperidine were added and the mixture stirred for 10 
minutes. Water (5.0 mL) was added and stirring continued at r.t. until a 
solution was obtained. The solution was extracted with EtOAc (3 x 1.2 mL) 
and the combined organic layers were washed with brine (2 x 1.0 mL), then 
dried over Na2SO4, filtered and evaporated to obtain a yellow oil. The crude 
was purified by flash column chromatography (SiO2, pentane/EtOAc 3:1) to 
obtain the desired N-oxide product. 
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(R)-N-(2-((benzoyloxy)amino)-3-methylbutyl)octanamide (2.102a):  
Colorless oil (298 mg, 0.89 mmol, 56%, from 
2.101a); Rf = 0.27 (SiO2, pentane/EtOAc 3:1); 
Optical rotation: 𝛼 !!"   = –1.2 (c 0.18, CHCl3); 
FTIR (neat): ν = 3289, 3066, 2967, 2927, 2857, 
1724, 1643, 1544, 1491, 1452, 1380, 1335, 1263, 1178, 1090, 1025, 982, 
858, 786, 707 cm-1; 1H NMR (400 MHz, CDCl3) δ = 8.01 – 7.98 (m, 2H), 7.64 
– 7.59 (m, 2H), 7.50 – 7.45 (m, 2H), 6.38 (bs, 1H), 3.73 – 3.65 (m, 1H), 3.33 – 
3.26 (m, 1H), 2.98 – 2.93 (m, 1H), 2.25 – 2.21 (m, 2H), 1.90 (m, J = 6.7 Hz, 
1H), 1.68 – 1.60 (m, 2H), 1.30 – 1.23 (m, 8H), 1.10 (d, J = 6.8 Hz, 3H), 1.06 
(d, J = 6.9 Hz, 3H), 0.87 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 
173.6, 167.0, 133.8, 129.5, 128.8, 128.2, 66.7, 38.3, 37.0, 31.8, 29.4, 29.2, 
28.3, 25.9, 22.8, 19.5, 19.4, 14.2; HRMS (ESI) m/z calcd for C20H32N2O3 
[M+H]+: 349.2486, found: 349.2490.  
 
(S)-N-(2-((benzoyloxy)amino)-3-methylbutyl)octanamide (2.102b): 
Colorless oil (81.8 mg, 0.235 mmol, 69% from 
2.101b); Optical rotation: 𝛼 !!"   = +0.7 (c 0.17, 
CHCl3). 
 
 
(R)-N-(2-((benzoyloxy)amino)propyl) octanamide (2.135a): 
Colorless oil (137 mg, 0.427 mmol, 16%, from 
2.134b); Rf = 0.39 (SiO2, pentane/EtOAc 1:1); 
Optical rotation: 𝛼 !!"   = +5.7 (c 0.10, CHCl3); 
FTIR (neat): ν = 3305, 2954, 2927, 2856, 1722, 
1647, 1543, 1452, 1264, 1177, 1087, 1063, 1025, 797, 707 cm-1; 1H NMR 
(400 MHz, CDCl3) δ = 8.03 – 8.00 (m, 2H), 7.63 – 7.59 (m, 1H), 7.47 (t, J = 
7.8 Hz, 2H), 6.12 (bs, 1H), 3.51 – 3.45 (m, 1H), 3.42 – 3.30 (m, 2H), 2.22 (t, J 
= 7.7 Hz, 2H), 1.68 – 1.61 (m, 2H), 1.36 – 1.26 (m, 8H), 1.19 (d, J = 6.3 Hz, 
3H), 0.87 (t, J = 7.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 173.7, 167.2, 
133.8, 129.5, 128.8, 128.1, 56.5, 41.5, 37.0, 31.8, 29.4, 29.2, 25.9, 22.8, 15.7, 
14.2; HRMS (ESI) m/z calcd for C18H29N2O3 [M+H]+: 321.2173, found: 
321.2174. 
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(R)-N-(2-((benzoyloxy)amino)-3-methylbutyl)hexanamide (2.139a):  
Colorless oil (7.41 mg, 23.1 µmol, 77%, from 
2.138a); Rf = 0.28 (SiO2, pentane/EtOAc 3:1); 
Optical rotation: 𝛼 !!" = –10.3 (c 0.18, CHCl3); FTIR 
(neat): ν  = 3297, 3067, 2957, 2931, 2870, 2361, 
1721, 1643, 1543, 1450, 1370, 1268, 1178, 1090, 1066, 1025, 853, 794, 708, 
656, 627 cm-1; 1H NMR (CDCl3, 400 MHz) δ = 7.99 (d, J = 6.9 Hz, 2H), 7.63 – 
7.59 (m, 1H), 7.47 (t, J = 7.8 Hz, 2H), 6.36 (s, 1H), 3.69 (ddd, J = 14.2, 6.0, 
3.5 Hz, 1H), 3.28 (ddd, J = 13.8, 8.1, 5.0 Hz, 1H), 2.94 (td, J = 7.7, 3.5 Hz, 
1H), 2.22 (t, J = 7.6 Hz, 2H), 1.98 – 1.89 (m, 1H), 1.68 – 1.61 (m, 3H), 1.35 – 
1.25 (m, 4H), 1.10 (d, J = 6.8 Hz, 3H), 1.05 (d, J = 6.8 Hz, 3H), 0.90 – 0.87 
(m, 3H); 13C NMR (CDCl3, 101 MHz) δ = 173.8, 166.8, 133.9, 129.6, 128.8, 
66.8, 38.2, 36.9, 31.6, 28.3, 25.5, 24.8, 22.6, 19.6, 19.3, 14.1; HRMS (ESI) 
m/z calcd for C18H29N2O3 [M+H]+: 321.2173, found 321.2173. 
 
(R)-N-(2-((benzoyloxy)amino)-3-methylbutyl)palmitamide (2.139b): 
Colorless oil (4.7 mg, 0.01 mmol, 
43%, from 2.138b); Rf = 0.27 
(SiO2, pentane/EtOAc 3:1); 
Optical rotation:    𝛼 !!"  = –1.2 
(c 0.41, CHCl3); FTIR (neat): ν = 
3314, 2916, 2852, 1720, 1640, 1549, 1469, 1450, 1428, 1270, 1179, 1107, 
1097, 1068, 1026, 794, 702, 687 cm-1; 1H NMR (400 MHz, CDCl3) δ = 8.01 –
7.98 (m, 2H), 7.88 (bs, 1H), 7.62 – 7.57 (m, 1H), 7.48 – 7.44 (m, 2H), 6.23, (t, 
J = 5.6 Hz, 1H), 3.69 – 3.63 (m, 1H), 3.28 – 3.21 (m, 1H), 2.89 – 2.85 (m, 1H), 
2.20 (t, J = 7.9 Hz, 2H), 1.95 – 1.83 (m, 1H), 1.67 – 1.59 (m, 2H), 1.28 – 1.24 
(m, 24H), 1.08 (d, J = 6.7 Hz, 3H), 1.03 (d, J = 6.7 Hz, 3H), 0.87 (t, J = 7.1 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ = 173.6, 167.1, 133.7, 129.5, 128.8, 128.5, 
128.2, 126.9, 66.6, 38.3, 37.0, 32.1, 29.8, 29.8, 29.8, 29.7, 29.5, 29.5, 28.3, 
25.6, 22.8, 19.5, 19.4, 14.3; HRMS (ESI) m/z calcd for C28H49N2O3 [M+H]+: 
461.3738, found: 461.3741. 
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(R)-N-(2-((benzoyloxy)amino)-4-methylpentyl)octanamide (2.135b): 
Colorless oil (111 mg, 0.306 mmol, 42%, from 
2.134b); Rf = 0.23 (SiO2, pentane/EtOAc 5:1); 
Optical rotation:   𝛼 !!" = +6.4 (c 0.35, CHCl3); 
FTIR (neat): ν = 3301, 3065, 2928, 2857, 1721, 
1640, 1620, 1544, 1449, 1369, 1269, 1176, 1091, 1025, 852, 789, 707 cm-1; 
1H NMR (400 MHz, CDCl3) δ = 8.01 – 7.98 (m, 2H), 7.60 (t, J = 7.5, 1.3 Hz, 
1H), 7.49 – 7.45 (m, 2H), 6.27 (bs, 1H), 3.53 – 3.47 (m, 1H), 3.36 – 3.26 (m, 
2H), 2.21 (t, J = 7.7 Hz, 2H), 1.85 – 1.75 (m, 1H), 1.68 – 1.60 (m, 3H), 1.46 – 
1.36 (m, 1H), 1.35 – 1.24 (m, 9H), 0.94 (d, J = 6.6 Hz, 6H), 0.86 (t, J = 6.9 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ = 173.6, 167.1, 133.7, 129.5, 128.8, 128.5, 
126.9, 59.0, 40.4, 38.6, 37.0, 31.8, 29.4, 29.1, 25.9, 24.9, 23.0, 22.7, 14.2; 
HRMS (ESI) m/z calcd for C21H35N2O3 [M+H]+: 363.2642, found: 363.2642. 
 
(R)-N-(2-((benzoyloxy)amino)-3-phenylpropyl)octanamide (2.135c): 
Colorless oil (88.1 mg, 0.22 mmol, 46%, from 
2.134c); Rf = 0.20 (SiO2, pentane/EtOAc 3:1); 
Optical rotation: 𝛼 !!" = +19.1 (c 0.24, CHCl3); 
FTIR (neat): ν = 3296, 2927, 2856, 1722, 1646, 
1519, 1453, 1360, 1251, 1162, 1064, 1026, 800, 704 cm-1; 1H NMR (400 
MHz, CDCl3) δ = 7.91 (d, J = 7.6 Hz, 2H) 7.55 (t, J = 7.6 Hz, 1H), 7.40 (t, J = 
7.7 Hz, 2H), 7.32 – 7.25 (m, 3H), 7.21 – 7.17 (m, 2H), 6.32 (bt, J = 5.4 Hz, 
1H), 3.58 – 3.53 (m, 1H), 3.43 – 3.39 (m, 1H), 3.36 – 3.30 (m, 1H), 2.82 (d, J 
= 6.9 Hz, 2H), 2.17 (t, J = 7.8 Hz, 2H), 1.62 – 1.47 (m, 3H), 1.26 – 1.19 (m, 
8H), 0.82 – 0.78 (m, 3H); 13C NMR (101 MHz, CDCl3) δ = 173.7, 166.8, 137.2, 
133.7, 129.5, 129.3, 129.0, 128.8, 128.2, 127.1, 62.3, 40.2, 37.0, 36.4, 31.8, 
29.4, 29.1, 25.9, 22.7, 14.2; HRMS (ESI) m/z calcd for C24H33N2O3 [M+H]+: 
397.2486, found: 397.2488. 
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General procedure for the benzoyl-cleavage: 
 
The N-oxidized product (23.4 µmol, 1 eq) was dissolved in dry and degassed 
EtOH (0.5 mL, thaw/freeze method, 3 cycles) and hydrazine monohydrate 
(0.91 mmol, 39.0 eq) was added and the mixture stirred at r.t. for 2.5 h. The 
mixture was evaporated and then suspended in ACN. The suspension was 
filtered over cotton and then evaporated. The filtrate was dissolved in Et2O 
(1.5 mL) and aq. HCl (0.25 M, 0.5 mL) and the aq. layer was extracted with 
Et2O (3 x 1.0 mL). To the acidic aq. layer was added aq. NaOH solution  
(10 N) until a basic pH was reached. The basic layer was extracted with Et2O 
(4 x 1.5 mL) and the combined organic layers were dried over Na2SO4, filtered 
and evaporated to obtain the desired hydroxylamine as a white solid. 
 
(R)-N-(2-(hydroxyamino)-3-methylbutyl)octanamide (2.91a):  
White solid (36.0 mg, 0.147 mmol, 53%, from 
2.102a); M.p.: 107.1 – 107.7 °C; Rf = 0.16 (SiO2, 
pentane/EtOAc 1:1); Optical rotation :   𝛼 !!"   =  
–12.3 (c 0.26, CHCl3); FTIR (neat): ν = 3311, 3264, 3194, 2950, 2920, 2860, 
2852, 1633, 1561, 1466, 1374, 1244, 1163, 1116, 1067, 1003, 912, 832, 721, 
671 cm-1; 1H NMR (400 MHz, CDCl3) δ = 6.10 (bs, 1H), 5.34 (bs, 2H), 3.63 – 
3.57 (m, 1H), 3.33 – 3.26 (m, 1H), 2.54 (dt, J = 7.7, 3.3 Hz, 1H), 2.19 (t, J = 
7.6 Hz, 2H), 1.86 – 1.74 (m, 1H), 1.65 – 1.59 (m, 2H), 1.29 – 1.25 (m, 8H), 
0.98 (d, J = 6.9 Hz, 3H), 0.95 (d, J = 6.9 Hz, 3H), 0.88 – 0.85 (m, 3H); 13C 
NMR (101 MHz, CDCl3) δ = 175.0, 67.2, 38.2, 37.0, 31.8, 29.4, 29.2, 27.5, 
25.9, 22.8, 19.7, 19.5, 14.2; HRMS (ESI) m/z calcd for C13H29N2O2 [M+H]+: 
245.2224, found: 245.2226.  
 
(S)-N-(2-(hydroxyamino)-3-methylbutyl)octanamide (2.91b): 
White solid (3.21 mg, 13.2 µmol, 56% from 
2.102b); Optical rotation: 𝛼 !!"   = +12.5 (c 0.16, 
CHCl3). 
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General procedure for the formation of C-diazeniumdiolates: 
 
The hydroxylamine (0.14 mmol, 1.0 eq) was dissolved in degassed EtOH (1.4 
mL, thaw/freeze method, 3 cycles), isopentyl nitrite (0.97 mmol, 7.0 eq) was 
added and NH3 gas was bubbled through the solution for two minutes and 
after 10 minutes again for one minute. After stirring 30 minutes at r.t., the 
mixture was evaporated and then extracted with aq. NaOH (1.0 M, 0.4 mL) 
and Et2O (4 x 1.0 mL). The basic aq. layer was then acidified with aq. HCl (1.0 
M 0.5 mL,) and extracted with Et2O (4 x 1.2 mL). The combined organic layer 
was washed with brine (1 mL), dried over Na2SO4, filtered and evaporated to 
obtain the C-diazeniumdiolate as a white solid  
 
(R,Z)-2-hydroxy-1-(3-methyl-1-octanamidobutan-2-yl)diazene 1-oxide 
(2.80a):  
White solid (31.4 mg, 0.12 mmol, 83%, from 
2.91a); M.p.: 75.2 – 75.9 °C; Rf = 0.32 (SiO2, 
CH2Cl2/MeOH 20:1); Optical rotation: 𝛼 !!"   =  
–97.7 (c 0.54, CHCl3); –134.2 (c 0.53, EtOH); 
FTIR (neat): ν = 3300, 2961, 2926, 2857, 1622, 1566, 1521, 1466, 1424, 
1269, 1058, 931, 707 cm-1; 1H NMR (400 MHz, CDCl3) δ = 11.75 (bs, 1H), 
5.73 (bs, 1H), 4.20 (td, J = 9.2, 3.0 Hz, 1H), 3.85 (dq, J = 14.2, 3.1 Hz, 1H), 
3.63 – 3.56 (m, 1H), 2.27 – 2.12 (m, 3 H), 1.61 – 1.54 (m, 2H), 1.33 – 1.22 (m, 
8H), 1.07 (d, J = 6.8 Hz, 3H), 0.90 (d, J = 6.8 Hz, 3H), 0.87 (t, J = 7.0 Hz, 3H); 
13C NMR (101 MHz, CDCl3) δ = 173.7, 78.0, 39.1, 36.6, 31.8, 29.3, 29.1, 29.1, 
25.7, 22.7, 19.1, 18.9, 14.2; HRMS (ESI) m/z calcd for C13H27N3O3Na 
[M+Na]+: 296.1945, found: 296.1945; X-ray crystal structure is given in the 
appendices section. 
 
(S,Z)-2-hydroxy-1-(3-methyl-1-octanamidobutan-2-yl)diazene 1-oxide 
(2.80b): 
White solid (9.46 mg, 35 µmol, 83% from 2.91b); 
Optical rotation: 𝛼 !!"  = +126.2 (c 0.50, CHCl3); 𝛼 !!" = +147.0 (c 0.47, EtOH). Me
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(R,Z)-2-hydroxy-1-(1-octanamidopropan-2-yl)diazene 1-oxide (2.136a): 
White solid (12.9 mg, 53.0 µmol, 65%, over two 
steps from 2.135a); M.p.: 48.3 – 48.7 °C; Rf = 0.08 
(SiO2, CH2Cl2/MeOH 20:1); Optical rotation: 𝛼 !!"  = –110 (c 0.30, CHCl3); FTIR (neat): ν = 3310, 2954, 2927, 2848, 1650, 
1547, 1446, 1380, 1332, 1285, 1266, 1250, 1109, 1046, 946, 689, 667, 637 
cm-1; 1H NMR (400 MHz, CDCl3) δ = 11.53 (bs, 1H), 5.85 (t, J = 6.3 Hz, 1H), 
4.70 – 4.59 (m, 1H), 3.74 (ddd, J = 14.5, 6.4, 3.3 Hz, 1H), 3.56 – 3.46 (m, 1H), 
2.18 – 2.13 (m, 2H), 1.58 (quin., J = 7.1 Hz, 2H), 1.48 (d, J = 6.8 Hz, 3H), 1.30 
– 1.24 (m, 8H), 0.89 – 0.84 (m, 3H); 13C NMR (101 MHz, CDCl3) δ = 173.9, 
68.1, 41.8, 36.6, 31.8, 29.3, 29.1, 25.8, 22.7, 15.9, 14.2; HRMS (ESI) m/z 
calcd for C11H23N3O3Na [M+Na]+: 268.16316, found: 268.16291. 
 
(R,Z)-1-(1-hexanamido-3-methylbutan-2-yl)-2-hydroxydiazene 1-oxide 
(2.140a): 
White solid (6.46 mg, 17.8 µmol, 31% over two steps 
from 2.139a); M.p.: 51.5 – 52.7 °C; Rf = 0.14 (SiO2, 
CH2Cl2/MeOH 20:1); Optical rotation: 𝛼 !!"= –88.2 
(c 0.08, CHCl3); FTIR (neat): ν = 3294, 2962, 2929, 
2862, 2362, 1621, 1529, 1459, 1425, 1268, 1057, 930, 876, 800, 710 cm-1; 1H 
NMR (CDCl3, 400 MHz) δ = 11.60 (s, 1H), 5.71 (s, 1H), 4.21 (td, J = 9.2, 3.1 
Hz, 1H), 3.86 (ddd, J = 14.4, 6.0, 3.1 Hz, 1H), 3.60 (ddd, J = 14.3, 9.4, 6.0 Hz, 
1H), 2.25 – 2.11 (m, 3H), 1.62 – 1.55 (m, 2H), 1.34 – 1.25 (m, 4H), 1.07 (d, J 
= 6.8 Hz, 3H), 0.91 – 0.87 (m, 6H); 13C NMR (CDCl3, 101 MHz) δ = 173.7, 
78.0, 39.1, 36.6, 31.4, 29.1, 25.4, 22.5, 19.2, 18.9, 14.0; HRMS (ESI) m/z 
calcd for C11H23N3NaO3 [M+Na]+: 268.1632, found 268.1633; X-ray crystal 
structure is given in the appendices section. 
 
(R,Z)-2-hydroxy-1-(3-methyl-1-palmitamidobutan-2-yl)diazene 1-oxide 
(2.140b):  
White solid (3.02 mg, 8.0 µmol, 
52%, over two steps from 2.139b); 
M.p.: 93.5 – 93.9 °C Rf = 0.08 
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(SiO2, CH2Cl2/MeOH 20:1); Optical rotation:   𝛼 !!" = –70.7 (c 0.27, CHCl3); 
FTIR (neat): ν = 3325, 2915, 2847, 1651, 1544, 1472, 1462, 1250, 1055, 730, 
714, 685, 619 cm-1; 1H NMR (400 MHz, CDCl3) δ = 11.69 (s, 1H), 5.70 (t, J = 
5.5 Hz, 1H), 4.20 (td, J = 9.2, 3.1 Hz, 1H), 3.89 – 3.83 (m, 1H), 3.64 – 3.56 
(m, 1H), 2.25 – 2.18 (m, 1H), 2.16 – 2.12 (m, 2H), 1.61 – 1.54 (m, 2H), 1.32 – 
1.21 (m, 24H), 1.07 (d, J = 6.9 Hz, 3H), 0.91 (d, J = 6.8 Hz, 3H), 0.90 – 0.86 
(m, 3H); 13C NMR (101 MHz, CDCl3) δ = 173.7, 78.0, 39.1, 36.7, 32.1, 29.9, 
29.9, 29.8, 29.8, 29.8, 29.8, 29.6, 29.5, 29.5, 29.3, 29.1, 25.8, 22.9, 19.2, 
18.9, 14.3; HRMS (ESI) m/z calcd for C21H43N3O3Na [M+Na]+: 408.31966, 
found: 408.31932. 
 
(R,Z)-2-hydroxy-1-(4-methyl-1-octanamidopentan-2-yl)diazene 1-oxide 
(2.136b):  
White solid (17.8 mg, 62.0 µmol, 38% over two 
steps from 2.135b); M.p.: 74.0 – 74.4 °C; Rf = 
0.15 (SiO2, CH2Cl2/MeOH 20:1); Optical 
rotation:    𝛼 !!"  = –72.1 (c 0.25, CHCl3); FTIR 
(neat): ν = 3316, 2953, 2927, 2656, 2360, 1623, 1566, 1523, 1455, 1424, 
1360, 1326, 1271, 1222, 1173, 1143, 1088, 1062, 1030, 1007, 947, 696, 615, 
cm-1; 1H NMR (400 MHz, MeOD) δ = 4.60 – 4.53 (m, 1H), 3.53 – 3.39 (m, 2H), 
2.15 (t, J = 7.6 Hz, 2H), 1.92 – 1.85 (m, 1H), 1.61 – 1.53 (m, 2H), 1.51 – 1.37 
(m, 2H), 1.33 – 1.27 (m, 8H), 0.95 – 0.88 (m, 9H); 13C NMR (101 MHz, 
MeOD) δ = 177.0, 71.7, 42.5, 39.4, 36.9, 32.8, 30.2, 30.1, 27.0, 26.0, 23.7, 
23.3, 21.7, 14.4; HRMS (ESI) m/z calcd for C14H29N3O3Na [M+Na]+: 
310.21011, found: 310.20954. 
 
(R,Z)-2-methoxy-1-(3-methyl-1-octanamidobutan-2-yl)diazene 1-oxide 
(2.141):  
(−)-Fragin (2.80a) (4.4 mg, 16.1 µmol, 1.0 eq) 
was dissolved in dry MeOH (0.20 mL) and 
Na2CO3 (2.05 mg, 19.3 µmol, 1.2 eq) was added 
and cooled to 0 °C. Dimethyl sulfate (1.7 µl, 17.7 µmol, 1.1 eq) was added 
and the mixture stirred at 0 °C for 15 minutes and then allowed to warm to r.t. 
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After 2.5 h, the mixture was diluted with water (0.2 mL) and then extracted 
with EtOAc (4 x 0.2 mL), the combined organic layers were dried over MgSO4, 
filtered and evaporated. The residual was purified by flash column 
chromatography (SiO2, pentane/EtOAc 2:1) to obtain methylated fragin 2.141 
(3.15 mg, 11.4 µmol, 71%) as a colorless oil: Rf = 0.20 (SiO2, pentane/EtOAc 
2:1); Optical rotation: 𝛼 !!" = –8.7 (c 0.31, CHCl3); FTIR (neat): ν = 3321, 
2961, 2928, 2857, 1674, 1655, 1543, 1501, 1464, 1263, 1062, 1012, 801  
cm-1; 1H NMR (400 MHz, CDCl3) δ = 5.90 (t, J = 5.7 Hz, 1H), 4.10 (td, J = 9.3, 
3.2 Hz, 1H), 4.06 (s, 3H), 3.80 (ddd, J = 14.3, 6.0, 3.2 Hz, 1H), 3.56 (ddd, J = 
14.3, 9.2, 6.1 Hz, 1H), 2.22 – 2.09 (m, 3H), 1.59 (quin., J = 7.1 Hz, 2H), 1.31 – 
1.23 (m, 8H), 1.04 (d, J = 6.8 Hz, 3H), 0.93 (d, J = 6.6 Hz, 3H), 0.89 – 0.85 
(m, 3H); 13C NMR (101 MHz, CDCl3) δ = 173.7, 78.7, 61.6, 39.4, 36.7, 31.8, 
29.3, 29.2, 28.9, 25.9, 22.8, 19.3, 18.9, 14.2; HRMS (ESI) m/z calcd for 
C14H29N3O3Na [M+Na]+: 310.21011, found: 310.2999. 
 
(E)-1,2-bis((R)-3-methyl-1-octanamidobutan-2-yl)diazene 1,2-dioxide 
(2.109): 
Hydroxylamine 2.91a (29.1 mg, 0.12 
mmol, 1.0 eq) was dissolved in 
CHCl3 (0.1 mL) and cooled to 0 °C. 
A solution of m-CPBA (32.3 mg, 
0.13 mmol, 1.1 eq) in CHCl3 (0.1 mL) was added and the mixture stirred at  
0 °C for 2 h, and then 1 h at r.t. The mixture was diluted with CHCl3 (0.2 mL) 
and washed with sat. aq. NaHCO3 (3 x 0.1 mL) and brine (0.1 mL). The 
organic layer was dried over Na2SO4, filtered and evaporated to obtain the 
dimer 2.109 (103 mg, 61.0 µmol, quant.) as a white solid: M.p.: 90.8 – 91.5 
°C; Rf = 0.37 (SiO2, pentane/EtOAc 1:1); Optical rotation: 𝛼 !!"  = +7.9 
(c 0.47, CHCl3); FTIR (neat): ν = 3377, 3259, 3072, 2953, 2923, 2870, 1636, 
1546, 1465, 1377, 1266, 1203, 1039, 928, 802, 725, 679, 614 cm-1; 1H NMR 
(400 MHz, CDCl3) δ = 6.36 (bs, 2H), 5.21 (td, J = 7.9, 2.3 Hz, 2H), 3.85 – 3.79 
(m, 2H), 3.64 – 3.57 (m, 2H), 2.30 – 2.22 (m, 2H), 2.17 (t, J = 7.8 Hz, 4H), 
1.64 – 1.57 (m, 4H), 1.30 – 1.27 (m, 16H), 1.04 (d, J = 6.8 Hz, 6H), 0.95 (d,  
J = 6.6 Hz, 6H), 0.87 (t, J = 6.9 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ = 
Me
Me
N
H
O
Me
N+-O
Me
Me
H
N
O
Me
N+
O-
EXPERIMENTAL PART 
	  
195 
173.8, 72.5, 38.2, 36.6, 31.9, 29.4, 29.2, 28.3, 25.8, 22.8, 19.8, 18.5, 14.2; 
HRMS (ESI) m/z calcd for C26H53N4O4 [M+H]+: 485.4061, found: 485.4063. 
 
Cu-Fragin (2.144): 
(−)-Fragin (2.80a) (2.24 mg, 8.2 
µmol, 1.0 eq) was dissolved in dry 
MeOH (0.1 mL) and Cu(OAc)2 (2.23 
mg, 0.012 mmol, 1.5 eq) was added 
and the mixture stirred at r.t. for 18 
h. Water (0.1 mL) was then added 
and the precipitate filtered over cotton and washed with water (3 x 0.1 mL).  
The filter was flushed with MeOH (1.0 mL) and the organic layer was dried 
over NaSO4, filtered and evaporated to obtain Cu-fragin complex 2.144 (2.27 
mg, 7.5 µmol, 91%) as a blue solid. M.p.: 154.2 – 154.9 °C; FTIR (neat): ν = 
3270, 3074, 2959, 2926, 2858, 1638, 1552, 1408, 1465, 1408, 1348, 1277, 
1248, 1179, 1124, 998, 934, 861, 796, 709 cm-1; HRMS (ESI) m/z calcd for 
C26H53Cu1N6O6 [M+H]+: 608.3317, found: 608.3316; UV-VIS: λmax = 238 nm; 
X-ray crystal structure is given in the appendices section.  
 
(R)-2-(hydroxyamino)-3-methylbutan-1-ol (2.107a) and  
(S)-2-(hydroxyamino)-3-methylbutan-1-ol (2.107b):  
Was synthesized according to the literature of 
Breuning and co-workers and the data were in good 
agreement. 99  
 
(R,Z)-2-hydroxy-1-(1-hydroxy-3-methylbutan-2-yl)diazene 1-oxide 
(valdiazen 2.105a): 
Hydroxylamine 2.107a (14.7 mg, 0.123 mmol, 1.0 eq) was 
dissolved in methanolic ammonia solution  (7 N, 0.5 mL) and 
isopentyl nitrite (43.2 mg, 49.1 mL, 0.369 mmol, 3.0 eq) was 
added and the mixture stirred at r.t. The colorless solution immediately turned 
yellow. After 5 minutes a white solid precipitated. After 45 min, the mixture 
was evaporated and the residue dissolved in Et2O (3.0 mL) and aq. NaOH (1 
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M, 0.7 mL) was added. The aq. layer was extracted with Et2O (4 x 1.0 mL), 
acidified with aq. HCl (1 M) to pH = 1 and then extracted with Et2O (4 x 1.0 
mL). The combined organic layers were washed with brine (1.0 mL), dried 
over MgSO4, filtered and evaporated to obtain valdiazen (2.105a) (8.44 mg, 
0.057 mmol, 46%) as a white solid. M.p.: 51.4 – 51.9 °C; Rf = 0.07 (SiO2, 
CH2Cl2/MeOH 20:1); Optical rotation: 𝛼 !!"  = –1.5 (c 0.84, CHCl3); FTIR 
(neat): ν = 3281, 3036, 2974, 2920, 2807, 1549, 1417, 1275, 1253, 1138, 
1079, 1043, 1017, 927, 877, 859, 701, 643 cm-1; 1H NMR (400 MHz, MeOD)  
δ = 4.04 – 3.96 (m, 2H), 3.87 – 3.80 (m, 1H), 2.18 – 2.06 (m, 1H), 1.02 (d, J = 
6.8 Hz, 3H), 0.90 (d, J = 6.8 Hz, 3H); 13C NMR (101 MHz, MeOD) δ = 82.3, 
61.2, 29.3, 19.4, 19.4; HRMS (ESI) m/z calcd for C5H12N2O3Na [M+Na]+: 
171.07401, found: 171.07378; X-ray crystal structure is given in the 
appendices section. 
 
(S,Z)-2-hydroxy-1-(1-hydroxy-3-methylbutan-2-yl)diazene 1-oxide 
(valdiazen 2.105b):  
White solid (16.3 mg, 0.11 mmol, 41% from 2.107b; Optical 
rotation: 𝛼 !!" = +1.0 (c 0.60, CHCl3). 
 
 
Cu-Valdiazen (2.145): 
Fragin-NH3 (2.105c) (5.81 mg, 35.0 µmol, 1.0 eq) was 
dissolved in dry MeOH (0.1 mL) and Cu(OAc)2 (4.48 mg, 
25.0 µmol, 0.7 eq) was added and the mixture stirred at r.t. 
for 15 h. The blue solution was diluted with H2O (0.1 mL) 
and extracted with EtOAc (3 x 0.25 mL). The combined 
organic layers were dried over MgSO4, filtered and 
evaporated to obtain the desired Cu-valdiazen complex (2.145) (6.14 mg, 
34.0 µmol, 98%) as a blue solid. M.p.: 154.8 – 155.6 °C; FTIR (neat): ν = 
3415, 2971, 2880, 1714, 1417, 1246, 1167, 1074, 1023, 935, 716, 692 cm-1; 
HRMS (ESI) m/z calcd for C10H23Cu1N4O6 [M+H]+: 358.09081, found: 
358.09049; UV-VIS: λmax = 237 nm; X-ray crystal structure is given in the 
appendices section.  
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3-Methyl-1-nitrobutan-2-ol  (2.87):  
Isobutyraldehyde (2.86) (1.27 mL, 13.9 mmol, 1.0 eq) was 
dissolved in nitromethane (3.86 mL, 69.3 mmol, 5.0 eq) and 
freshly distilled NEt3 (0.199 mL, 1.39 mmol, 0.1 eq) was added at r.t. over 10 
min. The colorless solution turned slightly yellow. After 14 h, the mixture was 
evaporated and then purified by flash column chromatography (SiO2, 
pentane/EtOAc 19:1) to yield the desired alcohol 2.87 as a colorless oil (1.74 
g, 13.1 mmol, 94%). Rf = 0.16 (SiO2, pentane/EtOAc 95:5); 1H NMR (400 
MHz, CDCl3) δ = 4.52 – 4.34 (m, 2H), 4.17 – 4.05 (m, 2H), 2.47 (s, 1H), 1.80 
(m, 1H), 1.25 (td, J = 7.1, 0.7 Hz, 1H), 0.99 (dd, J = 6.8, 5.6 Hz, 6H); the data 
are in good agreement with the reported.402 
 
1-amino-3-methylbutan-2-ol (2.88):  
3-Methyl-1-nitrobutan-2-ol (2.87) (876 mg, 6.59 mmol, 1.0 eq) 
was dissolved in MeOH (70 mL). Pd/C (10% Pd, 701 mg, 0.658 
mmol, 0.1 eq) was added and a H2 ballon (1 bar) was placed. The reaction 
was allowed to stir at r.t. for 24. The mixture was filtered over Celite and the 
filter cake washed with MeOH. The solvent was evaporated to yield the 
desired amine 2.88 (550 mg, 3.36 mmol, 81%) as a colorless solid. 1H NMR 
(400 MHz, CDCl3) δ = 3.26 (ddd, J = 9.3, 6.3, 3.1 Hz, 1H), 2.90 (dd, J = 12.6, 
3.1 Hz, 1H), 2.57 (dd, J = 12.5, 9.1 Hz, 1H), 2.32 (s, 3H), 1.70 – 1.61 (m, 1H), 
0.93 (dd, J = 22.6, 6.8 Hz, 6H); the data are in good agreement with the 
reported.403 
 
N-(2-hydroxy-3-methylbutyl)octanamide (2.89):   
To a solution of 1-amino-3-methylbutan-2-ol 
(2.88) (550 mg, 5.33 mmol, 1.0 eq) in dry CH2Cl2 
(27.5 mL) and DMF (2.75 mL), octanoic acid 
(0.844 mL, 5.33 mmol, 1.0 eq) and HATU (2.23 g, 5.86 mmol, 1.1 eq) were 
added. The solution was cooled to 0 °C and DIPEA (2.71 mL, 16.0 mmol, 3.0 
eq) was added dropwise. The reaction was allowed to warm to r.t. and stirred 
                                                                                                    
402	  	  J.	  A.	  Weeden,	  J.	  D.	  Chisholm,	  Tetrahedron	  Lett.	  2006,	  47,	  9313.	  
403	  	  W.	  Jin,	  X.	  Li,	  Y.	  Huang,	  F.	  Wu,	  B.	  Wan,	  Chem.	  Eur.	  J.	  2010,	  16,	  8259.	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for 24 h. The reaction was quenched with aq. HCl (1 M, 5.0 mL) and extracted 
with EtOAc (3 x 5.0 mL). The combined organic layers were washed with aq. 
sat. NaHCO3 (4.0 mL), water (3.0 mL) and brine (3.0 mL), dried over Na2SO4 
and evaporated. The extract was purified by flash column chromatography 
(SiO2, pentane/EtOAc 1:2) to yield the desired amide 2.89 as a colorless oil 
(964 mg, 4.21 mmol, 79%). Rf = 0.62 (SiO2, pentane/EtOAc 1:2); M.p.: 47.8 – 
48.5 °C; FTIR (neat): ν = 3308, 3212, 2957, 2926, 2858, 2326, 1634, 1555, 
1465, 1354, 1258, 1143, 1070, 1013, 975, 845, 631 cm-1; 1H NMR (400 MHz, 
CDCl3) δ = 5.97 (s, 1H), 3.51 (ddd, J = 13.9, 6.6, 2.7 Hz, 1H), 3.42 (ddd, J = 
8.7, 6.3, 2.7 Hz, 1H), 3.16 (ddd, J = 13.5, 8.4, 4.7 Hz, 1H), 2.36 (s, 1H), 2.22 – 
2.19 (m, 2H), 1.75 – 1.59 (m, 3H), 1.33 – 1.25 (m, 8H), 0.95 (dd, J = 13.5, 6.8 
Hz, 6H), 0.89 – 0.86 (m, 3H); 13C NMR (101 MHz, CDCl3) δ = 174.8, 43.8, 
36.8, 32.3, 31.8, 29.4, 29.1, 25.9, 22.7, 18.7, 18.0, 14.2; HRMS (ESI) m/z 
calcd for C13H28NO2 [M+H]+: 230.2115, found 230.2118. 
 
N-(3-methyl-2-oxobutyl)octanamide (2.85):  
Alcohol 2.89 (964 mg, 4.21 mmol, 1.0 eq) and 
DMP (5.4 g, 12.6 mmol, 3.0 eq) were dissolved in 
CH2Cl2 (57 mL) and stirred at r.t. for 4 h. EtOAc 
(90 mL) was added and the organic layer was washed with aq. sat. Na2S2O3 
(15 mL), aq. sat. NaHCO3 (2 x 10 mL) and brine (10 mL). The crude mixture 
was purified by flash column chromatography (SiO2, pentane/EtOAc 1:3) to 
yield the desired ketone 2.85 (440 mg, 1.94 mmol, 46%) as a colorless solid. 
Rf = 0.16 (pentane/EtOAc 3:1); FTIR (neat): ν = 3318, 2954, 2855, 2336, 
1716, 1637, 1532, 1468, 1385, 1236, 1102, 1022, 803, 645 cm-1; 1H NMR 
(400 MHz, CDCl3) δ = 6.21 (s, 1H), 4.21 (d, J = 4.3 Hz, 2H), 2.66 (hept, J = 
7.0 Hz, 1H), 2.25 – 2.22 (m, 2H), 1.67 – 1.61 (m, 2H), 1.31 – 1.27 (m, 8H), 
1.16 (d, J = 6.9 Hz, 6H), 0.89 – 0.86 (m, 3H); 13C NMR (101 MHz, CDCl3,) δ = 
209.5, 173.4, 47.4, 39.2, 36.7, 31.8, 29.4, 29.1, 25.8, 22.8, 18.3, 14.2; HRMS 
(ESI) m/z calcd for C13H26NO2 [M+H]+: 228.1958, found 228.1960. 
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N-(2-(hydroxyimino)-3-methylbutyl)octanamide (2.90): 
N-(3-Methyl-2-oxobutyl)octanamide (2.85) (793 
mg, 3.49 mmol, 1.0 eq), NH2OH x HCl 
(544 mg, 7.68 mmol, 2.2 eq) and NaOAc (555 
mg, 6.63 mmol, 1.9 eq) were dissolved in MeOH (120 mL) and the mixture 
heated to 85 °C for 8 h. The solvent was removed under reduced pressure 
and water was added to the residue. The mixture was cooled to 0 °C and the 
resulting crystals were filtered off and dissolved in CH2Cl2. The solvent was 
evaporated and the residue was purified by flash column chromatography 
(SiO2, pentane/EtOAc 3:1) to yield the desired product 2.90 (368 mg, 1.52 
mmol, 44%) as a colorless solid. Rf = 0.33 (pentane/EtOAc 3:1); FTIR (neat): ν = 3302, 3092, 2959, 2925, 2850, 2459, 2361, 1636, 1555, 1460, 1413, 
1327, 1261, 1224, 1096, 1031, 943, 798, 702, 616 cm-1; 1H NMR (400 MHz, 
MeOD) δ = 4.09 (s, 2H), 2.54 (hept, J = 6.9 Hz, 1H), 2.20 (t, J = 7.5 Hz, 2H), 
1.64 – 1.57 (m, 2H), 1.35 – 1.29 (m, 8H), 1.08 (d, J = 6.9 Hz, 6H), 0.90 (t, J = 
6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 176.1, 162.2, 36.9, 35.6, 32.9, 
32.5, 30.2, 30.1, 27.0, 23.7, 20.4, 14.4; HRMS (ESI) m/z calcd for C13H27N2O2 
[M+H]+: 243.2067, found 243.2068. 
 
N-(3-methyl-2-nitrobutyl)octanamide (2.108):  
Oxime (2.90) (8.0 mg, 33.0 µmol, 1.0 eq), 
Na2HPO4 (40.2 mg, 0.277 mmol, 8.4 eq) and 
powdered urea (11.1 mg, 0.182 mmol, 5.5 eq) 
were dissolved in dry ACN (0.45 mL) and heated to reflux for 30 minutes. The 
white mixture was allowed to cool to r.t. and m-CPBA (70%, 15.5 mg, 62.7 
µmol, 1.9 eq) was added portionwise over 2 minutes. The white mixture was 
heated to reflux for 2 h. The mixture was allowed to cool to r.t., filtered over 
cotton and rinsed with ACN. The colorless solution was evaporated, the 
residue suspended in CH2Cl2 and washed with sat. aq. NaHCO3 (0.3 mL), sat. 
aq. Na2S2O3 (0.3 mL) and water (0.3 mL). The organic layer was dried over 
Na2SO4, filtered and evaporated. The residue was purified by flash column 
chromatography (SiO2, pentane/EtOAc 6:1 to 4:1) to yield the desired nitro 
compound 2.108 as a colorless oil (4.63 mg, 18.0 µmol, 54%). Rf = 0.17 
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(pentane/EtOAc 4:1); FTIR (neat): ν = 3281, 2957, 2927, 2857, 1650, 1549, 
1465, 1363, 1269, 792, 670, 628 cm-1; 1H NMR (400 MHz, CDCl3) δ = 5.74 (s, 
1H), 4.50 (ddd, J = 10.2, 7.5, 2.8 Hz, 1H), 3.93 (ddd, J = 14.6, 6.7, 2.8 Hz, 
1H), 3.49 (ddd, J = 14.4, 10.0, 5.5 Hz, 1H), 2.28 – 2.20 (m, 2H), 2.17 – 2.14 
(m, 2H), 1.63 – 1.56 (m, 2H), 1.31 – 1.23 (m, 8H), 1.05 (d, J = 6.8 Hz, 3H), 
1.01 (d, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 173.8, 93.4, 39.8, 
36.6, 31.8, 30.8, 29.3, 29.1, 25.7, 22.7, 19.0, 18.7, 14.2; HRMS (ESI) m/z 
calcd for C13H27N2O3 [M+H]+: 259.2016, found: 259.2015. 
 
Isolation of valdiazen (2.105): 
 
The yellow supernatant (500 mL, hamF mutant) was set to pH 11 with aq. 
NaOH (1.0 M, 150 mL) and the aq. layer was extracted with CH2Cl2 (3 x 150 
mL). The organic layer was discarded. The basic aq. layer was set to pH 4.0 
with aq. HCl (1.0 M) and then extracted with CH2Cl2 (3 x 200 mL) and the 
combined organic layers were dried over Na2SO4, filtered and evaporated to 
obtain a yellow oil. Further purifications were performed by HPLC. 
 
Column:         Synergi 4u Hydro-RP 80Å, 250 x 4.6 mm, 4   
           micron (Phenomenex) 
Mobile Phase A:      20 mM aq. NH4OAc (pH = 4.0) 
Mobile Phase B:      acetonitrile 
Flow rate:        1.0 mL/min 
Column temperature:    40 °C 
Decection (DAD):      220 nm 
Retention time valdiazen:  9.5 – 10 min (broad peak) 
Eluent program:     0 min 2% B; 15 min 50% B; 22.1 min 100% B  
 
The isolated fractions were evaporated to dryness and the isolate was 
dissolved in CH2Cl2, filtered over wool and evaporated to dryness to yield 0.5 
mg of pure valdiazen (2.105). 
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Figure 7.1: HPLC-trace of synthetic valdiazen (2.105). 
 
Chiral HPLC measurement conditions for valdiazen (2.105): 
 
Column:        Chiralpak OD-H, 250 x 4.6 mm, 10 µm (Daicel, cat. 
          No. DAIC14325) 
Mobile Phase:      hexane/EtOH (8:2) 
Isocratic Eluent:     hexane/EtOH (8:2) 
Flow rate:       0.8 mL/min 
Column temperature:   38 °C 
Decection (DAD):     228 nm (BW 6 nm) 
Injection volume:     5 µL  
Sample conc.:      2.0 mg/mL MeOH 
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pKa-measurement of valdiazen (2.105): 
 
 
Figure 7.2: pka-mesruements of valdiazen (2.105). 
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NO-release measurements of (−)-fragin (2.80a): 
 
A stock solution of 5 mg DAN in CHCl3:AcOH (50 mL; 45:5) was prepared. To 
the DAN-stock solution (4.0 mL) (−)-fragin (2.80a) (0.8 mg) was added and 
the mixture sonicated for 10 minutes. Three separate samples (each 1.0 mL) 
were quenched with NaOH (1 M, 3.0 mL) after 1 h, 5 h and 24 h and the 
fluorescence was measured; (excitation = 365 nm, emission = 405 nm; DAN = 
2,3-diaminonaphthalene; WAA = water acetic acid mixture). 
NaNO2 was used as a positive control. 
 
   
Figure 7.3: DAN-stock solution. 
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Figure 7.4: Quenched DAN-solution (negative control). 
   
Figure 7.5: NaNO2-DAN-solution. 
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Figure 7.6: Quenched NaNO2-DAN-solution (positive control). 
 
   
Figure 7.8: Quenched Fragin-DAN-solution after 1 h. 
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Figure 7.9: Quenched Fragin-DAN-solution after 5 h. 
   
Figure 7.10: Quenched Fragin-DAN-solution after 24 h. 
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UV-VIS measurements of Cu-fragin (2.144) and Cu-valdiazen (2.145).  
 
       
Figure 7.11: UV-VIS spectra of Cu-fragin complex (2.144) (λmax = 238 nm) 
 
       
Figure 7.12: UV-VIS spectra of Cu-valdiazen complex (2.145) (λmax = 237 nm) 
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7.3 Synthetic Studies Towards (2R)-Hydroxynorneomajucin 
 
Methyl (2R)-2-methyl-5-(propan-2-ylidene)cyclopentane-1-carboxylate 
(3.118): 
(R)-(+)-Pulegone (3.83) (20.0 g, 121 mmol, 1.0 eq) and NaHCO3 
(3.05 g, 36.3 mmol, 0.3 eq) were dissolved in Et2O (150 ml). The 
reaction mixture was stirred at 0 °C and Br2 (19.4 g, 6.2 ml, 121 
mmol, 1.0 eq) was added dropwise over a period of 30 min. The mixture was 
stirred for another 30 min at this temperature, filtered and transferred into a 
cold solution of NaOMe (25% in MeOH, 64 ml, 280 mmol, 2.3 eq). The 
mixture was stirred at reflux for 3 h and then cooled to r.t. The reaction was 
quenched with aq. HCl (1 M, 80 ml) and the aqueous layer was extracted with 
Et2O (3 x 100 ml). The combined organic layers were washed with brine (60 
ml), dried over Na2SO4, filtered and the solvent was removed under reduced 
pressure. The extract was purified by flash column chromatography (SiO2, 
pentane/Et2O 50:1) to afford a diastereomeric mixture of alkene 3.118 (17.6 g, 
96.6 mmol, 80%, d.r. = 1:1) as a slightly yellow oil. The analytic data is in 
good agreement with the literature.404 
 
tert-Butyl(2-iodoethoxy)dimethylsilane (3.138):  
 
Iodoethanol (15.5 g, 90.0 mmol, 1.0 eq) was dissolved in CH2Cl2 
(250 ml). Imidazole (9.38 g, 135 mmol, 1.5 eq) and TBSCl (15.2 g, 
99.0 mmol, 1.1 eq) were added and the mixture was stirred at r.t. for 16 h. 
The reaction mixture was washed with water (2 x 50 ml) and brine (2 x 50 ml), 
dried over Na2SO4, filtered and the solvent was removed under reduced 
pressure to afford silyl ether 3.138 (25.3 g, 88.0 mmol, 98%) as a colorless 
liquid. The analytic data is in good agreement with the literature.205 
  
                                                                                                    
404	   T.	  Hudlicky,	  R.	  P.	  Short,	  J.	  Org.	  Chem.	  1982,	  47,	  1522.	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Methyl (1R,2R)-1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-methyl-5-
(propan-2-ylidene)-cyclopentane-1-carboxylate (3.139):  
Freshly distilled diisopropylamine (20.0 ml, 135 mmol,  
1.4 eq) was added to THF (50 ml) and cooled to –78 °C.  
n-BuLi (1.6 M in hexane, 79.0 ml, 126 mmol, 1.3 eq) was 
slowly added and the solution stirred for 15 min at this temperature. The 
reaction mixture was allowed to warm to 0 °C and was stirred for 1 h at this 
temperature. The solution was cooled to –78 °C and ester 8 (17.6 g, 97.0 
mmol, 1.0 eq) and DMPU (62.0 g, 59.0 ml, 483 mmol, 5.0 eq) was added 
slowly and the solution stirred for 15 min at this temperature and then stirred 
for 1 h at 0 °C. The yellow mixture was cooled to –78 °C and a solution of 
3.118 (33.2 g, 116 mmol, 1.2 eq) in THF (50 ml) was added. The mixture was 
stirred for 1 h at this temperature and then allowed to warm to r.t. over 1 h. 
The reaction was quenched with aq. HCl (1 M, 200 ml). The aqueous layer 
was extracted with Et2O (4 x 150 ml). The combined organic layers were 
washed with brine (100 ml), dried over Na2SO4, filtered and the solvent was 
removed under reduced pressure. The extract was purified by flash column 
chromatography (SiO2, pentane/Et2O 40:1, then 20:1 and 8:1) to afford 
alkylated ester 3.139 (25.3 g, 74.4 mmol, 77%) as a yellow oil. Rf = 0.24 
(SiO2, pentane/Et2O 40:1); Optical rotation: 𝛼 !!"  = +37.8 (c 0.790, CHCl3); 
FTIR (neat): ν = 2953, 2933, 2858, 1727, 1462, 1434, 1253, 1218, 1186, 
1155, 1095, 1004, 837, 775, 631 cm–1; 1H NMR (400 MHz, CDCl3) δ = 3.63 
(s, 3H), 3.62 – 3.53 (m, 2H), 2.49 (dd, J = 15.4, 7.3 Hz, 1H), 2.29 – 2.17 (m, 
2H), 2.17 – 2.04 (m, 1H), 1.96 (ddd, J = 14.2, 9.0, 6.4 Hz, 1H), 1.77 – 1.69 (m, 
1H), 1.64 (d, J = 1.7 Hz, 3H), 1.62 – 1.53 (m, 1H), 1.50 (d, J = 1.7 Hz, 3H), 
0.90 – 0.89 (m, 3H), 0.88 (s, 9H), 0.03 (d, J = 1.7 Hz, 6H); 13C NMR (101 
MHz, CDCl3) δ = 176.6, 137.7, 125.0, 60.4, 57.2, 51.4, 44.6, 36.9, 32.6, 32.2, 
26.1, 22.4, 20.6, 18.4, 14.9, –5.1, –5.1; HRMS (ESI) m/z calcd. for C19H37O3Si 
[M+H]+ 341.2506, found: 341.2507. 
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Methyl (1R,2R)-1-(2-hydroxyethyl)-2-methyl-5-(propan-2-ylidene)-
cyclopentane-1-carboxylate (3.140):  
TBS-protected alcohol 3.139 (2.32 g, 6.81 mmol, 1.0 eq) was 
dissolved in THF (50 ml) and cooled to 0 °C. Acetic acid (1.0 
ml) and TBAF (5.99 g, 6.81 mmol, 1.0 eq) were added slowly. 
The solution was allowed to warm to r.t. and stirred for 18 h. 
The solution was cooled to 0 °C and quenched with aq. sat. NaHCO3 (80 ml). 
The aqueous layer was extracted with Et2O (3 x 100 ml) and the combined 
organic layers were washed with brine (50 ml). The organic layer was dried 
over Na2SO4, filtered and evaporated under reduced pressure. The crude 
material was purified by flash column chromatography (SiO2, pentane/Et2O 
1:1) to obtain alcohol 3.139 (1.22 g, 5.39 mmol, 79%) as slightly yellow oil. Rf 
= 0.27 (SiO2, pentane/Et2O 1:1); Optical rotation: 𝛼 !!"  = +35.4 (c 0.432, 
CHCl3); FTIR (neat): ν = 3428, 2952, 2334, 1725, 1457, 1226, 1032, 891,  
768 cm-1; 1H NMR (400 MHz, CDCl3) δ = 3.75 – 3.62 (m, 2H), 3.66 (s, 3H), 
2.52 (dd, J = 15.6, 7.1 Hz, 1H), 2.29 – 1.99 (m, 5H), 1.83 – 1.74 (m, 1H), 1.65 
(d, J = 1.9 Hz, 3H), 1.54 (dd, J = 2.8, 1.0 Hz, 3H), 1.53 – 1.46 (m, 1H), 0.92 
(d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 177.3, 138.7, 125.5, 59.9, 
57.4, 51.7, 44.6, 37.8, 32.8, 32.0, 22.5, 20.7, 15.3; HRMS (ESI) m/z calcd. for 
C13H23O3 [M+H]+: 227.1642, found: 227.1642.  
 
Methyl (1R,2R)-2-methyl-1-(2-oxoethyl)-5-(propan-2-ylidene)-
cyclopentane-1-carboxylate (3.141):  
Alcohol 3.140 (3.35 g, 14.8 mmol, 1.0 eq) was dissolved in 
CH2Cl2 (150 ml). DMP (7.05 g, 16.3 mmol, 1.1 eq) was added 
and the reaction mixture was stirred for 2 h at r.t. Sat. aq. 
NaHCO3 (50 ml) was added and the aqueous layer was extracted with CH2Cl2 
(5 x 50 ml). The combined organic layers were washed with brine (25 ml), 
dried over Na2SO4, filtered and the solvent was removed under reduced 
pressure. The crude was purified by flash column chromatography (SiO2, 
pentane/Et2O 4:1) to obtain aldehyde 3.141 (2.95 g, 13.2 mmol, 89%) as a 
colorless oil. Rf = 0.38 (SiO2, pentane/Et2O 5:1); Optical rotation: 𝛼 !!"  = 
+23.6 (c 0.591, CHCl3); FTIR (neat): ν = 2952, 2735, 2361, 1722, 1457, 1222, 
Me
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1058, 892, 767 cm-1; 1H NMR (400 MHz, CDCl3) δ = 9.66 (t, J = 2.9 Hz, 1H), 
3.68 (s, 3H), 2.93 (dd, J = 16.1, 2.8 Hz, 1H), 2.74 (dd, J = 16.1, 3.1 Hz, 1H), 
2.56 (dd, J = 15.8, 7.5 Hz, 1H), 2.31 – 2.13 (m, 2H), 1.89 – 1.79 (m, 1H), 1.66 
(d, J = 1.7 Hz, 3H), 1.61 (m, 1H), 1.56 (dd, J = 2.6, 1.1 Hz, 3H), 0.93 (d, J = 
6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 202.5, 175.3, 137.4, 126.6, 56.2, 
51.9, 48.3, 45.9, 32.6, 32.0, 22.6, 20.7, 14.6; HRMS (ESI) m/z calcd. for 
C13H21O3 [M+H]+: 225.1485, found: 225.1485.  
 
Methyl (1R,2R)-1-(4-ethoxy-2,4-dioxobutyl)-2-methyl-5-(propan-2-
ylidene)cyclopentane-1-carboxylate (3.134):  
Ethyl diazoacetate (3.07 g, 26.4 mmol, 2.0 eq) was dissolved 
in CH2Cl2 (25 ml), SnCl2 (255 mg, 1.32 mmol, 0.1 eq) was 
added and the reaction mixture was stirred at r.t. A solution of 
aldehyde 3.141 (2.95 g, 13.2 mmol, 1.0 eq) in CH2Cl2 (30 ml) was added 
dropwise. The mixture turned yellow and formation of N2 was observed. The 
reaction mixture was stirred for 12 h at r.t., then it was diluted with CH2Cl2 (50 
ml), filtrered over Celite and the solvent was removed under reduced 
pressure. The crude was purified by flash column chromatography (SiO2, 
pentane/Et2O 7:1 to 2:1) to obtain the β-ketoester 3.134 (3.82 g, 12 mmol, 
24.6 mmol, 93%, keto/enol form 10:1) as a slightly orange oil. Rf = 0.24 (SiO2, 
pentane/Et2O 5:1); Optical rotation: 𝛼 !!"   = +49.6 (c 0.748, CHCl3); FTIR 
(neat): ν = 2950, 1717, 1644, 1454, 1306, 1224, 1183, 1155, 1033 cm-1; 1H 
NMR (400 MHz, CDCl3) δ = 4.17 (q, J = 7.1 Hz, 2H), 3.65 (d, J = 1.8 Hz, 3H), 
3.41 (d, J = 5.5 Hz, 2H), 3.23 (d, J = 16.7 Hz, 1H), 2.95 (d, J = 16.7 Hz, 1H), 
2.57 – 2.41 (m, 2H), 2.41 – 2.25 (m, 1H), 1.85 – 1.73 (m, 1H), 1.66 – 1.61 (m, 
3H), 1.55 – 1.46 (m, 1H), 1.52 (d, J = 1.5 Hz, 3H), 1.26 (t, J = 7.1 Hz, 3H), 
0.85 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 201.2, 175.8, 167.3, 
138.5, 124.6, 61.4, 56.9, 51.7, 50.8, 46.6, 43.6, 32.8, 31.9, 22.5, 20.5, 14.7, 
14.2; HRMS (ESI) m/z calcd. for C17H27O5 [M+H]+: 311.1853, found: 
311.1855.  
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6-Ethyl 3a-methyl (3R,3aR,6R)-6-chloro-3,7,7-trimethyl-5-oxo-2,3,4,5,6,7-
hexahydro-3aH-indene-3a,6-dicarboxylate (3.142):  
β-Ketoester 3.134 (40.0 mg, 129 µmol, 1.0 eq) was dissolved 
in degassed Ac2O (3.0 ml, thaw freeze method, 3 cycles). 
Flame-dried LiCl (54.7 mg, 1.29 mmol, 10 eq) was added and 
the reaction mixture was heated to 50 °C. Mn(OAc)3 · 2 H2O (141 mg, 516 
µmol, 4.0 eq) was added and the reaction mixture was stirred for 5 h at this 
temperature. Water (5 ml) was added and the mixture was extracted with 
EtOAc (5 x 5 ml). The combined organic layers were washed with brine (5 ml), 
dried over Na2SO4, filtered and evaporated under reduced pressure. The 
crude material was purified by flash column chromatography (SiO2, 
pentane/Et2O 6:1 to 3:1) to obtain oxo-dicarboxylate 3.142 (17.1 mg, 50.3 
µmol, 39%) as a white solid. M.p.: 66.7 − 67.4 °C; Rf = 0.26 (SiO2, 
pentane/Et2O 6:1); Optical rotation: 𝛼 !!"  = –53.2 (c 0.730, CHCl3); FTIR 
(neat): ν = 2982, 2931, 1728, 1459, 1408, 1385, 1366, 1346, 1246, 1225, 
1105, 1034, 979, 894, 833, 757, 708, 606 cm-1; 1H NMR (400 MHz, CDCl3) δ 
= 5.91 – 5.90 (m, 1H), 4.36 – 4.21 (m, 2H), 3.68 (s, 3H), 3.49 (d, J = 15.3 Hz, 
1H), 2.99 (d, J = 15.5 Hz, 1H), 2.55 – 2.42 (m, 2H), 2.35 – 2.23 (m, 1H), 1.38 
(s, 3H), 1.32 (t, J = 7.1 Hz, 3H), 1.21 (s, 3H), 0.97 (d, J = 6.7 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ = 199.7, 173.9, 165.8, 146.1, 129.9, 79.0, 62.7, 
60.2, 52.1, 50.8, 45.2, 43.6, 39.2, 24.1, 22.1, 14.2, 14.1; HRMS (ESI) m/z 
calcd. for C17H24O5Cl [M+H]+: 343.1307, found: 343.1308.  
 
6-Ethyl 3a-methyl (3R,3aR,5R,6R)-6-chloro-5-hydroxy-3,7,7-trimethyl-
2,3,4,5,6,7-hexahydro-3aH-indene-3a,6-dicarboxylate (3.143):  
A solution of oxo-dicarboxylate 3.142 (1.05 g, 3.05 mmol, 1.0 
eq) was dissolved in MeOH (50 ml) and cooled to 0 °C and 
NaBH4 (294 mg, 7.63 mmol, 2.5 eq) was added in small 
portions. The reaction mixture was stirred at 0 °C for 1 h, then 
the cooling bath was removed and the reaction mixture was stirred at r.t. for 
3 h. The reaction mixture was cooled to 0 °C and quenched with brine (50 ml). 
The aqueous layer was extracted with EtOAc (5 x 50 ml) and the combined 
organic layers were washed with brine (30 ml), dried over Na2SO4, filtered 
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and evaporated under reduced pressure. The crude material was purified by 
flash column chromatography (SiO2, pentane/Et2O 6:1 to 3:1) to afford 
hydroxy-dicarboxylate 3.143 (904 mg, 2.62 mmol, 86%) as a white solid. M.p.: 
82.1 – 83.0 °C; Rf = 0.14 (SiO2, pentane/Et2O 6:1); Optical rotation: 𝛼 !!"  = 
+42.4 (c 0.282, CHCl3); FTIR (neat): ν = 3457, 2967, 2929, 2338, 1734, 1692, 
1450, 1409, 1384, 1363, 1284, 1239, 1193, 1105, 1088, 1032, 995, 912, 887, 
853, 819, 757, 702, 627 cm-1; 1H NMR (400 MHz, CDCl3) δ = 5.87 (dd, J = 
3.2, 1.7 Hz, 1H), 4.50 (s, 1H), 4.36 – 4.21 (m, 3H), 3.69 (s, 3H), 2.88 (dd, J = 
14.7, 2.8 Hz, 1H), 2.42 (ddd, J = 14.9, 7.4, 3.1 Hz, 1H), 2.32 – 2.20 (m, 1H), 
2.17 (ddd, J = 14.9, 10.3, 1.7 Hz, 1H), 2.03 (dd, J = 14.8, 3.7 Hz, 1H), 1.53 (s, 
3H), 1.38 – 1.31 (m, 6H), 0.97 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) 
δ = 176.6, 170.7, 147.6, 129.6, 75.0, 74.2, 62.2, 56.4, 51.7, 49.9, 42.3, 38.9, 
35.8, 26.5, 26.1, 14.7, 14.1; HRMS (ESI) m/z calcd. for C17H26O5Cl [M+H]+: 
345.1463, found: 345.1462; X-ray crystal structure is given in the 
appendices section. 
 
9-Ethyl 5a-methyl (1R,4R,5aR,6R,9R)-9-chloro-1,6-dimethyl-1,2,4,5,6,7-
hexahydro-5aH-1,E-methanocyclopenta[d]oxepine-5a,9-dicarboxylate 
(3.144) and 6-ethyl 3a-methyl (3R,3aR,5R,6R,7S)-6-chloro-5-hydroxy-7-
(iodomethyl)-3,7-dimethyl-2,3,4,5,6,7-hexahydro-3aH-indene-3a,6-
dicarboxylate (3.146):  
Hydroxy-dicarboxylate 3.143 (872 mg, 2.53 
mmol, 1.0 eq) was dissolved in degassed 
cyclohexane (48 ml, thaw freeze method, 3 
cycles) and Pb(OAc)4 (872 mg, 10.1 mmol, 
4.0 eq), iodine (1.97 g, 7.59 mmol, 3.0 eq) and CaCO3 (1.03 g, 10.1 mmol, 4.0 
eq) were added. The reaction mixture was stirred at r.t. and irradiated using a 
low pressure Hg-lamp for 8 h. The violet reaction mixture was cooled to 0 °C 
and sat. aq. Na2S2O3 (50 ml) was added until the mixture turned colorless. 
The mixture was extracted with EtOAc (4 x 25 ml), washed with brine (25 ml), 
dried over Na2SO4, filtered and evaporated under reduced pressure. The 
extract was purified by flash column chromatography SiO2, (pentane/Et2O 5:1 
to 3:1) to afford chloro-furan 3.144 (507 mg, 1.48 mmol, 58%) as colorless 
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solid and the iodo compound 3.146 (87 mg, 17.7 µmol, 7%) as a colorless 
light sensitive oil. 
 
Chloro-furan 3.144: M.p.: 96.5 - 97.1 °C; Rf = 0.16 (SiO2, pentane/Et2O 4:1); 
Optical rotation: 𝛼 !!"  = –50.5 (c 0.372, CHCl3); FTIR (neat): ν = 2961, 2945, 2906, 2360, 1736, 1721, 1453, 1383, 1228, 
1081, 1031, 981, 936, 876, 772, 726 cm-1; 1H NMR (400 MHz, 
CDCl3) δ = 5.83 (s, 1H), 4.71 (d, J = 4.8 Hz, 1H), 4.24 (q, J = 
7.1 Hz, 1H), 3.85 (dd, J = 8.1, 0.8 Hz, 1H), 3.72 – 3.66 (m, 3H), 3.59 (d, J = 
8.2 Hz, 1H), 3.07 (dd, J = 14.4, 4.9 Hz, 1H), 2.46 – 2.32 (m, 2H), 2.21 – 2.02 
(m, 1H), 1.90 (d, J = 14.2 Hz, 1H), 1.35 (s, 3H), 1.29 (td, J = 7.1, 0.8 Hz, 3H), 
0.91 (d, J = 6.6 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 173.8, 168.5, 145.6, 
129.8, 79.6, 73.7, 73.6, 62.4, 57.5, 51.8, 49.5, 48.7, 39.4, 37.0, 15.1, 14.1, 
13.4; HRMS (ESI) m/z calcd. for C17H23O5ClNa [M+Na]+: 365.1126, found: 
365.1125; X-ray crystal structure is given in the appendices section. 
 
Iodo compound 3.146: Rf = 0.31 (SiO2, pentane/Et2O 4:1); Optical rotation: 𝛼 !!"  = +39.2 (c 0.607, CHCl3); FTIR (neat): ν = 3481, 2955, 
2360, 1735, 1435, 1378, 1228, 1092, 1033, 888, 796, 734  
cm-1; 1H NMR (400 MHz, CDCl3) δ = 5.98 (d, J = 2.5 Hz, 1H), 
4.54 (q, J = 2.9 Hz, 1H), 4.45 (d, J = 3.3 Hz, 1H), 4.29 (q, J = 
7.2 Hz, 2H), 3.91 (d, J = 10.5 Hz, 1H), 3.74 (d, J = 0.7 Hz, 3H), 3.67 (d, J = 
10.5 Hz, 1H), 2.85 (dd, J = 14.8, 2.7 Hz, 1H), 2.46 – 2.38 (m, 1H), 2.34 – 2.23 
(m, 2H), 2.10 (dd, J = 14.9, 3.7 Hz, 1H), 1.69 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H), 
0.98 (d, J = 6.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 176.9, 170.0, 142.1, 
134.9, 73.8, 71.1, 62.7, 56.1, 52.1, 50.6, 46.0, 38.8, 35.5, 26.5, 16.5, 14.4, 
14.0; HRMS (ESI) m/z calcd. for C17H24O5IClNa [M+Na]+: 493.0249, found: 
493.0254.  
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Cyclization of iodo compound 3.146 to chloro-furan 3.144: 
Iodo compound 3.146 (6.83 mg, 
14.5 µmol, 1.0 eq) was dissolved in 
acetone (0.5 ml) and covered with 
aluminum foil. AgOAc (4.7 mg, 
43.5 µmol, 3.0 eq) was added and the reaction mixture was heated to 65 °C 
for 12 h. After cooling to r.t., the reaction mixture was filtered over Celite and 
the solvent was removed under reduced pressure. The crude material was 
purified by flash column chromatography (SiO2, pentane/Et2O 4:1) to afford 
chloro-furan 3.144 (4.3 mg, 0.11 mmol, 88%) as a colorless solid. 
 
9-Ethyl 5a-methyl (1R,4R,5aR,6R,9R)-9-chloro-1,6-dimethyl-1,2,4,5,6,7-
hexahydro-5aH-1,4-methanocyclopenta[d]oxepine-5a,9-dicarboxylate 
(3.144) and 9-Ethyl 5a-methyl (1R,2R,4R,5aR,6R,9R)-2-acetoxy-9-chloro-
1,6-dimethyl-1,2,4,5,6,7-hexahydro-5aH-1,4-methanocyclopenta[d]-
oxepine-5a,9-dicarboxylate (3.145) 
Hydroxy-dicarboxylate 3.143 (3.48 g, 10.1 
mmol, 1.0 eq) was dissolved in degassed 
cyclohexane (200 ml, thaw freeze method, 3 
cycles). Pb(OAc)4 (11.5 g, 25.2 mmol, 2.5 
eq), iodine (6.54 g, 25.2 mmol, 2.5 eq) and CaCO3 (4.04 g, 40.4 mmol, 4.0 eq) 
were added. The reaction mixture was stirred at r.t. and irradiated using a low 
pressure Hg-lamp for three days and Pb(OAc)4 (45.7 g, 101 mmol, 10 eq), 
iodine (26.2 g, 101 mmol, 10 eq) and CaCO3 (10.3 g, 101 mmol, 10 eq) were 
added in four equal portions (each 2.5 eq) during this time. The violet reaction 
mixture was cooled to 0 °C and sat. aq. Na2S2O3 (400 ml) was added until the 
mixture turned colorless. The mixture was extracted with EtOAc (4 x 200 ml), 
washed with brine (100 ml), dried over Na2SO4, filtered and evaporated under 
reduced pressure. The crude material was purified by flash column 
chromatography (SiO2, pentane/Et2O 5:1 to 3:1) to afford chloro-furan 3.144 
(2.82 g, 8.2 mmol, 81%) as a colorless solid and furan-acetate 3.145 (600 mg, 
1.5 mmol, 15%) as a colorless solid.  
 
 
MeO
O
OEt
Cl
OH
Me
OMe
I
MeO
O
OEtMe
O Cl
OMe
MeO
O
OEtMe
O Cl
OMe MeO
O
OEtMe
O Cl
O
MeO
OMe
+
3.144 3.145
CHAPTER 7 
	  
216 
Acetyl-furan 3.145: M.p.: 130.5 − 131.5 °C; Rf = 0.31 (SiO2, 
pentane/Et2O 2:1); Optical rotation: 𝛼 !!"  = +31.8 (c 0.565, 
CHCl3); FTIR (neat): ν = 2959, 1755, 1724, 1440, 1377, 1255, 
1218, 1178, 1078, 1019, 991, 934, 882, 776, 738 cm-1; 1H 
NMR (500 MHz, CDCl3) δ = 6.04 – 6.02 (m, 1H), 5.97 (s, 1H), 5.15 (d, J = 4.5 
Hz, 1H), 4.33 – 4.18 (m, 2H), 3.73 (s, 3H), 3.12 (dd, J = 14.4, 5.2 Hz, 1H), 
2.46 – 2.37 (m, 2H), 2.18 – 2.09 (m, 1H), 1.97 (s, 3H), 1.90 (dd, J = 14.5, 0.8 
Hz, 1H), 1.43 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H), 0.94 (d, J = 6.6 Hz, 3H); 
13C NMR (101 MHz, CDCl3) δ = 173.4, 169.0, 168.0, 142.8, 132.9, 97.6, 80.1, 
71.2, 62.4, 57.6, 54.0, 52.1, 48.5, 39.3, 36.0, 21.1, 15.2, 14.1, 12.5; HRMS 
(ESI) m/z calcd. for C19H25O7ClNa [M+Na]+: 423.1181, found: 423.1188; X-ray 
crystal structure is given in the appendices section. 
 
Conversion of acetyl-furan 3.145 to chloro-furan 3.144 
Acetyl-furan 3.145 (702 mg, 1.75 
mmol, 1.0 eq) was dissolved in CH2Cl2 
(120 ml) and cooled to –78 °C. 
Triethylsilane (514 mg, 4.38 mmol, 2.5 
eq) and boron trifluoride etherate (621 mg, 4.38 mmol, 2.5 eq) were added. 
The reaction mixture was stirred at –78 °C for 1 h and then allowed to warm 
to r.t. over a period of 12 h. The reaction mixture was cooled to 0 °C and 
water (80 ml) was slowly added. The mixture was extracted with Et2O (3 x 80 
ml) and the combined organic layers were washed with brine (50 ml), dried 
over Na2SO4, filtered and evaporated under reduced pressure. The crude 
material was purified by flash column chromatography (SiO2, pentane/Et2O 
4:1) to afford the chloro-furan 3.144 (525 mg, 1.53 mmol, 88%) as a colorless 
solid. 
 
9-Ethyl 5a-methyl (1R,4R,5aR,6R,9S)-1,6-dimethyl-1,2,4,5,6,7-hexahydro-
5aH-1,4-methanocyclopenta[d]oxepine-5a,9-dicarboxylate (3.148):  
Chloro-furan 3.144 (483 mg, 1.41 mmol, 1.0 eq) was dissolved 
in benzene (35 ml). Sn(Bu)3H (487 mg, 1.62 mmol, 1.15 eq) 
and AIBN (23.9 mg, 0.14 mmol, 0.1 eq) were added and the 
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mixture was heated to 100 °C and stirred for 2 h. After cooling to r.t. volatiles 
were evaporated under reduced pressure. The crude material was purified by 
flash column chromatography (SiO2, pentane/Et2O 3:1) to afford hydro-furan 
3.148 (411 mg, 1.34 mmol, 95%) as a colorless oil. Rf = 0.16 (SiO2, 
pentane/Et2O 3:1); Optical rotation: 𝛼 !!"  = +9 (c 0.776, CHCl3); FTIR (neat): ν = 2955, 2880, 1725, 1450, 1378, 1337, 1196, 1155, 1049, 1023, 989, 925, 
664, 627 cm-1; 1H NMR (400 MHz, CDCl3) δ = 5.72 (s, 1H), 4.56 (t, J = 5.2 Hz, 
1H), 4.20 – 4.04 (m, 2H), 3.78 (d, J = 7.7 Hz, 1H), 3.69 (s, 3H), 3.46 (d, J = 
7.7 Hz, 1H), 3.01 (dd, J = 14.2, 4.7 Hz, 1H), 2.83 (dd, J = 5.9, 1.1 Hz, 1H), 
2.39 – 2.23 (m, 2H), 2.13 – 2.03 (m, 1H), 1.71 (d, J = 14.5 Hz, 1H), 1.35 (s, 
3H), 1.23 (t, J = 7.1 Hz, 3H), 0.90 (d, J = 6.6 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ = 174.3, 169.7, 145.8, 126.6, 77.4, 76.7, 60.3, 58.3, 55.7, 51.7, 48.9, 
44.8, 39.0, 37.7, 17.4, 15.2, 14.4; HRMS (ESI) m/z calcd. for C17H25O5 
[M+H]+: 309.1697, found: 309.1698.  
 
6-Ethyl 3a-methyl (3R,3aR,6S,7R)-5-acetoxy-7-(acetoxymethyl)-3,7-
dimethyl-2,3,4,5,6,7-hexahydro-3aH-indene-3a,6-dicarboxylate (3.149) 
and 6-Ethyl 3a-methyl (3R,3aS,7R)-7-(acetoxymethyl)-3,7-dimethyl-
2,3,6,7-tetrahydro-3aH-indene-3a,6-dicarboxylate (3.150):  
Hydro-furan 3.148 (44.7 mg, 145 µmol, 
1.0 eq) was dissolved in Ac2O  
(0.9 ml). The solution was cooled to –20 
°C and boron trifluoride etherate (63.2 mg, 
435 µmol, 3.0 eq) was added. The reaction was allowed to warm to r.t. over 
12 h. The reaction mixture was cooled to 0 °C and water (1.0 ml) was added 
dropwise. The reaction mixture was stirred for 10 min and warmed to r.t. The 
mixture was extracted with Et2O (3 x 1.5 ml), washed with brine (1.5 ml), dried 
over Na2SO4, filtered and evaporated under reduced pressure. The crude 
material was purified by flash column chromatography (SiO2, pentane/Et2O 
2:1) to afford diacetylated compound 3.149 (35.4 mg, 87 µmol, 60%) as a 
yellow oil and monoacetylated compound 3.150 (31.7 mg, 46 µmol, 32%) as a 
colorless oil.  
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Diacetyl 3.149: Rf = 0.17 (SiO2, pentane/Et2O 2:1); Optical rotation:  𝛼 !!"  = +8.9 (c 0.344, CHCl3); FTIR (neat): ν = 3480, 2956, 
1727, 1440, 1367, 1224, 1028, 908, 790, 664 cm-1; 1H NMR 
(400 MHz, CDCl3) δ = 5.83 (s, 1H), 5.30 – 5.23 (m, 1H),  
4.19 – 4.03 (m, 2H), 3.77 (d, J = 11.3 Hz, 1H), 3.70 (d, J = 
11.4 Hz, 1H), 3.65 (s, 3H), 3.13 (d, J = 5.4 Hz, 1H), 2.65 (dd, J = 12.3, 4.8 Hz, 
1H), 2.51 – 2.36 (m, 2H), 2.26 – 2.14 (m, 1H), 2.07 (s, 3H), 2.03 – 1.97 (m, 
1H), 1.99 (s, 3H), 1.23 (t, J = 7.1 Hz, 3H), 1.15 (s, 3H), 0.94 (d, J = 6.4 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ = 174.3, 170.9, 170.8, 169.9, 143.3, 131.1, 
68.8, 68.7, 60.3, 59.5, 51.8, 49.5, 49.1, 40.5, 39.1, 34.5, 21.5, 21.1, 21.0, 
14.5; HRMS (ESI) m/z calcd. for C21H30O8Na [M+Na]+: 433.1833, found: 
433.1835.  
 
Monoacetyl 3.150: Rf = 0.32 (SiO2, pentane/Et2O 2:1); Optical rotation: 𝛼 !!"  = +223.8 (c 0.141, CHCl3); FTIR (neat): ν = 2957, 1725, 
1454, 1372, 1320, 1222, 1141, 1033, 793 cm-1; 1H NMR (400 
MHz, CDCl3) δ = 6.22 (d, J = 10.0 Hz, 1H), 5.82 (s, 1H), 5.58 
(dd, J = 10.0, 5.1 Hz, 1H), 4.14 – 4.01 (m, 2H), 3.92 (d, J = 
10.9 Hz, 1H), 3.74 (d, J = 10.9 Hz, 1H), 3.65 (s, 3H), 3.15 (d, J = 5.1 Hz, 1H), 
2.48 – 2.29 (m, 3H), 2.04 (s, 3H), 1.22 (t, J = 7.1 Hz, 3H), 1.19 (s, 3H), 1.03 
(d, J = 6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 173.1, 171.3, 170.9, 
143.2, 132.3, 129.8, 122.1, 68.3, 60.8, 59.3, 51.8, 50.2, 47.9, 39.7, 38.8, 21.0, 
19.4, 14.4, 14.3. HRMS (ESI) m/z calcd. for C19H27O6 [M+H]+: 351.1802, 
found: 351.1800. 
 
Methyl (3aR,5aS,6R,8bR)-6,8b-dimethyl-3-oxo-1,3,3a,6,7,8b-hexahydro-
5aH-indeno[4,5-c]furan-5a-carboxylate (3.164):  
Monoacetate 3.150 (36.8 mg, 105 µmol, 1.0 eq) was dissolved 
in MeOH (7.5 ml). K2CO3 (104 mg, 735 µmol, 7.0 eq) was 
added and the reaction mixture was stirred at r.t. for 18 h. The 
slightly yellow solution was diluted with EtOAc (15 ml) and aq. HCl (1 M, 10 
ml) was added. The aq. layer was extracted with EtOAc (3 x 15 ml), the 
combined organic layers were washed with brine (10 ml), dried over Na2SO4, 
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filtered and the solvent was removed under reduced pressure. The crude 
material was purified by flash column chromatography (SiO2, pentane/EtOAc 
3:1) to afford lactone 3.164 (10 mg, 39 µmol, 37%) as a white solid. M.p.: 
134.1 – 134.5 °C; Rf = 0.30 (SiO2, pentane/Et2O 2:1); Optical rotation: 𝛼 !!"   
= –43.6 (c 0.195, CHCl3); FTIR (neat): ν = 2969, 2922, 1763, 1720, 1436, 
1233, 1218, 1167, 1067, 1001, 897, 836, 797, 741, 705, 667 cm-1; 1H NMR 
(400 MHz, CDCl3) δ = 6.17 (ddd, J = 9.9, 2.7, 0.8 Hz, 1H), 5.98 (d, J = 3.0 Hz, 
1H), 5.60 (dd, J = 10.0, 3.2 Hz, 1H), 3.94 (d, J = 9.2 Hz, 1H), 3.85 (d, J = 9.2 
Hz, 1H), 3.70 (s, 3H), 2.81 (t, J = 3.0 Hz, 1H), 2.50 – 2.36 (m, 1H), 2.34 – 2.22 
(m, 2H), 1.41 (s, 3H), 1.05 (d, J = 6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 
176.0, 173.3, 142.1, 132.2, 130.9, 119.9, 74.3, 58.7, 52.2, 52.1, 47.9, 41.4, 
38.8, 23.4, 14.5; HRMS (ESI) m/z calcd. for C15H19O4 [M+H]+: 263.1278, 
found: 263.1275; X-ray crystal structure is given in the appendices section. 
 
(3aR,5aS,6R,8bR)-6,8b-Dimethyl-3-oxo-1,3,3a,6,7,8b-hexahydro-5aH-
indeno[4,5-c]furan-5a-carboxylic acid (3.173):  
Monoacetate 3.150 (30.0 mg, 58.0 µmol, 1.0 eq) was 
dissolved in iPrOH (5.0 ml) at r.t. NaOH (34 mg, 86.2 µmol, 10 
eq) was added and the solution was stirred for 16 h. Aq. HCl 
(3 M, 3.0 ml) was added and the aq. layer was extracted with EtOAc (5 x 5.0 
ml). The combined organic layers were dried over Na2SO4, filtered and 
evaporated under reduced pressure. The crude material was purified by flash 
column chromatography (SiO2, pentane/EtOAc 1:4) to afford carboxylic acid 
3.173 (17.3 mg, 85.6 µmol, 81%) as a colorless oil. Rf = 0.27 (SiO2, 
pentane/EtOAc 1:4); Optical rotation: 𝛼 !!"  = –65.7 (c 0.427, CHCl3); FTIR 
(neat): ν = 2964, 2929, 2851, 2361, 1768, 1728, 1467, 1381, 1234, 1167, 
1114, 1029, 1015, 897, 808, 755, 671 cm-1; 1H NMR (400 MHz, CDCl3) δ = 
6.15 (dd, J = 10.0, 2.7 Hz, 1H), 6.01 (d, J = 2.7 Hz, 1H), 5.64 (dd, J = 10.0, 
3.2 Hz, 1H), 4.08 (d, J = 9.2 Hz, 1H), 3.90 (d, J = 9.3 Hz, 1H), 2.84 (t, J = 2.9 
Hz, 1H), 2.49 – 2.41 (m, 1H), 2.38 – 2.28 (m, 2H), 1.43 (s, 3H), 1.15 (d, J = 
6.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 178.0, 175.9, 141.9, 131.6, 
131.4, 120.5, 74.3, 58.4, 52.2, 48.0, 41.5, 38.8, 23.4, 14.5; HRMS (ESI) m/z 
calcd. for C14H17O4 [M+H]+: 249.1121, found: 249.1118. 
MeO
Me
OH
O
O
H
CHAPTER 7 
	  
220 
6-Ethyl 3a-methyl (3R,3aR,6S,7R)-5-hydroxy-7-(hydroxymethyl)-3,7-
dimethyl-2,3,4,5,6,7-hexahydro-3aH-indene-3a,6-dicarboxylate (3.152):  
Diacetyl 3.149 (38.7 mg, 94.3 µmol, 1.0 eq) was dissolved in 
MeOH (1.5 ml), K2CO3 (53.6 mg, 38.4 µmol, 4.0 eq) was 
added and the reaction mixture was stirred at r.t. for 16 h. The 
reaction mixture was diluted with EtOAc (5 ml), aq. HCl (1 M, 
2.0 ml) was added and the mixture was extracted with EtOAc (3 x 2.0 ml). The 
combined organic layers were washed with brine (1.5 ml), dried over Na2SO4, 
filtered and the solvent was removed under reduced pressure. The crude 
material was purified by flash column chromatography (SiO2, pentane/EtOAc 
1:1) to afford the diol 3.152 (30.1 mg, 92.4 µmol, 98%) as a colorless sticky 
oil. Rf = 0.45 (SiO2, pentane/EtOAc 1:1); Optical rotation: 𝛼 !!"  = –1.9 (c 
0.254, CHCl3); FTIR (neat): ν = 3448, 2954, 1721, 1448, 1178, 1027, 885, 
780, 710, 660 cm-1; 1H NMR (400 MHz, CDCl3) δ = 5.86 (s, 1H), 4.20 – 4.05 
(m, 3H), 3.70 (s, 3H), 3.20 (d, J = 11.3 Hz, 1H), 3.07 (d, J = 11.3 Hz, 1H), 2.67 
– 2.62 (m, 2H), 2.50 – 2.39 (m, 2H), 2.16 – 2.02 (m, 4H), 1.24 (t, J = 7.1 Hz, 
3H), 1.17 (s, 3H), 0.96 (d, J = 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 
175.4, 171.5, 142.5, 132.8, 66.6, 66.3, 60.4, 59.9, 54.3, 52.2, 48.6, 43.0, 39.0, 
37.8, 21.4, 14.7, 14.4; HRMS (ESI) m/z calcd. for C17H26O6Na [M+Na]+: 
349.1622, found: 349.1626. 
 
6-Ethyl 3a-methyl (3R,3aR,7S)-7-formyl-5-hydroxy-3,7-dimethyl-2,3,4,7-
tetrahydro-3aH-indene-3a,6-dicarboxylate (3.153):  
Dimethyl sulfide (17.2 mg, 20 µmol, 4.3 eq) was dissolved in 
CH2Cl2 (1.0 ml) and NCS (34.0 mg, 0.26 mmol, 4.0 eq) was 
added. The solution was cooled to –78 °C and stirred for 1 h. 
A solution of diol 3.152 (21.0 mg, 64.0 µmol, 1.0 eq) in CH2Cl2 
(1.0 ml) was added to white suspension. The reaction mixture was stirred for 
1 h at –78 °C, then a solution of triethylamine (36 µL, 0.25 mmol, 4.0 eq) in 
CH2Cl2 (0.5 ml) was added and the mixture was warmed to r.t., aq. HCl (1 M, 
1.0 ml) was added and the aq. layer was extracted with CH2Cl2 (3 x 1.5 ml). 
The combined organic layers were washed with brine (1 ml), dried over 
Na2SO4, filtered and evaporated under reduced pressure. The crude was 
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purified by flash column chromatography (SiO2, pentane/Et2O 3:1) to afford 
the enol 3.153 (15 mg, 46 µmol, 72%) as a colorless oil. Rf = 0.39 (SiO2, 
pentane/Et2O 3:1); Optical rotation: 𝛼 !!"  = –124.9 (c 0.611, CHCl3); FTIR 
(neat): ν = 2960, 2934, 2848, 1728, 1642, 1607, 1458, 1402, 1297, 1228, 
1076, 863, 732, 631 cm-1; 1H NMR (400 MHz, CDCl3) δ = 12.94 (s, 1H), 9.13 
(s, 1H), 5.98 (s, 1H), 4.27 – 4.12 (m, 2H), 3.63 (s, 3H), 3.25 (d,  
J = 16.4 Hz, 1H), 2.54 (ddd, J = 15.3, 7.3, 3.1 Hz, 1H), 2.37 – 2.19 (m, 2H), 
2.16 (d, J = 16.3 Hz, 1H), 1.47 (s, 3H), 1.23 (t, J = 7.1 Hz, 3H), 1.02 (d, J = 
6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 197.3, 175.8, 172.8, 171.5, 
141.3, 133.3, 99.0, 61.1, 60.2, 51.9, 50.8, 46.4, 39.8, 38.9, 22.7, 15.0, 14.1; 
HRMS (ESI) m/z calcd. for C17H23O6 [M+H]+: 323.1489, found: 323.1490. 
 
Alternative procedure for the synthesis of enol 3.153:  
 
To a flask charged with flame-dried molecular sieves (4 Å, 120 mg) was 
added a solution of diol 3.152 (58.1 mg, 178 µmol, 1.0 eq) in CH2Cl2 (5 ml). 
NMO (56.0 mg, 463 µmol, 2.6 eq) was added at r.t. and the reaction mixture 
was stirred for 20 min. TPAP (12.9 mg, 35 µmol, 0.2 eq) was added and the 
solution was stirred at r.t. for 24 h, during which the color turned from green to 
dark blue. The reaction mixture was filtered over Celite and the solvent was 
removed under reduced pressure. The crude material was purified by flash 
column chromatography (SiO2, pentane/Et2O 3:1) to yield enol 3.153 (39.0 
mg, 121 µmol, 68%) as a colorless oil. 
 
6-Ethyl 3a-methyl (3R,3aR,7S)-7-formyl-6-hydroxy-3,7-dimethyl-5-oxo-
2,3,4,5,6,7-hexa-hydro-3aH-indene-3a,6-dicarboxylate (3.154):  
Enol 3.153 (89.0 mg, 276 µmol, 1.0 eq) was dissolved in 
iPrOH (5.0 ml) and the solution degassed (thaw freeze 
method, 2 cycles) and the atmosphere refilled with oxygen. 
CeCl3 · 7 H2O (105 mg, 276 µmol, 1.0 eq) was added at r.t. 
and oxygen was bubbled through the colorless solution for 15 min. The 
solution was stirred under oxygen atmosphere at r.t. for 20 h. Water (5.0 ml) 
was added, the mixture was extracted with EtOAc (3 x 5.0 ml), the combined 
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organic layers were washed with brine (3.0 ml), dried over Na2SO4, filtered 
and the solvent was removed under reduced pressure. The crude was purified 
by flash column chromatography (SiO2, pentane/Et2O 2:1) to afford  
α-hydroxylated product 3.154 (40.3 mg, 119 µmol, 43%) as a colorless oil.  
Rf = 0.37 (SiO2, pentane/Et2O 1:1); Optical rotation: 𝛼 !!"  = –68.8 (c 0.527, 
CHCl3); FTIR (neat): ν = 3454, 2959, 1724, 1453, 1373, 1217, 1162, 1099, 
1001, 916, 859, 732, 653 cm-1; 1H NMR (400 MHz, CDCl3) δ = 9.40 (s, 1H), 
6.11 (s, 1H), 4.31 (q, J = 7.1 Hz, 2H), 3.91 (s, 1H), 3.64 (s, 3H), 3.51 (d, J = 
14.7 Hz, 1H), 2.84 (d, J = 14.7 Hz, 1H), 2.59 – 2.45 (m, 2H), 2.32 – 2.20 (m, 
1H), 1.40 (s, 3H), 1.28 (t, J = 7.2 Hz, 3H), 0.98 (d, J = 6.7 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ = 202.8, 197.3, 172.5, 170.4, 138.8, 135.1, 82.9, 63.8, 
61.1, 58.7, 52.2, 50.6, 44.4, 39.3, 14.6, 14.5, 14.1; HRMS (ESI) m/z calcd. for 
C17H23O7 [M+H]+: 339.1438, found: 339.1441. 
 
Methyl (3aR,5aR,6R,8bR)-3a,4-dihydroxy-6,8b-dimethyl-3-oxo-
1,3,3a,4,5,6,7,8b-octahydro-5aH-indeno[4,5-c]furan-5a-carboxylate 
(3.160):  
α-Hydroxyester 3.154 (3.35 mg, 9.90 µmol, 1.0 eq) was 
dissolved in MeOH (0.2 ml) and cooled to 0 °C. NaBH4 (1.87 
mg, 49.5 µmol, 5.0 eq) was added in small portions and the 
reaction mixture was allowed to warm to r.t. over 12 h. The 
reaction mixture was cooled to 0 °C and water (1.5 ml) was added. The aq. 
layer was extracted with EtOAc (4 x 1.5 ml) and the combined organic layers 
were dried over Na2SO4, filtered and the solvent was removed under reduced 
pressure to afford crude diol 3.160 as colorless solid. The diol 3.160 was used 
without further purification. Rf = 0.11 (SiO2, pentane/EtOAc 3:1); HRMS (ESI) 
m/z calcd. for C15H20O6 [M+Na]+: 319.1152, found: 319.1153. 
 
(3aR,4R,6aR,7R,9bR)-3a-Hydroxy-7,9b-dimethyl-1,3a,4,7,8,9b-hexahydro-
3H,6H-4,6a-methanocyclopenta[c]furo[3,4-e]oxepine-3,6-dione (3.161):  
Diol 3.160 (6.0 mg, 20 µmol, 1.0 eq) was dissolved in toluene 
(0.4 ml) and p-toluenesulfonic acid monohydrate (0.8 mg, 4 
µmol, 0.2 eq) was added. The reaction mixture was stirred at 
O
OMe
O
Me
OH
O
MeO
Me
OH
OMe
OH
O
O
EXPERIMENTAL PART 
	  
223 
70 °C for 2 h. The reaction mixture was diluted with EtOAc (3 ml) and washed 
with aq. sat. NaHCO3 (2 ml). The aq. layer was extracted with EtOAc (3 x 1.5 
ml), the combined organic layer was washed with brine (1.5 ml), dried over 
Na2SO4, filtered and the solvent was removed under reduced pressure. The 
crude material was purified by flash column chromatography (SiO2, 
pentane/EtOAc 3:1) to afford dilactone 3.161 (0.7 mg, 2.6 µmol, 27%, over 
two steps) as a white solid. M.p.: 129.5 − 130.2 °C; Rf = 0.53 (SiO2, 
pentane/EtOAc 2:1); Optical rotation: 𝛼 !!"  = +56.7 (c 0.21, CHCl3); FTIR 
(neat): ν = 3448, 2921, 2851, 1782, 1753, 1457, 1376, 1326, 1221, 1185, 
1113, 1016, 1000, 938, 818, 732, 639 cm-1; 1H NMR (400 MHz, CDCl3) δ = 
5.87 (s, 1H), 4.63 (d, J = 5.9 Hz, 1H), 3.98 (q, J = 9.5 Hz, 2H), 2.58 (ddd, J = 
15.6, 8.1, 2.9 Hz, 1H), 2.48 (dd, J = 11.9, 5.9 Hz, 1H), 2.44 – 2.37 (m, 1H), 
2.32 (ddd, J = 15.5, 9.7, 1.9 Hz, 1H), 2.21 (d, J = 12.1 Hz, 1H), 1.36 (s, 3H), 
1.32 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 177.7, 174.9, 140.6, 
129.8, 78.9, 78.0, 74.4, 56.6, 43.3, 39.2, 37.0, 35.0, 21.4, 13.3; HRMS (ESI) 
m/z calcd. for C14H16O5Na [M+Na]+: 287.0890, found: 287.0894. 
 
(3aR,4R,6aR,7S,9bR)-3a-Hydroxy-7,9b-dimethyl-1,3a,4,9b-tetrahydro-
3H,6H-4,6a-methanocyclopenta[c]furo[3,4-e]oxepine-3,6,8(7H)-trione 
(3.162):  
CrO3 (21.0 mg, 0.21 mmol, 15.0 eq) was dissolved in CH2Cl2 
(3.0 ml) and 3,5-dimethylpyrazole (20.4 mg, 0.21 mmol,  
15 eq) was added. The reaction mixture was stirred for 30 
min at r.t. and the color turned to dark red. A solution of dilactone 3.161 (3.7 
mg, 14 µmol, 1.0 eq) in CH2Cl2 (1 ml) was added and the solution was stirred 
at r.t. for 48 h. Celite was added and the reaction was stirred for 16 h. The 
reaction mixture was filtered over Celite and the solvent was removed under 
reduced pressure. The crude material was purified by flash column 
chromatography (pentane/EtOAc 1:1) to afford enone 3.162 (yield not 
determined due to low amount and impurity). Rf = 0.33 (pentane/EtOAc 1:1); 
1H NMR (250 MHz, CDCl3) δ = 6.29 (s, 1H), 4.82 (s, 1H), 4.16 – 4.03 (m, 3H), 
2.75 – 2.48 (m, 3H), 1.52 (s, 3H), 1.41 (d, J = 7.4 Hz, 3H); (ESI) m/z calcd. for 
C28H27O12 [2M-H]-: 555.15, found: 555.1  
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(3aR,4R,6aR,7S,9bR)-3a,8-Dihydroxy-7,9b-dimethyl-1,3a,4,7,8,9b-
hexahydro-3H,6H-4,6a-methanocyclopenta[c]furo[3,4-e]oxepine-3,6-
dione (3.163) 
Enone 3.162 (1.0 mg, 3.6 µmol, 1.0 eq) was dissolved in 
MeOH/THF (0.4 ml, 1:3) and CeCl3 · 7 H2O (12.1 mg, 
32.4 µmol, 9.0 eq) was added. The reaction mixture was 
stirred for 10 min and then cooled to –78 °C. NaBH4 (1.2 mg, 32.4 µmol, 9.0 
eq) was added in small portions and the reaction mixture was stirred at –
78 °C for 2 h. The cooling bath was removed and the reaction mixture was 
stirred at r.t. for 12 h. Brine (1.0 ml) was added and the aq. layer was 
extracted with EtOAc (5 x 2 ml). The combined organic layers were washed 
with brine (1.5 ml), dried over Na2SO4, filtered and the solvent was removed 
under reduced pressure. The crude material was purified by flash column 
chromatography (SiO2, pentane/EtOAc 1:4) to afford allylic alcohol 3.163 
(yield not determined due to low amount) as a single diastereomer. Rf = 0.48 
(SiO2, pentane/EtOAc 1:4); 1H NMR (400 MHz, CDCl3) δ = 5.90 (d, J = 1.0 
Hz, 1H), 4.79 (dd, J = 7.7, 1.6 Hz, 1H), 4.66 (d, J = 5.9 Hz, 1H), 4.00 (d, J = 
9.5 Hz, 1H), 3.91 (dd, J = 9.5, 0.9 Hz, 1H), 2.48 (dd, J = 12.5, 6.2 Hz, 1H), 
2.31 (d, J = 12.2 Hz, 1H), 2.16 – 2.08 (m, 1H), 1.40 (d, J = 0.8 Hz, 3H), 1.37 
(d, J = 7.2 Hz, 3H); HRMS (ESI) m/z calcd. for C14H16O6Na [M+Na]+: 
303.0839, found: 303.0838. 
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7.4 Preparation of Antimalarial Endoperoxides 
 
Synthesis of allylic alcohol 4.52 was performed according to the reported 
procedure with the exception of ketoaldehyde 4.51.277 
 
Generel procedure for the endoperoxide synthesis: 
 
Method A: Diketone 4.55 (64.0 µmol, 1.0 eq) was allowed to react in an 
open-flask (or dissolved in EtOAc) exposed to sunlight and air. After 16 h, the 
yellow solid was dissolved in EtOAc and purified by flash column 
chromatography (SiO2, pentane/EtOAc 12:1) to give the endoperoxides 4.48 
and 4.49 as white solids. 
 
Method B: Diketone 4.55 (13.2 µmol, 1.0 eq) was dissolved in AcOH (0.36 
ml), Mn(OAc)3 (1.99 µmol, 0.15 eq) was added, and the reaction flask was 
charged with a balloon containing O2. The yellow solution was stirred at r.t. for 
19 h and then quenched with H2O (0.2 ml) and sat. aq. NaHCO3 solution (0.8 
ml). The aqueous phase was extracted with EtOAc (4 x 1 ml) and the 
combined organic layers were washed with sat. aq. NaHCO3 solution (1 ml) 
and brine (0.5 ml), then dried over Na2SO4, filtered and the solvent removed 
in vacuo. The residue was purified by flash column chromatography (SiO2) to 
obtain the endoperoxides 4.48 and 4.49 as white solids. 
 
(3R,3aS,5aR,9aR,11aR)-5a-Hydroxy-3-isopropyl-11a-methyloctahydro-
1H-3a,9a-methanobenzo[c]cyclopenta[g][1,2]dioxocin-9(10H)-one (4.48): 
White solid (3.16 mg, 10.2 µmol, 77%); Rf = 0.63 (SiO2, 
pentane/EtOAc 4:1); M.p.: 124.6 – 126.4 °C; Optical 
rotation: 𝛼 !!"  = –116.0 (c 0.236, CHCl3); FTIR (neat): ν = 
3452, 3395, 2952, 2927, 2867, 1696, 1470, 1260, 1179, 1163, 
1068, 1012, 991, 891, 762 cm-1; 1H NMR (400 MHz, CDCl3) δ = 3.14 (s, 1H), 
2.63 – 2.54 (m, 1H), 2.33 – 2.27 (m, 1H), 2.16 (d, J = 13.5 Hz, 1H), 2.08 – 
2.01 (m, 3H), 1.93 – 1.89 (m, 1H), 1.76 – 1.72 (m, 2H), 1.70 – 1.66 (m, 2H), 
1.65 – 1.64 (m, 2H), 1.57 – 1.50 (m, 5H), 1.19 (s, 3H), 1.04 (d, J = 6.4 Hz, 
MeMe
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3H), 0.85 (d, J = 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 211.1, 103.4, 
90.5, 60.5, 50.6, 45.7, 40.2, 35.8, 34.5, 30.8, 28.7, 28.5, 28.4, 27.3, 23.8, 
22.2, 22.0, 19.4; HRMS (ESI) m/z calcd for C18H28O4Na [M+Na]+: 331.1880, 
found 331.1881. 
 
(3R,3aR,5aS,9aS,11aR)-5a-Hydroxy-3-isopropyl-11a-methyloctahydro 
1H-3a,9a-methanobenzo[c]cyclopenta[g][1,2]dioxocin-9(10H)-one (4.49): 
White solid (0.79 mg, 2.56 µmol, 19%); Rf = 0.50 (SiO2, 
pentane/EtOAc 4:1); M.p.: 147.5 – 149.1 °C; Optical 
rotation: 𝛼 !!"  = +118.2 (c 0.045, CHCl3); FTIR (neat): ν = 
3501, 3428, 2965, 2923, 1456, 1377, 1313, 1261, 1250, 1160, 
1068, 1160, 1068, 999, 961, 885, 799, 785, 619 cm-1; 1H NMR (400 MHz, 
CDCl3) δ = 3.23 (s, 1H), 2.73 – 2.57 (m, 2H), 2.43 (dd, J = 13.9, 2.1 Hz, 1H), 
2.32 (dd, J = 15.7, 4.0 Hz, 1H), 2.15 – 2.10 (m, 1H), 2.03 (d, J = 13.8 Hz, 1H), 
1.99 – 1.96 (m, 1H), 1.89 – 1.81 (m, 2H), 1.76 – 1.70 (m, 1H), 1.68 – 1.63 (m, 
2H), 1.59 – 1.55 (m, 2H), 1.47 – 1.38 (m, 2H), 1.34 – 1.25 (m, 2H), 1.06 (d, J 
= 6.3 Hz, 3H), 0.96 (s, 3H), 0.89 (d, J = 6.6 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ = 211.0, 103.4, 98.0, 52.8, 52.1, 45.9, 36.2, 35.7, 33.0, 30.5, 29.1, 
28.4, 26.7, 24.9, 24.6, 23.4, 22.2, 19.6; HRMS (ESI) m/z calcd for 
C18H28O4Na [M+Na]+: 331.1880, found 331.1880; X-ray crystal structure is 
given in the appendices section. 
 
(S)-3-Isopropyl-6-oxoheptanal (4.51): 
The olefin277 (1.85 g, 13.4 mmol, 1.0 eq) was 
dissolved in MeOH (7.0 ml) and CH2Cl2 (35.0 
ml). The colorless solution was cooled to −78 
°C and ozone was bubbled through the solution until it turned blue. The 
reaction was stirred for additional 5 min at −78 °C and oxygen was bubbled 
through the blue solution until the color disappeared. Zn (1.75 g, 26.8 mmol, 
2.0 eq) and AcOH (2.30 ml, 2.41 g, 40.1 mmol, 3.0 eq) were added at −78 °C 
and the mixture was allowed to warm to r.t. for 1 h and stirred for additional 15 
min at this temperature. The suspension was filtered over Celite and the filter 
cake washed with CH2Cl2 (3 x 15 ml). The organic layer was extracted with 
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sat. NaHCO3 solution (15 ml) and the aqueous layer was extracted with 
CH2Cl2 (2 x 10 ml). The combined organic layers were dried over Na2SO4, 
filtered and evaporated to obtain pale yellow oil. The residue was purified by 
flash chromatography (SiO2, pentane/Et2O 4:1) to yield the ketoaldehyde 4.51 
as pale yellow oil (1.85 g, 10.8 mmol, 81%). The analytical data were in good 
agreement as previously reported.277 
 
2-((1R,3R)-3-Isopropyl-1-methyl-2-methylenecyclopentyl)-N,N-
dimethylacetamide (4.53):  
The allyl alcohol 4.52 (18 mg, 0.12 mmol, 1.0 eq) was 
dissolved in p-xylene (1.0 ml) and 1,1-
dimethoxyethyl(dimethyl)amine (90% in MeOH, 173 mg, 1.17 
mmol, 10 eq) was added. Argon was bubbled for 2 minutes 
through the yellow solution, and the reaction vessel was then sealed and 
heated to 150 °C behind a blast shield. After 16 h, the mixture was allowed to 
cool to r.t. and then completely evaporated to obtain an orange oil. The 
residue was purified by flash chromatography (SiO2, pentane/EtOAc 4:1 to 
3:1) to yield the amide 4.53 (24.8 mg, 0.11 mmol, 95%, d.r. 24:1) as a slightly 
yellow oil. Rf = 0.08 (SiO2, pentane/Et2O 4:1); Optical rotation:   𝛼 !!"  = +23.1 
(c 0.074, CHCl3); FTIR (neat): ν = 2955, 2870, 1642, 1466, 1394, 1264, 1126, 
882 cm-1; 1H NMR (400 MHz, CDCl3) δ = 4.80 (d, J = 2.9 Hz, 1H), 4.77 (d, J = 
2.5 Hz, 1H), 3.00 (s, 3H), 2.92 (s, 3H), 2.59 – 2.52 (m, 1H), 2.53 (d, J = 15.1, 
Hz, 1H), 2.37 (d, J = 15.1, 1H), 2.01 – 1.93 (m, 1H), 1.87 – 1.79 (m, 1H), 1.67 
– 1.59 (m, 2H), 1.45 – 1.35 (m, 1H), 1.09 (s, 3H), 0.97 (d, J = 6.9 Hz, 3H), 
0.77 (d, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 171.8, 163.4, 103.3, 
50.9, 45.2, 43.8, 38.0, 37.5, 35.5, 28.9, 27.6, 23.3, 22.0, 16.6; HRMS (ESI) 
m/z calcd for C14H26NO [M+H]+: 224.2009, found 224.2015. 
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2-((1R,3R)-3-Isopropyl-1-methyl-2-methylenecyclopentyl)acetaldehyde 
(4.54): 
The amide 4.53 (4.3 mg, 19.3 µmol, 1.0 eq) was dissolved in dry 
THF (0.2 ml), 1,1,3,3-tetramethyldisiloxane (8.01 mg, 10 µl, 57.9 
µmol, 3.0 eq) and titanium(IV)isopropoxide (16.7 mg, 20 µl, 57.9 
µmol, 3.0 eq) were added, and the reaction mixture was stirred at 
r.t. for 18 h. Et2O (1.0 ml) was added, the mixture was washed with aq. HCl (1 
M, 3 x 0.3 ml), and the combined aqueous layers were re-extracted with Et2O 
(3 x 0.5 ml). The combined organic layers were washed with brine (0.5 ml), 
dried over Na2SO4 and the solvent was removed in vacuo. The residue was 
purified by flash chromatography (SiO2, pentane/Et2O 4:1) to yield the 
aldehyde 4.54 (3.3 mg, 18.3 µmol, 95%) as a colorless oil. The analytical data 
were in good agreement as previously reported.277 
 
2-(2-((1R,3R)-3-Isopropyl-1-methyl-2-methylenecyclopentyl)ethyl)-
cyclohexane-1,3-dione (4.55):  
Aldehyde 4.54 (5.68 g, 31.5 mmol, 1.0 eq) was dissolved in 
CH2Cl2 (300 ml). Cyclohexan-1,3-dione (10.8 g, 94.4 mmol, 
3.0 eq), Hantzsch ester (16.3 g, 63.0 mmol, 2.0 eq) and L-
proline (370 mg, 3.15 mmol, 0.1 eq) were added. The yellow 
mixture was stirred at room temperature for 19 h and was 
subsequently washed with water (20 ml), aq. HCl (10%, 3 x 15 ml) and brine 
(15 ml). The combined aqueous layer was extracted with CH2Cl2 (20 ml) and 
the combined organic layers were dried over Na2SO4. The solvent was 
removed in vacuo and the residue was purified by flash chromatography 
(SiO2, pentane/EtOAc 4:1 to 1:1) to yield the diketone 4.55 (7.92 g, 28.7 
mmol, 91%) as an instable yellow solid. HRMS (ESI) m/z calcd for C18H29O2 
[M+H]+: 277.2162, found 277.2162. 
 
General method for Ag2O mediated O-alkylation of endoperoxides: 
To a solution of endoperoxide (4.48 or 4.49) (3.74 µmol, 1.0 eq) in MeCN  
(0.10 ml), MeI (131 µmol, 35 eq) and Ag2O (14.2 µmol, 3.8 eq) were added, 
and the reaction mixture was stirred at 40 °C for 16 h. The mixture was 
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allowed to cool to r.t. and was then filtered over Celite and rinsed with EtOAc 
(3 x 0.3 ml). The solvent was removed in vacuo and the yellow solid was 
purified by flash column chromatography (SiO2) to yield the corresponding 
methylated endoperoxides 4.61 and 4.62. 
 
(3R,3aR,5aS,9aS,11aR)-3-Isopropyl-5a-methoxy-11a-methyloctahydro-
1H-3a,9a-methanobenzo[c]cyclopenta[g][1,2]dioxocin-9(10H)-one (4.61): 
Flash column chromatography (SiO2, pentane/Et2O 10:1); white 
solid (5.22 mg, 16.0 µmol, 88%); Rf = 0.55 (pentane/Et2O 3:1); 
M.p.: 136.6 – 137.9 °C; Optical rotation: 𝛼 !!"  = +98.1 (c 
0.058, CHCl3); FTIR (neat): ν = 2954, 2924, 2863, 1711, 1460, 
1263, 1181, 1092, 1066, 1035, 928, 784 cm-1; 1H NMR (400 MHz, CDCl3) δ = 
3.24 (s, 3H), 2.71 – 2.53 (m, 3H), 2.31 – 2.26 (m, 1H), 2.14 – 2.08 (m, 1H), 
1.92 – 1.79 (m, 5H), 1.78 – 1.67 (m, 2H), 1.66 – 1.61 (m, 1H), 1.60 – 1.53 (m, 
2H), 1.45 – 1.35 (m, 2H), 1.30 – 1.23 (m, 1H), 1.05 (d, J = 6.3 Hz, 3H), 0.94 
(s, 3H), 0.87 (d, J = 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 211.1, 105.3, 
97.5, 52.9, 51.9, 47.7, 45.9, 36.1, 35.8, 32.9, 30.4, 29.1, 26.7, 24.6, 23.9, 
23.3, 22.3, 22.2, 19.3; HRMS (ESI) m/z calcd for C19H30O4Na [M+Na]+: 
345.2036, found 345.2040; X-ray crystal structure is given in the 
appendices section. 
 
(3R,3aS,5aR,9aR,11aR)-3-Isopropyl-5a-methoxy-11a-methyloctahydro-
1H-3a,9a-methanobenzo[c]cyclopenta[g][1,2]dioxocin-9(10H)-one (4.62):  
Flash column chromatography (SiO2, pentane/Et2O 12:1); white 
solid (10.8 mg, 33.0 µmol, 54%); Rf = 0.59 (pentane/Et2O 5:1); 
M.p.: 84.7 – 85.9 °C; Optical rotation: 𝛼 !!"  = –59.5 (c 0.043, 
CHCl3); FTIR (neat): ν = 2954, 2869, 1707, 1455, 1378, 1316, 
1262, 1200, 1060, 1031, 993, 899, 662, 628 cm-1; 1H NMR (400 MHz, CDCl3) 
δ = 3.32 (s, 3H), 2.65 – 2.49 (m, 2H), 2.39 – 2.33 (m, 1H), 2.21 – 2.13 (m, 
2H), 2.03 – 1.96 (m, 1H), 1.93 – 1.86 (m, 2H), 1.84 – 1.75 (m, 2H), 1.67 – 
1.58 (m, 4H), 1.55 – 1.48 (m, 1H), 1.46 – 1.40 (m, 2H), 1.37 – 1.32 (m, 1H), 
1.13 (s, 3H), 1.03 (d, J = 6.3 Hz, 3H), 0.85 (d, J = 6.7 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ = 211.7, 106.7, 89.1, 57.4, 53.8, 49.8, 45.4, 42.4, 37.7, 36.8, 
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34.2, 29.3, 27.2, 24.1, 24.0, 22.5, 21.8, 21.5, 18.5; HRMS (ESI) m/z calcd for 
C19H30O4Na [M+Na]+: 345.2036, found 345.2041; X-ray crystal structure is 
given in the appendices section. 
 
(3R,3aS,5aR,9aR,11aR)-3-Isopropyl-11a-methyl-9-oxodecahydro-1H-
3a,9a-methanobenzo[c]cyclopenta[g][1,2]dioxocin-5a-yl acetate (4.63): 
A solution of endoperoxide 4.48 (4.47 mg, 14.5 µmol, 1.0 eq) in 
CH2Cl2 (0.32 ml) was cooled to 0 °C. DMAP (1.08 mg, 8.7 µmol, 
0.6 eq), 2-tert-butyl-1,1,3,3-tetramethylguanidine (Barton’s 
Base, 0.06 ml, 0.29 mmol, 20 eq) and Ac2O (28.0 µl, 0.29 mmol, 
20 eq) were added. The mixture was warmed to r.t. and stirred for 18 h. Et2O 
(1 ml) was added and washed with aq. HCl (1 M, 2 x 0.3 ml) and sat. aq. 
NaHCO3 solution (0.3 ml) and brine (0.3 ml). The organic layer was dried over 
Na2SO4, filtered and the solvent removed in vacuo. The residue was purified 
by flash column chromatography (pentane/Et2O 6:1 to 4:1) to obtain the 
acetylated endoperoxide 4.63 as colorless sticky oil (3.88 mg, 11.1 µmol, 
76%). Rf = 0.53 (SiO2, pentane/Et2O 2:1); Optical rotation: 𝛼 !!"  = –13.9 (c 
0.15, CHCl3); FTIR (neat): ν = 2951, 2927, 2869, 1762, 1709, 1459, 1369, 
1259, 1209, 1170, 1013, 961, 630 cm-1; 1H NMR (400 MHz, CDCl3) δ = 2.82 
(dt, J = 14.7, 4.6 Hz, 1H), 2.59 – 2.42 (m, 3H), 2.17 – 2.10 (m, 1H), 2.07 (s, 
3H), 2.04 – 1.93 (m, 3H), 1.88 – 1.81 (m, 1H), 1.77 – 1.70 (m, 1H), 1.68 – 
1.65  (m, 2H), 1.62  – 1.58 (m, 2H), 1.55 – 1.51 (m, 1H), 1.46 – 1.40 (m, 2H), 
1.38 – 1.33 (m, 1H), 1.06 (s, 3H), 1.03 (d, J = 6.4 Hz, 3H), 0.87 (d, J = 6.7 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ = 210.2, 168.8, 110.9, 90.2, 57.0, 53.3, 
45.1, 40.0, 38.3, 36.6, 34.6, 28.8, 27.5, 26.6, 23.8, 21.9, 21.6, 21.5, 20.9, 
18.6; HRMS (ESI) m/z calcd for C20H30O5Na [M+Na]+: 373.1985, found 
373.1992. 
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In Vitro Assay’s were performed by the Swiss Tropical and Health 
Institute (Basel) 
 
Activity against P. falciparum: In vitro activity against erythrocytic stages of P. 
falciparum was determined using a 3H-hypoxanthine incorporation 
assay, 405 , 406  using the drug-sensitive NF54 strain (Schipol Airport, The 
Netherlands) 407  and the standard drugs chloroquine (Sigma C6628) and 
artemisinin (Sigma 361593). Compounds were dissolved in DMSO at 10 
mg/ml and added to parasite cultures incubated in RPMI 1640 medium 
without hypoxanthine, supplemented with HEPES (5.94 g/l), NaHCO3 (2.1 g/l), 
neomycin (100 U/ml), Albumax (5 g/l) and washed human red cells A+ at 
2.5% haematocrit (0.3% parasitaemia). Serial drug dilutions of eleven 3-fold 
dilution steps covering a range from 100 to 0.002 µg/ml were prepared. The 
96-well plates were incubated in a humidified atmosphere at 37 °C, 4% CO2, 
3% O2, 93% N2. After 48 h 50 µl of 3H-hypoxanthine (=0.5 µCi) was added to 
each well of the plate. The plates were incubated for a further 24 h under the 
same conditions. The plates were then harvested with a Betaplate™ cell 
harvester (Wallac, Zurich, Switzerland), and the red blood cells transferred 
onto a glass fibre filter and then washed with distilled water. The dried filters 
were inserted into a plastic foil with 10 ml of scintillation fluid, and counted in a 
Betaplate™ liquid scintillation counter (Wallac, Zurich, Switzerland). IC50 
values were calculated from sigmoidal inhibition curves by linear regression 
using Microsoft Excel.408  
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   1979,	  16,	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406	  	  H.	  Matile,	  J.	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  L.	  Pink,	  in	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  Lefkovits	  and	  B.	  Pernis	  (ed.),	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  Methods,	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  Press,	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  1990.	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  1981,	  33,	  50.	  
408	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  Koella,	  Acta	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  1993,	  55,	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In vitro cytotoxicity with L-6 cells: Assays were performed in 96-well microtiter 
plates, each well containing 100 µl of RPMI 1640 mediumsupplemented with 
1% L-glutamine (200 mM) and 10% fetal bovine serum, and 4000 L-6 cells (a 
primary cell line derived from rat skeletal myoblasts). 409 , 410  Serial drug 
dilutions of eleven 3-fold dilution steps covering a range from 100 to 0.002 
µg/ml were prepared. After 70 hours of incubation the plates were inspected 
under an inverted microscope to assure growth of the controls and sterile 
conditions. 10 µl of Alamar Blue was then added to each well and the plates 
incubated for another 2 hours. Then the plates were read with a Spectramax 
Gemini XS microplate fluorometer (Molecular Devices Cooperation, 
Sunnyvale, CA, USA) using an excitation wavelength of 536 nm and an 
emission wavelength of 588 nm. The IC50 values were calculated by linear 
regression[4] from the sigmoidal dose inhibition curves using SoftmaxPro 
software (Molecular Devices Cooperation, Sunnyvale, CA, USA). 
Podophyllotoxine (Sigma P4405) was used as control. 
  
                                                                                                    
409	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  3,	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7.5 Synthetic Studies Towards Striatal A 
 
2-(2-((1R,3R)-3-isopropyl-1-methyl-2-methylenecyclopentyl)ethyl)-2-
methylcyclohexane-1,3-dione (5.110): 
The diketone 4.55 (7.85 g, 28.4 mmol, 1.0 eq) was 
dissolved in THF (90 ml) and dried LiCl (5.76 g, 42.6 mmol, 
1.5 eq) and DBU (6.55 g, 6.42 ml, 42.6 mmol, 1.5 eq) were 
added. After stirring at r.t. for 30 minutes. Iodomethane 
(12.2 g, 5.36 ml, 85.2 mmol, 3.0 eq) was added and the mixture stirred at 80 
°C for 15 h. The brown solution was allowed to cool to r.t. and then poured on 
ice-water (60 ml). The mixture was extracted with Et2O (4 x 50 ml) and the 
combined organic layer were dried over Na2SO4, filtered and evaporated to 
obtain a dark-red oil. The crude was purified by flash column chromatograpy 
(SiO2, pentane/EtOAc 10:1 to 8:1) to yield the methyldiketone 5.110 (2.77 g, 
9.54 mmol, 34%) as a yellow oil. Rf = 0.76 (SiO2, pentane/EtOAc 4:1); Optical 
rotation: 𝛼 !!"  = +38.7 (c 0.08, CHCl3); FTIR (neat): ν = 2955, 2870, 1726, 
1695, 1459, 1373, 1315, 1270, 1025, 881 cm-1; 1H NMR (400 MHz, CDCl3)  
δ = 4.76 (d, J = 2.5 Hz, 1H), 4.72 (d, J = 2.9 Hz, 1H), 2.73 – 2.65 (m, 2H), 
2.60 – 2.54 (m, 2H), 2.37 – 2.29 (m, 1H), 2.07 – 1.99 (m, 1H), 1.97 – 1.90 (m, 
1H), 1.86 – 1.77 (m, 1H), 1.77 – 1.69 (m, 2H), 1.62 – 1.53 (m, 1H),  
1.45 – 1.32 (m, 3H), 1.32 – 1.28 (m, 1H), 1.19 (s, 3H), 1.17 – 1.11 (m, 1H), 
0.95 (d, J = 6.9 Hz, 3H), 0.92 (s, 3H), 0.75 (d, J = 6.8 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ = 210.6, 210.5, 161.9, 103.8, 65.9, 51.3, 45.6, 38.1, 38.0, 
36.6, 35.7, 33.4, 28.8, 27.6, 23.1, 22.0, 18.2, 17.9, 16.5; HRMS (ESI) m/z 
calcd for C19H31O2 [M+H]+: 291.2319, found: 291.2318. 
 
2-(2-((1R,3R)-3-isopropyl-1-methyl-2-oxocyclopentyl)ethyl)-2-
methylcyclohexane-1,3-dione (5.111): 
The olefin 5.110 (13.2 mg, 45.4 µmol, 1.0 eq) was 
dissolved in dry MeOH (2.0 ml) and cooled to −78 °C. O3 
was bubbled through the colorless solution until a 
persistent blue color was obtained (2 minutes). O2 was 
bubbled through the blue solution until a clear colorless solution as obtained. 
MeMe
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To the colorless solution DMS (5.7 mg, 6.7 µmol, 2.0 eq) was added and the 
mixture stirred at −78 °C for 30 min. The colorless solution was allowed to 
warm to r.t. over 2 h and then evaporated to obtain a colorless oil. The crude 
material was purified by flash column chromatography (SiO2, pentane/EtOAc 
6:1) to obtain the desired ketone 5.111 (5.3 mg, 18.0 µmol, 40%) as a 
colorless oil. Rf = 0.29 (pentane/EtOAc 4:1); FTIR (neat): ν = 2959, 2872, 
1725, 1694, 1459, 1373, 1316, 1132, 1068, 1025, 840 cm-1; 1H NMR (400 
MHz, CDCl3) δ = 2.71 – 2.57 (m, 4H), 2.18 – 2.10 (m, 1H), 2.05 – 1.96 (m, 
2H), 1.93 – 1.81 (m, 3H), 1.69 – 1.63 (m, 3H), 1.27 – 1.15 (m, 6H), 0.97 (d, J 
= 6.9 Hz, 3H), 0.89 (s, 3H), 0.79 (d, J = 6.7 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ = 223.4, 210.4, 210.3, 65.5, 55.9, 48.5, 38.1, 33.4, 32.3, 21.0, 27.4, 
21.2, 21.0, 20.5, 19.4, 18.5, 17.8; HRMS (ESI) m/z calcd for C18H29O3 [M+H]+: 
293.2111, found: 293.2110 
 
2-(2-((1R,3R)-3-isopropyl-1-methyl-2-methylenecyclopentyl)ethyl)-2-
methylcyclohexane-1,3-diol (5.116): 
The diketone 5.110 (6.7 mg, 23.1 µmol, 1.0 eq) was 
dissolved in THF (0.2 ml) and cooled to 0 °C. LTBA (1.0 M 
in THF, 47.2 mg, 52.4 µl, 2.5 eq) was slowly added and 
stirred at 0 °C for 40 minutes and then allowed to stirr at r.t. 
for 2 h. The mixture was recooled to 0 °C and another portion of LTBA (1.0 M 
in THF, 47.2 mg, 52.4 ml, 2.5 eq) was added. The mixture was stirred for 1 h 
at r.t. Sat. aq. NH4Cl (0.1 ml), aq. HCl (10%, 10 drops) were added and the 
mixture extracted with EtOAc (3 x 2.0 ml). The combined organic layer were 
dried over Na2SO4, filtered and evaporated. The crude material was purified 
by flash column chromatography (SiO2, pentane/EtOAc 7:1) to obtain the diol 
5.116 (4.4 mg, 15.0 µmol, 64%) as a colorless oil. Rf = 0.63 (SiO2, 
pentane/EtOAc 6:1); Optical rotation: 𝛼 !!"  = +38.5 (c 0.15, CHCl3); FTIR 
(neat): ν = 3334, 2949, 2870, 1728, 1645, 1455, 1422, 1382, 1253, 1172, 
1047, 1102, 948, 878, 631 cm-1; 1H NMR (400 MHz, CDCl3) δ = 4.81 (d, J = 
2.9 Hz, 1H), 4.77 (d, J = 2.4 Hz, 1H), 3.62 (bs, 1H), 3.57 (bs, 1H), 2.83 (d, J = 
8.0 Hz, 1H), 2.66 (d, J = 5.9 Hz, 1H), 2.44 – 2.39 (m, 1H), 2.01 – 1.89 (m, 
2H), 1.84 – 1.75 (m, 2H), 1.71 – 1.67 (m, 3H), 1.62 – 1.57 (m, 2H), 1.53 – 
MeMe
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1.46 (m, 2H), 1.43 – 1.36 (m, 4H), 0.99 (s, 3H), 0.97 (d, J = 6.9 Hz, 3H), 0.84 
(s, 3H), 0.77 (d, J = 6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 163.9, 102.9, 
74.8, 74.3, 51.6, 46.1, 39.6, 36.6, 34.1, 29.7, 28.9, 28.8, 28.8, 27.8, 23.2, 
22.1, 20.9, 16.5, 14.2; HRMS (ESI) m/z calcd for C19H35O2 [M+H]+: 295.2632, 
found: 295.2627. 
 
2-(2-((1R,3R)-3-isopropyl-1-methyl-2-methylenecyclopentyl)ethyl)-2-
methylcyclohexane-1,3-diyl dimethanesulfonate (5.117):  
The diol 5.116 (128.0 mg, 0.44 mmol, 1.0 eq) was 
dissolved in py (1.76 ml) and the solution cooled to 0 °C. 
MsCl (150 mg, 0.1 ml, 1.31 mmol, 3.0 eq) and DMAP (5.32 
mg, 43.6 µmol, 0.1 eq) were added. The mixture was 
stirred at 0 °C for 10 minutes. The mixture was then stirred at r.t. for 15 h. 
Water (1.0 ml) and aq. HCl (1 M, 1.0 ml) was added and the mixture extracted 
with Et2O (3 x 2.0 ml). The combined organic layers were washed with HCl  
(1 M, 1.0 ml), dried over Na2SO4, filtered and evaporated. The crude product 
was purified by flash column chromatography (SiO2, pentane/EtOAc 5:1 to 
3:1) to yield the mesylated product 5.117 (155.0 mg, 0.34 mmol, 79%) as a 
white solid upon storage at r.t. M.p.: 67.8 – 68.9 °C; Rf = 0.18 (SiO2, 
pentane/EtOAc 4:1); Optical rotation: 𝛼 !!"  = +17.5 (c 0.12, CHCl3); FTIR 
(neat): ν = 2954, 2877, 1465, 1337, 1314, 1170, 961, 906, 865, 805, 760  
cm-1; 1H NMR (400 MHz, CDCl3) δ = 4.79 – 4.77 (dd, J = 2.9, 4.7 Hz, 2H), 
4.50 – 4.45 (m, 2H), 3.02 (s, 3H), 3.02 (s, 3H), 2.41 – 2.35 (m, 1H), 1.97 – 
1.89 (m, 6H), 1.63 – 1.57 (m, 2H), 1.50 – 1.38 (m, 7H), 1.11 (s, 3H), 0.97 (d,  
J = 6.8 Hz, 3H), 0.97 (s, 3H), 0.77 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ = 162.6, 103.7, 84.8, 84.5, 51.3, 45.9, 41.5, 39.1, 39.1, 36.9, 34.3, 
28.9, 27.5, 27.2, 27.2, 23.2, 22.1, 21.3, 16.6; HRMS (ESI) m/z calcd for 
C21H38O6S2Na [M+Na]+: 473.2002, found: 473.2005. 
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2-(2-((1R,3R)-3-isopropyl-1-methyl-2-oxocyclopentyl)ethyl)-2-
methylcyclohexane-1,3-diyl dimethanesulfonate (5.118): 
The olefin 5.117 (8.05 mg, 17.9 µmol, 1.0 eq) was 
dissolved in dry CH2Cl2 (2.0 ml) and cooled to −78 °C. O3 
was bubbled through the colorless solution until a 
persistent blue color was obtained (2 minutes). O2 was 
bubbled through the blue solution until a clear colorless solution as obtained. 
To the colorless solution DMS (2.22 mg, 35.7 µmol, 2.0 eq) was added and 
the mixture stirred at −78 °C for 30 min. The colorless solution was allowed to 
warm up to r.t. over 2 h and then evaporated to obtain a colorless oil. The 
crude material was purified by flash column chromatography (SiO2, 
pentane/EtOAc 2:1) to obtain the desired ketone 5.118 (2.42 mg, 5.0 µmol, 
30%) as colorless oil and the allylic alcohol 5.119 (2.87 mg, 6.34 mmol, 34%) 
as colorless oil. Rf = 0.30 (pentane/EtOAc 2:1); Optical rotation: 𝛼 !!"  = 
+31.3 (c 0.18, CHCl3); FTIR (neat): ν = 2958, 2877, 2327, 1727, 1464, 1332, 
1171, 967, 917, 877, 801, 734, 629 cm-1; 1H NMR (400 MHz, CDCl3) δ = 4.50 
– 4.48 (m, 2H), 3.08 (s, 3H), 3.02 (s, 3H), 2.18 – 2.05 (m, 2H), 1.97 – 1.89 (m, 
5H), 1.80 – 1.73 (m, 1H), 1.71 – 1.68 (m, 1H), 1.66 – 1.57 (m, 3H), 1.52 – 
1.46 (m, 3H), 1.41 – 1.34 (m, 1H), 1.10 (s, 3H), 0.98 (d, J = 6.9 Hz, 3H), 0.93 
(s, 3H), 0.80 (d, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 223.9, 84.1, 
83.9, 56.2, 48.8, 41.3, 39.2, 39.1, 33.4, 30.7, 27.3, 27.2, 21.7, 21.2, 21.1, 
20.6, 18.5. 
 
Alternative procedure  
The olefin 5.117 (9.76 mg, 21.7 µmol, 1.0 eq) was dissolved in t-BuOH (0.5 
ml) and water (0.13 ml). NMO (4.40 mg, 36.8 µmol, 1.7 eq) was added and 
the mixture cooled to 0 °C. OsO4 (4% in water, 0.01 ml, 1.1 µmol, 0.05 eq) 
was added and stirred at r.t. for 2.3 d. Sat. aq. Na2S2O3 (0.3 ml) was added 
and the mixture stirred for 30 minutes. The mixture was extracted with EtOAc 
(3 x 0.3 ml) and the combined organic layers were dried over Na2SO4, filtered 
and evaporated. The crude material was dissolved in THF (0.16 ml) and water 
(0.08 ml) and NaIO4 (15.0 mg, 65.2 µmol, 3.2 eq) were added and the mixture 
stirred for 2.5 h at r.t. EtOAc (0.4 ml) was added, the mixture filtered over 
O
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Na2SO4 and thoroughly washed with EtOAc (2 x 0.3 ml). The combined 
organic layers were evaporated and the crude material was purified by flash 
column chromatography (SiO2, pentane/EtOAc 2:1) to yield the desired 
ketone 5.118 (4.79 mg, 11.0 µmol, 51%) as a colorless oil. 
 
(2R,5R)-5-isopropyl-2-methyl-2-(2-(1-methylcyclohexa-2,5-dien-1-yl)-
ethyl)cyclopentan-1-one (5.120): 
Mesylate 5.118 (9.3 mg, 20.5 µmol, 1.0 eq) was dissolved 
in DMF (0.1 ml). Anhydrous LiBr (4.55 mg, 51.4 µmol, 2.5 
eq) and Li2CO3 (3.87 mg, 51.4 µmol, 2.5 eq) were added 
and the mixture heated to 140 °C for 4 h. After cooling to 
r.t. water (0.2 ml) was added and the mixture extracted with Et2O (3 x 1.0 ml). 
The combined organic layer was dried over Na2SO4, filtered and evaporated. 
The crude material was purified by flash column chromatography (SiO2, 
pentane/EtOAc 98:2) to yield the olefin 5.120 (3.95 mg, 15.0 µmol, 74%) as 
slightly colorless oil containing small impurities. Rf = 0.50 (SiO2, 
pentane/EtOAc 19:1); 1H NMR (400 MHz, CDCl3) δ = 5.71 – 5.66 (m, 2H), 
5.38 – 5.32 (m, 2H), 2.57 – 2.55 (m, 2H), 2.18 – 2.11 (m, 1H), 2.09 – 2.03 (m, 
1H), 1.93 – 1.86 (m, 1H), 1.70 – 1.58 (m, 4H), 1.36 – 1.30 (m, 3H), 1.01 (s, 
3H), 0.97 (d, J = 6.9 Hz, 3H), 0.88 (s, 3H), 0.79 (d, J = 6.8 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ = 224.2, 133.9, 133.8, 123.5, 56.0, 48.8, 37.2, 36.1, 33.5, 
33.3, 30.2, 27.3, 26.5, 21.5, 21.3, 20.6, 18.5. 
 
(R)-(5-isopropyl-2-methylcyclopent-1-en-1-yl)methyl 1-methylcyclohexa-
2,5-diene-1-carboxylate (5.122): 
The acid 5.121 (300 mg, 2.17 mmol, 1.0 eq) was 
dissolved in CH2Cl2 (10.0 ml) and DMAP (79.6 mg, 0.65 
mmol, 0.3 eq) was added. A solution of the allyl alcohol 
4.52 (335 mg, 2.17 mmol, 1.0 eq) in CH2Cl2 (6.5 ml) was 
added at 0 °C. EDC x HCl (832 mg, 4.34 mmol, 2.0 eq) was added and the 
mixture stirred at 0 °C for 10 minutes. The mixture was allowed to warm to r.t. 
and stirred for 15 h. The mixture was washed with aq. HCl (5%, 5.0 ml), sat. 
aq. NaHCO3 (5.0 ml) and water (2 x 3.0 ml). The org. layer was dried over 
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Na2SO4, filtered and evaporated. The crude product was purified by flash 
column chromatography (SiO2, pentane/Et2O 20:1) to yield the ester 5.122 
(488 mg, 1.78 mmol, 82%) as a colorless oil. Rf = 0.75 (SiO2, pentane/Et2O 
19:1); Optical rotation: 𝛼 !!"  = −17.9 (c 0.35, CHCl3); FTIR (neat): ν = 3033, 
2955, 2871, 1727, 1453, 1367, 1268, 1229, 1200, 1106, 944, 703 cm-1; 1H 
NMR (400 MHz, CDCl3) δ = 5.82 – 5.71 (m, 4H), 4.64 (d, J = 12.4 Hz, 1H), 
4.57 (d, J = 12.2 Hz, 1H), 2.73 (bs, 1H), 2.65 – 2.63 (m, 2H), 2.29 – 2.20 (m, 
2H), 1.96 – 1.88 (m, 1H), 1.81 – 1.73 (m, 1H), 1.71 (bs, 3H), 1.63 – 1.55 (m, 
1H), 1.32 (s, 3H), 0.89 (d, J = 6.9 Hz, 3H), 0.67 (d, J = 6.7 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ = 175.4, 139.9, 131.8, 129.0, 124.5, 60.6, 52.8, 44.2, 
38.1, 28.9, 27.5, 26.1, 21.9, 21.5, 16.1, 14.3; HRMS (ESI) m/z calcd for 
C18H26O2Na [M+Na]+: 297.1825, found: 297.1828. 
 
2-((1R,3R)-3-isopropyl-1-methyl-2-methylenecyclopentyl)-1-(1-
methylcyclohexa-2,5-dien-1-yl)ethan-1-one (5.124): 
The ester 5.122 (19.6 mg, 71.5 µmol, 1.0 eq) was dissolved 
in degassed THF (0.6 ml) and Cp2TiCl2 (1.78 mg, 7.15 
µmol, 0.1 eq) in THF (0.3 ml) was added. Cp2TiMe2366 (17% 
in toluene, 0.392 ml, 0.36 mmol, 5.0 eq) was added and the 
Schlenk tube covered with aluminum foil. The mixture was stirred at 65 °C for 
22 h. The mixture was allowed to cool to r.t., then diluted with Et2O (1.5 ml), 
dried over Na2SO4 and filtered over Celite. The crude material was purified by 
flash column chromatography (basic alumina, pentane/Et2O/Et3N 19:1:0.1, 
spot on top) to yield the enol 5.123 (5.76 mg, 21.0 µmol, 30%) as a yellow oil. 
The enol 5.123 was directly diluted with toluene (0.5 ml) and stirred for 19 h at 
173 °C. The mixture was allowed to cool to r.t. and directly evaporated. The 
crude material was purified by flash column chromatography (SiO2, 
pentane/Et2O 98:2) to yield the desired ketone 5.124 (3.53 mg, 13.0 µmol, 
44%, d.r. = 9:1) as a yellow oil. Rf = 0.73 (SiO2, pentane/Et2O 19:1); 1H NMR 
(400 MHz, CDCl3) δ = 5.88 – 5.84 (m, 2H), 5.53 – 5.47 (m, 2H), 4.70 (dd, J = 
8.3, 3.1 Hz, 2H), 2.77 – 2.59 (m, 3H), 2.59 – 2.53 (m, 1H), 2.00 – 1.94 (m, 
1H), 1.64 – 1.58 (m, 4H), 1.17 (s, 3H), 0.99 (s, 3H), 0.97 (d, J = 6.9 Hz, 3H), 
0.76 (d, J = 6.7 Hz, 3H). 
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(R)-(5-isopropyl-2-methylcyclopent-1-en-1-yl)methyl benzoate (5.126): 
 
The acid 5.125 (200 mg, 1.64 mmol, 1.0 eq) was 
dissolved in CH2Cl2 (7.6 ml) and DMAP (60.6 mg, 0.49 
mmol, 0.3 eq) was added. A solution of the allyl alcohol 
4.52 (253 mg, 1.64 mmol, 1.0 eq) in CH2Cl2 (4.9 ml) was added at 0 °C. EDC 
x HCl (634 mg, 3.28 mmol, 2.0 eq) was added and stirred at 0 °C for 10 
minutes. The mixture was allowed to warm to r.t. and stirred for 22 h. The 
mixture was washed with aq. HCl (5%, 4.0 ml), sat. aq. NaHCO3 (4.0 ml) and 
water (2 x 2.5 ml). The org. layer was dried over Na2SO4, filtered and 
evaporated. The crude product was purified by flash column chromatography 
(SiO2, pentane/Et2O 20:1) to yield the ester 5.126 (370 mg, 1.43 mmol, 88%) 
as a colorless oil. Rf = 0.73 (SiO2, pentane/Et2O 19:1); Optical rotation: 𝛼 !!"  = −17.7 (c 0.24, CHCl3); FTIR (neat): ν = 2956, 2871, 2843, 1717, 1603, 
1452, 1381, 1314, 1268, 1175, 1110, 1069, 1026, 936, 713, 632 cm-1; 1H 
NMR (400 MHz, CDCl3) δ = 8.05 – 8.02 (m, 2H), 7.55 (tt, J = 7.5, 1.3 Hz, 1H), 
7.46 – 7.41 (m, 2H), 4.91 (d, J = 12.1 Hz, 1H), 4.80 (d, J = 12.2 Hz, 1H), 2.85 
(bs, 1H), 2.32 – 2.27 (m, 2H), 2.07 – 2.00 (m, 1H), 1.86 – 1.76 (m, 4H), 1.67 – 
1.58 (m, 1H), 0.93 (d, J = 6.9 Hz, 3H), 0.73 (d, J = 7.0 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ = 166.9, 140.7, 132.9, 131.8, 130.7, 129.7, 128.5, 60.4, 53.0, 
38.1, 29.0, 22.0, 21.6, 16.1, 14.3; HRMS (ESI) m/z calcd for C17H22O2Na 
[M+Na]+: 281.1512, found: 281.1515. 
 
2-((1R,3R)-3-isopropyl-1-methyl-2-methylenecyclopentyl)-1-phenylethan-
1-one (5.128): 
The ester 5.126 (24.5 mg, 94.8 µmol, 1.0 eq) was dissolved 
in degassed THF (0.8 ml) and Cp2TiCl2 (2.36 mg, 9.48 
µmol, 0.1 eq) in THF (0.3 ml) was added. Cp2TiMe2366 (17% 
in toluene, 0.61 ml, 0.47 mmol, 5.0 eq) was added and the 
Schlenk tube covered with aluminium foil. The mixture was stirred at 65 °C for 
13 h. The mixture was allowed to cool to r.t. and then diluted with Et2O (2.0 
ml) and dried over Na2SO4 and filtered over Celite. The crude material was 
purified by flash column chromatography (basic alumina, pentane/Et2O/Et3N 
100:1:0.5, spot on top) to yield the enol 5.127 as a colorless oil. The enol 
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5.127 was directly diluted with toluene (1.0 ml) and stirred for 19 h at 100 °C. 
The mixture was allowed to cool to r.t. and directly evaporated. The crude was 
purified by flash column chromatography (SiO2, pentane/Et2O 95:5) to yield 
the desired ketone 5.128 (18.9 mg, 73.0 µmol, 79% over two steps) as a 
colorless oil. Rf = 0.61 (SiO2, pentane/Et2O 19:1); Optical rotation: 𝛼 !!"  = 
+41.1 (c 0.17, CHCl3); FTIR (neat): ν = 3327, 3065, 2957, 2870, 1690, 1674, 
1597, 1448, 1351, 1238, 1198, 1106, 1003, 882, 751, 691, 657, 625 cm-1; 1H 
NMR (400 MHz, CDCl3) δ = 7.95 – 7.92 (m, 2H), 7.45 (td, J = 7.3, 2.1 Hz, 1H), 
7.47 – 7.42 (m, 2H), 4.86 (d, J = 3.0 Hz, 1H), 4.79 (d, J = 2.7 Hz, 1H), 3.20 (d, 
J = 16.3 Hz, 1H), 3.08 (d, J = 16.3 Hz, 1H), 2.63 – 2.56 (m, 1H), 2.05 – 1.94 
(m, 1H), 1.82 – 1.75 (m, 1H), 1.70 – 1.62 (m, 2H), 1.48 – 1.38 (m, 1H), 1.12 
(s, 3H), 0.99 (d, J = 6.9 Hz, 3H), 0.79 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ = 199.7, 163.1, 138.5, 132.8, 128.6, 128.6, 128.2, 103.6, 50.8, 49.1, 
45.0, 37.4, 28.8, 27.6, 23.4, 22.0, 16.6; HRMS (ESI) m/z calcd for 
C18H24O1Na [M+Na]+: 279.1719, found: 279.1719. 
 
(E)-5-((1R,3R)-3-isopropyl-1-methyl-2-methylenecyclopentyl)pent-3-en-2-
one (5.144):  
LiCl (112 mg, 2.63 mmol, 2.5 eq) was dried and 
suspended in ACN (6.0 ml). Dimethyl 2-
oxopropylphosphonate (437 mg, 2.63 mmol, 2.5 eq) and 
DIPEA (313 mg, 0.4 ml, 2.42 mmol, 2.3 eq) were added. The mixture was 
stirred at r.t. for 20 minutes and a solution of the aldehyde 4.54 (190 mg, 1.05 
mmol, 1.0 eq) in ACN (2.0 ml) was added at r.t. and the mixture stirred for 5 h 
at r.t. Brine (2.0 ml) was added and the mixture extracted with EtOAc (3 x 4.5 
ml). The combined organic layers were dried over Na2SO4, filtered and 
evaporated. The crude oil was purified by flash column chromatography 
(SiO2, pentane/Et2O 19:1) to yield the desired unsaturated ketone 5.144 (183 
mg, 0.83 mmol, 79%) as a colorless oil. Rf = 0.19 (SiO2, pentane/Et2O 19:1); 
Optical rotation: 𝛼 !!"  = +79.6 (c 0.51, CHCl3); FTIR (neat): ν = 3215, 3113, 
2945, 2867, 1700, 1643, 1595, 1507, 1464, 1417, 1361 cm-1; 1H NMR (400 
MHz, CDCl3) δ = 6.79 – 6.71 (m, 1H), 6.07 (dt, J = 15.9, 1.4 Hz, 1H), 4.85 – 
4.84 (m, 2H), 2.44 – 2.36 (m, 1H), 2.33 – 2.31 (m, 2H), 2.24 (s, 3H), 2.00 – 
1.93 (m, 1H), 1.66 – 1.58 (m, 1H), 1.53 – 1.49 (m, 1H), 1.47 – 1.39 (m, 2H), 
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1.02 (s, 3H), 0.98 (d, J = 6.8 Hz, 3H), 0.78 (d, J = 6.8 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ = 198.7, 161.6, 146.2, 133.5, 104.5, 51.1, 46.1, 44.9, 37.2, 
29.1, 27.6, 27.1, 23.2, 22.0, 16.7; HRMS (ESI) m/z calcd for C15H25O [M+H]+: 
221.1900, found: 221.1897. 
5-((1S,3R)-3-isopropyl-1-methyl-2-methylenecyclopentyl)pentan-2-one 
(5.145): 
 
Toluene (2.7ml) and t-BuOH (0.13 ml) were degassed and 
added to a mixture of Cu(OAc)2 (14.6 mg, 71.9 µmol,  
0.1 eq) and 1.2-bis(diphenylphospino)benzene (16.4 mg, 
35.9 µmol, 0.05 eq). The mixture was stirred for 20 minutes at r.t. and PMHS 
(0.1 ml) was added and the blue solution turned green to yellow over 10 
minutes. A solution of the unsaturated ketone 5.144 (158 mg, 0.72 mmol, 1.0 
eq) in a mixture of toluene (3.0 ml) and t-BuOH (0.14 ml) was added to the 
green/yellow solution. The mixture was stirrred at r.t. for 2.5 h and then diluted 
with EtOAc (8.0 ml) and washed with aq. NaOH (1 M, 3.0 ml), aq. HCl (1 M, 
3.0 ml) and brine (3.0 ml). The combined aq. layers were rextracted with 
EtOAc (4.0 ml) and the combined organic layers were dried over Na2SO4, 
filtered and evaporated. The crude was purified by flash column 
chromatography (SiO2, pentane/Et2O 19:1) to obtain ketone 5.145 (127 mg, 
0.57 mmol, 80%) as a colorless oil. Rf = 0.28 (SiO2, pentane/Et2O 19:1); 
Optical rotation: 𝛼 !!"  = +45.4 (c 0.21, CHCl3); FTIR (neat): ν = 3068, 2954, 
2870, 1717, 1645, 1510, 1462, 1517, 1366, 1269, 1165, 1053, 1029, 880, 
779, 675, 628 cm-1; 1H NMR (400 MHz, CDCl3) δ = 4.76 (dd, J = 5.3, 2.7 Hz, 
2H), 2.39 (t, J = 7.2 Hz, 3H), 2.12 (s, 3H), 2.01 – 1.90 (m, 1H), 1.62 – 1.55 (m, 
2H), 1.54 – 1.47 (m, 2H), 1.44 – 1.37 (m, 3H), 1.33 – 1.26 (m, 1H), 0.97 (d, J 
= 7.0 Hz, 3H), 0.95 (s, 3H) 0.77 (d, J = 6.8 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ = 209.5, 140.4, 134.9, 50.3, 44.7, 39.3, 34.9, 30.0, 28.3, 27.2, 25.7, 
21.5, 21.2, 19.5, 9.4; HRMS (ESI) m/z calcd for C15H27O [M+H]+: 223.2056, 
found: 223.2055. 
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(S)-5-(2-(hydroxymethyl)-3-isopropyl-1-methylcyclopent-2-en-1-
yl)pentan-2-one (5.147): 
The olefin 5.145 (1.18 g, 5.31 mmol, 1.0 eq) was dissolved 
in CH2Cl2 (50.0 ml) and the solution cooled to 0 °C.  
m-CPBA (2.09 g, 8.49 mmol, 1.6 eq) was added and the 
mixture stirred at 0 °C for 10 minutes and then at r.t. for 4 h. The mixture was 
diluted with EtOAc (20.0 ml) and washed with sat. Na2S2O3 (9.0 ml), sat. aq. 
NaHCO3 (9.0 ml) and brine (9.0 ml). The organic layer was dried over 
Na2SO4, filtered and evaporated. The crude material was purified by flash 
column chromatography (SiO2, pentane/Et2O 3:1) to yield the allylic alcohol 
5.147 (900 mg, 3.77 mmol 71%) as a colorless oil. Rf = 0.30 (SiO2, 
pentane/Et2O 3:1); Optical rotation: 𝛼 !!"  = +19.8 (c 0.33, CHCl3); FTIR 
(neat): ν = 2956, 2873, 1716, 1575, 1462, 1367, 1229, 1166, 995, 927, 817, 
753, 675, 628 cm-1; 1H NMR (400 MHz, CDCl3) δ = 4.08 (m, 2H), 2.86 (hept, J 
= 6.9 Hz, 1H), 2.48 – 2.37 (m 2H), 2.27 – 2.18 (m, 2H), 2.12 (s, 3H), 1.78 – 
1.72 (m, 1H), 1.54 – 1.45 (m, 5H), 1.36 – 1.32 (m, 2H), 1.04 (s, 3H), 1.02 (d, J 
= 7.0 Hz, 3H), 1.00 (d, J = 7.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 209.7, 
148.5, 138.7, 56.0, 50.1, 44.1, 40.3, 35.4, 30.2, 28.4, 27.3, 27.0, 22.0, 21.7, 
19.0; HRMS (ESI) m/z calcd for C15H27O2 [M+H]+: 239.2006, found: 239.2004. 
 
(S)-2-isopropyl-5-methyl-5-(4-oxopentyl)cyclopent-1-ene-1-carbaldehyde 
(5.148): 
The allylic alcohol 5.147 (172 mg, 72.3 mmol, 1.0 eq) was 
dissolved in CH2Cl2 (10.0 ml) and DMP (501 mg, 1,16 
mmol, 1.6 eq) was added and the mixture stirred at r.t. for 
19 h. EtOAc (10.0 ml) was added and the mixture washed 
with sat. Na2S2O3 (5.0 ml), sat. aq. NaHCO3 (5.0 ml) and brine (5.0 ml) and 
the organic layer was dired over Na2SO4, filtered and evaporated. The crude 
material was purified by flash column chromatography (SiO2, pentane/Et2O 
3:1) to obtain the aldeyhde 5.148 (119 mg, 0.50 mmol, 70%) as a colorless 
oil. Rf = 0.17 (SiO2, pentane/Et2O 3:1); Optical rotation: 𝛼 !!"  = +2.5 (c 0.21, 
CHCl3); FTIR (neat): ν = 2957, 2872, 1713, 1668, 1616, 1459, 1409, 1363, 
1260, 1230, 1168, 1132, 631 cm-1; 1H NMR (400 MHz, CDCl3) δ = 10.0 (s, 
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1H), 3.46 – 3.39 (m, 1H), 2.48 – 2.44 (m, 2H), 2.40 – 2.37 (m, 2H), 2.11 (s, 
3H), 1.86 – 1.78 (m, 1H), 1.68 – 1.59 (m, 1H), 1.56 – 1.47 (m, 3H), 1.33 – 
1.27 (m, 1H), 1.17 (s, 3H), 1.13 (d, J = 6.9 Hz, 3H), 1.11 (d, J = 6.8 Hz, 3H); 
13C NMR (101 MHz, CDCl3) δ = 209.4, 188.4, 173.0, 141.4, 49.6, 44.4, 38.7, 
35.1, 30.2, 30.1, 26.9, 25.9, 21.9, 21.7, 19.5; HRMS (ESI) m/z calcd for 
C15H25O2 [M+H]+: 237.1849, found: 237.1852. 
 
5-((S)-2-(hydroxymethyl)-3-isopropyl-1-methylcyclopent-2-en-1-
yl)pentan-2-ol (5.157): 
The ketone 5.147 (81.4 mg, 0.34 mmol, 1.0 eq) was 
dissolved in dry THF (8.0 ml) and cooled to 0 °C. LiAlH4 
(15.9 mg, 0.41 mmol, 1.2 eq) was added and stirred at  
0 °C. Sat. aq NH4Cl (1.8 ml) was added slowly after 1 h at 
0 °C and then extracted (3 x 3.0 ml) with Et2O. The combined organic layers 
were washed with sat. aq NH4Cl (1.5 ml) and brine (2 x 1.5 ml). The organic 
layer was dried over Na2SO4, filtered and evaporated to obtain a colorless oil. 
The crude material was purified by flash column chromatography (SiO2, 
pentane/Et2O 1:1) to obtain the secondary alcohol 5.157 (82.1 mg, 0.34 
mmol, quant., combined diastereomers) as a colorless oil. Rf = 0.30 (SiO2, 
pentane/Et2O 1:1); FTIR (neat): ν = 3385, 2957, 2873, 1462, 1376, 1126, 
986, 928, 820, 677, 630 cm-1; 1H NMR (400 MHz, CDCl3) δ = 4.15 – 4.02 (m, 
4H), 3.86 – 3.75 (m, 2H), 2.83 (hept, J = 7.0 Hz, 2H), 2.28 – 2.16 (m, 4H), 
1.79 – 1.69 (m, 2H), 1.56 – 1.54 (m, 3H), 1.52 – 1.48 (m, 2H), 1.47 – 1.36 (m, 
7H), 1.35 – 1.20 (m, 6H), 1.17 – 1.15 (m, 6H), 1.94 (s, 3H), 1.04, (s, 3H), 1.02 
– 0.98 (m, 12H); 13C NMR (101 MHz, CDCl3) δ = 148.5, 148.2, 139.3, 138.6, 
68.3, 67.1, 56.1, 56.1, 50.1, 50.0, 40.7, 40.1, 40.0, 39.5, 35.7, 35.3, 28.5, 
28.3, 27.4, 27.3, 27.2, 26.5, 23.7, 23.7, 22.0, 22.0, 21.7, 21.7, 21.2, 20.6; 
HRMS (ESI) m/z calcd for C15H29O2 [M+H]+: 241.2162, found: 241.2158. 
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(5S)-5-(4-hydroxypentyl)-2-isopropyl-5-methylcyclopent-1-ene-1-
carbaldehyde (5.158): 
Allylic alcohol 5.157 (41.5 mg, 0.173 mmol, 1.0 eq) was 
dissolved in CH2Cl2 (1.0 ml) and BaMnO4 (197 mg, 0.69 
mmol, 4.0 eq) and added and stirred for 19 h at r.t. The 
mixture was diluted with CH2Cl2 (1.0 ml) and filtered over Celite and washed 
with CH2Cl2 (2 x 1.0 ml). The combined organic layers were evaporated and 
the residue purified by flash column chromatography (SiO2, pentane/Et2O 1:1) 
to obtain aldehyde 5.158 (36.4 mg, 0.11 mmol, 64%) as colorless oil, which 
was directly used in the next step. Rf = 0.28 (SiO2, pentane/Et2O 1:1). 
 
(Z)-1-((5S)-5-(4-hydroxypentyl)-2-isopropyl-5-methylcyclopent-2-en-1-
ylidene)butan-2-one (5.161): 
Diisopropylamine (84.6 mg, 0.12 ml, 0.84 mmol, 11.0 eq) 
was dissolved in THF (1.0 ml) and the solution cooled to 
−78 °C. n-BuLi (0.52 ml, 1 M in THF, 0.84 mmol, 11.0 eq) 
was added and the mixture stirred at −78 °C for 35 minutes. 1.2-
Dibromopropane was added and the mixture stirred at r.t. for 20 minutes. The 
mixture was cooled to −78 °C and a solution of the aldehyde 5.158 (18.1 mg, 
76.0 µmol, 1.0 eq) in THF (0.8 ml) was added and the mixture stirred at r.t. for 
17 h. Water (0.3 ml) and Et2O (2.0 ml) were added and the organic layer was 
washed with brine (0.4 ml), dried over Na2SO4, filtered and evaporated. The 
crude material was purified by flash column chromatography (SiO2, 
pentane/Et2O 1:1) to obtain the alkyne 5.159 (18.0 mg, 65.0 µmol, 85%) as 
slightly yellow oil. The alkyne 5.159 (5.0 mg, 18.0 µmol, 1.0 eq) was dissolved 
in CH2Cl2 (0.32 ml) and EtOH (0.08 ml) and Cu(OTf)2 (0.33 mg, 0.9 µmol, 
0.05 eq) were added and the mixture stirred at r.t. for 2.5 h. The crude mixture 
was directly evaporated and the residue was purified by flash column 
chromatography (SiO2, pentane/Et2O 1:1) to obtain the ketone 5.161 (3.2 mg, 
11.0 µmol, 64%) as a brown oil. Rf = 0.40 (SiO2, pentane/Et2O 1:1); Optical 
rotation: 𝛼 !!"  = +25.1 (c 0.10, CHCl3); FTIR (neat): ν = 3414, 2962, 2927, 
2870, 1679, 1575, 1459, 1376, 1299, 1124, 1044, 1010, 856, 803, 667, 626 
cm-1; 1H NMR (400 MHz, CDCl3) δ = 6.23 (t, J = 2.9 Hz, 1H), 6.08 (d, J = 4.3 
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Hz, 1H), 3.83 – 3.72 (m, 1H), 2.54 – 2.48 (m, 3H), 2.25 – 2.20 (m, 1H), 1.66 – 
1.57 (m, 1H), 1.51 – 144 (m, 1H), 1.44 – 1.34 (m, 3H), 1.30 (d, J = 10.4 Hz, 
3H), 1.15 – 1.07 (m, 15H); 13C NMR (101 MHz, CDCl3) δ = 201.5, 201.0, 
170.1, 169.8, 151.5, 151.4, 139.1, 139.0, 115.7, 115.5, 68.2, 67.6, 47.7, 47.3, 
47.3, 39.9, 39.7, 38.2, 38.2, 38.2, 38.0, 26.1, 25.7, 25.7, 25.6, 23.6, 23.6, 
22.3, 22.3, 22.1, 22.1, 21.4, 21.2, 8.8; HRMS (ESI) m/z calcd for C18H31O2 
[M+H]+: 279.2319, found: 279.2315. 
 
5-((1S,3R)-3-isopropyl-1-methyl-2-methylenecyclopentyl)pentan-2-ol 
(5.165): 
The ketone 5.145 (233 mg, 1.05 mmol, 1.0 eq) was 
dissolved in THF (10.0 ml) and the solution cooled to  
0 °C. LiAlH4 (48.7 mg, 1.26 mmol, 1.2 eq) was added and 
the mixture stirred for 70 minutes at 0 °C. EtOAc (5.0 ml), sat. aq. NH4Cl (3.0 
ml) was added at 0 °C. The mixture was allowed to warm to r.t. The organic 
layer was washed with sat. aq. NH4Cl (3.0 ml) and brine (3.0 ml). The 
combined aq. layers were extracted with EtOAc (3.0 ml) and the combined 
organic layers were dried over Na2SO4, filtered and evaporated. The crude 
material was purified by flash column chromatography (SiO2, pentane/Et2O 
3:1) to obtain the secondary alcohol 5.165 (186 mg, 0.83 mmol, 79% 
combined diastereomers) as a colorless oil. (Only the major diastereomer 
could be obtained in pure form and is described here). Rf = 0.27 (SiO2, 
pentane/Et2O 3:1); FTIR (neat): ν = 2955, 2871, 1461, 1369, 1129, 879, 632, 
534 cm-1; 1H NMR (400 MHz, CDCl3) δ = 4.76 (dd, J = 9.4, 2.7 Hz, 1H), 3.80 
(dt, J = 11.6, 5.9 Hz, 1H), 2.44 – 2.36 (m, 2H), 2.02 – 1.90 (m, 2H), 1.63 – 
1.56 (m, 3H), 1.51 – 1.47 (m, 2H), 1.46 – 1.37 (m, 11H), 1.35 – 1.31 (m, 3H), 
1.30 – 1.28 (m, 3H), 1.18 (d, J = 6.2 Hz, 3H), 0.97 (d, J = 6.9 Hz, 3H), 0.95 (s, 
3H), 0.77 (d, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 163.1, 163.0, 
103.2, 103.2, 68.3, 68.3, 51.4, 51.3, 46.0, 42.0, 42.0, 40.3, 40.3, 37.1, 37.0, 
28.9, 28.9, 27.5, 27.4, 23.7, 23.7, 23.2, 22.1, 21.1, 21.1, 16.6; HRMS (ESI) 
m/z calcd for C15H28ONa [M+Na]+: 247.2032, found: 247.2034. 
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tert-butyl((5-((1S,3R)-3-isopropyl-1-methyl-2-
methylenecyclopentyl)pentan-2-yl)oxy)dimethylsilane (5.166): 
The alcohol 5.165 was used as a diastereomeric 
mixture. The alcohol 5.165 (178 mg, 0.79 mmol, 1.0 eq) 
was dissolved in CH2Cl2 (18.0 ml) and 2.6-lutidine (339 
mg, 0.37 ml, 3.16 mmol, 4.0 eq) was added and the 
mixture was cooled to −20 °C. TBSOTf (418 mg, 0.36 ml, 1.58 mmol, 2.0 eq) 
was added and the mixture stirred at −20 °C for 10 minutes and then at r.t. for 
another 14 h. Water (5.0 ml) was added and the mixture extracted with 
CH2Cl2 (3 x 5.0 ml). The combined organic layers were dried over Na2SO4, 
filtered and evaporated. The crude material was purified by flash column 
chromatography (SiO2, pentane) to obtain the protected alcohol 5.166 (253 
mg, 0.75 mmol, 95%) as a colorless oil. Rf = 0.32 (SiO2, pentane); FTIR 
(neat): ν = 2957, 2866, 2374, 1462, 1371, 1255, 1133, 880, 835, 773, 632, 
537 cm-1; 1H NMR (400 MHz, CDCl3) δ = 4.75 (dd, J = 6.7, 2.7 Hz, 4H), 3.82 – 
3.71 (m, 2H), 2.43 – 2.33 (m, 2H), 2.05 – 1.87 (m, 2H), 1.64 – 1.27 (m, 20H), 
1.11 (d, J = 6.2 Hz, 6H), 0.97 (d, J = 6.9 Hz, 6H), 0.95 (s, 6H), 0.88 (s, 18H), 
0.77 (d, J = 6.8 Hz, 6H), -0.04 (s, 12H); 13C NMR (101 MHz, CDCl3) δ = 
163.2, 163.1, 103.1, 69.0, 68.9, 51.4, 51.3, 46.1, 42.3, 42.2, 40.8, 40.7, 37.2, 
37.1, 29.0, 28.9, 27.4, 27.3, 26.1, 24.1, 24.1, 23.3, 22.1, 21.3, 18.3, 16.7, 0.2, 
-4.2, -4.2, -4.5, -4.5; HRMS (ESI) m/z calcd for C21H43OSi [M+H]+: 339.3078, 
found: 339.3076. 
 
tert-butyl((5-((3R,4S,7R)-7-isopropyl-4-methyl-1-oxaspiro[2.4]heptan-4-
yl)pentan-2-yl)oxy)dimethylsilane (5.167): 
The olefin 5.166  was used as a diastereomeric mixture. 
Olefin 5.166 (50.0 mg, 0.15 mmol, 1.0 eq) was 
dissolved in CH2Cl2 (1.5 ml) and the solution cooled to 
0 °C. NaHCO3 (37.2 mg, 0.44 mmol, 3.0 eq) and m-CPBA (51.0 mg, 0.21 
mmol, 1.4 eq) was added. The mixture was stirred at 0 °C for 10 minutes and 
then allowed to warm to r.t. After 19 h, the mixture was quenched with EtOAc 
(3.0 ml) and then washed with sat. aq. Na2S2O3 (1.0 ml), sat. aq. NaHCO3 (2 
x 1.0 ml) and brine (1.0 ml). The combined aq. layers were extracted with 
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EtOAc (2 x 1.0 ml) and the combined organic layers were dried over Na2SO4, 
filtered and evaporated. The crude material was purified by flash column 
chromatography (SiO2, pentane/Et2O 30:1) to obtain the epoxide 5.167 (41.7 
mg, 0.12 mmol, 80%, combined diastereomers) as colorless oil.  
1st diastereomer 5.167a (7.05 mg, 19.5 µmol, 13%: Rf = 0.41 (SiO2, 
pentane/Et2O 30:1); FTIR (neat): ν = 2954, 2930, 2857, 1462, 1373, 1254, 
1133, 1063, 834, 773 cm-1; 1H NMR (400 MHz, CDCl3) δ = 3.81 – 3.73 (m, 
2H), 2.69 (dd, J = 4.8, 2.1 Hz, 2H), 2.56 (d, J = 4.8 Hz, 2H) 2.08 – 2.02 (m, 
2H), 1.66 – 1.57 (m, 4H), 1.54 – 1.42 (m, 6H), 1.41 – 1.28 m, 6H), 1.25 – 1.14 
(m, 6H), 1.11 (d, J = 6.0 Hz, 6H), 0.90 – 0.88 (m, 24H), 0.86 (d, J = 2.8 Hz, 
6H), 0.80 (m, 6H), 0.04 (m, 12H); 13C NMR (101 MHz, CDCl3) δ = 69.9, 69.9, 
68.8, 68.8, 48.8, 48.8, 47.2, 47.1, 42.7, 40.8, 40.8, 39.7, 39.6, 36.3, 36.2, 
26.5, 26.1, 26.1, 24.1, 24.0, 23.3, 23.3, 22.8, 21.1, 21.0, 20.7, 20.5, 19.4, 
18.3, -4.1, -4.2, -4.5, -4.5; HRMS (ESI) m/z calcd for C21H43O2Si [M+H]+: 
355.3027, found: 355.3027. 
2nd diastereomer 5.167b (34.7 mg, 99.0 µmol, 66%: Rf = 0.30 (SiO2, 
pentane/Et2O 30:1); FTIR (neat): ν = 3326, 2956, 2930, 2858, 1463, 1375, 
1252, 1138, 1064, 1042, 988, 834, 806, 772, 665 cm-1; 1H NMR (400 MHz, 
CDCl3) δ = 3.81 – 3.74 (m, 2H), 2.78 (d, J = 4.4 Hz, 2H), 2.60 (d, J = 4.5 Hz, 
2H), 2.06 (ddd, J = 11.7, 7.8, 4.2 Hz, 2H), 1.71 – 1.64 (m, 2H), 1.60 – 1.54 (m, 
6H), 1.46 – 1.16 (m, 14H), 1.11 (d, J = 6.0 Hz, 6H), 1.04 – 0.97 (m, 2H), 0.90 
– 0.86 (m, 28H), 0.84 (d, J = 6.9 Hz, 6H), 0.04 (s, 12H); 13C NMR (101 MHz, 
CDCl3) δ = 71.2, 71.2, 68.9, 68.8, 49.8, 49.8, 49.1, 49.1, 42.0, 42.0, 40.8, 
40.8, 37.2, 37.1, 37.1, 37.0, 26.6, 26.1, 26.1, 24.1, 23.2, 23.1, 22.1, 22.1, 
22.1, 21.0, 20.9, 18.3, 17.9, 17.9, -4.2, -4.5, -4.5; HRMS (ESI) m/z calcd for 
C21H43O2Si [M+H]+: 355.3027, found: 355.3027. 
 
((5S)-5-(4-((tert-butyldimethylsilyl)oxy)pentyl)-2-isopropyl-5-
methylcyclopent-1-en-1-yl)methanol (5.168): 
The epoxide 5.167 (53.9 mg, 0.15 mmol, 1.0 eq) was 
dissolved in EtOAc (1.4 ml) and SiO2 (400 mg) was 
added. The mixture was heated to 105 °C for 24 h. After 
cooling to r.t. the mixture was evaporated. The crude material was purified by 
MeMe
Me OTBS
Me
OH
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flash column chromatography (SiO2, pentane/Et2O 6:1) to obtain the allylic 
alcohol 5.168 (36.1 mg, 0.10 mmol, 67%, diastereomeric mixture) as colorless 
oil. Rf = 0.43 (SiO2, pentane/Et2O 5:1); FTIR (neat): ν = 2956, 2929, 2859, 
1463, 1373, 1361, 1254, 1134, 1064, 1038, 992, 834, 773, 664, 630, 537  
cm-1; 1H NMR (400 MHz, CDCl3) δ = 4.13 – 4.01 (m, 2H), 3.80 – 3.72 (m, 1H), 
2.84 (hept, J = 6.7, 1.4 Hz, 1H), 2.29 – 2.16 (m, 2H), 1.77 – 1.70 (m, 1H), 1.54 
– 1.46 (m, 1H), 1.44 – 1.28 (m, 5H), 1.26 – 1.13 (m, 2H), 1.10 (dd, J = 6.1, 1.0 
Hz, 1H), 1.05 (d, J = 2.2 Hz, 1H), 1.03 – 0.98 (m, 2H), 0.88 (d, J = 0.9 Hz, 
3H), 0.04 (s, 3H), 0.03 (s, 3H); 13C NMR (101 MHz, CDCl3) δ = 148.2, 148.1, 
139.6, 139.4, 69.0, 68.8, 56.2, 56.2, 50.1, 50.0, 41.0, 40.8, 40.8, 40.7, 35.6, 
35.6, 28.3, 28.3, 27.3, 27.3, 26.9, 26.7, 26.1, 24.1, 24.0, 21.9, 21.9, 21.9, 
21.8, 21.4, 18.3, -4.2, -4.5, -4.5; HRMS (ESI) m/z calcd for C21H42O2SiNa 
[M+Na]+: 377.2846, found: 377.2847. 
 
1-((5S)-5-(4-((tert-butyldimethylsilyl)oxy)pentyl)-2-isopropyl-5-
methylcyclopent-1-en-1-yl)but-3-en-1-ol (5.170): 
The allylic alcohol 5.168 (463 mg, 1.31 mmol, 1.0 eq) 
was dissolved in CH2Cl2 (30 ml) and pyridinium 
dichromate (551 mg, 1.44 mmol, 1.1 eq) was added at 
r.t. After stirring for 3.5 h, EtOAc (8.0 ml) was added and the mixture filtered 
over Celite and the filter cake washed thoroughly with EtOAc (2 x 5.0 ml). The 
organic layer was washed with sat. aq. NaHCO3 (5.0 ml) and brine (4.0 ml). 
The organic layer was dried over Na2SO4, filtered and evaporated. The crude 
mixture was dissolved in THF (18.0 ml) and cooled to −78 °C. Allylmagnesium 
bromide (3.88 ml, 1 M in Et2O, 3.88 mmol, 3.0 eq) was added. After stirring at 
−78 °C for 5 minutes the cooling bath was removed and stirring continued for 
1 h. The mixture was cooled to 0 °C, diluted with Et2O (9.0 ml) and washed 
with sat. aq. NH4Cl (5.0 ml) and sat. aq. NaHCO3 (5.0 ml). The combined aq. 
layers were extracted with Et2O (5.0 ml) and the combined organic layers 
were washed with brine (5.0 ml) and then dried over Na2SO4, filtered and 
evaporated. The crude material was purified by flash column chromatography 
(SiO2, pentane/Et2O 15:1) to obtain the allylated alcohol 5.170 (321 mg, 0.81 
mmol, 63%, complex diastereomeric mixture) as a colorless oil. Rf = 0.30 
MeMe
Me OTBS
Me
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(SiO2, pentane/Et2O 15:1); FTIR (neat): ν = 2957, 2930, 2858, 1640, 1463, 
1373, 1361, 1254, 1134, 1036, 1004, 912, 834, 773, 664, 627, 544 cm-1; 1H 
NMR (400 MHz, CDCl3) δ = 5.93 – 5.78 (m, 2H), 5.13 – 5.04 (m, 4H), 4.20 (dt, 
J = 10.0, 3.3 Hz, 1H), 4.12 (ddd, J = 10.3, 7.2, 3.7 Hz, 1H), 3.78 – 3.68 (m, 
2H), 3.19 – 3.02 (m, 2H), 2.51 – 2.42 (m, 2H), 2.28 – 2.19 (m, 2H), 2.16 – 
2.12 (m, 3H), 1.77 – 1.60 (m, 3H), 1.52 – 1.19 (m, 15H), 1.10 – 1.02 (m, 11H), 
0.98 – 0.92 (m, 13H), 0.86 – 0.81 (m, 19H), 0.00 (s, 12H); 13C NMR (101 
MHz, CDCl3) δ = 146.1, 146.1, 145.9, 145.9, 141.6, 141.4, 141.4, 141.2, 
136.3, 136.3, 117.5, 117.5, 117.4, 69.0, 69.0, 68.8, 68.5, 68.5, 68.5, 50.8, 
50.6, 50.5, 42.7, 42.5, 42.5, 41.4, 41.1, 40.8, 40.8, 40.8, 40.7, 40.4, 36.0, 
35.9, 35.8, 35.7, 27.9, 27.9, 27.9, 27.9, 27.6, 27.6, 27.1, 26.8, 26.3, 26.1, 
26.0, 24.1, 24.1, 24.6, 24.0, 21.8, 21.7, 21.6, 21.5, 21.4, 21.4, 21.4, 21.3, 
18.3, 18.3, -4.2, -4.5, -4.5, -4.5; HRMS (ESI) m/z calcd for C24H46O2SiNa 
[M+Na]+: 417.3159, found: 417.3161. 
 
1-((5S)-5-(4-((tert-butyldimethylsilyl)oxy)pentyl)-2-isopropyl-5-
methylcyclopent-1-en-1-yl)but-3-en-1-yl acetate (5.172): 
The secondary alcohol 5.170 (35.9 mg, 91 µmol, 1.0 
eq) was dissolved in CH2Cl2 (0.3 ml) and cooled to 0 
°C. Et3N (13.8 mg, 19.2 µl, 0.14 mmol, 1.5 eq), Ac2O 
(13.9 mg, 12.8 µl, 0.14 mmol, 1.5 eq) and DMAP (1.11 mg, 91.0 µmol, 0.1 eq) 
were added. The reaction was stirred at 0 °C for 1 h and then at r.t. for 30 
minutes. EtOAc (0.5 ml) was added and the mixture washed with sat. aq. 
NaHCO3 (0.3 ml) and brine (0.3 ml). The combined aq. layer were extracted 
with EtOAc (0.5 ml) and the combined organic layer was dried over Na2SO4, 
filtered and evaporated. The crude material was purified by flash column 
chromatography (SiO2, pentane/Et2O 30:1) to obtain the allylated alcohol 
5.172 (31.6 mg, 72.0 µmol, 80%, diastereomeric mixture) as colorless oil. Rf = 
0.37 (SiO2, pentane/Et2O 30:1); FTIR (neat): ν = 2958, 2930, 2857, 1741, 
1643, 1463, 1368, 1233, 1133, 1020, 915, 835, 773, 665, 628, 547 cm-1; 1H 
NMR (400 MHz, CDCl3) δ = 5.78 – 5.68 (m, 2H), 5.54 – 5.41 (m, 2H), 5.09 – 
5.01 (m, 4H), 3.79 – 3.66 (m, 2H), 3.15 – 3.00 (m, 2H), 2.60 – 2.51 (m, 2H), 
2.37 – 2.27 (m, 2H), 2.22 – 2.14 (m, 4H), 2.00 (s, 3H), 2.00 (s, 3H), 1.77 – 
MeMe
Me OTBS
Me
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1.62 (m, 2H), 1.54 – 1.22 (m, 13H), 1.11 – 1.07 (m, 10H), 1.01 – 0.95 (m, 
15H), 0.89 – 0.87 (m, 18H), 0.05 – 0.02 (m, 12H); 13C NMR (101 MHz, CDCl3) 
δ = 170.2, 170.1, 170.1, 147.5, 147.4, 147.1, 137.8, 137.5, 137.5, 137.3, 
134.9, 134.9, 134.9, 117.3, 117.3, 117.2, 70.5, 70.4, 70.1, 70.0, 69.2, 69.0, 
68.8, 68.7, 50.8, 50.7, 50.6, 50.6, 41.7, 41.4, 41.0, 40.9, 40.8, 40.7, 40.6, 
40.4, 40.4, 36.5, 36.3, 36.0, 35.8, 29.9, 28.1, 28.1, 28.0, 27.9, 27.8, 27.7, 
27.6, 27.6, 27.4, 27.1, 26.2, 26.1, 25.8, 24.1, 24.1, 24.0, 24.0, 21.7, 21.6, 
21.6, 21.5, 21.4, 21.4, 21.4, 21.4, 21.3, 21.3, 21.2, 21.1, 21.1, 21.0, 18.3, 
18.3, 1.2, -4.2, -4.3, -4.4, -4.5, -4.5; HRMS (ESI) m/z calcd for C26H48O3SiNa 
[M+Na]+: 459.3265, found: 459.3267. 
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8 Appendices 
 
8.1 List of Abbreviations, Acronyms and Symbols 
 
(g)         gas 
°C         degrees centigrade 
3.5-DMP       3.5-dimethylpyrazole  
9-BBN        9-borabicyclo[3.3.1]nonane 
Å          Ångström 
Ac         acetyl 
Ac2O        acetic anhydride 
acac         acetylacetone 
AChE        acetylcholinesterase 
ACN         acetonitrile 
AcOH        acetic acid 
ACP         acyl-carrier protein 
AD-mix        asymmetric dihydroxylation mixture 
ADS         amorphadiene synthase 
AIBN        2,2′-azobis(2-methylpropionitrile)  
AIDS        acquired immune deficiency syndrome 
ALS         amyotrophic lateral sclerosis 
aq.         aqueous 
BHT         butylated hydroxytoluene          
           (dibutylhydroxytoluene) 
brsm         based on recovered starting material 
BSA         bis(trimethylsilyl)acetamide 
BTPP        tert-butyl-imino-tri(pyrrolidino)phosphorane  
Bu         butyl 
Bz         benzoyl 
c          concentration   
calcd        calculated 
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CAN         ceric ammonium nitrate 
cat.         catalyst or catalytic 
CBS         Corey-Bakshi-Shibata 
CDI         1,1'-carbonyldiimidazole 
cGMP         cyclic guanosine monophosphate      
CoA         coenzyme A 
Cp         cyclopentadienyl 
D          deuterium 
d          doublet or day(s) 
d.r.         diastereomeric ratio 
Da         dalton(s) 
DAN         2,3-diaminonaphthalene  
DAST        (diethylamino)sulfur trifluoride 
DATMP       diethylaluminium 2,2,6,6-tetramethylpiperidide 
DBU         1,8-diazabicyclo[5.4.0]undec-7-en  
DCC         N,N′-dicyclohexylcarbodiimide  
DDQ         2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DEAD        diethyl azodicarboxylate 
DIBAL-H         diisobutylaluminium hydride 
DMA         N,N-dimethylacetamide 
DMAP        4-dimethylaminopyridine  
DMAPP       dimethylallyl pyrophosphate 
DMDO        dimethyldioxirane 
DME         dimethoxyethane 
DMF         dimethylformamide   
DMP         Dess-Martin periodinane  
DMPU        1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-    
           pyrimidinone  
DMS         dimethyl sulfide  
DMSO        dimethyl sulfoxide  
DPPA        diphenyl phosphoryl azide 
DU145        human prostate cancer cell 
EDC         1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDTA        ethylenediaminetetraacetic acid 
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ee         enantiomeric excess  
EI          electron impact ionization  
eq.         equivalent 
ESI         electrospray ionization 
Et          ethyl 
Et2O         diethylether 
Et3N         triethylamine  
EtOAc        ethyl acetate  
EtOH        ethanol 
FDA         Food and Drug Administration 
Fmoc        fluorenylmethyloxycarbonyl 
FPP         farnesyl pyrophosphate 
FTIR         Fourier transform infrared spectroscopy 
g          gram(s) 
GABA        gamma-aminobutyric acid 
GC         gas chromatography 
GSH         glutathione 
h          hour(s) 
ham         human antifungal metabolite 
Hantzsch ester     diethyl 1,4-dihydro-2,6-dimethyl-3,5-     
           pyridinedicarboxylate 
HATU        1-[bis(dimethylamino)methylene]-1H-1,2,3-  
           triazolo[4,5-b]pyridinium 3-oxid        
           hexafluorophosphate 
HCl         hydrochloric acid 
HDAC        histone deacetylase  
HeLa        immortal cell line 
HL-60        human myeloid leukemia  
HMG-CoA reductase   3-hydroxy-3-methyl-glutaryl-coenzyme A    
           reductase 
HMPA        hexamethylphosphoramide  
HNO         nitroxyl 
HPLC        high-performance liquid chromatography  
HRMS        high-resolution mass spectrometry 
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HSQC        heteronuclear single quantum coherence 
HWE        Horner-Wadsworth-Emmons 
Hz          hertz [s-1] 
hn         light  
IBX         2-iodoxybenzoic acid  
IC50         50% inhibition concentration  
IEDDA        inverse-electron-demanding Diels-Alder 
Imid.         imidazole 
IPP         isopentenyl pyrophosphate 
iPr         isopropyl 
J          coupling constant 
Jones reagent     sulfuric acid-chromium trioxide mixture 
KHMDS       potassium bis(trimethylsilyl)amide  
L-selectride      lithium-tri-sec-butylborohydride 
LAB         lithium aminoborohydride (LiBH3NR2) 
LD50         50% lethale dosis 
LDA         lithium diisopropylamide  
LiTMP        lithium 2,2,6,6-tetramethylpiperidide 
LTBA        tri-tert-butoxyaluminium hydride 
M          molarity (mol/L)  
m          multiplet 
m-CPBA       meta-chloroperoxybenzoic acid 
M.p.         melting point 
MAPK        mitogen-activated protein kinase  
Me         methyl 
MeOH        methanol 
mg         milligram(s)     
min         minute(s) 
mM         millimolar 
mmol        millimole 
MPM        4-methoxybenzyl 
Ms         mesyl 
MS         molecular sieve 
n.d.         not determined 
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NADPH       nicotinamide adenine dinucleotide phosphate 
NaHMDS       sodium bis(trimethylsilyl)amide 
NAT         1-[H]-naphthotriazole 
NCS         N-chlorosuccinimide 
NfF         nonafluorobutane sulfonyl fluoride  
NGF         nerve growth factor 
NIS         N-iodosuccinimide 
nmol         nanometer(s) 
nM         nanomolar 
nm         nanomole 
NMO        N-methylmorpholine N-oxide  
NMP         N-methyl-2-pyrrolidone 
NMR        nuclear magnetic resonance spectroscopy  
NOESY       nuclear Overhauser effect spectroscopy  
NOS         nitric oxide synthase 
NRPS        nonribosomal peptide synthase 
p-TsOH       p-toluenesulfonic acid 
P.          Plasmodium 
PABA         p-aminobenzoate  
PC12        cell line (rat adrenal gland phaeochromocytoma) 
PCC         pyridinium chlorochromate  
Pd(quinox)Cl2     dichloro[2-(4,5-dihydro-2         
          oxazolyl)quinoline]palladium(II) 
Petasis reagent     Cp2TiMe2 
Ph         phenyl 
pH         potential hydrogen 
PHABA        p-hydroxylaminobenzoate 
PhH         toluene 
PIDA        (diacetoxyiodo)benzene 
PMP         p-methoxyphenyl 
PNBA        p-nitrobenzoate 
PPh3         triphenylphospine 
ppm         parts per million 
PPTS        pyridinium p-toluenesulfonate 
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proton sponge     1,8-bis(dimethylamino)naphthalene, N,N,N′,N′- 
           tetramethyl-1,8-naphthalenediamine 
py          pyridine 
q          quartet 
quant.        quantitative 
r.t.         room temperature 
RCM        ring closing metathesis 
Red-Al        sodium bis(2-methoxyethoxy)aluminumhydride 
Rf          retention factor 
RNI         reactive nitrogen intermediates  
ROS         reactive oxygen species  
s          singlet 
SAHA        suberoylanilide hydroxamic acid 
SAR         structure-activity relationship 
SET         single electron transfer 
SH-SY5Y       neuroblast from neural tissue 
SI                selectivity index 
SN1         unimolecular nucleophilic substitution 
SN2         bi-molecular nucleophilic substitution 
SN2’         bi-molecular nucleophilic conjugate substitution 
SOMO        single occupied molecular orbital 
super-hydride     lithium triethylborohydride 
t          triplet 
t-BuOOH       tert-butylhydroperoxide 
TBAF        tetrabutylammonium fluoride  
TBDPS        tert-butyldiphenylsilyl 
TBHP        tert-butylhydroperoxide 
TBS         tert-butyldimethylsilyl 
TBTU        O-(benzotriazol-1-yl)-N,N,N′,N′-       
           tetramethyluronium tetrafluoroborate    
TEMPO       2,2,6,6-tetramethylpiperidin-1-yloxy  
TESOTf       trimethylsilyl trifluoromethanesulfonate 
Tf          trifluoromethanesulfonyl 
TFA         trifluoroacetic acid 
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THF         tetrahydrofuran  
TMEDA       N,N,N',N’-tetramethylethylenediamine 
TMS         trimethylsilyl  
TosMIC       p-toluenesulfonylmethyl isocyanide 
TPAP        tetrapropylammonium perruthenate 
Ts         tosyl 
WHO        World Health Organization 
δ             chemical shift 
µM         micromolar 
µmol         micromole 
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8.2 Crystal Structures 
 
    
 
 
 
Table 8.1: Crystal data for 2.80a. 
formula                                C13H27N3O3 
formula weight                        273.38 
Z, calculated density                 4, 1.145 Mg · m-3 
F(000)                                  600 
description and size of crystal    colourless block,         
               0.050 · 0.110 · 0.190 mm3 
absorption coefficient                0.660 mm-1 
min/max transmission                0.93 / 0.97 
temperature                            123K 
radiation(wavelength)                 Cu Kα (λ = 1.54178 Å) 
Crystal system, space group         orthorhombic, P 21 21 21 
a                                       5.6786(4) Å 
b                                       9.1130(6) Å 
c                                       30.633(2) Å 
α                                       90° 
β                                       90° 
γ                                       90° 
V                                     1585.26(19) Å3 
min/max Θ                              5.063° / 68.828° 
number of collected reflections     19332 
number of independent reflections   2887 (merging r = 0.036) 
number of observed reflections      2847 (I>2.0σ(I)) 
number of refined parameters        173 
r                                        0.0290 
rW                                      0.0241 
goodness of fit                   0.9594 
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Table 8.2: Crystal data for 2.140a. 
formula                                C11H21N3O3 
formula weight                        243.31 
Z, calculated density                 2, 1.144 Mg · m-3 
F(000)                                  263.998 
description and size of crystal    colourless block,  
               0.030 · 0.070 · 0.190 mm3 
absorption coefficient                0.689 mm-1 
min/max transmission                0.95 / 0.98 
temperature                            123K 
radiation(wavelength)                 Cu Kα (λ = 1.54180 Å) 
Crystal system, space group         triclinic, P 1 
a                                       5.9207(7) Å 
b                                       10.1597(12) Å 
c                                       11.7692(15) Å 
α                                       87.404(9)° 
β                                       87.059(7)° 
γ                                       89.796(7)° 
V                                     1706.29(9) Å3 
min/max Θ                              3.764° / 68.514° 
number of collected reflections     10810 
number of independent reflections   4617 (merging r = 0.048) 
number of observed reflections      3916 (I>2.0σ(I)) 
number of refined parameters        308 
r                                        0.1030 
rW                                      0.1253 
goodness of fit                   1.0499 
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Table 8.3: Crystal data for (−)-valdiazen (2.105a). 
formula                                C5H12N2O3 
formula weight                        148.17 
Z, calculated density                 4, 1.276 Mg · m-3 
F(000)                                  320 
description and size of crystal      colourless plate, 0.03 · 0.22 · 0.22  
               mm3 
absorption coefficient                0.890 mm-1 
min/max transmission                 0.62289 / 1.00000 
temperature                            160(2)K 
radiation(wavelength)                 Cu Kα (λ = 1.54184 Å) 
Crystal system, space group         ???, ??? 
a                                       6.14476(18) Å 
b                                       9.3078(3) Å 
c                                       13.4817(5) Å 
α                                       90° 
β                                       90° 
γ                                       90° 
V                                       771.08(5) Å3 
min/max Θ                             5.776° / 74.175° 
number of collected reflections     7248 
number of independent reflections   1558 (merging r = 0.0715) 
number of observed reflections      1558 (I > 2σ(I)) 
number of refined parameters        101 
r                                        0.0379 
rW                                      0.0999 
goodness of fit                        1.042 
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Table 8.4: Crystal data for Cu-valdiazen (2.145). 
formula                                C10H22Cu N4O6 
formula weight                        357.85 
Z, calculated density                 2, 1.556 Mg · m-3 
F(000)                                  374 
description and size of crystal      blue prism, 0.08 · 0.11 · 0.25 mm3 
absorption coefficient                1.461 mm-1 
min/max transmission                 0.89316 / 1.00000 
temperature                            160(2)K 
radiation(wavelength)                 Mo Kα (λ = 0.71073 Å) 
Crystal system, space group         ???, ??? 
a                                       9.39300(15) Å 
b                                       6.89236(11) Å 
c                                       11.95735(18) Å 
α                                       90° 
β                                       99.2698(15)° 
γ                                       90° 
V                                       764.01(2) Å3 
min/max Θ                              2.197° / 30.517° 
number of collected reflections     18905 
number of independent reflections   4261 (merging r = 0.0289) 
number of observed reflections      4261 (I > 2σ(I)) 
number of refined parameters        202 
r                                        0.0230 
rW                                      0.0530 
goodness of fit                        1.041 
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Table 8.5: Crystal data for Cu-fragin (2.144). 
formula                                C26H50Cu1N6O6 
formula weight                        606.27 
Z, calculated density                 3, 1.234 Mg · m-3 
F(000)                                  975.000 
description and size of crystal      blue needle, 0.030 · 0.040 · 0.190   
               mm3 
absorption coefficient                1.312 mm-1 
min/max transmission                 0.95 / 0.96 
temperature                            123K 
radiation(wavelength)                 Cu Kα (λ = 1.54178 Å) 
Crystal system, space group         trigonal, P 32 2 1 
a                                       14.3908(18) Å 
b                                       14.3908(18) Å 
c                                       13.6423(18) Å 
α                                       90° 
β                                       90° 
γ                                       120° 
V                                       2446.7(3) Å3 
min/max Θ                              3.546° / 68.667° 
number of collected reflections     23414 
number of independent reflections   3010 (merging r = 0.042) 
number of observed reflections      2886 (I>2.0σ(I)) 
number of refined parameters        242 
r                                        0.0635 
rW                                      0.0764 
goodness of fit                        1.0153 
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Table 8.6: Crystal data for 3.143. 
CCDC             1478756 
Formula            C17H25Cl1O5  
formula weight          344.83 
Z, calculated density        4, 1.312 Mg · m-3  
F(000)             736  
description and size of crystal    colourless block, 0.110 · 0.170 ·   
               0.250 mm3  
absorption coefficient       2.132 mm-1  
min/max transmission       0.70 / 0.79  
temperature           123K  
radiation(wavelength)       Cu Kα (λ = 1.54178 Å)  
Crystal system, space group     orthorhombic, P 21 21 21  
a               7.6753(6) Å  
b                  9.7959(7) Å  
c                                       23.2215(17) Å  
α                                       90°  
β                                       90°  
γ                                       90°  
V                                       1745.94(13) Å3  
min/max Θ                              4.900° / 68.960°  
number of collected reflections     8802  
number of independent reflections   3112 (merging r = 0.032)  
number of observed reflections      3031 (I>2.0σ(I))  
number of refined parameters        209  
r                                        0.0260  
rW                                      0.0298  
goodness of fit                        1.0925 
  
CHAPTER 8 
	  
264 
 
 
 
 
 
 
 
 
Table 8.7: Crystal data for 3.144. 
CCDC             1478757 
formula                                C17H23Cl1O5  
formula weight                        342.82  
Z, calculated density                 2, 1.327 Mg · m-3  
F(000)                                  364  
description and size of crystal      colourless block, 0.020 · 0.110 ·   
               0.140 mm3  
absorption coefficient                2.168 mm-1  
min/max transmission                 0.79 / 0.96  
temperature                            123K  
radiation(wavelength)                 Cu Kα (λ = 1.54178 Å)  
Crystal system, space group         monoclinic, P 21  
a                                       10.6723(7) Å  
b                                       7.1954(4) Å  
c                                       11.9267(8) Å  
α                                       90°  
β                                       110.456(4)°  
γ                                       90°  
V                                       858.11(6) Å3  
min/max Θ                              4.422° / 68.888°  
number of collected reflections     6396  
number of independent reflections   2940 (merging r = 0.030)  
number of observed reflections      2628 (I>2.0σ(I))  
number of refined parameters        209  
r                                        0.0413  
rW                                      0.0487  
goodness of fit                        1.0949 
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Table 8.8: crystal data for 3.145. 
CCDC             1478759 
formula                                C19H25Cl1O7  
formula weight                        400.86  
Z, calculated density                 4, 1.334 Mg · m-3  
F(000)                                  847.995  
description and size of crystal      colourless plate, 0.020 · 0.110 ·   
               0.180 mm3  
absorption coefficient                2.022 mm-1  
min/max transmission                 0.80 / 0.96  
temperature                            123K  
radiation(wavelength)                 Cu Kα (λ = 1.54178 Å)  
Crystal system, space group         orthorhombic, P 21 21 21  
a                                       7.1620(5) Å  
b                                       12.0359(8) Å  
c                                       23.1600(14) Å  
α                                       90°  
β                                       90°  
γ                                       90°  
V                                       1996.42(12) Å3  
min/max Θ                              3.817° / 69.292°  
number of collected reflections     23952  
number of independent reflections   3699 (merging r = 0.039)  
number of observed reflections      3338 (I>2.0σ(I))  
number of refined parameters        245  
r                                        0.0277  
rW                                      0.0333  
goodness of fit                        1.0976 
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Table 8.9: Crystal data for 3.164. 
CCDC             1478760 
formula                                C15H18O4  
formula weight                        262.31  
Z, calculated density                 4, 1.299 Mg · m-3  
F(000)                                  560  
description and size of crystal      colourless plate, 0.020 · 0.170 ·   
               0.250 mm3  
absorption coefficient                0.768 mm-1  
min/max transmission                 0.88 / 0.98  
temperature                            123K  
radiation(wavelength)                 Cu Kα (λ = 1.54178 Å)  
Crystal system, space group         orthorhombic, P 21 21 21  
a                                       6.6415(5) Å  
b                                       8.3791(6) Å  
c                                       24.1022(17) Å  
α                                       90°  
β                                       90°  
γ                                       90°  
V                                       1341.28(9) Å3  
min/max Θ                              3.668° / 68.824°  
number of collected reflections     8778  
number of independent reflections   2351 (merging r = 0.039)  
number of observed reflections      2123 (I>2.0σ(I))  
number of refined parameters        173  
r                                        0.0272  
rW                                      0.0307  
goodness of fit                        1.1332  
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Table 8.10: Crystal data for 4.49.    
CCDC              914565 
formula                                C18H28O4 
formula weight                        308.42 
Z, calculated density                 8, 1.287 Mg · m-3 
F(000)                                  1344 
description and size of crystal           colorless plate, 0.030 · 0.110 ·    
               0.320 mm3 
absorption coefficient                0.089 mm-1 
min/max transmission                 0.99 / 1.00 
temperature                            123K 
radiation(wavelength)                 Mo Kα (λ = 0.71073 Å) 
Crystal system, space group         tetragonal, P 41 21 2 
a                                       7.3830(3) Å 
b                                       7.3830(3) Å 
c                                       58.407(3) Å 
α                                       90° 
β                                       90° 
γ                                       90° 
V                                       3183.7(3) Å3 
min/max Θ                              1.395° / 27.484° 
number of collected reflections     12591 
number of independent reflections   2311 (merging r = 0.096) 
number of observed reflections      1905 (I>2.0σ(I)) 
number of refined parameters        199 
r                                        0.1061 
rW                                      0.0784 
goodness of fit                        1.1005 
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Table 8.11: Crystal data for 4.62.     
CCDC              1054561 
formula                                C19H30O4 
formula weight                        322.44 
Z, calculated density                 4, 1.221 Mg · m-3 
F(000)                                  703.994 
description and size of crystal      colorless needle        
               0.030 · 0.080 · 0.210 mm3 
absorption coefficient                0.671 mm-1 
min/max transmission                 0.95 / 0.98 
temperature                            123K 
radiation(wavelength)                 Cu Kα (λ = 1.54178 Å) 
Crystal system, space group         monoclinic, P c 
a                                       14.9923(19) Å 
b                                       9.5834(11) Å 
c                                       12.5518(15) Å 
α                                       90° 
β                                       103.442(2)° 
γ                                       90° 
V                                       1754.0(2) Å3 
min/max Θ                              3.030° / 69.128° 
number of collected reflections     23344 
number of independent reflections   6318 (merging r = 0.059) 
number of observed reflections      6292 (I>2.0σ(I)) 
number of refined parameters        415 
r                                        0.0372 
rW                                      0.0409 
goodness of fit                        1.0900 
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Table 8.12:Crystal data for 4.61.     
CCDC              914569 
formula                                C19H30O4 
formula weight                        322.44 
Z, calculated density                 2, 1.255 Mg · m-3 
F(000)                                  352 
description and size of crystal     colorless plate,  
               0.010 · 0.170 · 0.260 mm3 
absorption coefficient                0.086 mm-1 
min/max transmission                 0.99 / 1.00 
temperature                            123K 
radiation(wavelength)                 Mo Kα (λ = 0.71073 Å) 
Crystal system, space group         monoclinic, P 1 21 1  
a                                       7.6255(11) Å 
b                                       7.0963(11) Å 
c                                       15.962(2) Å 
α                                       90° 
β                                       99.002(9)° 
γ                                       90° 
V                                       853.1(2) Å3 
min/max Θ                              2.584° / 28.289° 
number of collected reflections     9053 
number of independent reflections   2233 (merging r = 0.094) 
number of observed reflections      2223 (I>2.0σ(I)) 
number of refined parameters        208 
r                                        0.0612 
rW                                      0.1476 
goodness of fit                        0.91
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8.3 NMR-spectra 
8.3.1 Total Syntheses and SAR-Studies on (−)-Fragin and Valdiazen 
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8.3.2 Synthetic Studies Towards (2R)-Hydroxynorneomajucin 
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8.3.3 Preparation of Antimalarial Endoperoxides 
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8.3.4 Synthetic Studies Towards Striatal A 
 
 
 
 
 
 
CHAPTER 8 
	  
330 
 
 
 
 
 
 
 
APPENDICES 
	  
331 
 
 
 
 
 
 
 
CHAPTER 8 
	  
332 
 
 
 
 
 
 
 
APPENDICES 
	  
333 
 
 
 
 
 
 
 
CHAPTER 8 
	  
334 
 
 
 
 
 
 
 
APPENDICES 
	  
335 
 
 
 
 
 
 
 
CHAPTER 8 
	  
336 
 
 
 
 
 
 
 
APPENDICES 
	  
337 
 
 
 
 
 
 
 
CHAPTER 8 
	  
338 
 
 
 
 
 
 
 
APPENDICES 
	  
339 
 
 
 
 
 
 
 
CHAPTER 8 
	  
340 
 
 
 
 
 
 
 
APPENDICES 
	  
341 
 
 
 
 
 
 
 
CHAPTER 8 
	  
342 
 
 
 
 
 
 
 
APPENDICES 
	  
343 
 
 
 
 
 
 
 
CHAPTER 8 
	  
344 
 
 
 
 
 
 
 
APPENDICES 
	  
345 
 
 
 
 
 
 
 
CHAPTER 8 
	  
346 
 
 
 
 
 
 
 
APPENDICES 
	  
347 
 
 
 
 
 
 
 
CHAPTER 8 
	  
348 
 
 
 
 
 
 
 
APPENDICES 
	  
349 
 
 
 
 
 
 
 
CHAPTER 8 
	  
350 
 
 
 
 
 
 
 
APPENDICES 
	  
351 
 
 
 
 
  
CHAPTER 8 
	  
352 
8.4 Acknowledgments 
 
I’m deeply thankful to my supervisor, Prof. Dr. Karl Gademann, for his 
passion and enthusiasm for complex and challenging natural products. His 
motivation and encouraging mentality was inspiring in every aspect of my 
PhD. 
 
Prof. Dr. Andreas Pfaltz is deeply acknowledged for accepting the co-
examination of my thesis as well as for the support concerning my future 
footsteps in chemistry.  
 
I’m also grateful to Prof. Dr. Christof Sparr for chairing my defense and for 
helpful and fruitful discussions in any aspects of chemistry. 
 
I’m thankful to our collaborators Prof. Dr. Leo Eberl and Christian Jenul 
(University of Zurich), Dr. Marcel Kaiser (Swiss Tropical and Health Institute 
Switzerland) and Dr. Dominic Hoepfner (Novartis Pharma AG) for the fruitful 
work at the frontiers of biology and chemistry. My dear colleague Dr. Simon 
Sieber is acknowledged for the help and support in the fragin project and for 
sharing his wisdom and awesome taste for excellent cheese and fantastic 
whisky with me. 
 
Dr. Erika Crane, Dr. Regina Berg, Dr. Simon Sieber, Dr. Elias Kaufmann, 
Dr. Nadine Bohni, Dr. Florian Huber, MSc Robin Wehlauch, MSc Manuel 
Scherer and MSc Vidya Mannancherril are acknowledged for helpful input 
and corrections of this thesis. 
 
I’m thankful to my highly talented students Joel Rösslein and Vidya 
Mannancherril for their significant synthetic contribution to this work. 
Furthermore, I’m especially proud of you that you continued to proceed in 
your own PhD-studies and I’m looking forward and of course expect from you 
high yields, excellent diastereomeric ratios as well as a fruitful work. On this 
behalf, I wish you only the best for your scientific careers. 
APPENDICES 
	  
353 
 
I would like to especially thank all former and present members of the 
Gademann group. The senior PhDs who always had a critical look at the 
undergraduates and always gave good advices in chemistry but mostly on all 
social aspect and events, thanks to Dr. José Gomes (my mentor and 
outstanding chemist), Dr. Patrick Burch (I still got more hair than you), Dr. 
Samuel Bader (Mr. Wisdom), Dr. Johannes Hoecker (“if you can buy it, buy 
it”), Dr. Malika Makhlouf (“he always looks at scientific papers”), Dr. Hideki 
Miyatake-Ondozabal (“chin-chin”), Dr. Suman de Sarkar (so many T-shirts on 
the tree…) Dr. Simon Sieber (a good whisky is all you need), Dr. Christophe 
Thommen (the one with the real name), Dr. Verena Grundler (“finally done”), 
Dr. Elias Kaufmann (“I need that Spongebob”) and Dr. Fabian Schmid (1 city 
1 song). The current members of the Gademann group, Dr. Erika Crane (“Oh 
boy”), Dr. Regina Berg (Ms. Wisdom), Dr. Nadine Bohni (Miss analytics), 
Manuel Scherer (Mr. Beach Bar), Robin Wehlauch (“DnB 4 life”), Isabel 
Kerschgens (Miss Fado), Simone Grendelmeier (coyote), Jan Hanusch 
(Nafzger vo Wängi), Hiromu Hattori (work work work work work), Dr. Chien-
Chi Hsiao (work work work work work), Dr. Florian Huber (Panini), Raphael 
Liffert (Mr. TGL), Andrea Meier (let the bacteria grow), Ellen Piel (“good 
morning in the morning”), Joel Rösslein (FTM) and Mathieu Szponarski (ham-
man). I wish the current group members all the best for their scientific career 
and hope to see many publications from you.  
 
I would like to especially highlight my all-time labmate Manuel Scherer for 
sharing all associated ups and downs in chemistry as well as his excellent 
taste for good music. On this behalf, reach for the moon, even if you miss it, 
you will land at the beach bar. 
 
The members of the Sparr group, Achim Link (Starnberger See), Dominik 
Lotter (hair-brother), Christian Fischer (“you can read this in my publication”), 
Reto Witzig (Thurgau), Vincent Fäseke (chocolate boy), as well as their 
mentor Dr. Christof Sparr for sharing the lab and all chemistry-based and not 
so chemistry-based discussions. 
  
CHAPTER 8 
	  
354 
My scientific colleagues from the bachelor studies at the FHNW as well as 
from the University of Basel, especially Ina Bodoky, Stefanie Geigle, Livia 
Glanzmann, Samantha Brianza, Natalie Huber, Cathrin Ertl, Annika Büttner, 
Daniel Ebner, Manuel Scherer, Philipp Raschle, Simon Glauser, Luca 
Schweighauser, Patrick Wilhelm, Martin Rother and Severin Sigg. 
 
The Rhino–crew, Manuel Riedo, Rafael Sande, Marco Felder, Severin 
Giger and Timm Hettich, are acknowledged for all the beautiful holiday trips in 
Europe, from drinking whisky in Scotland, all the friendly Hallo’s we met in 
Budapest, as well as the amazing trip in Canada (I can’t see any forests 
anymore) and the United States (what happens in Vegas, stays in Vegas). My 
personal highlight was our trip to Cuba. The astonishing scenery and the 
relaxed atmosphere (and of course the cigars, langoustes and daiquiris) will 
be unforgotten. Our fascinating trips could not be better described with the 
words: “Ça c’est bon pour la moral”. 
 
The Chöpfli-crew for spending a short but intense weekend in Munich with 
more forgotten than actually happened moments. 
 
Meeting my friends from my beloved hometown gave me always-good 
flashbacks of beautiful and especially funny moments. Many thanks to the city 
of Bern (where my heart belongs) and my friends from this town, Dominic 
Herren, Ramon Wymann, Riv Vakili, Alex Stöckli, Fabian Albertin, Fabian 
Lehmann and Christian Herren for spending good times outside the 
laboratory. 
 
Without the help for several analytical measurements, many results 
couldn’t be realized. From the University of Basel: Dr. Markus Neuburger, Dr. 
Heinz Nadig, Dr. Daniel Häussinger and Dr. Collin Morris. From Zurich: Prof. 
Dr. Oliver Zerbe and his NMR-Team, Dr. Anthony Linden and the MS-service 
of PD Dr. Laurent Bigler, especially Miss Jrène Lehmann for chiral HPLC-
measurements. 
 
APPENDICES 
	  
355 
For the entire secretary-related paper work I would like to thank Marina 
Mambelli-Johnson, Beatrice Erismann, Brigitte Howald (Basel) and the HR-
team of Zurich, as well as the technical staff from Basel who are keeping the 
building alive and in shape: Markus Ast, Andres Koller, Andreas Sohler, 
Fabrice Cabrera, Manuel Hermida, Markus Hauri, Roy Lips (Basel) and the 
Werkstatt team from Zurich. 
 
I’m thankful to my parents Ginette and André, my brother Jérôme and my 
grandmother Selma for their support in all aspects of my PhD-studies. 
 
My girlfriend Vidya, for her love, patience and support. Many things would 
not be possible without her warm attitude. Merci für aues mi Schatz. Always. 
                   
